
May 17, 2003

Dear Colleagues and Guests:

Welcome to the 156th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year’s Annual Meeting theme is “The Promise of Science, The Power of Healing.” Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Monday and Tuesday afternoon Presidential Symposia, Monday from 2:00 p.m.-5:00 p.m., entitled,” Moral and Philosophical Issues in Psychiatry” and Tuesday from 2:00 p.m.-5:00 p.m., entitled, “The Foundation of Medical Ethics/Informed Consent.”

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in San Francisco. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 6:00 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented by the distinguished social and political commentator, Charles Krauthammer, M.D.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Geetha Jayaram and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting.

Welcome to San Francisco 2003.

Sincerely,

Paul S. Appelbaum, M.D.
APA President
Welcome to San Francisco, CA, and the 156th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “The Promise of Science - The Power of Healing,” chosen by our President, Dr. Paul S. Appelbaum. Let me draw your attention to just a few of the many exciting sessions presented this week. The Presidential Symposia will be presented on Monday and Tuesday from 2:00 p.m.-5:00 p.m., entitled, "Moral and Philosophical Issues in Psychiatry" and “The Foundation of Medical Ethics/Informed Consent.” Robin Munro, M.D., will present the APA’s Patient Advocacy Award Lecture on Monday, at 9:00 a.m.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation of Distinguished Fellows will begin at 6:00 p.m., on Monday, May 20. Charles Krauthammer, M.D., will present the William C. Menninger Memorial Lecture during the Convocation.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

You will note in the Program Book that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting.

Once again, welcome to San Francisco. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Geetha Jayaram, M.D., M.B.A
Chairperson
Scientific Program Committee
APA 156th ANNUAL MEETING

San Francisco, CA • May 17-22, 2003

KEY LOCATIONS - MOSCONIE CENTER

<table>
<thead>
<tr>
<th>Location</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Journal of Psychiatry</td>
<td>APA Resource Center</td>
</tr>
<tr>
<td>Annual Meetings Office</td>
<td>Rooms 200/202/206/212, Mezzanine Level</td>
</tr>
<tr>
<td>APA Communications Center</td>
<td>Rooms 250-262, Mezzanine Level</td>
</tr>
<tr>
<td>APA Resource Center</td>
<td>Hall D, Exhibit Level</td>
</tr>
<tr>
<td>A/V Preview Room</td>
<td>Room 232, Mezzanine Level</td>
</tr>
<tr>
<td>CME Course Enrollment</td>
<td>Hall D, Exhibit Level</td>
</tr>
<tr>
<td>Computerized Evaluation</td>
<td>APA Resource Center</td>
</tr>
<tr>
<td>Daily Bulletin</td>
<td>Rooms 250-262, Mezzanine Level</td>
</tr>
<tr>
<td>Education Office</td>
<td>Room 226, Mezzanine Level</td>
</tr>
<tr>
<td>Exhibit Office</td>
<td>Exhibit Level</td>
</tr>
<tr>
<td>Exhibits/Publishers' Bookfair</td>
<td>Hall A-C, Exhibit Level</td>
</tr>
<tr>
<td>IMG Hospitality Suite</td>
<td>Room 224, Mezzanine Level</td>
</tr>
<tr>
<td>Information/Locator Center</td>
<td>Upper Lobby South</td>
</tr>
<tr>
<td>Lost &amp; Found</td>
<td>Rooms 200/202/206/212, Mezzanine Level</td>
</tr>
<tr>
<td>Message Center</td>
<td>Upper Lobby South</td>
</tr>
<tr>
<td>On-Site Job Bank and Placement Center</td>
<td>APA Resource Center</td>
</tr>
<tr>
<td>Psychiatric Services</td>
<td>APPI Bookstore, Halls A-C, Exhibit Level</td>
</tr>
<tr>
<td>Registration</td>
<td>Hall D, Exhibit Level</td>
</tr>
<tr>
<td>Women's Hospitality Center</td>
<td>Room 224, Mezzanine Level</td>
</tr>
</tbody>
</table>

FIRST AID

Located across from Room 106 and 124, Exhibit Level, Moscone Center and also in the Esplanade Lobby. Hours of operation: Tuesday, May 13, through Thursday, May 22, opens one hour prior to show opening and closes one hour after the last event of the evening. This station will be operated by Registered Nurses. Information on emergency services may be found on page VII.

COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 17, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, including nighttime activities, and will conclude on Thursday, May 22, at 6:00 p.m. The Moscone Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Services Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page VI for the location of hotels in relation to Moscone Center.

EXHIBITS

Commercial and educational exhibits are located in Halls A-C, Exhibit Level, Moscone Center, along with the Publishers' Bookfair. As a convenience to registrants, the Publishers Bookfair will open on Saturday, May 17, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 18, 11:00 a.m.-4:30 p.m.; Monday and Tuesday, May 19-20, 10:00 a.m.-6:00 p.m.; and Wednesday, May 21, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 21 at 3:00 p.m. Please refer to the APA Exhibits Guide for additional information on participating companies. APA periodicals will be located in the APPI Bookstore.

INFORMATION/LOCATOR CENTER

Located on the Upper Lobby South, Moscone Center and staffed during registration hours (with the exception of Thursday, May 21, when the center will be open until 5:00 p.m.). Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER

Located on the Upper Lobby South, Moscone Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere in Moscone Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

APA RESOURCE CENTER

Located in Hall D, Exhibit Level, Moscone Center. Hours of operation will be: Saturday, May 17, 10:00 a.m.-5:00 p.m.; Sunday, May 18, 8:00 a.m.-4:30 p.m.; Monday and Tuesday, May 19-20, 10:00 a.m.-6:00 p.m.; and Wednesday, May 21, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APAs internet-based programs, continuing medical education, quality improvement, psychiatric services, managed care services, and APA Job Bank.

APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. The on-line APA Job Bank will power the popular on-site Job Bank providing tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank go to the APA web site, www.psych.org, and click on the Job Bank icon.

APA COMMUNICATIONS OFFICE/PRESS OFFICE

Located in Rooms 250-262, Mezzanine Level, Moscone Center. Hours of operation: Saturday, May 17, 12 noon-5:00 p.m.; Sunday-Wednesday, May 18-21, 8:00 a.m.-6:00 p.m.; and Thursday, May 22, 8:00 a.m.-12 noon. The Press Office is for the use of registered press only.

DAILY BULLETIN

The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Rooms 250-262, Mezzanine Level, by 12 noon prior to the date of publication.

WOMEN'S RESOURCE CENTER

Located in Room 224, Mezzanine Level, Moscone Center. Hours of operation: Sunday, May 18, through Monday, May 19, 7:00 a.m.-5:00 p.m. Meet and network with other women psychiatrists and peruse materials on women's programs offered by APA and other organizations. The Center is funded by an unrestricted educational grant from Wyeth Pharmaceuticals.

IMG HOSPITALITY CENTER

Located in Room 224, Mezzanine Level, Moscone Center. Hours of operation: Tuesday, May 20, through Wednesday, May 21, 8:00 a.m.-6:00 p.m. Stop by the Center to meet and network with your colleagues.

RESIDENTS' RESOURCE CENTER

Located in the Pacific Conference Suite I, Fourth Floor, Marriott. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 18, through Wednesday, May 21. Daily activities are scheduled for residents (such as the Residents Only Discussion Groups) and for medical students as well. Meet and network with leaders in psychiatry and your colleagues. Resources specifically for residents and medical students available are available here.
CENTER FOR INTERNATIONAL GUESTS

Due to a lack of funding, we regret we are unable to provide an International Visitor Center this year.

BUSINESS CENTERS

Moscone Center
Location: Southwest Lower Lobby, Adjacent to Room 105
Times of operation: Monday-Sunday, 8:00 a.m.-5:00 p.m.

Marriott
Location: Golden Gate Hall, B2 Level
Times of operation: Monday-Friday, 5:30 a.m.-8:00 p.m.
Saturday-Sunday, 8:00 a.m.-4:00 p.m.

Hilton
Location: Bldg. 2, Lobby
Times of operation: Monday-Friday, 8:00 a.m.-5 p.m.
Saturday - Sunday, To be posted.

REGISTRATION

ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE

Located in Hall D, Exhibit Level, Moscone Center. Hours of operation: Saturday, May 17, 10:00 a.m.-5:00 p.m.; Sunday, May 18, 7:30 a.m.-5:00 p.m.; Monday-Tuesday, May 19-20, 7:30 a.m.-6:00 p.m.; Wednesday, May 21, 7:30 a.m.-5:00 p.m.; and Thursday, May 22, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS
Full-Time Registration (North American Members).......................... $275.00
Full-Time Registration (International Members).......................... $425.00
Members-in-Training (Member Class MT)...................................... $ 75.00
Daily Registration (North American Members).......................... $140.00
Daily Registration (International Members).......................... $215.00
Medical Students........................................................................... no charge

NONMEMBERS
Full-Time Registration.................................................................... $790.00
Nonmember Residents, Students, Advocacy.................................. $250.00
Group Members, or Mental Health Chaplains................................. $95.00
Daily Registration (all "Nonmember" categories)........................... $400.00
Medical Students........................................................................... no charge

GUEST REGISTRATION

One only per full-time registrant...................................................... 100.00

Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.

One-Day Exhibit Hall Only Pass (18 and older)............................. 10.00

(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by cash, check, money order, American Express, Visa or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Chaplains (with proper identification), and nonmember program participants (only for the day(s) they present).

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

For most categories, a copy of the Program Book and APA Exhibits Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

NAME BADGES

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Black-Temporary Moscone Personnel.

Registered exhibitors will receive red badges, which allow access only to his/her own booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT

TICKET PURCHASE REQUIRED FOR CME COURSES

Located in Hall D, Exhibit Level, Moscone Center. Hours of operation: Saturday, May 17, 10:00 a.m.-5:00 p.m.; Sunday, May 18, 7:30 a.m.-5:00 p.m.; Monday through Tuesday, May 19-20, 7:30 a.m.-6:00 p.m.; Wednesday, May 21, 7:30 a.m.-5:00 p.m.; and Thursday, May 22, 7:30 a.m.-2:00 p.m. Tickets for CME Courses not sold by April 13 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 17. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION

Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH

Located on the Upper Lobby South, Moscone Center. Hours of operation: Saturday, May 17, through Wednesday, May 21, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

APA PERIODICALS

Complimentary copies of the latest issues of The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, The American Journal of Geriatric Psychiatry, The Journal of Neuropsychiatry and Clinical Neurosciences, Psychopharmacology, and APA's new CME journal, Focus, may be obtained at the APA/APPI Periodicals Exhibit in the APPI Bookstore. Complimentary copies of Psychiatric News will be available at stands located throughout Moscone Center. Staff will sell discounted subscriptions to all APA/APPI journals and demonstrate online access for subscribers. They will also show authors and reviewers how to use Manuscript Central, the new Web-based manuscript submission and review system. Staff of the American Journal of Psychiatry and Psychiatric Services will be available to answer authors' questions. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office, Rooms 200/202/208/212, Mezzanine Level, Moscone Center. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobitape Booth located on the Upper Lobby South, in Moscone Center.
CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

• Better understand new research findings in the fields of psychiatry and neuroscience;
• Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
• Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
• Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
• Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Psychotherapy, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Oral/Slide Sessions, Research Advance in Medicine, Presidential Symposia, Review of Psychiatry, Scientific and Clinical Reports, Symposia, and Workshops. Other program activities may be considered Category 2: Debate, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultations. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA Members are required to maintain their own records of CME hours.

To document CME credit earned at this Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance log sheet found in the front of the 2003 Annual Meeting CME Syllabus & Proceedings Summary Book. Credit is earned on an hour-for-hour basis. A parchment Certificate of Attendance is also available.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Department of CME at the APA. Staff will be available in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. Before you leave the meeting, please complete your form and drop it in one of the evaluation boxes located throughout the meeting sites. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Resource Center, all located in Moscone Center) or by completing the computerized general evaluation in the APA Resource Center.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

* Please find seating as far forward as possible.
* Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
* Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
* If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. Non-media registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session. More detailed guidelines for media representatives may be obtained in the Press Office.

SMOKING POLICY

There will be no smoking in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

CHILD CARE SERVICE

ACCENT on Children's Arrangements, Inc., the official youth program provider for APA, has planned an exciting on-site children's activity program called Camp APA. Camp APA offers both parents and their children a safe, nurturing, and positive experience. ACCENT's professional, specially trained supervisors are certified in both CPR and pediatric first aid. The ACCENT staff are teachers, professional childcare providers, or mothers who simply love working with children and have completed ACCENT's specialized training program. Camp APA is headquartered at the San Francisco Marriott for the exclusive use of APA registrants and their families. Children aged 6 months to 17 years are welcome and will be provided with developmentally appropriate programs designed specifically for their age group. Activities will take place on site for all children younger than 6 years old. The older children will enjoy arts and crafts projects, active games, and much more. Field Trips will depart and return to the on-site Camp APA activity Center each day. ACCENT provides an exceptional caregiver to child ratio: 1:2 for children 6-12 months; 1:3 for children 13-36 months; 1:5 for children 3-12 years and 1:8 for children 12 years and older.

GUIDE TO THE PROGRAM BOOK

On page V, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Moscone Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green badges. Please feel free to direct your questions to them.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Floor Plans for Moscone Center, Argent, Hilton, Marriott, and Westin St. Francis</td>
<td>VI-XV</td>
</tr>
<tr>
<td>City Map</td>
<td>XVI</td>
</tr>
<tr>
<td>Local Information</td>
<td>XVII</td>
</tr>
<tr>
<td>Special Acknowledgments</td>
<td>XVIII-XIX</td>
</tr>
<tr>
<td>Format Descriptions</td>
<td>XX-XXI</td>
</tr>
<tr>
<td>Disclosure Information</td>
<td>XXII-XXX</td>
</tr>
<tr>
<td>Saturday Sessions</td>
<td>1-3</td>
</tr>
<tr>
<td>Audiotape Sales Information</td>
<td>4</td>
</tr>
<tr>
<td>Sunday Sessions</td>
<td>5-12</td>
</tr>
<tr>
<td>Monday Sessions</td>
<td>13-34</td>
</tr>
<tr>
<td>Tuesday Sessions</td>
<td>35-59</td>
</tr>
<tr>
<td>2003 Institute on Psychiatric Services</td>
<td>60</td>
</tr>
<tr>
<td>Wednesday Sessions</td>
<td>61-82</td>
</tr>
<tr>
<td>Thursday Sessions</td>
<td>83-98</td>
</tr>
<tr>
<td>Call for 2004 Annual Meeting Papers</td>
<td>98</td>
</tr>
<tr>
<td>Topic Index</td>
<td>99-112</td>
</tr>
<tr>
<td>Participant Index</td>
<td>113-123</td>
</tr>
<tr>
<td>American Psychiatric Publishing Inc.</td>
<td>124-125</td>
</tr>
<tr>
<td>Industry-Supported Symposia</td>
<td>126-151</td>
</tr>
<tr>
<td>APA Resource Center</td>
<td>Back Cover</td>
</tr>
</tbody>
</table>

Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, Hospitality Lounge, and Dining Facilities in Moscone Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

© American Psychiatric Association.
Esplanade & Lobbies Level
The Argent Hotel
San Francisco
50 Third Street, San Francisco CA 94103
415-974-6400

SECOND LEVEL

THIRD LEVEL
Hilton
San Francisco & Towers
333 O'Farrell Street, San Francisco, CA 94102
(415) 771-1400

Ballroom Level/Bldgs. 1, 2, 3
Hilton
San Francisco & Towers
4th Floor/Bldg. 3
Golden Gate Hall
(B2 Level)
San Francisco Marriott

Yerba Buena Ballroom
(Lower B2 Level)
San Francisco Marriott

Pacific, Sierra Conference Suites and Club Room
(Fourth, Fifth & Atrium Levels)
Convention Facilities
WEATHER/WHAT TO WEAR
San Francisco is blessed with a temperate marine climate and enjoys mild weather year-round. Temperatures seldom rise above 70°F (21°C) or fall below 40°F (5°C). Morning and evening fogs roll in during the summer months, but rarely persist. Visitors are most comfortable with a light jacket or coat handy for cool evening wear. Lightweight summer clothes are seldom practical in San Francisco.

TOBACCO RESTRICTIONS
In California, it is illegal to smoke tobacco products in any public gathering space including restaurants and bars, stores, and office buildings. Please observe signs for designated smoking areas.

ACCESSIBILITY
When using public transportation, request a copy of the Muni Access Guide, Muni Accessible Services Programs, 987 Presidio Avenue, San Francisco, CA 94115; for assistance call 415.923.6142 or 415.673.MUNI (6864). The MUNI operates more than 41 accessible bus lines in addition to accessible Metro service. The San Francisco Convention & Visitors Bureau maintains a TDD information line at 415.777.5115. For additional information, visit the web site at www.accesssca.com.

AIRPORT
With the completion of its new International Terminal in December 2000, San Francisco International Airport set several records. The addition of the new terminal doubles the size of SFO. International passengers enjoy faster processing; an estimated 5,000 individuals each hour pass through U.S. Customs and Immigration. San Francisco is a mere 14 miles away and a Bay Area Rapid Transit (BART) station (slated to open in December 2000, San Francisco's city center. For more information on San Francisco International Airport, visit the Web site at www.flsfo.com.

AIRPORT TRANSPORTATION
American Airporter Shuttle provides 24-hour, door-to-door airport/ground transportation. Major credit cards are accepted. At SFO depart from the red sign, request American Airporter Shuttle on the upper level center island at Continental, British Air, and United. Each way $14 adult, $12 ages 2-12, under 2 free. Fares are subject to change.

GETTING AROUND
Getting around San Francisco is easy — there are several options when it comes to public transportation. Cable cars operate on three routes: Powell-Mason, Powell-Hyde, and California Street. The fare is $.25. For streetcars and buses, the fare is $1 (55 cents for seniors, children, and disabled persons). Purchase a MUNI Passport, good on all three, at the kiosk at Market and Powell streets. One-day ($6), three-day ($10), and seven-day ($15) passes are available; call 415.673.MUNI. BART (Bay Area Rapid Transit) trains operate daily from San Francisco and the East Bay; call 650.992.2278. Fares begin at $1.10. For sightseeing cruises and ferry service Blue & Gold Fleet departs from Pier 39/41; call 415.705.5444.

TAXI COMPANIES
Luxor Cab
415.282.4141
Veterans Taxicab Company
415.552.1300
Yellow Cab Cooperative, Inc.
415.626.2345

FOREIGN CURRENCY EXCHANGE
Bank of America Downtown
650.615.4700
Thomas Cook Currency Services, Inc.
415.362.3452
Western Union
800.325.4176

MEDICAL EMERGENCIES
Downtown Medical/Travel Medicine — Dr. Lawrence Bryson, Physician, 450 Sutter Street, Suite 1723, 415.362.7177. Immediate, same-day appointments specifically for the traveler or visitor. Familiar with travel-related medical conditions and infections, along with gynecology. Full laboratory and pharmacy on-site.

Saint Francis Memorial Hospital — 900 Hyde Street. Open 24 hours, 415.353.6000
UCSF Stanford Medical Center — 505 Parnassus Avenue. Mon.-Fri. 8:00 a.m.-5:00 p.m., Sat. 8:00 a.m.-4:00 p.m. walk-in clinic open.
General Information: 415.476.1000
Emergency Services: 415.476.1037

San Francisco Dental Office — Dr. Michael H. Sandler, DDS, owner, 131 Steuart Street, Suite 323, 415.777.5115.

Near convention sites and public transit, office includes in-house dental appliance laboratory. Emergency treatment available. Open daily early mornings and evenings.

Traveller Medical Group, A Medical Corporation — Dr. Jim Y. Savage, President, 490 Post Street, Suite 225, 415.981.1102. One of the best medical services for travelers, available daily 24 hours. Immediate office and hotel visits with physician trained in internal medicine with hospital privileges in the city. Accept most major insurance with prior-authorization and credit cards.

24 Hours/7 Days Synapse Medical Group — Dr. Jordan Shlain, Managing Director, 490 Post Street, Suite 710, 415.732.7039. Providing prompt, daily, 24-hour medical services to the traveler with a network of doctors and hospitals for all medical needs.

TOURS/VISITOR INFORMATION
Attendees are encouraged to use their hotel's concierge services to assist them with local tours and leisure-time activities. There are several web sites available with information on the city; sfchamber.com; sftvisor.org; sfstation.com.

APA GOLF TOURNAMENT
The Golfers of the APA (GAPA) invite you to participate in their 2003 golf tournament to benefit the American Psychiatric Foundation. The tournament is scheduled for Monday, May 19, 2003 at the Presidio Golf Course, San Francisco, home to a unique golfing legacy forged by the giants of history and golf's greatest legends. Tee it up here and find yourself in the company of Teddy Roosevelt, Dwight Eisenhower, Joe DiMaggio, Byron Nelson, Ben Hogan, and Arnold Palmer. This majestic, tree-lined course is the perfect setting for our golf outing. Cost per person will be $200, including round-trip transportation, greens fees, cart, lunch, gifts, and prizes. To enter please contact Stan Jennings, M.D. by e-mail at walerjennings@hotmail.com, by fax at 804.320.2050, by phone at 804.320.7881 or by mail, W.S. Jennings, Jr., M.D., 7149 Jahnke Road, Richmond, VA 23225.
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Symposia, "Diagnosis and Treatment: Mood Stabilizers Across the Psychiatric Spectrum," Sunday, May 18, 8:00 a.m.; "Bipolar Disorder Across the Life Cycle," Tuesday, May 20, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "Impairment of Structural Plasticity in Severe Mood Disorders: Cause or Coculential?" Monday, May 19, and Tuesday, May 20, 7:00 a.m., and support of the internet village.

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 18, 2:30 p.m.

American Psychiatric Foundation: co-support of the APA Award for Research in Psychiatry, support of the Disaster Psychiatry Fellowship, and support of the APIRE Practice Research Network (PRN).

Association of Women Psychiatrists: support of the joint AWP/APA Women's Career reception and meeting.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Genetics and Psychiatry: Real Genes, Real Progress," Saturday, May 17, 6:00 p.m.; "Issues in Treating Mania: Acute and Conniuation Phase," Sunday, May 18, 8:00 a.m.; "A Rational Algorithm for Selecting Atypical Drugs in Schizophrenia and Bipolar Disorders," Sunday, May 18, 7:00 p.m.; the George Tarjan Award Lecture, Wednesday, May 22, 9:00 a.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 21, 5:30 p.m., and support of the APIRE/AstraZeneca Young Minds in Psychiatry Award.

Aventis: support of the Travel Fellowship for Women Resident Leaders in Psychiatry and Leadership Luncheon, Sunday, May 18, 12:00 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Symposia, "Biological and Psychological Advances in the Treatment of Schizophrenia: Revising and Updating Meyer's Psychobiology for the 21st Century," Tuesday, May 20, 7:00 p.m.; "Novel Therapeutic Options for Psychotic Disorders," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Managing the Spectrum of Psychotic Disorders," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; the APA's Solomon Carter Fuller Lecture Award Lecture, Thursday, May 21, 11:00 a.m.

Bristol-Myers Squibb Sweden: support of the Luncheon for US and International Residents: "Patients Who Want to Die: Are they Suicidal and Where do they Fit Into the DSM?" Sunday, May 18, 12 noon.

Center for Mental Health Services: support of the APIRE Practice Research Network, and support of APA's HIV-related education programs and materials (PRN).

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN).

Cephalon Inc.: support of the Industry-Supported Symposia, "Depression, Apathy, and Fatigue in Neuropsychiatric Disorders," Sunday, May 18, 1:30 p.m.; and the Industry-Supported Breakfast Symposium, "Managing Anxiety and Sleep: A New Era for Gamma-Aminobutyric Acid," Monday, May 19, and Tuesday, May 20, 7:00 a.m.

Eisai Inc., Pfizer Inc.: support of the Industry-Supported Symposium, "Challenges in Dementia: Evidence-Based Considerations From Early Diagnosis to Long-Term Management," Wednesday, May 21, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "Enhancing Outcomes by Addressing Clinical Challenges in the Treatment of Schizophrenia," Saturday, May 17, 6:00 p.m.; "An Integrated Approach to the Management of Bipolar Disorder: An Alliance of Science and Medicine," Sunday, May 18, 8:00 a.m.; "Pharmacological Treatment of Chronic Pain Comorbidity With Depression and Other Psychotic Disorders," Sunday, May 18, 1:30 p.m.; "Medical Considerations in the Management of Special Patient Populations," Sunday, May 18, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Treatin Depression: What Matters?" Monday, May 19, and Tuesday, May 20, 7:00 a.m., and partial support of the Simon Bolivar Award Lecture, Monday, May 19, 2:00 p.m., the APA/Lilly Resident Research Awards; partial support of the New Resident Abstract and New Research Program Books; and support of the Daniel Freedman Congressional Fellowship.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Thursday, May 22, 9:00 a.m.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards in child and adolescent psychiatry.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "Anxiety Disorders: Sources, Signs, and Solutions," Saturday, May 17, 12:30 p.m.; "Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter?" Saturday, May 17, 6:00 p.m.; and "New Challenges in the Management of Depression," Sunday, May 18, 1:30 p.m.

Foundations' Fund for Research in Psychiatry: co-support of the APA Award for Research in Psychiatry.

GlaxoSmithKline: support of the Industry-Supported Symposia, "Bipolar Disorder: Strategies for Stabilizing Patients Over the Long Term," Saturday, May 17, 12:30 p.m.; "Moods, Cycles, and Motherhood," Sunday, May 18, 8:00 a.m.; "Barriers to Optimal Outcome in Anxiety and Depression," Sunday, May 18, 1:30 p.m.; "Real-World Challenges in Depression and Anxiety," Tuesday, May 20, 7:00 p.m.; "Combined Pharmacotherapy for Bipolar Disorders," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Bipolar Disorder in Women: Special Considerations and Evolving Treatment," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; the APA/GlaxoSmithKline Fellowship Program; the annual contribution to the APA Presidential Fund, the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry; support of the APIRE/GlaxoSmithKline Health Services Research Awards; support of the APIRE/GlaxoSmithKline Severe Mental Illness Fellowship; and the registration portfolio.

Gralnick Foundation: support of the Alexander Gralnick, M.D., Award for Research in Schizophrenia.

Ittleson Foundation, Inc.: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "Schizophrenia Treatment in the Community: The Role of Long-Acting Antipsychotics," Saturday, May 17, 12:30 p.m.; "New Strategies for Managing Bipolar Disorder," Saturday, May 17, 6:00 p.m.; "Treatment of Comorbidities in Neuropsychiatric Disorders in Children and Adolescents," Sunday, May 18, 7:00 p.m.; "Facing Unmet Needs: Atypical Antipsychotics for Mood and Anxiety," Tuesday, May 20, 7:00 p.m.; "Compassionate and Safe Emergent Care: Best Practices in Antipsychotic Use," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Neuropsychiatry in the Age of Polypharmacy," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.; and the American Psychiatric Institute for Research and Education: Janssen Research scholars on Severe Mental Illness Program.

Lilly Research Laboratories, a division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.
SPECIAL ACKNOWLEDGMENTS

May 18, 7:00 p.m.; support of the William C. Menninger Memorial Convocation Lecture, Monday, May 19, 6:00 p.m.; and an unrestricted educational grant in support of various scientific sessions.

National Institute of Mental Health: support of American Psychiatric Institute for Research and Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Research Colloquium for Junior Investigators.

National Institute on Drug Abuse: support of the American Psychiatric Institute for Research and Education/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSP).

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposium, "Reducing Suicidality in Schizophrenia and Bipolar Disorder," Sunday, May 18, 7:00 p.m.; "Slowing Disease Progression and the Long-Term Management of Dementia," Tuesday, May 20, 7:00 p.m.; "Juvenile Bipolar Disorder: Contemporary Issues in Research," Wednesday, May 21, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "Treating ADHD Across the Life Cycle," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.

Otsuka Pharmaceuticals: support for the International Medical Graduate (IMG) Hospitality Suite.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 18, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposium, "Beyond Benzodiazepines: New Molecules for the Treatment of Anxiety," Saturday, May 17, 6:00 p.m.; "Psychiatry and Medicine: Common Patients, Different Perspectives," Sunday, May 18, 7:00 p.m., and "Optimizing Treatment for Patients With Schizophrenia: Targeting Positive Patient Outcomes," Tuesday, May 20, 7:00 p.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 20, 7:00 a.m.; the "Abstracts-On-Disk" Program; and the APA Daily Bulletin newspaper, partial support of the Simon Bolivar Award Lecture, Monday, May 19, 2:00 p.m.

Sanofi-Synthelabo, Inc.: support of the Industry-Supported Breakfast Symposium, "Insomnia in Today's Society: Consequences and Treatments," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.; support of the Residents, Medical Student, and Training Directors Luncheon, Tuesday, May 20, 12 noon.

Shire U.S., Inc.: support of the four APA/Shire Child and Adolescent Psychiatry Fellowships.

Solvay Pharmaceuticals, Inc.: support of the Industry-Supported Breakfast Symposium, "Impulsivity, Aggression, and Suicide: Versatility of Lithium and Mood Stabilizers," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; and the beverage service in the exhibit hall.

Substance Abuse and Mental Health Services Administration: sponsorship of the APA/SAMHSA Minority Fellowship Program.

University of California — Davis, Department of Psychiatry: support of the Residents, Fellows and Medical Student’s Reception, Monday, May 19, 5:00 p.m.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposium, "Remission in Psychiatric Disorders: Definitions, Issues, and Treatments," Sunday, May 18, 8:00 a.m.; "Stress, Psychopathology, and the Brain: Novel Intervention Strategies," Sunday, May 18, 1:30 p.m.; "Women and Psychiatric Disorders: Does Gender Matter for Treatment?" Tuesday, May 20, 7:00 p.m.; "Striving to Heal the Mind: The Challenge of PTSD," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Evidence-Based Treatment of Psychiatric Disorders," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D./Ph.D. Psychiatric Research Fellowship; the Women’s Resource Center and Display; the Alexandra Symonds Award Lecture, Wednesday, May 21, 2:00 p.m.; the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, "APA Event News Network."
ADVANCES IN PSYCHOTHERAPY
This three-and-one-half hour session will summarize important new clinical and research findings in the treatments of selected psychiatric disorders, with an emphasis on psychotherapeutic interventions. The symposium will be based in part, on material contained in the American Psychiatric Publishing textbook edited by Glen Gabbard, M.D., and entitled, The Treatments of Psychiatric Disorders, Third Edition. Authors of selected chapters from the textbook will present material from their chapters. The topics were selected by the editor to represent disorders of particular current interest to psychiatrists and to focus on aspects of psychotherapy that may be of greatest importance to APA members.

ADVANCES IN RESEARCH
This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

DEBATES
Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH
This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; and Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussion.
FORMAT DESCRIPTIONS

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and oral or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires oral disclosure of discussion of unapproved uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter's name, the manufacturer's name, and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Lilly Research</td>
<td>56, 77, 96</td>
</tr>
<tr>
<td>Michael H. Allen, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9, 80</td>
</tr>
<tr>
<td>David B. Allison, Ph.D.</td>
<td>Ortho-McNeil Pharmaceuticals</td>
<td>61</td>
</tr>
<tr>
<td>Lori L. Altshuler, M.D.</td>
<td>Forest Laboratories, Inc.; Cephalon</td>
<td>35, 81</td>
</tr>
<tr>
<td>Michael G. Aman, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Celgene Corporation</td>
<td>32</td>
</tr>
<tr>
<td>Paul J. Ambrosini, M.D.</td>
<td>Shire Pharmaceutical</td>
<td>68</td>
</tr>
<tr>
<td>Peter D. Anderson, Pharm.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Stuart A. Anfang, M.D.</td>
<td>UnumProvident Corporation</td>
<td>65</td>
</tr>
<tr>
<td>David B. Arciniegas, M.D.</td>
<td>Organon Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Scott C. Armstrong, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>37</td>
</tr>
<tr>
<td>John W. Ashford, Jr., M.D.</td>
<td>Janssen Pharmaceuticals, Bowles-Langley Technology (BLT)</td>
<td>54</td>
</tr>
<tr>
<td>Ron Aubert, Ph.D.</td>
<td>Medco Health Solutions, Inc.</td>
<td>90</td>
</tr>
<tr>
<td>Peter M. Aupperle, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories</td>
<td>62</td>
</tr>
<tr>
<td>Rahn K. Bailey, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>41</td>
</tr>
<tr>
<td>Robert W. Baket, M.D.</td>
<td>Eli Lilly and Company</td>
<td>16, 22, 25</td>
</tr>
<tr>
<td>Claudia F. Baldassano, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>11</td>
</tr>
<tr>
<td>Ross J. Baldessarini, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>12</td>
</tr>
<tr>
<td>John Barry, M.D.</td>
<td>GlaxoSmithKline; Cyberonics</td>
<td>5</td>
</tr>
<tr>
<td>Elizabeth A. Baxter, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>32</td>
</tr>
<tr>
<td>Anne E. Becker, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>70</td>
</tr>
<tr>
<td>Jeffrey L. Berlant, M.D.</td>
<td>Ortho-McNeil Pharmaceutical</td>
<td>31</td>
</tr>
<tr>
<td>John L. Beyer, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; SmithKline Beecham Pharmaceuticals; Organon Inc</td>
<td>81</td>
</tr>
<tr>
<td>Rebecca S. Bierman, D.O.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Organon Inc.</td>
<td>40</td>
</tr>
<tr>
<td>Pierre Blier, M.D.</td>
<td>Organon Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Asahi</td>
<td>58</td>
</tr>
<tr>
<td>Mina S. Bobdey, M.R.C.</td>
<td>Central North West London NMS Trust (employer)</td>
<td>47</td>
</tr>
<tr>
<td>Howard E. Book, M.D.</td>
<td>American Psychiatric Press Inc.</td>
<td>7, 55</td>
</tr>
<tr>
<td>Jacques Bradwejn, M.D.</td>
<td>GlaxoSmithKline; Wyeth-Ayerst Laboratories; Servier; Novartis Pharmaceuticals Corporation</td>
<td>90</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>96</td>
</tr>
<tr>
<td>Stephen K. Brannan, M.D.</td>
<td>Eli Lilly and Company</td>
<td>44</td>
</tr>
<tr>
<td>Olga Brawman-Mintzer, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>58</td>
</tr>
<tr>
<td>William Breitbart, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Purdue Pharma; Ortho-Biotec; Cephalon; Bristol-Myers Squibb</td>
<td>10, 78, 94</td>
</tr>
<tr>
<td>Alan S. Brown, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>45</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>American Psychiatric Press Inc.; Cephalon; Eli Lilly and Company; GlaxoSmithKlineBeecham Healthcare; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgwood Pharmaceuticals; The Psychological Corporation; Yale University</td>
<td>1, 5, 14</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Steven L. Dubovsky, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Merck &amp; Co., Inc.; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Organon Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Mina K. Dulcan, M.D.</td>
<td>Eli Lilly and Company; Celltech Pharmaceuticals</td>
<td>28</td>
</tr>
<tr>
<td>Eduardo Dunayevich, M.D.</td>
<td>Eli Lilly and Company</td>
<td>15</td>
</tr>
<tr>
<td>David L. Dunner, M.D.</td>
<td>GlaxoSmithKline</td>
<td>59</td>
</tr>
<tr>
<td>Richard L. Elliott, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Pete M. Ellis, B.M.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Boots Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Shire Ridgewood Pharmaceuticals</td>
<td>79</td>
</tr>
<tr>
<td>C. Neill Epperson, M.D.</td>
<td>GlaxoSmithKline</td>
<td>6</td>
</tr>
<tr>
<td>Javier I. Escobar, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Johnson and Johnson</td>
<td>15, 51</td>
</tr>
<tr>
<td>Dwight L. Evans, M.D.</td>
<td>GlaxoSmithKline; Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Somerset Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Lofex Pharmaceuticals; Lichther Pharma GmbH</td>
<td>3</td>
</tr>
<tr>
<td>Stephen V. Farace, Ph.D.</td>
<td>McNeil Consumer &amp; Specialty Pharmaceutical; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.; GlaxoWellcome; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Sanofi-Synthelabo Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lundbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals, Inc.; Pharmavite; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Lofex Pharmaceuticals; Lichther Pharma GmbH</td>
<td>61, 81, 87</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.; GlaxoWellcome; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Sanofi-Synthelabo Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lundbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals, Inc.; Pharmavite; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Lofex Pharmaceuticals; Lichther Pharma GmbH</td>
<td>9, 89</td>
</tr>
<tr>
<td>Jacqueline M. Feldman, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Merck &amp; Co., Inc.</td>
<td>1</td>
</tr>
<tr>
<td>David Fischbain, M.D.</td>
<td>Eli Lilly and Company</td>
<td>9</td>
</tr>
<tr>
<td>Robert S. Fisher, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Ivax Medtronic, Nicolet; Cognetix; GlaxoSmithKline; Ortho-McNeil Pharmaceuticals; UCB Pharma; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>5</td>
</tr>
<tr>
<td>George A. Fournas, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>46</td>
</tr>
<tr>
<td>Richard J. Frances, M.D.</td>
<td>Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>86</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Eli Lilly and Company; Ortho-McNeil Pharmaceuticals; Abbott Laboratories; American Foundation for Suicide Prevention; GlaxoSmithKline; National Institute of Mental Health; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Stanley Foundation; Cephalon; Elan Pharmaceuticals, Eli Lilly and Company; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; UCB Pharma; Bristol-Myers Squibb</td>
<td>6, 11, 81</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories; American Foundation for Suicide Prevention; GlaxoSmithKline; National Institute of Mental Health; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Stanley Foundation; Cephalon; Elan Pharmaceuticals, Eli Lilly and Company; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; UCB Pharma; Bristol-Myers Squibb; Johnson and Johnson; Shire Pharmaceuticals; UCB Pharma, Inc.</td>
<td>2, 11, 81</td>
</tr>
<tr>
<td>Glen O. Gabbe, M.D.</td>
<td>Merck &amp; Co., Inc.</td>
<td>50, 78</td>
</tr>
<tr>
<td>Rollin Gallagher, M.D.</td>
<td>Eli Lilly and Company</td>
<td>9</td>
</tr>
<tr>
<td>David R. Gastfriend, M.D.</td>
<td>Earley Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Purdue; Tele-Sage, Inc.</td>
<td>31</td>
</tr>
<tr>
<td>Albert C. Gaw, M.D.</td>
<td>Eli Lilly and Company</td>
<td>66</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Solvay Pharmaceuticals, Inc./Dupha; Patke-Davis, Division of Warner-Lambert Company; Picker International; Dantec; Neotounus, Inc., Cyberonics, Inc. Dupont Pharma; Mediphysics/Amersham</td>
<td>8, 15</td>
</tr>
<tr>
<td>S. Nassir Ghaemi, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Abbott Laboratories; GlaxoSmithKline; Forest Laboratories, Inc.; Eli Lilly and Company; Merck Medco Managed Care; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Abbott Laboratories; GlaxoSmithKline; Forest Laboratories, Inc.; Eli Lilly and Company; Merck Medco Managed Care</td>
<td>2, 3, 16, 65, 81, 96</td>
</tr>
<tr>
<td>David L. Gansberg, M.D.</td>
<td>GlaxoSmithKline; Forest Laboratories, Inc.; Organon Inc.; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>9</td>
</tr>
<tr>
<td>Leslie H. Gise, M.D.</td>
<td>Merck Medco Managed Care</td>
<td>55</td>
</tr>
<tr>
<td>William M. Glazer, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation</td>
<td>32</td>
</tr>
<tr>
<td>Ira D. Glick, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Otsuka Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>13, 41, 79, 80</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; RW Johnson; Shire Pharmaceuticals; UCB Pharma, Inc.</td>
<td>6, 78, 81, 89, 96</td>
</tr>
</tbody>
</table>
Stephen M. Goldfinger, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; IVAX Pharmaceuticals; Mallinckrodt | 19, 40, 65, 72

Joseph Gonzalez-Heydrich, M.D. | Novartis Pharmaceuticals Corporation | 81

Frederick K. Goodwin, M.D. | Abbott Laboratories; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Elan Pharmaceuticals; Janssen Pharmaceutica and Research Foundation | 3, 36

Jack M. Gorman, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories | 3, 36

Kevin F. Gray, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation | 72

Grad Green, M.S.N. | Janssen Pharmaceutica and Research Foundation | 80

Laurence L. Greenhill, M.D. | Novartis Pharmaceuticals Corporation; McNeil Pharmaceuticals; Shire Ridgewood Pharmaceuticals; Janssen Pharmaceutica and Research Foundation | 44, 56

John H. Greist, M.D. | Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc. | 81

Robert E. Hales, M.D. | Bristol-Myers Squibb; GlaxoSmithKline; Forest Laboratories, Inc. | 13, 35

Ellen Haller, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Bristol-Myers Squibb | 8, 80

Scott D. Haltzman, M.D. | Distal-Lilly; Janssen Pharmaceutica and Research Foundation | 66

Richard Hargreaves, Ph.D. | Merck & Co., Inc. | 11

Patrice A. Harris, M.D. | Eli Lilly and Company | 32

Peter Hauser, M.D. | Schering Plough; Forest Laboratories, Inc. | 92

David C. Henderson, M.D. | Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb | 1, 28

Richard G. Hersh, M.D. | Wyeth-Ayerst Laboratories | 5

Keisuke Hirai, Ph.D. | Takeda Chemical Industries Ltd. | 68

Robert M.A. Hirschfeld, M.D. | Forest Laboratories, Inc.; Eli Lilly and Company | 6, 8

Max Hirshkowitz, Ph.D. | Neurocome; Cephalon; Takeda Pharmaceutica; Sepracore; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Savotli | 73

Eric Hollander, M.D. | Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline | 5, 13, 35, 56

William G. Honer, M.D. | AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Eli Lilly and Company | 40

Michael Y. Huang, M.D. | Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc. | 75, 85, 94

Philip G. Janicak, M.D. | Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Genentech; National Institutes of Health; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Sepracor; AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; Abbott Laboratories | 14

David C. Jimerson, M.D. | Abbott Laboratories | 6, 95

Lewis L. Judd, M.D. | Janssen Pharmaceutica and Research Foundation | 42

Ned H. Kalin, M.D. | Wyeth-Ayerst Laboratories; Merck & Co., Inc. | 9, 10, 11

John M. Kane, M.D. | Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Lundbeck; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Protarga; Aventis | 1, 19, 59

Flavio Kapczinski, Ph.D. | GlaxoSmithKline | 8

Siegfried Kasper, M.D. | GlaxoSmithKline; Servier, Lundbeck | 96

Walter H. Kaye, M.D. | Eli Lilly and Company | 30, 95

Paul E. Keck, Jr., M.D. | Eli Lilly and Company; Ortho-McNeil Pharmaceuticals | 6, 81

Richard S. Keefe, Ph.D. | Eli Lilly and Company; Wyeth-Ayerst Laboratories | 3, 14

Martin B. Keller, M.D. | Wyeth-Ayerst Laboratories | 82

Charles H. Kellner, M.D. | Somatics, Inc. | 14

Justine M. Kent, M.D. | Forest Laboratories, Inc. | 3

Ronald C. Kestler, Ph.D. | Wyeth-Ayerst Laboratories | 82

Steven A. King, M.D. | Eli Lilly and Company | 9

David G. Kingdon, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company | 41

Reidar Kjaer, M.D. | U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals | 50

Herbert D. Kleber, M.D. | Schering Plough Pharma | 57, 62

James H. Kocsis, M.D. | Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc. | 55

Lorrin M. Koran, M.D. | Forest Laboratories, Inc. | 27, 70, 96

Christopher J. Kratochvil, M.D. | Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Shire Ridgewood Pharmaceuticals; Alza Pharmaceuticals; McNeil Pharmaceuticals | 44

John E. Kraus, Jr., M.D. | Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories | 69

XXV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Ranga R. Krishnan, M.D.</td>
<td>Eisai Inc.; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals; Pfizer Inc.; Forest Laboratories, Inc.; Abbott Laboratories; GlaxoSmithKline; Merck &amp; Co., Inc.; Organon Inc.; AHP; Vela; Synaptic</td>
<td>14, 35, 39</td>
</tr>
<tr>
<td>Ziad A. Kronfol, M.D.</td>
<td>GlaxoSmithKline; Merck &amp; Co., Inc.</td>
<td>31</td>
</tr>
<tr>
<td>Robert Kushner, M.D.</td>
<td>Ortho-McNeil Pharmaceuticals</td>
<td>61</td>
</tr>
<tr>
<td>Beny Lafer, M.D.</td>
<td>Eli Lilly and Company</td>
<td>13</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>Cyberonics; Eli Lilly and Company; GlaxoSmithKline; Litebook, Inc.; Lundbeck; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Servier; Merck-Frost</td>
<td>8</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>51, 65</td>
</tr>
<tr>
<td>Arthur L. Lazarus, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>71</td>
</tr>
<tr>
<td>Leslie L. Lenert, M.D.</td>
<td>University of California, San Diego; Janssen Pharmaceutica and Research Foundation</td>
<td>33</td>
</tr>
<tr>
<td>Andrew F. Leuchter, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Pharmacia &amp; Upjohn Company, Inc.; Aspect Medical Systems, Inc.</td>
<td>24, 89</td>
</tr>
<tr>
<td>Alan L. Levenson, M.D.</td>
<td>APA Endorsed Psychiatrists’ Professional Liability Insurance Program</td>
<td>18</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Eli Lilly and Company</td>
<td>33</td>
</tr>
<tr>
<td>Thomas F. Liffick, M.D.</td>
<td>Eli Lilly and Company</td>
<td>3</td>
</tr>
<tr>
<td>Mack Lipkin, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Sarah H. Lisanby, M.D.</td>
<td>MagStim Company; Neuronetics</td>
<td>2, 36</td>
</tr>
<tr>
<td>R. Constantine Lykeotsos, M.D.</td>
<td>Organon Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Subramoniam Madhusoodanan, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; AstraZeneca Pharmaceuticals, Pfizer Inc.</td>
<td>21</td>
</tr>
<tr>
<td>Catherine L. Mancini, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Eli Lilly and Company; Janssen-Ortho, Inc.; Lundbeck; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>22</td>
</tr>
<tr>
<td>Husseini K. Manji, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>11, 13, 35</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>Eli Lilly and Company; Martek Biosciences; Cyberonics; Forest Laboratories, Inc.; Bristol-Myers Squibb; GlaxoWellcomeSmithKline; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>12</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td>14, 35, 79</td>
</tr>
<tr>
<td>John C. Markowitz, M.D.</td>
<td>American Psychiatric Press Inc.; Basic Books; Franco Angeli; Wyeth-Ayerst Laboratories</td>
<td>5, 55</td>
</tr>
<tr>
<td>Laura Marsh, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eisai Inc.; Eli Lilly and Company</td>
<td>51</td>
</tr>
<tr>
<td>Randall D. Marshall, M.D.</td>
<td>GlaxoSmithKline</td>
<td>92</td>
</tr>
<tr>
<td>Prakash S. Massand, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Health Care Technology; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Abbott Laboratories</td>
<td>22, 59, 61, 83</td>
</tr>
<tr>
<td>Matig R. Mavissakalian, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>70</td>
</tr>
<tr>
<td>Christopher J. McDougle, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation.</td>
<td>12</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Stanley</td>
<td>11, 56, 77, 83</td>
</tr>
<tr>
<td>Benton H. McFarland, M.D.</td>
<td>Abbott Laboratories; Wyeth-Ayerst Laboratories; Eli Lilly and Company</td>
<td>88</td>
</tr>
<tr>
<td>Patrick D. McGorry, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Sanofi Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>52</td>
</tr>
<tr>
<td>Hunter L. McQuistion, M.D.</td>
<td>Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation</td>
<td>79</td>
</tr>
<tr>
<td>Herbert Y. Melzter, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Sanofi</td>
<td>12, 59, 72</td>
</tr>
<tr>
<td>Alejandro Y. Mendoza, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>19</td>
</tr>
</tbody>
</table>

XXVI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ricardo P. Mendoza, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>41, 65</td>
</tr>
<tr>
<td>Matthew A. Menza, M.D.</td>
<td>National Institutes of Health; U.S. Pharmaceuticals, Pfizer Inc.; Merck &amp; Co., Inc.; Wyeth-Ayerst Laboratories; Cephalon; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Novartis Pharmaceuticals Corporation; Hoechst Marion Roussel; Bayer Corporation, Pharmaceutical Division</td>
<td>50, 51</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>40</td>
</tr>
<tr>
<td>Ivan W. Miller, Ph.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>6</td>
</tr>
<tr>
<td>Kenneth Maskoff, M.D.</td>
<td>ZiaLogic, Inc.</td>
<td>14</td>
</tr>
<tr>
<td>Shaia Misti, M.D.</td>
<td>GlaxoSmithKline</td>
<td>6, 48</td>
</tr>
<tr>
<td>James E. Mitchell, M.D.</td>
<td>Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>6, 30, 95</td>
</tr>
<tr>
<td>Stuart A. Montgomery, M.D.</td>
<td>Eli Lilly and Company</td>
<td>3</td>
</tr>
<tr>
<td>Robin M. Murray, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; SynthElabo; AstraZeneca Pharmaceuticals</td>
<td>25</td>
</tr>
<tr>
<td>Joseph C. Napoli, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squib; Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>36</td>
</tr>
<tr>
<td>Henry A. Nasrallah, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb</td>
<td>11, 59</td>
</tr>
<tr>
<td>Charles B. Nemerooff, M.D.</td>
<td>Abbott Laboratories; Acadia Pharmaceuticals; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Cephalon Pharmaceuticals; Concept; Cypress Biosciences; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; NARSAD; National Institute of Mental Health; Neurocrine Biosciences; Novartis Pharmaceuticals Corporation; Organon Inc.; Otsuka Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Sanofi Pharmaceuticals, Inc.; Somerset; Vela Pharmaceuticals; Pharmaica-Upjohn; Schering-Plough Corporation; Stanley Foundation/NAMI; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>11, 16, 58</td>
</tr>
<tr>
<td>Ruta M. Nonacs, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>13</td>
</tr>
<tr>
<td>Carol S. North, M.D.</td>
<td>Bristol-Myers Squibb; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>61</td>
</tr>
<tr>
<td>Andrei Novac, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline</td>
<td>66</td>
</tr>
<tr>
<td>Mary B. O'Malley, M.D.</td>
<td>Cephalon</td>
<td>10, 90</td>
</tr>
<tr>
<td>Mark Ofsson, M.D.</td>
<td>Bristol-Myers Squibb, Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>33</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems, Inc.</td>
<td>18, 25, 75, 94</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>58</td>
</tr>
<tr>
<td>Michelle T. Pato, M.D.</td>
<td>Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>29, 36, 55</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company</td>
<td>3, 11</td>
</tr>
<tr>
<td>Roy H. Perlis, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline</td>
<td>9, 44</td>
</tr>
<tr>
<td>Frederick Petty, M.D.</td>
<td>Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Ortho-McNeil Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>31</td>
</tr>
<tr>
<td>Edmond H.T. Pa, M.D.</td>
<td>Eli Lilly and Company</td>
<td>65, 94</td>
</tr>
<tr>
<td>Mark J. Pollack, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>58</td>
</tr>
<tr>
<td>Robert M. Post, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Johnson and Johnson; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; Shire Ridgewood Pharmaceuticals; UCB Pharma</td>
<td>2</td>
</tr>
<tr>
<td>Steven G. Potkin, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>58</td>
</tr>
<tr>
<td>David W. Preven, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>18, 66</td>
</tr>
<tr>
<td>Jefferson B. Prince, M.D.</td>
<td>Alza Pharmaceuticals; CellTech; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Shire Ridgewood Pharmaceuticals</td>
<td>1, 5, 14</td>
</tr>
<tr>
<td>Luis F. Ramirez, M.D.</td>
<td>Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>32, 76</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems</td>
<td>25</td>
</tr>
<tr>
<td>Penny K. Randall, M.D.</td>
<td>United Behavioral Health</td>
<td>47</td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>2, 43, 58</td>
</tr>
<tr>
<td>Steven A. Rasmussen, M.D.</td>
<td>Medtronic</td>
<td>75</td>
</tr>
<tr>
<td>William E. Reichman, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Eisai; Janssen Pharmaceutica and Research Foundation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>62</td>
</tr>
<tr>
<td>Roy O. Resnikoff, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>25, 86</td>
</tr>
</tbody>
</table>

**DISCLOSURE INDEX**

XXVII
## DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>8</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals</td>
<td>9, 59, 77</td>
</tr>
<tr>
<td>Murray Rosenthal, D.O.</td>
<td>Cephalon; Forest Laboratories, Inc.; Organon Inc.</td>
<td>88</td>
</tr>
<tr>
<td>Richard N. Rosenthal, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>31, 57, 97</td>
</tr>
<tr>
<td>Bryan L. Roth, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>59</td>
</tr>
<tr>
<td>Barbara O. Rothbaum, Ph.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Virtually Better</td>
<td>82</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Bristol-Myers Squibb; Cyberonics; Eli Lilly and Company; Forest Laboratories,</td>
<td>6, 11</td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Institute of Mental Health; Robert Wood Johnson Foundation; Stanley</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foundation; Wyeth-Ayerst Laboratories</td>
<td></td>
</tr>
<tr>
<td>J. Michael Ryan, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb</td>
<td>5, 13</td>
</tr>
<tr>
<td>Jeronimo Saiz-Ruiz, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S.</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, Pfizer Inc.</td>
<td></td>
</tr>
<tr>
<td>Floyd R. Salle, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Shire</td>
<td>27, 68, 96</td>
</tr>
<tr>
<td></td>
<td>Ridgewood Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Betty Jo Salmeron, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>61, 83</td>
</tr>
<tr>
<td>Randy A. Sansone, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>76</td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Abbott Laboratories; Aventis; Bristol-Myers Squibb; Concept; Eli Lilly and</td>
<td>6, 10, 73</td>
</tr>
<tr>
<td></td>
<td>Company; Forest Laboratories, Inc.; GlaxoSmithKline; Inapharma; Janssen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organon Inc.; Pharmacy &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somerset Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lan</td>
<td></td>
</tr>
<tr>
<td>Darryle Schoepp, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>77</td>
</tr>
<tr>
<td>S. Charles Schwartz, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Company; AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Michael J. Sennetak, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>92</td>
</tr>
<tr>
<td>Shawn C. Shea, M.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>8, 15</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>Abbott Laboratories; American Medical Association; Ancelote Foundation; AstraZeneca</td>
<td>3, 8</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Boots Pharmaceuticals;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb; Burroughs Wellcome; Charter Hospitals; Ciba Geigy; Dista</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Products Company; Eisai America, Inc.; Eli Lilly and Company; Excerpta Medica</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asia; Forest Laboratories; GlaxoSmithKline; Glaxo Pharmaceuticals; Glaxo-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wellcome; Hospital Corporation of America; Humana; ICI; International Clinical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research; Janssen Pharmaceutical Products, L.P.; Kal-Duphar; Marion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Merrill Dow; McNeil Pharmaceuticals; Mead Johnson; Merck Sharp &amp; Dohme;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Institute of Drug Abuse; National Institute of Health; Organon; Novo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nordisk; Parke-Davis; Pfizer, Inc.; Pharmacia &amp; Upjohn; Rhone-Novartis; Rhone-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poulec Rorer Pharmaceuticals; Roche Laboratories; Roerig; Sandoz Pharmaceuticals;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Schering Corporation; SmithKline Beecham; Solvay Pharmaceuticals; TAP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals; TGH-University Psychiatry Center; The Upjohn Company;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Warner Chilcott; Wyeth-Ayerst Company; Layton Bioscience; Medical Outcomes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>System; U.S. Pharmaceuticals, Pfizer Inc.; Quintiles; Tampa General</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospital-University Psychiatry Center; Warner Chilcott Pharmaceutical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Company; Worldwide Clinical Trials</td>
<td></td>
</tr>
<tr>
<td>Bruce Singh, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>86</td>
</tr>
<tr>
<td>Samuel G. Stres, M.D.</td>
<td>Eli Lilly and Company; Merck &amp; Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>56, 75, 85</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.</td>
<td>81</td>
</tr>
<tr>
<td>Shamshah B. Seeawalla, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>28, 59</td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>Abbott Laboratories; Alza Pharmaceuticals; Boston Life Sciences, Inc.; Bristol</td>
<td>44, 56, 61, 83</td>
</tr>
<tr>
<td></td>
<td>Myers Squibb; Cephalon; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gliatetch Inc.; Medeva Pharmaceuticals, Inc.; Novartis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgewood Pharmaceuticals;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td></td>
</tr>
<tr>
<td>Deborah Spitz, M.D.</td>
<td>Janssen-Cilag</td>
<td>26, 54, 73</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bayer Corporation,</td>
<td>2, 36</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Division; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lilly and Company; Fabre Kramer; Forest Laboratories, Inc.; Glaxo-Wellcome;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceutica and Research Foundation; Lofex; Lundbeck; Neurocrine;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals Corporation; Organon Inc.; Parke-Davis, Division of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacy &amp; Upjohn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Company, Inc.; Pierre Fabre; Roche Laboratories, a member of the Roche Group;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi; Sanofi Pharmaceuticals, Inc.; Searle; SmithKline Beecham Pharmaceuticals;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solvay Pharmaceuticals, Inc.; Sumitomo; Takeda Pharmaceuticals; Watson Laboratories, Inc; Watson Laboratories, Inc; Wyeth-Ayerst Laboratories; Yamanoichi</td>
<td></td>
</tr>
</tbody>
</table>
Jane B. Tornatore, Ph.D.
Alan C. Swann, M.D.
T. Scott Stroup, M.D.
Nada L. Stotland, M.D.
Donna E. Stewart, M.D.
Hans Steiner, M.D.
Murray B. Stein, M.D.
Mark A. Stein, Ph.D.
Rajiv Tandon, M.D.
Norman Sussman, M.D.
Patricia Suppes, M.D.
Stephen M. Strakowski, M.D.
Michael E. Thase, M.D.
Pierre N. Tariot, M.D.
Marijo B. Tamburrino, M.D.
Charlene M. Stubbs, Ph.D.
Adele C. Viguera, M.D.
Vilma Torres, M.S.W.
Timothy E. Wilens, M.D.
Richard H. Weisler, M.D.
Peter J. Weiden, M.D.
B.Timothy Walsh, M.D.
Werner Tschan, M.D.
Daniel Toledo, M.D.
Mauricio F. Tohen, M.D.
Rajiv Tandon, M.D.
AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.

Manufacturer(s)
McNeil Pharmaceuticals
Janssen Pharmaceuticals and Research Foundation; Forest Laboratories, Inc.
Abbott Laboratories; AstraZeneca Pharmaceuticals; Janssen Pharmaceutical and Research Foundation
Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories
GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.
Janssen Pharmaceutical and Research Foundation; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company
Bristol-Myers Squibb
Takeda Pharmaceuticals
Bristol-Myers Squibb
McNeil Pharmaceuticals
Ortho-McNeil Pharmaceuticals
AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.
Abbott Laboratories; Janssen Pharmaceutical and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.
Bristol-Myers Squibb, Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia & Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories
Eli Lilly and Company
Janssen Pharmaceutical and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Wyeth-Ayerst Laboratories
Screen Inc.
Safe Horizons; Families of Homicide Victims Program
Professional Risk Management Services, Inc.
GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.
AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories
Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical and Research Foundation; Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories
AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen-Cilag; U.S. Pharmaceuticals, Novartis Pharmaceuticals Corporation; Pfizer Inc.
GlaxoSmithKline; Forest Laboratories, Inc.
Eli Lilly and Company; Forest Laboratories, Inc.; Ortho-McNeil Pharmaceuticals
AstraZeneca Pharmaceuticals; Bristol-Myers Squibb
Merck & Co., Inc.
Mecta Corporation
Abbott Laboratories; AstraZeneca Pharmaceuticals; Biovalis; Bristol-Myers Squibb; Eisai Inc.; Cephalon; GlaxoSmithKline; Janssen Pharmaceutical and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Schering-Plough Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Syaptic Pharmaceutical Inc.; TAP Pharmaceuticals; UCB Pharma, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories
MHS
Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; McNeil Pharmaceuticals; National Institute on Drug Abuse; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgewood Pharmaceuticals; SmithKline Beecham Pharmaceuticals; GlaxoSmithKline; Celltech Mediava
Ortho-McNeil Pharmaceuticals
Drug Abuse Sciences; Schering-Plough; SmithKline Beecham Pharmaceuticals
GlaxoSmithKline; Wyeth-Ayerst Laboratories
## DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Williams, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmacutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Daniel R. Wilson, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Elan; GlaxoSmithKline; Janssen Pharmacutica and Research Foundation; SAMHSA; State of Nebraska; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>56, 63</td>
</tr>
<tr>
<td>Katherine Wilson, Ph.D.</td>
<td>Gender Identity Center of Colorado, Inc.</td>
<td>32</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Cephalon; Eli Lilly and Company; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>10, 48, 93</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; CoCensys; Dista Products, division of Eli Lilly Company; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Roerig Division, Pfizer, Inc.; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; The Upjohn Company (with Solvay); Wyeth-Ayerst Laboratories</td>
<td>28, 72</td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>89</td>
</tr>
<tr>
<td>Janet Wozniak, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>12, 80</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly Company; Mindstreet; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
<td>8, 17, 37, 65, 91</td>
</tr>
<tr>
<td>Pamela J. Weight-Etter, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>71</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Eli Lilly and Company; Otho-McNeil</td>
<td>6, 18, 30, 58</td>
</tr>
<tr>
<td>Lakshmi N. Yatham, M.B.</td>
<td>Astra/Merck Group, Division of Merck &amp; Co.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation</td>
<td>3</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>GlaxoSmithKline</td>
<td>6</td>
</tr>
<tr>
<td>L. Trevor Young, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline</td>
<td>81</td>
</tr>
<tr>
<td>Christoffel J. Yzermans, Ph.D.</td>
<td>Netherlands Institute for Health Services Research; Nivel</td>
<td>89</td>
</tr>
<tr>
<td>Mary C. Zanarini, Ed.D.</td>
<td>Eli Lilly and Company</td>
<td>21, 27, 78</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>31, 52</td>
</tr>
</tbody>
</table>

### DISCLOSURE INDEX

The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:

- William Arroyo, M.D. 89
- Gregory L. Barker 41
- Guido Bellasso, M.D. 89
- Joseph Biederman, M.D. 44, 56, 61, 78, 80, 83
- Eric G. Bing, M.D. 94
- Herve Bokobza, M.D. 59
- Charles L. Bowden, M.D. 2, 58, 74
- Gary Cobb 80
- Rachelle S. Doody, M.D. 41, 81
- James M. Ellison, M.D. 93
- Marvin Frazier 80
- Amarsingh M. Ghorpade, M.D. 48
- Jodi Goldstein, J.D. 76
- Norma Hatot 77
- Ruben J. Hernandez-Serrano, M.D. 84
- Dilip V. Jeste, M.D. 49, 70
- Samuel J. Keith, M.D. 33
- Michael J. Kittay, M.D. 90
- Louis J. Kraus, M.D. 89
- Earl C. Lawrence, M.A. 41
- Anton J.M. Loonen, M.D. 84
- Alexander MacLean, M.D. 59
- Cesure Maffei, M.D. 31
- Jacobo E. Manzer, M.D. 41, 62
- Dominique L. Musselman, M.D. 11
- David Shannahoff-Khalsa, B.S. 75
- Michael W. Smith, M.D. 15, 91
- Eric C. Strain, M.D. 62
- David L. Sulzer, M.D. 62
- James M. Swanson, M.D. 45
- Faris Tuma, Sc.D. 71
- John W. Tsuang, M.D. 5, 41
- Douglas Turkington, M.B. 41, 59
- Paul Volberding, M.D. 77
- Mike Ward 41
- Elizabeth B. Weller, M.D. 43, 72
- Wendy Williams 80
- Lishan Wockenhut, M.D. 42
- Lawson R. Watson, M.D. 45

XXX
8:00 a.m. Sessions

COURSES 1-4
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room 112, Exhibit Level, Moscone Center
ADD IN CHILDREN AND ADOLESCENTS
Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 2 8:00 a.m.-12 noon
Room 114, Exhibit Level, Moscone Center
EXTENDED COMMUNITY TREATMENT OF PATIENTS WITH BORDERLINE PERSONALITY DISORDER
Director: Lawrence L. Kennedy, M.D.

COURSE 3 8:00 a.m.-12 noon
Room 123, Exhibit Level, Moscone Center
Director: Leonardo Cortese, M.D.
Faculty: Michael Caligiuri, Ph.D., Richard Williams, M.D.

COURSE 4 8:00 a.m.-12 noon
Room 124, Exhibit Level, Moscone Center
DETERMINING MEDICAL FITNESS TO DRIVE: RELEVANT ISSUES FOR PSYCHIATRISTS
Director: Ian A. Gillespie, M.D.

9:00 a.m. Sessions

COURSES 5-8
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 5 9:00 a.m.-4:00 p.m.
Room 110, Exhibit Level, Moscone Center
INTEGRATED TREATMENT OF EATING DISORDERS
Co-Directors: Mae S. Sokol, M.D., Kathryn J. Zerbe, M.D.
Faculty: Kristina Hoffman-Rieken, R.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room 111, Exhibit Level, Moscone Center
DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT
Director: James F. Masterson, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.
Room 120, Exhibit Level, Moscone Center
INTERPERSONAL PSYCHOTHERAPY
Director: Scott P. Stuart, M.D.
Faculty: Michael W. O'Hara, Ph.D., Michael Robertson, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-3

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center
SCHIZOPHRENIA TREATMENT IN THE COMMUNITY: THE ROLE OF LONG-ACTING ANTI PSYCHOTICS
Chp.: John M. Kane, M.D.
A Key Issues in Long-Term Pharmacotherapy of Schizophrenia
William T. Carpenter, Jr., M.D.
B The Latest Advance in Long-Acting Antipsychotic Therapy
John M. Kane, M.D.
C Translating From Clinical Trials to Community Care for Patients With Schizophrenia
Jacqueline M. Feldman, M.D.
D Overcoming Obstacles to Patient Acceptance of Long-Acting Antipsychotics
David C. Henderson, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 2
12:30 p.m.-3:30 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

BIPOLAR DISORDER: STRATEGIES FOR STABILIZING PATIENTS OVER THE LONG TERM
Supported by GlaxoSmithKline

Chp.: Joseph R. Calabrese, M.D.

A New Results From the Stanley Bipolar Treatment Network
Robert M. Post, M.D.

B Update on Anticonvulsants for Bipolar Disorders
Charles L. Bowden, M.D.

C Practical Strategies to Avoid Medication-Induced Mood Destabilization in Bipolar Patients
Carlos M. Zarate, Jr., M.D.

D Psychosocial Strategies to Promote Stabilization and Enhance Coping in Patients With Bipolar Disorder
David J. Miklowitz, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3
12:30 p.m.-3:30 p.m.
Salon 9, Lower B-2 Level, Marriott

ANXIETY DISORDERS: SOURCES, SIGNS, AND SOLUTIONS
Supported by Forest Laboratories, Inc.

Chp.: Jonathan R.T. Davidson, M.D.

A Examining Anxiety's Underpinnings
Christine Heim, Ph.D.

B Anxious Body, Anxious Self, Anxious Psychiatrists
Mack Lipkin, M.D.

C Facing Up to Social Anxiety Disorder
Murray B. Stein, M.D.

D Generalized Anxiety Disorder: Beneath the Surface
Jonathan R.T. Davidson, M.D.

E The Neurobiology of Panic Disorder and OCD
Stephen M. Stahl, M.D.

1:00 p.m. Sessions

COURSES 9-12
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 9 1:00 p.m.-5:00 p.m.
Room 112, Exhibit Level, Moscone Center

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.
Faculty: Ehud M. Klein, M.D., Sarah H. Lisanby, M.D.

COURSE 10 1:00 p.m.-5:00 p.m.
Room 114, Exhibit Level, Moscone Center

GROUP THERAPY FOR PEOPLE WITH CHRONIC MENTAL ILLNESS

Director: Walter N. Stone, M.D.

COURSE 11 1:00 p.m.-5:00 p.m.
Room 121, Exhibit Level, Moscone Center

NEUROENDOCRINOLOGY IN MOOD DISORDERS: DYSREGULATION AND TREATMENT

Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.
Faculty: D. Jeffrey Newport, M.D.

COURSE 12 1:00 p.m.-5:00 p.m.
Room 124, Exhibit Level, Moscone Center

DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 4-8

INDUSTRY-SUPPORTED SYMPOSIUM 4
6:00 p.m.-9:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

NEW STRATEGIES FOR MANAGING BIPOLAR DISORDER
Supported by Janssen Pharmacuetica

Chp.: S. Nassir Ghaemi, M.D.
A Clinical Management of Bipolar Patients: A Difficult Task
Dwight L. Evans, M.D.

B Rational Polypharmacy in the Treatment of Patients With Bipolar Disorder
S. Nassir Ghaemi, M.D.

C Emerging Treatment for Bipolar Disorder: A New Role for Atypical Antipsychotics
Lakshmi N. Yatham, M.B.

D Complexities in the Treatment of Juvenile Bipolar Disorder
Robert L. Findling, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
6:00 p.m.-9:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

GENETICS AND PSYCHIATRY: REAL GENES, REAL PROGRESS
Supported by AstraZeneca Pharmaceuticals

Chp.: Daniel R. Weinberger, M.D.
A Genetic Engineering in Animals: New Insights About Anxiety and Antidepressants
Rene Hen, Ph.D.

B Recent Advances in Statistical and Gene-Finding Methods in Psychiatric Genetics
Richard Straub, Ph.D.

C Gene and Protein Expression in Brain: It Depends on Inheritance
Joel E. Kleinman, M.D.

D Rethinking the Concept of Phenotype in Psychiatry
Robert Freedman, M.D.

E Invivo Approaches to Identifying Genetic Mechanisms of Susceptibility
Daniel R. Weinberger, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
6:00 p.m.-9:00 p.m.
Continental Ballroom, Ballroom Level, Hilton

BEYOND BENZODIAZEPINES: NEW MOLECULES FOR THE TREATMENT OF ANXIETY
Supported by Pfizer Inc.

Chp.: Jack M. Gorman, M.D.
A Childhood Anxiety Disorders: Does Treatment Affect Long-Term Outcome?
Moira A. Rynn, M.D., Sarosh Khalid-Khan, M.D.

B The Burden of Anxiety Disorders
David V. Sheehan, M.D.

C Treatment for Generalized Anxiety Disorder: Current and Near Term
Stuart A. Montgomery, M.D.

D Future Directions: New Molecular Targets for the Treatment of Anxiety
Jack M. Gorman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7
6:00 p.m.-9:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

ENHANCING OUTCOMES BY ADDRESSING CRITICAL CHALLENGES IN THE TREATMENT OF SCHIZOPHRENIA
Supported by Eli Lilly and Company

Chp.: Diana O. Perkins, M.D.
A Schizophrenia: New Understandings of the Early Stage of Illness
Diana O. Perkins, M.D.

B Improving Cognition for Quality Outcomes
Richard S. Keefe, Ph.D.

C Treatment Challenges for the Patient With Acute Agitation
Leslie L. Citrome, M.D.

D Metabolic Issues With Antipsychotic Therapy
John B. Buse, M.D.

E Maintenance Strategies: Balancing Efficacy and Safety to Prevent Relapse
Thomas F. Liffick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8
6:00 p.m.-9:00 p.m.
Salon 9, Lower B-2 Level, Marriott

OPTIMIZING EFFICACY AND TOLERABILITY OF ANTIDEPRESSANT THERAPY: DOES SELECTIVITY OF ACTION MATTER?
Supported by Forest Laboratories, Inc.

Chp.: Michael E. Thase, M.D.
A The Alphabet Soup of Antidepressant Pharmacology: From TCA's and MAOI's to SSRI's, SNRI's, and Beyond
Pedro L. Delgado, M.D.

B Efficacy of Newer Antidepressants
Michael E. Thase, M.D.

C SSRI's and Beyond: Spectrum of Efficacy of Newer Antidepressants
Justine M. Kent, M.D.

D Generally Well Tolerated: Comparative Adverse-Event Profiles of Newer Antidepressants
Andrew A. Nierenberg, M.D.
American Psychiatric Association

Audiotapes
Recorded Live!

High Quality Continues for the 2003 Annual Meeting ...

Live recordings will be available for most of the following:

- Lectures • Advances in Psychotherapy • Advances in Research
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Moscone Center

Mobiltape Company, Incorporated
24730 Avenue Tibbits, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 • (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
SUNDAY, MAY 18, 2003

156TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 13-20
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 13 8:00 a.m.-12 noon
Franciscan Room B, Ballroom Level, Hilton

PSYCHIATRIC CONSULTATIONS IN MEDICAL SETTINGS: THE BASICS
Director: Richard L. Elliott, M.D.

COURSE 14 8:00 a.m.-12 noon
Franciscan Room D, Ballroom Level, Hilton

INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowitz, M.D.

COURSE 15 8:00 a.m.-12 noon
Imperial Ballroom A, Ballroom Level, Hilton

RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 16 8:00 a.m.-12 noon
Imperial Ballroom B, Ballroom Level, Hilton

ADD IN ADULTS
Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 17 8:00 a.m.-12 noon
Yosemite Room B, Ballroom Level, Hilton

PSYCHIATRIC DISORDERS RELATED TO EPILEPSY
Director: Dietrich P. Blumer, M.D.
Faculty: John Barry, M.D., Robert S. Fisher, M.D.

COURSE 19 8:00 a.m.-12 noon
Union Square 15 & 16, Fourth Floor, Hilton

CONTEMPORARY MALPRACTICE LIABILITY: A PRACTICAL GUIDE
Co-Directors: Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Richard G. Hersh, M.D., Jacqueline M. Melonas, J.D.

COURSE 20 8:00 a.m.-12 noon
Union Square 23 & 24, Fourth Floor, Hilton

ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT
Director: John W. Tsuang, M.D.
Faculty: Andrew P. Ho, M.D., Thomas Newton, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 9-13

INDUSTRY-SUPPORTED SYMPOSIUM 9
8:00 a.m.-11:00 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

DIAGNOSIS AND TREATMENT: MOOD STABILIZERS ACROSS THE PSYCHIATRIC SPECTRUM
Supported by Abbott Laboratories
Chp.: Carol A. Tamminga, M.D.

A A Systematic Approach to the Treatment of Impulsivity
Alan C. Swann, M.D.

B The Role of Mood Stabilizers in the Management of Agitation in Dementia
J. Michael Ryan, M.D.

C Efficacy of Treatment With Mood Stabilizers in Acute Schizophrenia
Carol A. Tamminga, M.D.

D Comorbidities and Treatment Issues in Substance Use Disorders
Hugh Myrick, M.D.

E Affective Instability and Impulsive Aggression in Cluster B and Developmental Disorders
Eric Hollander, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 10
8:00 a.m.-11:00 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

MOODS, CYCLES, AND MOTHERHOOD
Supported by GlaxoSmithKline

Chp.: Shaila Misri, M.D.

A Depression in Pregnancy and Lactation: Making Informed Decisions to Protect the Mother and Infant
Zachary N. Stowe, M.D., D. Jeffrey Newport, M.D.

B Mothers, Babies, and Children: Mental Health in the Postpartum and Beyond
Shaila Misri, M.D.

C Pharmacological Treatment of Premenstrual Dysphoria: What Is Sufficient?
Kimberly A. Yonkers, M.D.

D Is It Just Me or Is It Hot in Here? What Every Psychiatrist Should Know About Menopause
C. Neill Epperson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
8:00 a.m.-11:00 a.m.
Continental Ballroom, Ballroom Level, Hilton

ENHANCING SKILL TREATING COMORBID DEPRESSION AND NEUROLOGICAL ILLNESS
Supported by Organon Inc.

Chp.: Steven L. Dubovsky, M.D.

A Depression in Neurological Disorders
Gary J. Tucker, M.D.

B Depression in Dementing Disorders
Jeffrey L. Cummings, M.D.

C Depression Following Traumatic Brain Injury
David B. Arciniega, M.D.

D Treatment of Depression in Patients With Life-Threatening and Terminal Illness
Norman Sussman, M.D.

E Targeting Antidepressant Therapy to Medical Comorbidity
Steven L. Dubovsky, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Salons 7 & 8, Lower B-2 Level, Marriott

AN INTEGRATED APPROACH TO THE MANAGEMENT OF BIPOLAR DISORDER: AN ALLIANCE OF SCIENCE AND MEDICINE
Supported by Eli Lilly and Company

Chp.: Robert M.A. Hirschfeld, M.D.

A The Role of Genetics in Bipolar Disease
Wade H. Berrettini, M.D.

B The Importance of Mood Stabilization in the Treatment of Mania
John Cookson, M.B.

C Bipolar Depression and Substance Abuse: Which Is the Driving Force?
Joseph F. Goldberg, M.D.

D A Disease Management Strategy for Bipolar Disorder
Ellen Frank, Ph.D., David J. Kupfer, M.D., Holly A. Swartz, M.D., Andrea Fagiolini, M.D.

E Optimizing Treatment to Prevent Relapse
Paul E. Keck, Jr., M.D.

Discussant: Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
8:00 a.m.-11:00 a.m.
Salon 9, Lower B-2 Level, Marriott

REMISSION IN PSYCHIATRIC DISORDERS: DEFINITIONS, ISSUES, AND TREATMENTS
Supported by Wyeth Pharmaceuticals

Chp.: Alan J. Gelenberg, M.D.

A Psychosocial Functioning in Depression
Ivan W. Miller, Ph.D.

B Remission in Major Depression: A Frequently Illusive Goal
Alan F. Schatzberg, M.D.

C Response and Remission in GAD
Alan J. Gelenberg, M.D.

D Remission in Bipolar Disorder Across the Life Span
Kiki D. Chang, M.D.

E Response and Remission in Depression: The ACNP Consensus Report
A. John Rush, M.D.

9:00 a.m. Sessions

COURSES 21-27
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 21 9:00 a.m.-4:00 p.m.
Yosemite Room A, Ballroom Level, Hilton

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.
Faculty: Katherine A. Halmi, M.D., James E. Mitchell, M.D., Denise E. Wilfley, Ph.D., Joel Yager, M.D.
SUNDAY

COURSE 22  9:00 a.m.-4:00 p.m.
Yosemite Room C, Ballroom Level, Hilton

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY II: CARE MANAGEMENT, LAW, AND ETHICS
American Association of Psychiatric Administrators

Co-Directors: Christopher G. Fichtner, M.D., Wesley Sowers, M.D.
Faculty: Stephen H. Dinwiddie, M.D., H. Steven Moffic, M.D.,
John A. Talbott, M.D., William G. Wood, M.D.

COURSE 23  9:00 a.m.-4:00 p.m.
Union Square 1 & 2, Fourth Floor, Hilton

MEDICAL ETHICS 101

Director: Edmund G. Howe, M.D.

COURSE 24  9:00 a.m.-4:00 p.m.
Union Square 5 & 6, Fourth Floor, Hilton

BUILD YOUR OWN RELATIONAL DATABASE ELECTRONIC MEDICAL RECORD

Director: Daniel A. Deutschman, M.D.
Faculty: Joshua E. Freedman, M.D., John S. Lloyd, Ph.D.,
Seth M. Powsner, M.D., Terence L. Witham, M.D.

COURSE 25  9:00 a.m.-4:00 p.m.
Union Square 17 & 18, Fourth Floor, Hilton

CLINICAL APPLICATIONS AND RESEARCH IN TRANSPERSONAL PSYCHIATRY

Co-Directors: Bruce W. Scotton, M.D., Allan B. Chinen, M.D.
Faculty: John R. Battuta, M.D., William W. Foote, M.D.,
John F. Hiatt, M.D., Francis G. Lu, M.D., Lewis Mehl-Madrona, M.D., Bruce S. Victor, M.D., Roger N. Walsh, M.D.,
Seymore Borstein, M.D.

COURSE 26  9:00 a.m.-4:00 p.m.
Union Square 19 & 20, Fourth Floor, Hilton

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director: James Q. Schubmehl, M.D.
Faculty: Alan R. Beeber, M.D., Tewfik Said, M.D.

COURSE 27  9:00 a.m.-4:00 p.m.
Union Square 25, Fourth Floor, Hilton

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only*)
12:30 p.m.-1:30 p.m.
Room 301, Esplanade Level, Moscone Center

CALL TO ORDER
Paul S. Appelbaum, M.D., President

MEMORIAL TO DECEASED MEMBERS
ANNOUNCEMENT OF ELECTION RESULTS

Glenn H. Miller, M.D., Chairperson,
Committee of Tellers

REPORTS TO THE MEMBERSHIP

Secretary: Pedro Ruiz, M.D.
Treasurer: Carol A. Bernstein, M.D.
Speaker, Assembly: Albert C. Gau, M.D.
Speaker, Membership Committee: Prakash N. Desai, M.D.
Chairperson, By-Laws Committee:
Chairperson, Elections Committee:
Yvonne B. Ferguson, M.D.
Chairperson, Membership Committee:
Bernard A. Katz, M.D.
Medical Director: James H. Scully, Jr., M.D.

ANNUAL FORUM
ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 28-34
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 28  1:00 p.m.-5:00 p.m.
Imperial Ballroom B, Ballroom Level, Hilton

ORGANIZATIONAL AND GROUP INTERVENTIONS FOLLOWING DISASTERS

Director: John S. Kennedy, M.D.
COURSE 29 1:00 p.m.-5:00 p.m.
Yosemite Room B, Ballroom Level, Hilton

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Director: Jesse H. Wright, M.D.
Faculty: Aaron T. Beck, M.D., Jan L. Scott, M.D.

COURSE 30 1:00 p.m.-5:00 p.m.
Union Square 13, Fourth Floor, Hilton

TREATMENT ISSUES FOR WOMEN IN MINORITY GROUPS

Director: Susan R. Downs, M.D.
Faculty: Ellen Haller, M.D., Sylvia W. Olarte, M.D., Gloria Pitts, D.O., Alice C. Tso, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.
Union Square 14, Fourth Floor, Hilton

IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE

Director: Lois E. Krahn, M.D.
Faculty: Steven I. Altchuler, M.D., Mark R. Hansen, M.D., Jarrett W. Richardson, M.D.

COURSE 32 1:00 p.m.-5:00 p.m.
Union Square 15 & 16, Fourth Floor, Hilton

COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW (CADI)

Co-Directors: Paul R. Miller, M.D., Charles Chiu, M.D.
Faculty: Margaret Nazarey, M.S.N.

COURSE 33 1:00 p.m.-5:00 p.m.
Union Square 21, Fourth Floor, Hilton

INTEGRATIVE PSYCHOTHERAPY SUPERVISION: BASIC TOOLS

Director: Paul Rodenhauser, M.D.
Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

COURSE 34 1:00 p.m.-5:00 p.m.
Union Square 23 & 24, Fourth Floor, Hilton

EVIDENCE-BASED MANAGEMENT OF SAD: FOCUS ON LIGHT THERAPY

Co-Directors: Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 14-20

INDUSTRY-SUPPORTED SYMPOSIUM 14
1:30 p.m.-4:30 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

BARRIERS TO OPTIMAL OUTCOME IN ANXIETY AND DEPRESSION
Supported by GlaxoSmithKline

Chp.: David V. Sheehan, M.D.

A From Medication Noncompliance to Medication Interest: The Art of Discussing Medications With Patients
Shawn C. Shea, M.D.

B Controlled-Release Antidepressant Formulations: Advantages and Limitations
David V. Sheehan, M.D.

C An Evidence-Based Approach to Clinical Trials in Anxiety and Depression
Flavio Kapczinski, Ph.D.

D Case-Based Approach to Optimal Outcome in Depression and Anxiety
Lori Calabrese, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
1:30 p.m.-4:30 p.m.
Metropolitan, Second Level, Argent

NEW CHALLENGES IN THE MANAGEMENT OF DEPRESSION
Supported by Forest Laboratories, Inc.

Chp.: Karen D. Wagner, M.D.

A Solving the Conundrum of Childhood Depression
Karen D. Wagner, M.D.

B Achieving Rapid-Onset of Action and Remission in Depressed Adults
Robert M.A. Hirschfeld, M.D.

C Tickling the Brain: Advances in Antidepressant Brain Stimulation Techniques
Mark S. George, M.D.

D Enhancing Collaboration Between the Primary Care Physician and the Psychiatrist
Larry Culpepper, M.D.

E Maintaining Quality of Life in the Elderly
Steven P. Roose, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

ISSUES IN TREATING MANIA: ACUTE AND CONTINUATION PHASE
Supported by AstraZeneca Pharmaceuticals

Chp.: Michael H. Allen, M.D.
Co-Chp.: Gary S. Sachs, M.D.

A Managing Acute Mania in the Emergency Room
Michael H. Allen, M.D.

B Pharmacological Options for the Treatment of Pediatric Mania
Melissa P. DeBello, M.D.

C Approaches to the Treatment of Mania
Roy H. Perlis, M.D.

D Family Intervention and Pharmacotherapy in the Post-Episode Phase of Bipolar Disorder
David J. Miklowitz, Ph.D., Jeffery Richards, Elizabeth George

E Identifying Suicidal Behavioral and At-Risk Patients
Gary S. Sachs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
1:30 p.m.-4:30 p.m.
Continental Ballroom, Ballroom Level, Hilton

TRICKS OF THE TRADE IN THE LONG-TERM TREATMENT OF DEPRESSION
Supported by Organon Inc.

Chp.: Anita L.H. Clayton, M.D.
Co-Chp.: Maurizio Fava, M.D.

A Clinical Management of Psychiatric Comorbidities
R. Bruce Lydiard, M.D.

B Sexual Dysfunction in Depression
Anita L.H. Clayton, M.D.

C Sleep Changes During Long-Term Treatment With Antidepressants
Maurizio Fava, M.D.

D Antidepressant-Induced Cognitive Changes and Apathy: Are There any Antidotes?
Jerrold F. Rosenbaum, M.D.

E Practical Approaches to Antidepressant-Induced Weight Gain
David L. Ginsberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m.-4:30 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

PHARMACOLOGICAL TREATMENT OF CHRONIC PAIN: COMORBIDITY WITH DEPRESSION AND OTHER PSYCHOTIC DISORDERS
Supported by Eli Lilly and Company

Chp.: David Fishbain, M.D.

A Psychiatric and Other Comorbidities Associated With Chronic Pain
David Fishbain, M.D.

B The Neurobiology of Pain
Edward C. Covington, Jr., M.D.

C Adjuvants as Analgesics: Mechanism-Based Pharmacotherapy in Pain Medicine
Rollin Gallagher, M.D.

D Depression With Painful Physical Symptoms: Treatment With 5HT/Norepinephrine Antidepressants
Michael J. Detke, M.D.

E The Use of Opioid Analgesics for Chronic Pain: Controversies and Challenges
Steven A. King, M.D.

F Adjuvant Analgesics: Efficacy Evidence for the Treatment of Neuropathic Pain
David Fishbain, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Salon 9, Lower B-2 Level, Marriott

STRESS, PSYCHOPATHOLOGY, AND THE BRAIN: NOVEL INTERVENTION STRATEGIES
Supported by Wyeth Pharmaceuticals

Chp.: Ned H. Kalin, M.D.

A Overview of the Relationship Between Stress, Depression, and Anxiety
Christine Heim, Ph.D.

B The Potential for Gene Therapy in the Treatment of Stress and Related Disorders
Robert Sapolsky, Ph.D.

C The Biology of Stress and Vulnerability
Michael Meaney, Ph.D.

D Novel Pharmacological Strategies to Treat Stress-Related Psychopathology and Medical Illnesses
Ned H. Kalin, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 20
1:30 p.m.-4:30 p.m.
Grand Ballroom, Mezzanine Level, Westin St. Francis

DEPRESSION, APATHY, AND FATIGUE IN NEUROPSYCHIATRIC DISORDERS
Supported by Cephalon Inc.

Chp.: John W. Winkelman, M.D.

A Disorders of Motivation: The Third Domain of Psychopathology
Robert S. Marin, M.D.

B Fatigue and Depression in Cancer and AIDS
William Breitbart, M.D.

C Apathy in Neuropsychiatric Disorders
Jeffrey L. Cummings, M.D.

D Depression, Fatigue, and Excessive Daytime Sleepiness in Sleep Disorders
Mary B. O'Malley, M.D.

E Apathy in Schizophrenia
Donald C. Goff, M.D.

2:30 p.m. Session

LECTURE 1
2:30 p.m.-4:00 p.m.
Rooms 130/131, Exhibit Level, Moscone Center

AAPL/APA'S MANFRED S. GUTTMACHER AWARD LECTURE
Diane H. Schetky, M.D. and Elissa P. Benedek, M.D.

Expert Testimony in the Age of Daubert
Chp.: Deborah Spitz, M.D.

Clinical and legal issues in the psychiatric treatment of children and adolescents will be discussed by Diane H Schetky, M.D., coeditor with Elissa P. Benedek, M.D., of Principles and Practice of Child and Adolescent Forensic Psychiatry, for which they have received the 2003 Manfred S. Guttmacher Award for outstanding contribution to the literature of forensic psychiatry. Dr. Schetky is Clinical Associate Professor of Psychiatry at the University of Vermont College of Medicine at Maine Medical Center in Portland, Maine, and is in the private practice of psychiatry in Rockport, Maine. She has written numerous scientific papers and book chapters in the areas of child psychiatry and forensic psychiatry, is the author or editor of six books, and writes a bimonthly ethics column for American Academy of Child and Adolescent Psychiatry News. A Distinguished Life Fellow of the American Psychiatric Association, Dr. Schetky is a member of the APA Council on Psychiatry and Law and has been a member of APA task forces on clinical assessment in child custody and confidentiality of records in child custody disputes. Dr. Schetky received her medical degree from Case Western Reserve University School of Medicine in Cincinnati and completed her residency in psychiatry and a fellowship in child psychiatry at the University Hospitals in Cleveland.

THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION
5:00 p.m.-6:30 p.m.
Hall E, Exhibit Level, Moscone Center

CALL TO ORDER
Paul S. Appelbaum, M.D.
President

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSON OF THE SCIENTIFIC PROGRAM COMMITTEE
Geetha Jayaram, M.D.
Chairperson, Annual Meeting Scientific Program Committee

INTRODUCTION OF VISITING DIGNITARIES

PRESIDENTIAL ADDRESS
Paul S. Appelbaum, M.D.
To be introduced by Loren H. Roth, M.D.

RESPONSE OF THE PRESIDENT-ELECT
Marcia K. Goin, M.D.
To be introduced by Sherwyn M. Woods, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 21-27

INDUSTRY-SUPPORTED SYMPOSIUM 21
7:00 p.m.-10:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

PEPTIDES AND HORMONES AS TARGETS IN ANTIDEPRESSANT TREATMENT
Supported by Merck & Co., Inc.

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Ned H. Kalin, M.D.
A Development of a PET Tracer for Clinical Trials of Substance P Antagonists
Richard Hargreaves, Ph.D.

B Recent Studies on Substance P Antagonists
A. John Rush, M.D.

C The Therapeutic Potential of Corticotrophin-Releasing Factor Antagonists
Ned H. Kalin, M.D.

D Estrogen and Mood
Elizabeth A. Young, M.D.

E The Role of Antiglucocorticoid Agents in the Treatment of Major Depression
Charles DeBattista, M.D.

Discussant: Ned H. Kalin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m.-10:00 p.m.
Metropolitan, Second Level, Argent

A COMPREHENSIVE APPROACH TO MANAGING BIPOLAR DISORDER: BENCH TO BEDSIDE AND BEYOND
Supported by Ortho-McNeil Pharmaceuticals

Chp.: Gary S. Sachs, M.D.

A Neuroplasticity and Cellular Resilience in Bipolar Disorder
Husseini K. Manji, M.D., Gregory J. Moore, Ph.D., Grazyna Rajkowska, Ph.D., Guang Chen, Ph.D.

B The Treatment of Acute Mania
Mark A. Frye, M.D.

C Treatment of Bipolar Disorder With Comorbid Psychiatric or Medical Disorders
Susan L. McElroy, M.D.

D Management of Suicide Prevention in Bipolar Disorder Patients
Maria A. Oquendo, M.D., Michael F. Grunebaum, M.D., David J. Printz, M.D., Leo Sher, M.D., J. John Mann, M.D.

E Psychotherapy for Bipolar Disorder?
Ellen Frank, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
7:00 p.m.-10:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

A RATIONAL ALGORITHM FOR SELECTING ATYPICALS IN SCHIZOPHRENIA AND BIPOLAR DISORDERS
Supported by AstraZeneca Pharmaceuticals

Chp.: Henry A. Nasrallah, M.D.

A Efficacy of Atypical Antipsychotics: How Do They Compare?
Rajiv Tandon, M.D.

B Minimizing Specific Medical Problems by Customizing Antipsychotic Selection
Henry A. Nasrallah, M.D.

C Serious Medical Morbidity and Atypical: Defining and Avoiding Thresholds of Risk
Diana O. Perkins, M.D.

D Bipolar Disorders and Schizophrenia: Similarities and Differences in Susceptibilities to Side Effects
Claudia F. Baldassano, M.D.

E Efficacy to Effectiveness When Treating Schizophrenia
Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.-10:00 p.m.
Continental Ballroom, Ballroom Level, Hilton

PSYCHIATRY AND MEDICINE: COMMON PATIENTS, DIFFERENT PERSPECTIVES
Supported by Pfizer Inc.

Chp.: Charles B. Nemeroff, M.D.

A The Pathophysiology and Psychopharmacology of Comorbid Cardiovascular Disease and Depression
Charles B. Nemeroff, M.D.

B Medical Illness and Depression: A Delicate Interplay Between Biology and Brain
Dominique L. Musselman, M.D.

C Management of Anxiety Disorders in Primary Care: Implications for Psychiatrists
Risa B. Weisberg, Ph.D.

D Long-Term Treatment of Anxiety and Depression: Why, When, How?
Philip T. Ninan, M.D.

E The Successful Intervention: Management of the Patient With Medical Comorbidities
Larry Culpepper, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m.-10:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

MEDICAL CONSIDERATIONS IN THE MANAGEMENT OF SPECIAL PATIENT POPULATIONS
Supported by Eli Lilly and Company

Chp.: Pedro Ruiz, M.D.
A Medical Vulnerability in Schizophrenia
Donald C. Goff, M.D.
B Medical Considerations in Bipolar Disorder
Lauren B. Marangell, M.D.
C Medical Concerns in Pharmacotherapy for Complicated Pediatric Bipolar Patients
Charles S. Schultz, M.D.
D Course and Treatment of Bipolar Illness During Pregnancy, Postpartum, and Lactation
Lee S. Cohen, M.D.
E Medical Comorbidity and Bipolar Disorders in Old Age: Impact on Diagnosis, Treatment, and Outcome
Kenneth I. Shulman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Salon 9, Lower B-2 Level, Marriott

TREATMENT OF COMORBIDITY IN NEUROPSYCHIATRIC DISORDERS IN CHILDREN AND ADOLESCENTS
Supported by Janssen Pharmaceuticals

Chp.: Robert L. Findling, M.D.
A Child and Adolescent Psychiatric Disorders: Pediatric Bipolar Disorders as a Model
Janet Wozniak, M.D.
B Rational Management of Disruptive Behavior Disorders and Comorbidity
Jeffrey Newcom, M.D.
C Combined Pharmacotherapy in the Management of Bipolar Disorder
Robert L. Findling, M.D.
D Recent Advances in the Pharmacotherapy of Pervasive Developmental Disorders
Christopher J. McDougle, M.D., David J. Posey, M.D.
E Clinically Relevant Drug-Drug Interactions in Pediatric Psychiatry
Michael D. Reed, Pharm.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27
7:00 p.m.-10:00 p.m.
Grand Ballroom, Mezzanine Level, Westin St. Francis

REDUCING SUICIDALITY IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Supported by Novartis Pharmaceuticals Corporation

Chp.: Herbert Y. Meltzer, M.D.
A Suicidality and Its Management in Schizophrenia and Bipolar Disorder
Kay R. Jamison, Ph.D.
B A Model for Suicide Assessment
Douglas G. Jacobs, M.D.
C Reducing Suicidality in Schizophrenia and Schizoaffective Disorder
Herbert Y. Meltzer, M.D.
D Treatment and Suicide Risks
Ross J. Baldessarini, M.D., John Hennen, Ph.D., Leonardo Tondo, M.D.
Discussant: Jan A. Fawcett, M.D.
156TH ANNUAL MEETING

MONDAY, MAY 19, 2003

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 28-34

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1
7:00 a.m.-8:30 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

IMPAIRMENT OF STRUCTURAL PLASTICITY IN SEVERE MOOD DISORDERS: CAUSAL OR COLLATERAL?
Supported by Abbott Laboratories

Chp.: Pierre N. Tariot, M.D.
Co-Chp.: Husseini K. Manji, M.D.

A Stress, Glucocorticoids, and Neuron Damage: Current Status
Robert Sapolsky, Ph.D.

B Regulation of Functional Neurogenesis in the Adult Brain
Fred Gage, M.D.

C Neuromorphometric and Neuropathological Abnormalities in Mood Disorders
Wayne C. Drevets, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 1
7:00 a.m.-8:30 a.m.
Metropolitan, Second Level, Argent

IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS
Supported by Solvay Pharmaceuticals, Inc.

Chp.: Eric Hollander, M.D.

A Treating Impulsivity in Impulse Control and Personality Disorders
Eric Hollander, M.D., Stefano Pallanti, M.D., Erica Sood, B.A., Daphne Simeon, M.D.

B Primary and Secondary Disorders of Aggression in Youth: Mood Stabilizers, Atypicals, and Stimulants
Hans Steinert, M.D.

C Strategies for Augmentation of Psychopharmacological Interventions in Youth With Disorders of Aggression
Kirti Saxena, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

BIPOLAR DISORDER IN WOMEN: SPECIAL CONSIDERATIONS AND EVOLVING TREATMENT
Supported by GlaxoSmithKline

Chp.: Lee S. Cohen, M.D.
Co-Chp.: Martha J. Morrell, M.D.

A Bipolar Disorder in Women: Phenomenology and Response to Treatment
Ruta M. Nonacs, M.D.

B Course and Treatment of Bipolar Disorder During Pregnancy
Lee S. Cohen, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1
7:00 a.m.-8:30 a.m.
Continental Ballroom, Ballroom Level, Hilton

MANAGING THE SPECTRUM OF PSYCHOTIC DISORDERS
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Clinical Considerations in the Management of First-Episode and Acute Exacerbation of Schizophrenia
Ira D. Glick, M.D.

B Challenges in the Management of Psychosis in Special Populations
J. Michael Ryan, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1
7:00 a.m.-8:30 a.m.
Salons 7 & 8, Lower B-2 Level, Marriott

TREATING DEPRESSION: WHAT MATTERS?
Supported by Eli Lilly and Company

Chp.: Andrew A. Nierenberg, M.D.
Co-Chp.: Susan G. Kornstein, M.D.

A Brain Matters
Helen S. Mayberg, M.D.

B Gender Matters
Susan G. Kornstein, M.D.

C Time Matters
Beny Lafer, M.D.
MONDAY

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 1
7:00 a.m.-8:30 a.m.
Salon 9, Lower B-2 Level, Marriott

EVIDENCE-BASED TREATMENT OF PSYCHIATRIC DISORDERS
Supported by Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

A Evidence-Based Medicine: What Is It?
K. Ranga R. Krishnan, M.D.

B Evidence-Based Medicine and Depression Treatments
Michael E. Thase, M.D.

C Evidence-Based Medicine: Schizophrenia
Richard S. Keefe, Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom, Mezzanine Level, Westin St. Francis

MANAGING ANXIETY AND SLEEP: A NEW ERA FOR GAMMA-AMINOBUTYRIC ACID
Supported by Cephalon Inc.

Chp.: Philip T. Ninan, M.D.

A Nuances of Inhibition: Gamma-aminobutyric acid in the Human Brain
Philip T. Ninan, M.D.

B Gamma-aminobutyric acid Mechanisms in Sleep Disorders
Jed E. Black, M.D.

RESIDENT'S SESSION
7:00 a.m.-8:30 a.m.
Golden Gate Hall C, B-2 Level, Marriott

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Paul S. Appelbaum, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions

COURSES 35-42
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 35 8:00 a.m.-12 noon
Imperial Ballroom A, Ballroom Level, Hilton

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 36 8:00 a.m.-12 noon
Imperial Ballroom B, Ballroom Level, Hilton

DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.
Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D., Rajiv Tandon, M.D.

COURSE 37 8:00 a.m.-12 noon
Yosemite Room A, Ballroom Level, Hilton

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 38 8:00 a.m.-12 noon
Yosemite Room B, Ballroom Level, Hilton

ECT PRACTICE UPDATE

Director: Charles H. Kellner, M.D.
Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

COURSE 39 8:00 a.m.-12 noon
Yosemite Room C, Ballroom Level, Hilton

INTEGRATED MODEL FOR TREATMENT OF CO-OCCURRING PSYCHIATRIC AND SUBSTANCE DISORDERS

Director: Kenneth Minkoff, M.D.

COURSE 40 8:00 a.m.-12 noon
Union Square 13, Fourth Floor, Hilton

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyle, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.
COURSE 41  8:00 a.m.-12 noon
Union Square 21, Fourth Floor, Hilton
FAMILIES COPING WITH MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT MODEL
Director: John S. Rolland, M.D.

COURSE 42  8:00 a.m.-12 noon
Union Square 23 & 24, Fourth Floor, Hilton
USING NEUROFEEDBACK IN YOUR PRACTICE: LATEST TRENDS AND HANDS-ON EXPERIENCE
Director: Thomas M. Brod, M.D.
Faculty: Roger deBeus, Ph.D., Pedro Delgado, M.D., Julian Isaacs, Ph.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 121, Exhibit Level, Moscone Center
DIAGNOSTIC AND TREATMENT ISSUES IN THE CARE OF AN ADOLESCENT WITH COMORBID BIPOLAR DISORDER AND ADHD
Moderator: Earlene E. Strayhorn, M.D.
Discussant: Bente Clausen, M.S.
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1
9:00 a.m.-12 noon
Room 120, Exhibit Level, Moscone Center
TREATMENT OF THE VIP PATIENT: TWO PATIENTS, TWO THERAPISTS
Moderator: Richard L. Munich, M.D.
Presenter: Efram Bleiberg, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 43-50
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.
MONDAY

COURSE 50  9:00 a.m.-4:00 p.m.
Union Square 25, Fourth Floor, Hilton

THE CONCEPTUAL BASIS OF PSYCHIATRY
Co-Directors: S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

DEBATE
9:00 a.m.-10:30 a.m.
Room 307, Esplanade Level, Moscone Center

RESOLVED: PERSONALITY DISORDERS SHOULD BE LISTED IN AXIS I IN DSM-V
Moderator: John S. McIntyre, M.D.
Affirmative: Roger Peele, M.D.
Negative: John Oldham, M.D.

THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-4
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 Margaret G. Spinelli, M.D., on Infanticide: Psychosocial and Legal Perspectives of Mothers Who Kill (Meet the Authors)
Pacific Conference Suite B, 4th Floor, Marriott

2 Donna E. Stewart, M.D., on Depression in Perimenopausal Women
Pacific Conference Suite C, 4th Floor, Marriott

3 Pedro Ruiz, M.D., on Cross-Cultural Psychiatry: The Acculturation Process
Pacific Conference Suite E, 4th Floor, Marriott

4 Alan F. Schatzberg, M.D., on Some Recent Advancements in Psychopharmacology
Pacific Conference Suite F, 4th Floor, Marriott

LECTURES 2-3

LECTURE 2
9:00 a.m.-10:30 a.m.
Rooms 130/131, Exhibit Level, Moscone Center

APA'S PATIENT ADVOCACY AWARD LECTURE
Robin J. Munro
Labeling the Dissenter as Mad: Forensic Psychiatry in China and Its Political Abuses

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: David M. McDowell, M.D.

LECTURE 3
9:00 a.m.-10:30 a.m.
Rooms 303/305, Esplanade Level, Moscone Center

Charles B. Nemeroff, M.D.
The Neurobiological Consequences of Child Abuse

Chp.: Robert W. Baker, M.D.
Co-Chp.: Paul P. Yeung, M.D.

Preclinical and clinical studies have revealed that adverse experience such as maternal deprivation early in life is associated with alterations in central nervous system neurotransmitter circuits previously shown to be altered in many patients with depression. Charles B. Nemeroff, M.D., discusses the diagnostic and treatment implications of these findings. Dr. Nemeroff is Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine in Atlanta. The author of more than 700 research reports and reviews, Dr. Nemeroff is the Editor-in-Chief of Neuropsychopharmacology and the co-editor with Alan F. Schatzberg, M.D., of the American Psychiatric Press Textbook of Psychopharmacology. Dr. Nemeroff has received numerous honors for his contributions to research on the biological basis of neuropsychiatric disorders, including most recently the Menninger Prize from the American College of Physicians, the Research Award from the American Foundation for Suicide Prevention, and the Burlingame Prize from the Institute of Living.
Monday

Master Educator Clinical Consultations 1-2
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

Room 218, Mezzanine Level, Moscone Center

2. Glen O. Gabbard, M.D., on Psychotherapy of Personality Disorders
Room 220, Mezzanine Level, Moscone Center

These sessions are open to APA members only. Blue registration badge or APA membership card required for admittance.

New Research Young Investigators' Poster Session 1
9:00 a.m.-10:30 a.m.
Hall D, Exhibit Level, Moscone Center

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

Workshops

Components 1-3

Component Workshop 1
9:00 a.m.-10:30 a.m.
Golden Gate Hall A, B-2 Level, Marriott

Restrains: Strategies to Reduce and Optimize Patient Safety
APA Committee on Standards and Survey Procedures

Chp.: Charles E. Riordan, M.D.
Participants: Kathleen McCann, D.N.Sc, Steven I. Alchuler, M.D., Dennis J. Mülle, M.D., Martin R.A. Mattson, M.D.

Component Workshop 2
9:00 a.m.-10:30 a.m.
Pacific Conference Suite H, 4th Floor, Marriott

Early Intervention Following Mass Violence: Designing an Effective Approach
APA Committee on Psychiatric Dimensions of Disaster

Chp.: John S. Kennedy, M.D.
Participants: Joseph C. Napoli, M.D., Matthew J. Friedman, M.D., Beverley Raphael, M.D.

Component Workshop 3
9:00 a.m.-10:30 a.m.
Pacific Conference Suite J, 4th Floor, Marriott

Patient Safety in Psychiatry: Minimizing the Use of Restraint and Seclusion
APA Council on Quality

Co-Chp.: Alfred Herzog, M.D., Miles F. Shore, M.D.
Participant: Steven J. Karp, D.O.

Issues 1-24

Issue Workshop 1
9:00 a.m.-10:30 a.m.
Room 110, Exhibit Level, Moscone Center

Teaching Cognitive-Behavior Therapy: Effective Training in Unexpected Settings

Chp.: Donna M. Sudak, M.D.
Participants: Judith S. Beck, Ph.D., Jesse H. Wright, M.D., Robert M. Goisman, M.D.

Issue Workshop 2
9:00 a.m.-10:30 a.m.
Room 111, Exhibit Level, Moscone Center

Understanding Transgendered Youth: Treatment and Service Strategies

Co-Chp.: Richard R. Pleak, M.D., Sarah E. Herbert, M.D.

Issue Workshop 3
9:00 a.m.-10:30 a.m.
Room 112, Exhibit Level, Moscone Center

Moral Aspects of Clinical Practice: A Functional Approach

Chp.: John R. Peteet, M.D.
MONDAY

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.  Room 113, Exhibit Level, Moscone Center
MULTICULTURALITY SQUARED: TRAINING MULTICULTURAL RESIDENTS TO TREAT MULTICULTURAL PATIENTS
Co-Chps.: Susan Stabinsky, M.D., Harvey Stabinsky, M.D.
Participants: Henry L. McCurtis, M.D., David W. Preven, M.D.

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.  Room 114, Exhibit Level, Moscone Center
SANterIA AS A RELIGION IN MENTAL HEALTH PATIENTS
Chp.: Jose M. Soto, M.D.
Participants: Liliam Perez, M.D., Virginia Contreras, M.D.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.  Room 122, Exhibit Level, Moscone Center
RISK-MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE
Chp.: Alan I. Levenson, M.D.
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.  Room 123, Exhibit Level, Moscone Center
MEDITATION: THEORY, THERAPY, RESEARCH, AND PRACTICE
Chp.: Roger N. Walsh, M.D.
Participants: Charles Tart, Ph.D., Shauna Shapiro, Ph.D.

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.  Room 124, Exhibit Level, Moscone Center
INSTITUTE OF MEDICINE STUDY: INCORPORATING RESEARCH INTO RESIDENCY TRAINING
Chp.: Joel Yager, M.D.
Participants: Michael T. Abrams, M.P.H., James J. Hudziak, M.D., Michelle B. Riba, M.D.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.  Room 125, Exhibit Level, Moscone Center
EXPANDING TELePSYCHIATRY BEYOND PATIENT CARE: OPPORTUNITIES AND CHALLENGES
Co-Chps.: R. Andrew Harper III, M.D., Anu A. Matorin, M.D.
Participants: Jacqueline C. McGregor, M.D., Christopher R. Thomas, M.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.  Rooms 272/274/276, Mezzanine Level, Moscone Center
NONSEXUAL BOUNDARY VIOLATIONS
Chp.: Malkah T. Notman, M.D.
Participants: Elissa P. Benedek, M.D., Carl P. Malmquist, M.D., Linda M. Jorgenson, J.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.  Room 300, Esplanade Level, Moscone Center
PSYCHOLOGICAL MANAGEMENT OF PSYCHOSIS
Chp.: Eric R. Marcus, M.D.
Participants: Lewis A. Opler, M.D., Ian E. Alger, M.D., Clarice J. Kestenbaum, M.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.  Room 301, Esplanade Level, Moscone Center
WORKING THROUGH IN PSYCHOTHERAPY
Chp.: Steven H. Lipsius, M.D.

ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m.  Room 302, Esplanade Level, Moscone Center
DEPRESSION AND THE PHYSICIAN: WHEN BEING A "GOOD" DOCTOR IS NOT ENOUGH
Chp.: Michael F. Myers, M.D.
Participants: Daniel P. Chapman, Ph.D., Donna M. Norris, M.D.

ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m.  Room 304, Esplanade Level, Moscone Center
INNOVATIVE TREATMENT IN BULIMIA NERVOSA
Co-Chps.: Waguih W. Ishak, M.D., McLeod F. Gwynette, M.D.
Participants: Edi Cooke, Psy.D., Michelle McParland, R.D., Marlene Clark, R.D., Antonia N. Ludwag, M.F.T.

ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m.  Room 306, Esplanade Level, Moscone Center
MANAGEMENT OF DISINHABITION IN DEMENTIA
Co-Chps.: Theron C. Bowers, Jr., M.D., Sheila M. Loboprabhu, M.D.
Participants: Claudia Oreno, M.D., John H. Coverdale, M.D.
ISSUE WORKSHOP 16  9:00 a.m.-10:30 a.m.
Room 308, Esplanade Level, Moscone Center

PREPARING PSYCHIATRISTS FOR MASS-CASUALTY EVENTS

Chp.: Kenneth S. Thompson, M.D.
Participants: Anthony T. Ng, M.D., David A. Pollack, M.D.,
Stephen M. Goldfinger, M.D., Audrey R. Newell, M.D., Gina
Perez, M.D.

ISSUE WORKSHOP 17  9:00 a.m.-10:30 a.m.
Room 309, Esplanade Level, Moscone Center

IMPLEMENTING WEB-BASED PSYCHOPHARMACOLOGY ALGORITHMS: PROBLEMS AND SOLUTIONS

Co-Chps.: David N. Osser, M.D., Peter D. Anderson, Pharm.D.
Participants: Alejandro Y. Mendoza, M.D., William L.
Grapentine, M.D.

ISSUE WORKSHOP 18  9:00 a.m.-10:30 a.m.
Room 310, Esplanade Level, Moscone Center

TELEPSYCHIATRY WITH DEVELOPMENTALLY DISABLED: TEACHING, TRAINING, AND TREATING

Chp.: Roxanne F. Szeftel, M.D.
Participants: Syed S. A. Naqvi, M.D., Arom J. Evans, M.D.,
Henrik Zakari, M.D., Marina Bussel, M.D.

ISSUE WORKSHOP 19  9:00 a.m.-10:30 a.m.
Salons 1 & 2, Lower B-2 Level, Marriott

ETHNIC BIODIVERSITY IN SUBSTANCE ABUSE AND MENTAL HEALTH DISORDERS

Chp.: Jeffrey N. Wilkins, M.D.
Participants: Katherine G. Mellott, M.D., Jack Kuo, M.D.

ISSUE WORKSHOP 20  9:00 a.m.-10:30 a.m.
Salons 3 & 4, Lower B-2 Level, Marriott

DISTINGUISHING MENTAL ILLNESS FROM BAD BEHAVIOR IN PRISONERS

Chp.: Lee H. Rome, M.D.

ISSUE WORKSHOP 21  9:00 a.m.-10:30 a.m.
Salons 5 & 6, Lower B-2 Level, Marriott

LESSONS LEARNED FROM SEPTEMBER 11

Chp.: David C. Lindy, M.D.
Participants: Neil Pessin, Ph.D., Anand Pandya, M.D., Craig L.
Katz, M.D., Sander Koyfman, M.D.

ISSUE WORKSHOP 22  9:00 a.m.-10:30 a.m.
Salons 10 & 11, Lower B-2 Level, Marriott

A PSYCHIATRIST'S VIEW ON ARTISTS AND THE ARTS

Chp.: Frans de Jonghe, Ph.D.
Participants: Wilco Tumibreyer, M.D., Cecile M.T. Gijbers
van Wijk, M.D., Hetty M. Visser, M.D.

ISSUE WORKSHOP 23  9:00 a.m.-10:30 a.m.
Salons 12 & 13, Lower B-2 Level, Marriott

RESTORATIVE JUSTICE AND THERAPEUTIC JURISPRUDENCE: AN ENJOYABLE EXCHANGE OF IDEAS

Co-Chps.: Lawrence K. Richards, M.D., Abraham L. Halpern, M.D.
Participants: Patrick H. Gardner, J.D., Philip F. Kader, B.A.,
Honorable Peggy Hora, J.D., Pauline H. Tesler, J.D.

ISSUE WORKSHOP 24  9:00 a.m.-10:30 a.m.
Salons 14 & 15, Lower B-2 Level, Marriott

YOUTH VIOLENCE: PRINCIPLES OF PREVENTION

Co-Chps.: Paul J. Fink, M.D., Carl C. Bell, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH

10:30 a.m.-12:30 p.m.
Room 104, Exhibit Level, Moscone Center

LATEST DEVELOPMENTS IN THE GENETICS OF MOOD DISORDERS

APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.
Co-Chp.: Geetha Jayaram, M.D.

Participants: John M. Kane, M.D., on Pharmacological Treatment of Schizophrenia: What Now? What Next?
Constantine Lyketos, M.D., on Advances in the Treatment of Alzheimer's Disease
J. Raymond DePaulo, Jr., M.D., on the Latest Developments in the Genetics of Mood Disorder
THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 5-9

11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.
(Continued on next page)
MONDAY

5 Patricia Judd, on a Developmental Model of BPD: Understanding Variations in Course and Outcome
(Meet the Authors)
Pacific Conference Suite B, 4th Floor, Marriott

6 Leah J. Dickstein, M.D., on Gender and Cultural Issues in Diagnosis and Treatment
Pacific Conference Suite C, 4th Floor, Marriott

7 John M. Oldham, M.D., on Understanding the Severe Personality Disorders
Pacific Conference Suite E, 4th Floor, Marriott

8 Marc A. Schuckit, M.D., on New Developments in Substance Dependence: Genetics, Criteria, and Treatment
Pacific Conference Suite F, 4th Floor, Marriott

9 Marcia K. Goin, M.D., on Borderline Personality Disorder (For Residents Only)
Pacific Conference Suite I, 4th Floor, Marriott

LECTURES 4-5

LECTURE 4
11:00 a.m.-12:30 p.m.
Rooms 130/131, Exhibit Level, Moscone Center
Lucian L. Leape, M.D.
Making Health Care Safe
Chp.: Paul S. Appelbaum, M.D.
Co-Chp: Jeffrey S. Janofsky, M.D.

Spurred by a 1999 Institute of Medicine report noting the role of faulty systems in bringing about medical errors, a national patient safety movement has emerged. Much of the initial work in improving patient safety has concentrated on safe medication practices, a concern of special relevance to psychiatry. Lucian L. Leape, M.D., a member of the Institute of Medicine Committee that issued the 1999 report, examines the theoretical underpinnings and practical implications of the patient safety movement. Dr. Leape is Adjunct Professor in the Department of Health Policy and Management at the Harvard School of Public Health in Boston, MA. An advocate of the nonpunitive systems approach to the prevention of medical errors, he has conducted research demonstrating the application of systems theory to the prevention of adverse drug events. Dr. Leape was a member of the founders of the National Patient Safety Foundation, the Massachusetts Coalition for the Prevention of Medical Error, and the Harvard Kennedy School Executive Session on Medical Error. He is a recipient of the Distinguished Service Award of the American Pediatric Surgical Association, the Donabedian Award from the American Public Health Association, and a Robert Wood Johnson Foundation Investigator's Award in Health Policy Research. Dr. Leape received his medical degree from Harvard Medical School.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 5
11:00 a.m.-12:30 p.m.
Rooms 132/133, Exhibit Level, Moscone Center
Carl C. Bell, M.D.
Community Psychiatry: 1963-2003
Chp.: Stephanie LeMelle, M.D.
Co-Chp: Patricia I. Ordonca, M.D.

Carl C. Bell, M.D., is President and Chief Executive Officer of Community Mental Health Council and Foundation, Inc., and Director of Public and Community Psychiatry and Clinical Professor of Psychiatry and Public Health at the University of Illinois in Chicago. He is involved as a collaborator or a principal investigator in studies of methods for promoting adolescent mental health and preventing youth HIV risk in Chicago, South Africa, and New York City. A Fellow of the American Psychiatric Association and the American College of Psychiatrists, Dr. Bell has received a Special Presidential Commendation from APA for his work on prevention of violence. He is currently a member of the APA Council on Advocacy and Public Policy. An Associate Editor on the Editorial Board of American Psychiatric Publishing, Inc., Dr. Bell is the author of more than 200 articles and book chapters on mental health issues and the author or editor of several books, including Psychiatric Aspects of Violence, Suicide, and Homicide Among Adolescents, and Getting Rid of Rats: Perspectives of a Black Community Psychiatrist. A graduate of Meharry Medical College in Nashville, TN, Dr. Bell completed his residency in psychiatry at Illinois State Psychiatric Institute in Chicago.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 3-4

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served

3 Lori I. Altshuler, M.D., on Treating Bipolar Depression
Room 218, Mezzanine Level, Moscone Center
4 Albert C. Gaw, M.D., on Cross-Cultural Issues in Psychiatric Care
Room 220, Mezzanine Level, Moscone Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 1
11:00 a.m.-12:30 p.m.
Room 300, Esplanade Level, Moscone Center

ETHNICITY AND PHARMACOGENETICS
Chp.: Nyapati R. Rao, M.D.
Presenter: Keh-Ming Lin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-7

SCIENTIFIC AND CLINICAL REPORT SESSION 1
11:00 a.m.-12:30 p.m.
Room 110, Exhibit Level, Moscone Center

ADDITIONAL PSYCHIATRY
Chp.: R. Dale Walker, M.D.
Co-Chp.: Romulo A. Aromin, Jr., M.D.

11:00 a.m.
2 Differences in Peripheral Noradrenergic Function Among Actively Drinking and Recently Abstinent Alcohol-Dependent Individuals
Anup M. Desai, M.D., Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D., Stephen P. Weinstein, Ph.D., Michael J. Vergare, M.D.

11:30 a.m.
3 Changes in Peripheral Noradrenaline and 5HT Levels and Craving During Alcohol Withdrawal
Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D., Heather W. Murray, B.A., Anup M. Desai, M.D., Michael J. Vergare, M.D., Stephen P. Weinstein, Ph.D.

12 noon
4 Effect of Modafinil on Cocaine Abstinence and Treatment Retention in Cocaine Dependence: Preliminary Results From an Open-Label Study
Charles A. Dackis, M.D., Kyle M. Kampman, M.D., Helen Pettinati, Ph.D., Charles P. O’Brien, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Room 111, Exhibit Level, Moscone Center

CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY
Chp.: Catherine C. Crone, M.D.
Co-Chp.: Jayne M. Stevenson, M.D.

11:00 a.m.
5 Quetiapine Treatment of Hallucinations and Agitation of Lewy Body Disease
Andrius Baskys, M.D.

11:30 a.m.
6 Survey of Practice Preferences in the Pharmacotherapy of Delirium
Michael W. Kiang, M.D., Mark R. Katz, M.D., Susan E. Abbey, M.D.

12 noon
7 Hyponatremia Associated With the Use of Antidepressants in Geriatric Patients
Subramoniam Madhusoodanan, M.D., Olivera J. Bogunovic, M.D.

PERSONALITY DISORDERS
Chp.: Lisa A. Mellman, M.D.
Co-Chp.: Joanna E. Steinglass, M.D.

11:00 a.m.
8 Sexual Aversion Among Borderline Patients and Axis II Comparison Subjects
Mary C. Zanarini, Ed.D., Elizabeth A. Parachini, B.A., Frances R. Frankenburg, M.D., John Hennen, Ph.D.

11:30 a.m.
9 Effects of Personality Disorders on Functioning and Well-Being in MDD
Andrew E. Skodol II, M.D., Carlos M. Grilo, Ph.D., Maria E. Pagano, Ph.D., Donna S. Bender, Ph.D., John G. Gunderson, M.D., M. Tracie Shea, Ph.D., Thomas H. McGlashan, M.D.

12 noon
10 Supportive Therapy for BPD Patients With Self-Injurious Behavior
David J. Hellerstein, M.D., Ron B. Aviram, Ph.D., Jessica Gerson, Ph.D., Barbara H. Stanley, Ph.D.
MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 302, Esplanade Level, Moscone Center

ANXIETY DISORDERS

Chp.: Teodor T. Postolache, M.D.
Co-Chp.: Shannon T. Suo-Chan, M.D.

11:00 a.m.
11 The Prevalence of PTSD in Canada
Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,
Beth Pipe, B.S.N., Sandra Balseiro, Michael Boyle, Ph.D.

11:30 a.m.
12 A New Self-Report Screening Tool for DSM-IV Axis I
Diagnosis
Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D.,
Beth Pipe, B.S.N., Jonathan Oakman, Ph.D.

12 noon
13 Sexual Aversion Disorders in Primary Anxiety Disorders
Chris Watson, B.K.I.N, Michael A. Van Ameringen, M.D.,
Catherine L. Mancini, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room 308, Esplanade Level, Moscone Center

EVOLVING ISSUES IN ATYPICAL ANTIPSYCHOTICS

Chp.: Paul P. Yeung, M.D.
Co-Chp.: Yujuan Choy, M.D.

11:00 a.m.
14 Effects on Weight Change of Switching From
Olanzapine to Quetiapine
Prakash S. Masand, M.D., Sanjay Gupta, M.D., Subhdeep
Virk, M.D., Thomas L. Schwartz, M.D., Ahmad Hameed, M.D.,
Bradford L. Frank, M.D., Kari Lockwood, R.N.

11:30 a.m.
15 A Three-Week Comparison of Olanzapine Versus
Risperidone in the Treatment of Bipolar Mania:
Improvement in Manic and Depressive Symptoms and
Treatment Adherence
Robert W. Baker, M.D., Carlos M. Zarate, Jr., M.D., Eileen
Brown, Ph.D., Leslie Schuh, Ph.D., Mauricio F. Tohen, M.D.

12 noon
16 Olanzapine/Fluoxetine Combination and Olanzapine in
the Treatment of Bipolar Depression
Mauricio F. Tohen, M.D., Eduard Vieta, M.D., Joseph R.
Calabrese, M.D., Richard C. Riser, M.S., Robert W. Baker, M.D.,
Angela R. Evans, Ph.D., Sanjay Dube, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Pacific Conference Suite H, 4th Floor, Marriott

MEASURING MOOD DISORDERS

Chp.: David A. Casey, M.D.
Co-Chp.: Stephen C. Aron, M.D.

11:00 a.m.
17 Tridimensional Personality Questionnaire and Anxiety
Disorder Comorbidity in MDD
Dost Ongur, M.D., Amy H. Farabaugh, Ph.D., Maurizio
Fava, M.D.

11:30 a.m.
18 Difference in Subjective/Objective Sadness Predicts
Drug Response
Anand Pandya, M.D., Eric D. Peselow, M.D., Ronald R.
Fieve, M.D.

12 noon
19 Identifying Depression in Older Inpatients With the
Geriatric Depression Scale and Structured Clinical
Interview
George Fulop, M.D., James J. Strain, M.D., Glen Stettin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Pacific Conference Suite J, 4th Floor, Marriott

PSYCHIATRIC EDUCATION AND TELEPSYCHIATRY

Chp.: Gordon D. Strauss, M.D.
Co-Chp.: Jodi E. Star, M.D.

11:00 a.m.
20 Psychiatry Training in Primary Care: Current Status and
Satisfaction
Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna
Mallios, M.P.H.

11:30 a.m.
21 Retrospective Evaluation of Telemental Health Care
Services for Remote Military Populations
Brian J. Grady, M.D., Lisa Fore-Arcand, Ed.D.

12 noon
22 What Increases the Frequency at Which Medical
Students Ask Addiction Questions?
Kathleen M. Stack, M.D., Lisa Fore-Arcand, Ed.D.

THIS SESSION WILL BE AUDIOTAPED.
WORKSHOPS

COMPONENTS 4-9

COMPONENT WORKSHOP 4  11:00 a.m.-12:30 p.m.
Room 310, Esplanade Level, Moscone Center

AMBULATORY DETOXIFICATION FROM OPIOIDS: DOING IT WELL AND GETTING PAID TOO
APA Committee on Treatment Services for Patients with Addictive Disorders

Co-Chps.: George F. Kolodner, M.D., Samuel M. Silverman, M.D.
Participants: Thomas R. Kosten, M.D., Jonathan D. Book, M.D., Brealy M. Sellers, M.D.

COMPONENT WORKSHOP 5  11:00 a.m.-12:30 p.m.
Salons 1 & 2, Lower B-2 Level, Marriott

PRACTICE SETTINGS FOR EARLY CAREER PSYCHIATRISTS: A PRIMER
APA Assembly Committee of Early Career Psychiatrists

Chp.: Jeffrey A. Naser, M.D.
Participants: Angelique D. Goodhue, M.D., John R. Chamberlain, M.D., Adam R. Chester, D.O.

COMPONENT WORKSHOP 6  11:00 a.m.-12:30 p.m.
Salons 5 & 6, Lower B-2 Level, Marriott

THE RESEARCH BASE FOR NEW DIAGNOSTIC CRITERIA FOR DEPRESSION
APA Committee on Psychiatric Diagnosis and Assessment

Co-Chps.: Darrel A. Regier, M.D., Norman Sartorius, M.D.
Participants: J. John Mann, M.D., David Shaffer, M.D., Dennis S. Chaney, M.D., Wayne C. Drevets, M.D., T. Bedirhan Ustun, M.D., David J. Kupfer, M.D.

COMPONENT WORKSHOP 7  11:00 a.m.-12:30 p.m.
Salons 10 & 11, Lower B-2 Level, Marriott

MOOD DISORDERS IN PHYSICIANS, AN UPDATE: HOW TO IDENTIFY, DIAGNOSE, AND PROVIDE TREATMENT
APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: John A. Fromson, M.D.
Participants: Penelope P. Ziegler, M.D., Patti Tighe, M.D., Michael F. Myers, M.D.

COMPONENT WORKSHOP 8  11:00 a.m.-12:30 p.m.
Salons 12 & 13, Lower B-2 Level, Marriott

MEDICARE UPDATE 2003
APA Medicare Advisory Corresponding Committee

Chp.: Edward Gordon, M.D.
Participants: Irvin L. Muszynski, J.D., Ellen Jaffe, Seth P. Stein, J.D., Gerald Rogan, M.D.

COMPONENT WORKSHOP 9  11:00 a.m.-12:30 p.m.
Salons 14 & 15, Lower B-2 Level, Marriott

USING RADIO TO COMBAT STIGMA AND IMPROVE THE IMAGE OF PSYCHIATRY
APA Alliance

Co-Chps.: Harvey L. Ruben, M.D., Jo Ellen Fasanello
Participants: Michael Blumenfield, M.D., Frederick K. Goodwin, M.D., Linda S. Austin, M.D., Harry A. Croft, M.D.

ISSUES 25-34

ISSUE WORKSHOP 25  11:00 a.m.-12:30 p.m.
Room 112, Exhibit Level, Moscone Center

LONG-TERM STRUCTURED CARE: A FAMILY PERSPECTIVE

Co-Chps.: H. Richard Lamb, M.D., Carla Jacobs
Participants: Curtis Flory, M.B.A., E. Fuller Torrey, M.D.

ISSUE WORKSHOP 26  11:00 a.m.-12:30 p.m.
Room 113, Exhibit Level, Moscone Center

IMMINENT RISK OF SUICIDE IN CORRECTIONAL FACILITIES

Chp.: Karl E. Weaver, M.D.

ISSUE WORKSHOP 27  11:00 a.m.-12:30 p.m.
Room 114, Exhibit Level, Moscone Center

THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D., Edward K. Rynearrow, M.D.

ISSUE WORKSHOP 28  11:00 a.m.-12:30 p.m.
Room 121, Exhibit Level, Moscone Center

EVIDENCE-BASED MEDICINE: AN APPLICATION IN CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Co-Chps.: Norman E. Alessi, M.D., Robert A. Kowatch, M.D.

ISSUE WORKSHOP 29  11:00 a.m.-12:30 p.m.
Room 122, Exhibit Level, Moscone Center

PSYCHOTHERAPY WITH AFRICAN-AMERICAN PATIENTS: TRAINING PERSPECTIVES

Co-Chps.: Anu A. Matorin, M.D., Irma J. Bland, M.D.
Participants: Henry L. McCurtis, M.D., Pedro Ruiz, M.D., Sujit R. Varma, M.D.
MONDAY

ISSUE WORKSHOP 30 11:00 a.m.-12:30 p.m.
Room 123, Exhibit Level, Moscone Center

MIND-BODY CONNECTION IN TRADITIONAL CHINESE MEDICINE

Co-Chps.: Jing-Duan Yang, M.D., Daniel A. Monti, M.D.

ISSUE WORKSHOP 31 11:00 a.m.-12:30 p.m.
Room 124, Exhibit Level, Moscone Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 32 11:00 a.m.-12:30 p.m.
Room 125, Exhibit Level, Moscone Center

DISCUSSING THE CONCEPT OF MENTAL HEALTH COURTS

Chp.: Lawrence K. Richards, M.D.
Participants: Honorable Harold E. Shabo, J.D., Honorable Peggy Hora, J.D., Pauline H. Tesler, J.D., Meghan Lang, J.D.

ISSUE WORKSHOP 33 11:00 a.m.-12:30 p.m.
Room 304, Esplanade Level, Moscone Center

LEARNING PSYCHOTHERAPY IN PRIVATE PRACTICE

Co-Chps.: Bernard D. Beitman, M.D., Rodrigo A. Munoz, M.D.
Participants: Harold I. Eist, M.D., Roger Peele, M.D.

ISSUE WORKSHOP 34 11:00 a.m.-12:30 p.m.
Room 309, Esplanade Level, Moscone Center

PATIENT RESPONSIBILITY FOR ADDICTION TO PRESCRIBED SUBSTANCES

Chp.: Harold J. Bursztajn, M.D.
Participants: Paul K. Robindra, D.P.H., Brian Johnson, M.D.

ISSUE WORKSHOP 35 11:00 a.m.-12:30 p.m.
Room 306, Esplanade Level, Moscone Center

MUSICAL THERAPY

Chp.: M. Omer Taser, M.D.

ISSUE WORKSHOP 36 11:00 a.m.-12:30 p.m.
Room 310, Esplanade Level, Moscone Center

THE PLACEBO EFFECT: SCIENCE, BELIEF, AND CLINICAL PRACTICE

Chp.: Philip R. Muskin, M.D.
Co-Chp.: Andrew F. Leuchter, M.D.
Participants: Howard Fields, M.D., David Spiegel, M.D.

ISSUE WORKSHOP 37 11:00 a.m.-12:30 p.m.
Room 311, Esplanade Level, Moscone Center

MUSIC AND THE MIND: GEORGE GERSHWIN

Chp.: Richard Kogan, M.D.

FORUM 2 12 noon-1:30 p.m.
Room 306, Esplanade Level, Moscone Center

THE PLACEBO EFFECT: SCIENCE, BELIEF, AND CLINICAL PRACTICE

Chp.: Philip R. Muskin, M.D.
Co-Chp.: Andrew F. Leuchter, M.D.
Participants: Howard Fields, M.D., David Spiegel, M.D.

FORUM 3 12 noon-1:30 p.m.
Golden Gate Hall B, B-2 Level, Marriott

MUSIC AND THE MIND: GEORGE GERSHWIN

Chp.: Richard Kogan, M.D.

1:00 p.m. Sessions

COURSES 51-59
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 51 1:00 p.m.-5:00 p.m.
Imperial Ballroom A, Ballroom Level, Hilton

COGNITIVE THERAPY: THE BASICS

Director: Dean Schuyler, M.D.

COURSE 52 1:00 p.m.-5:00 p.m.
Imperial Ballroom B, Ballroom Level, Hilton

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: BASIC

Director: John S. Luo, M.D.
Faculty: Carlyle H. Chan, M.D., Raymond J. Kloss, M.D., Richard A. Montgomery, M.D., Charles J. Rainey, M.D., Hendry Ton, M.D.

COURSE 53 1:00 p.m.-5:00 p.m.
Yosemite Room B, Ballroom Level, Hilton

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.
Faculty: Kathryn A. Lee, Ph.D.

COURSE 54 1:00 p.m.-5:00 p.m.
Yosemite Room C, Ballroom Level, Hilton

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.
2:00 p.m. Sessions

ADVANCES IN PSYCHOTHERAPY
2:00 p.m.-5:30 p.m.
Room 104, Exhibit Level, Moscone Center

AN UPDATE ON PSYCHIATRIC TREATMENT FOR PSYCHIATRIC DISORDERS
Chp.: Glenn O. Gabbard, M.D.

1 Mind and Brain in Psychiatric Treatment
Glenn O. Gabbard, M.D.

2 Treatment of PTSD
Barbara O. Rothbaum, Ph.D.

3 Psychoeducational Psychotherapies for Depression
Michael E. Thase, M.D.

4 Gender Issues in Psychotherapy
Carol C. Nadelson, M.D.

5 Treatment of Personality Disorders
John G. Gunderson, M.D.

LECTURES 6-7

LECTURE 6
2:00 p.m.-3:30 p.m.
Rooms 130/131, Exhibit Level, Moscone Center

Robin M. Murray, M.B.

Schizophrenia Is More Than a Neurodevelopmental Disease

Chp.: Anand Pandurangi, M.D.
Co-Chp.: Robert W. Baker, M.D.

Robin M. Murray, M.B., will discuss how schizophrenia results from the cumulative effect of a number of physical and social risk factors. The individual inherits an unfortunate combination of genes, each of which is not uncommon in the general population. The resultant deviant traits may be compounded by pre- and perinatal complications, and consequently many preschizophrenic children show minor developmental delays and cognitive difficulties. These propel the child on a trajectory of increasing oddness and alienation from his peers, and he may begin to have quasi-psychotic ideas about them. However, additional factors in early adult life such as drug abuse (psychostimulants and cannabis) and/or social adversity (e.g. life events, isolation, migration) are generally required to push the
MONDAY

individual over a threshold into the expression of frank psychosis. Robin M. Murray, M.B., received his medical degree from the University of Glasgow, Scotland, and trained in Internal Medicine there. He studied psychiatry at the Maudsley Hospital, London, and has remained there ever since, apart from one year at NIH in Washington, DC. He is now Professor of Psychiatry at the Institute of Psychiatry, and is a recent President of the Association of European Psychiatrists. His department contains some 120 schizophrenia researchers. In the decade, 1991-2000, he was the most widely cited schizophrenia researcher. He also runs a clinical unit at the Bethlem Hospital (Bedlam), which takes referrals from all over England for people with resistant psychotic illnesses.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPELED.

LECTURE 7
2:00 p.m.-3:30 p.m.
Rooms 132/133, Exhibit Level, Moscone Center

APA'S SIMON BOLIVAR AWARD LECTURE
Juan J. Lopez-Ibor, Jr., M.D.

The Commitment of Psychiatrists: Lesson From Al-Andalus
Chp.: Ana E. Campo, M.D.

Juan J. Lopez-Ibor, Jr., M.D., is Professor of Psychiatry and Head of the Psychiatric Unit of San Carlos Hospital of the Complutense University in Madrid; coordinator for Mental Health for Madrid Area 7; and Director, World Health Organization Research and Training Center for Spain. He has twice held the offices of Secretary General and President of the World Psychiatric Association and has been President of the International College of Psychosomatic Medicine, the Spanish Society of Psychiatry, and the Spanish Society for Biological Psychiatry. He is the author of more than 200 scientific papers and 100 book chapters and the author or editor of several books, including the New Oxford Textbook of Psychiatry. A Fellow of the Royal National Academy of Medicine in Spain, Dr. Lopez-Ibor was awarded the commendation of the Civil Order of Health in 1998, the highest award in Spain's health care sector. Dr. Lopez-Ibor received his medical and doctoral degrees from the Complutense University of Madrid and completed psychiatry training at the University of Frankfurt in Germany, the Maudsley and St. Bartholomew's Hospitals in London, and the Cantonal Hospital of Vaud in Switzerland.

THIS SESSION WILL BE AUDIOTAPELED.

PRESIDENTIAL SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room 300, Esplanade Level, Moscone Center

MORAL AND PHILOSOPHICAL ISSUES IN PSYCHIATRY

Chp.: Deborah Spitz, M.D.

A Values-Based Medicine (VBM): A First for Psychiatry
Kenneth Fulford, D.Phil.

B What Is Good Diagnostic Practice?
John Z. Sadler, M.D.

C Ethical Issues in Behavioral Genetics
Kenneth F. Schaffner, M.D.

D Personal Identity and Mental Disorder
Jennifer Radden, Ph.D.

E The Self in a Scientifically Driven Psychiatry
James E. Phillips, M.D.

THIS SESSION WILL BE AUDIOTAPELED.

SYMPOSIA 1-28

SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room 100, Exhibit Level, Moscone Center

BORDERLINE PATIENTS AT THE BORDER OF TREATABILITY

Chp.: Michael H. Stone, M.D.

A Managing the Real Risk of Suicide in Borderline Patients
John G. Gunderson, M.D.

B Treatment Utilization by Patients With Severe BPD
Donna S. Bender, Ph.D., Andrew E. Skodol II, M.D.

C Eroticized Transferences in Therapy With Borderline Patients
Frank E. Yeomans, M.D.

D The Almost-Un treatable Narcissistic Patient
Otto F. Kernberg, M.D.

E An Empirical Approach to the Border of Treatability in BPD Patients
John F. Clarkin, Ph.D.

F Borderline Patients With Antisocial Features: Special Treatment Issues
Michael H. Stone, M.D.

Discussant: Michael H. Stone, M.D.
THIS SESSION WILL BE AUDIOTAPELED.
SYMPOSIUM 2 2:00 p.m.—5:00 p.m.
Room 101, Exhibit Level, Moscone Center

MINERAL/VITAMIN MODIFICATION OF MENTAL DISORDERS AND BRAIN FUNCTION

Chp.: Charles W. Popper, M.D.
Co-Chp.: Bonnie J. Kaplan, Ph.D.

A Nutrients Alter IQ and Mood in Healthy Volunteers: A Plausible Hypothesis?
David Benton, Ph.D.

B Influence of Micronutrients on Antisocial Behavior of Young-Adult Prisoners
C. Bernard Gesch, C.Q.S.W., Sean M. Hammond, Ph.D., Sarah E. Hampson, Ph.D., Anita Eves, Ph.D., Martin J. Crowder, Ph.D.

C Nutrient Treatment of Adult Bipolar Disorder and Childhood Mood Lability
Bonnie J. Kaplan, Ph.D.

D Clinical Questions and Concerns Raised by Micronutrient Treatments
Charles W. Popper, M.D.

Discussant: Floyd R. Sallee, M.D.

SYMPOSIUM 4 2:00 p.m.—5:00 p.m.
Room 106, Exhibit Level, Moscone Center

PATHOLOGICAL BODY SCULPTING IN THE ATHLETE
International Society for Sport Psychiatry

Chp.: Antonia L. Baum, M.D.

A Little Girls in Pretty Boxes: The Making and Breaking of Elite Gymnasts and Figure-Skaters
Joan Ryan

B Eating Disorders in the Male Athlete
Antonia L. Baum, M.D.

C Risk Factors for Anabolic-Adrogenic Steroid Abuse: A Case-Control Study
Harrison G. Pope, Jr., M.D., Gen Kanayama, M.D., Geoffrey Cohane, B.A., James I. Hudson, M.D.

SYMPOSIUM 5 2:00 p.m.—5:00 p.m.
Room 113, Exhibit Level, Moscone Center

COMPULSIVE BUYERS: TREATING THE CASUALTIES OF CONSUMERISM

Chp.: Lorrin M. Koran, M.D.

A Phenomenology and Epidemiology of Compulsive Buying
Donald W. Black, M.D.

B Examination and Explanation of the Triggers for Compulsive Buying Disorders
Ronald J. Faber, Ph.D.

C Pharmacotherapy for Compulsive Buying
Kim D. Bullock, M.D., Helen W. Chuong, M.S., Lorrin M. Koran, M.D.

D Group Psychotherapy for Compulsive Shopping: Pilot Data
Heidi Hartston, Ph.D., Lorrin M. Koran, M.D.

E A One-Year Naturalistic Follow-Up of Patients With Compulsive Buying Disorder
Elias Aboujaoude, M.D., Lorrin M. Koran, M.D., Kim D. Bullock, M.D., Helen W. Chuong, M.S.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 6  2:00 p.m.-5:00 p.m.
Room 114, Exhibit Level, Moscone Center

QUALITY OF CARE FOR CHILDREN AND ADOLESCENTS

Chp.: Joseph R. MaWhinney, M.D.
Co-Chp.: Farifteh F. Duffy, Ph.D.

A Estimating Quality of ADHD Treatment In Primary Care and Mental Health Settings
Regina Bussing, M.D., Cynthia W. Garraw, Ph.D., Bonnie T. Zima, M.D.

B Quality of Care for Children in Routine Psychiatric Practice
Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., William E. Narrow, M.D., Donald S. Rae, M.A., Maritza Rubio-Stipec, Sc.D.

C Quality of Care for Children and Adolescents With MDD
William E. Narrow, M.D., Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., Donald S. Rae, M.A., Maritza Rubio-Stipec, Sc.D.

D The Use of Multiple Informants in Quality of Care: Are They Interchangeable?
Maritza Rubio-Stipec, Sc.D., Garrett Fitzmaurice, Sc.D., Gloria Canino, Ph.D.

Discussant: Mina K. Dulcan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7  2:00 p.m.-5:00 p.m.
Room 120, Exhibit Level, Moscone Center

PRACTICING PSYCHIATRY IN 2003

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: Harold I. Eist, M.D.

A The Future of Psychiatry
Brian Crowley, M.D., John C. Urbaitis, M.D.

B The ABC's of Private Practice
Garry M. Vickar, M.D.

C Private and Public Psychiatric Patient Advocacy
Lee H. Beecher, M.D., Roger Peele, M.D.

D The Practice of Complete Psychiatry
Ronald D. Abramson, M.D., Robert L. Pyles, M.D.

Discussants: Edward Gordon, M.D., Janis G. Chester, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8  2:00 p.m.-5:00 p.m.
Room 121, Exhibit Level, Moscone Center

CHALLENGES IN CROSS-CULTURAL PSYCHIATRY: FOCUS ON DEPRESSION AND ETHNOPSYPHARMACOLOGY

Chp.: Rajesh M. Parikh, M.D.
Co-Chp.: Shamsah B. Sonawalla, M.D.

A Impact of Cultural Beliefs on the Treatment of Depressed Chinese-Americans
Albert Yeung, M.D.

B Diagnosis and Treatment of Depressive Disorders in the Asian-Indian Population
Shamsah B. Sonawalla, M.D.

C Management of Depression in the Hispanic Population
David Mischoulon, M.D.

D Principles of Ethnopsychopharmacology
David C. Henderson, M.D.

Discussant: Claudio N. Soares, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9  2:00 p.m.-5:00 p.m.
Room 122, Exhibit Level, Moscone Center

CORE COMPETENCIES: HOW THEY FIT INTO CERTIFICATION AND RECERTIFICATION

Chp.: Stephen C. Scheiber, M.D.

A History of the Core Competency Movement
Thomas A.M. Kramer, M.D.

B ABPN Works on Core Competencies
Daniel K. Winstead, M.D.

C The Relationship Between Core Competencies and Maintenance of Certification
James H. Scully, Jr., M.D.

Discussants: Linda B. Andrews, M.D., Carol A. Bernstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10  2:00 p.m.-5:00 p.m.
Room 123, Exhibit Level, Moscone Center

PSYCHIATRY AND THE PHARMACEUTICAL INDUSTRY: WHERE IS THE BOUNDARY?

Chp.: Amy C. Brodkey, M.D.

A Pharmaceutical Promotion: Effects on the Practice of Psychiatry
Amy C. Brodkey, M.D.
B Academia, Medical Education, and the Pharmaceutical Industry
Frederick S. Sierles, M.D.

C The Pharmaceutical Industry and Public Psychiatry Practice
Robert M. Factor, M.D.

D Industry-Sponsored Medical Education: When Educators Serve Two Masters
Diana M. Kozziupa, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Room 124, Exhibit Level, Moscone Center

EVALUATING CLINICAL COMPETENCE: CURRENT OPTIONS, FUTURE DIRECTIONS
Chp.: Mantosh J. Dewan, M.D.

A Encompassing Assessment of Competency
Siegfried Streufert, Ph.D., Usha G. Satish, Ph.D.

B Evaluating Competence in Psychotherapy
John Manning, M.D., Bernard D. Beitman, M.D., Mantosh J. Dewan, M.D.

C Toward Improved Evaluations: Training Competency
Usha G. Satish, Ph.D., Siegfried Streufert, Ph.D., Mantosh J. Dewan, M.D., John Manning, M.D., Sarah Vander Voort, B.S.
Discussant: Bernard D. Beitman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.
Room 125, Exhibit Level, Moscone Center

OCD SPECTRUM ILLNESSES: WHAT DOES IT MEAN? DOES IT HELP OUR TREATMENT?
Chp.: Michelle T. Pato, M.D.

A BDD and Hypochondriasis: Are They Part of the OCD Spectrum?
Fugen Neziroglu, Ph.D., Dean McKay, Ph.D., Jose A. Yaryura-Tobias, M.D.

B ADHD and OCD: Cognitive Characteristics
Paul D. Arnold, M.D., Russell Schachar, M.D., Shirley Chen, M.D., Abel Ickowicz, M.D.

C Complex Psychopathology and Descriptive Symptomatology in Children
Jose A. Yaryura-Tobias, M.D., Dena Rabinowitz, Ph.D., Fugen Neziroglu, Ph.D.

D A Preliminary Investigation of the Genetic Basis of Grooming Disorders
Margaret A. Richter, M.D., Paul D. Arnold, M.D., Emanuela Mundo, M.D., Sam Fariba, B.S.C., James L. Kennedy, M.D.
Discussant: Michelle T. Pato, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

EVALUATION OF THE SOCIAL BRAIN: IMPLICATIONS FOR MEDICAL EDUCATION AND TREATMENT
The World Psychiatric Association's Psychotherapy Section
Chp.: Russell Gardner, M.D.
Co-Chp.: David Spiegel, M.D.

A Stressed Students Benefit From Focused Social Boosting Signals
Russell Gardner, M.D.

B Feeling and Healing: Emotional and Social Expression Among Cancer Patients
David Spiegel, M.D., Janine Giese-Davis, Ph.D., Cheryl Koopman, Ph.D., Lisa D. Butler, Ph.D., Catherine Classen, Ph.D., Matthew J. Cordova, Ph.D.

C The Sociodynamics of Personal Identity and Therapeutic Change
John O. Beahrs, M.D.

D Nature Disrupted: Darwin and the Borderline Personality
Mark T. Erickson, M.D.

E The Evolved Social Brain and Child Development
John R. Evaldson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
Room 301, Esplanade Level, Moscone Center

ABORTION: SCIENTIFIC DATA TO INFORM CLINICAL CARE
Chp.: Nada L. Stotland, M.D.

A An Overview of Abortion in the U.S.
Stanley Henshaw, Ph.D., Annie Keating

B Surgical and Medical Abortion in the 21st Century: Update for Psychiatrists
Karen Meckstroth, M.D.

C Female Feticide: A Cross-Cultural Perspective
Geetha Jayaram, M.D.

(Continued on next page)
D Abortion and the Law
Jennifer Dalven, J.D.

E Abortion and Psychiatry: Caring for Women and Families
Nada L. Stotland, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
Room 302, Esplanade Level, Moscone Center

SPIRITUALITY AND WORLD VIEW IN CLINICAL PRACTICE

Chp.: Allan M. Josephson, M.D.
Co-Chp.: John R. Peteet, M.D.

A The Weltanschauung of Sigmund Freud: Clinical Implications
Armand M. Nicholi, Jr., M.D.

B The Clinical Assessment of the Patient’s World View
Irving S. Wiesner, M.D.

C Diagnosis and Formulation: Integrating Spiritual and Religious Perspectives
Mark E. Servis, M.D., Allan M. Josephson, M.D.

D Therapeutic Implications of World View
John R. Peteet, M.D.

E Clinical Perspectives on Specific World Views
John R. Peteet, M.D., Allan M. Josephson, M.D., Abba E. Borowich, M.D., S. Atezaz Saeed, M.D., Mark E. Servis, M.D., Samuel B. Thielman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Room 304, Esplanade Level, Moscone Center

COGNITIVE THERAPY IN NOVEL CLINICAL SITUATIONS: RATIONALE, ISSUES, AND CONTROVERSIES

Chp.: Anton C. Trinidad, M.D.

A Developing Cognitive Therapy for Adults With ADHD: Why Bother?
Stephen P. McDermott, M.D.

B Cognitive-Behavior Therapy for Individuals With Schizophrenia
Jan L. Scott, M.D.

C Psychiatric Aspects in Oncology: End-of-Life Decisions
Anton C. Trinidad, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Room 306, Esplanade Level, Moscone Center

EATING DISORDERS 2003: FROM LABORATORY TO PRACTICE

Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Update: Genetics of Anorexia and Bulimia Nervosa
Walter H. Kaye, M.D., Wade H. Berrettini, M.D., Bernie Devlin, Ph.D., Andrew Bergen, Ph.D., Cynthia M. Bulik, Ph.D., Dorothy E. Grice, M.D., The Price Foundation Group

B Realities and Consternations of Outpatient Treatment for Anorexia Nervosa
Katherene A. Haloi, M.D., W. Stewart Agras, M.D., Scott J. Crow, M.D., James E. Mitchell, M.D., G. Terrence Wilson, Ph.D.

C Feeding Laboratory Studies in Patients With Eating Disorders
James E. Mitchell, M.D., Blake A. Gosnell, Ph.D., James L. Roenigk, Ph.D., Martina deZwaan, M.D., Stephen A. Wonderlich, Ph.D., Melissa A. Burgard, Beth N. Wambach

D Are Eating Disorders and Substance Use Disorders Related?
David B. Herzog, M.D., David J. Dorer, Ph.D., Debra L. Franko, Ph.D., Pamela K. Keel, Ph.D., Valerie Charat, B.A., Erica C. Hutchins, B.A., Rebecca Renn, B.A.

E Common and Uncommon Mistakes in Managing Eating Disorders
Joel Yager, M.D., Arnold E. Andersen, M.D., E.L. Danes, J.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Room 307, Esplanade Level, Moscone Center

ADVANCES IN THE TREATMENT OF CHILDHOOD TRAUMATIC GRIEF

Chp.: Robert S. Pynoos, M.D.

A Assessing and Treating Preschool Traumatic Grief After Domestic Violence
Alicia F. Lieberman, Ph.D.

B Assessment and Group-Based Treatment of Traumatically Bereaved Adolescents
Christopher M. Layne, Ph.D., William S. Saltzman, Ph.D., Berina Arslanagic, M.D., Rob Davies, B.A., Robert S. Pynoos, M.D., Gary Burlingame, Ph.D.

C Intervention for Child Survivors of Suicide
Cynthia R. Pfeffer, M.D.
D Terrorism and the Treatment of Childhood Traumatic Grief: Lessons Learned From 9/11
Robin F. Goodman, Ph.D.

Discussant: Judith A. Cohen, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19
2:00 p.m.-5:00 p.m.
Room 308, Esplanade Level, Moscone Center

NOVEL CLINICAL PERSPECTIVES ON THE PATHOPHYSIOLOGY AND TREATMENT OF PTSD
Chp.: Lori L. Davis, M.D.

A Animal Models of PTSD: Can Basic Science Inform the Clinic?
Frederick Petty, M.D.

B Gamma-Aminobutyric Acid Neurohormonal Modulation in PTSD and Treatment With Anticonvulsants
Lori L. Davis, M.D.

C Topiramate Therapy for PTSD
Jeffrey L. Berlant, M.D.

Discussant: Charles R. Marmar, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20
2:00 p.m.-5:00 p.m.
Room 309, Esplanade Level, Moscone Center

INTEGRATING INTERPERSONAL NEUROBIOLOGY IN PSYCHIATRIC TRAINING AND PRACTICE
Chp.: Daniel J. Siegel, M.D.
Co-Chp.: Marilyn B. Benoit, M.D.

A Integrating Neuroscience Into Clinical Practice
Marilyn B. Benoit, M.D.

B Integrating Brain, Mind, and Environment in Psychiatric Education
Eugene V. Beresin, M.D.

C The Neuroscience of Psychotherapy
Louis Cozolino, Ph.D.

D Interpersonal Neurobiology in the Palm of Your Hand
Daniel J. Siegel, M.D.

E Living Without Empathy: The Mirror Neurons
Nancy S. Wolf, M.D.

Discussant: Marcia K. Goin, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 23  2:00 p.m.-5:00 p.m.
Salons 3 & 4, Lower B-2 Level, Marriott

ROADS TO HEALING IN MENTAL HEALTH IN THE AMERICAS
Inter-American Council of Psychiatric Organizations

Chp.: Roberto E. Chaskel, M.D.
Co-Chp.: Amelia E. Musacchio, M.D.

A Folded Roots of Latin-American Psychiatry: The Concept of Illness and Healing
Carlos Leon-Andrade, M.D., Roberto E. Chaskel, M.D.

B Diagnostic Issues in Latin-American Patients: Are We on the Right Road?
Miguel R. Jorge, M.D., Monchablow Alberto

C The Promise of Psychoeducation and Psychopharmacology in the Lives of Latin-American Patients
Ruben J. Hernandez-Serrano, M.D., Antonio Pacheco, M.D.

D Psychotherapy: The Application of a Transcultural Healing Technique
Amelia E. Musacchio, M.D., Rodolfo D. Fahrer, M.D.

E The Promise of Science and its Delivery in the Americas
Andres Meerlein, M.D., Nestor F. Marchant, M.D.

Discussants: Renato D. Alarcon, M.D., Luis F. Ramirez, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24  2:00 p.m.-5:00 p.m.
Salons 5 & 6, Lower B-2 Level, Marriott

SEXUAL AND GENDER IDENTITY DISORDERS: QUESTIONS FOR DSM-V

Chp.: Dan H. Karasic, M.D.
Co-Chp.: Jack Drescher, M.D.

A Gender Identity Disorder in Children and Adolescents: A Critical Review
Darryl B. Hill, Ph.D., Chris Rozanski, M.S.W., Jessica Carfaginini, B.A., Brian Willoughby

B Disordering Gender Identity: Issues of Diagnostic Reform
Katherine Wilson, Ph.D., Arlene I. Lev, C.S.W.

C DSM-IV-TR and the Paraphilias: An Argument for Removal
Charles A. Moser, M.D., Peggy J. Kleinplatz, Ph.D.

Discussants: Robert L. Spitzer, M.D., Paul J. Fink, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25  2:00 p.m.-5:00 p.m.
Salons 10 & 11, Lower B-2 Level, Marriott

CONFRONTING CRISIS IN EDUCATION, MENTAL HEALTH, AND JUVENILE JUSTICE

Chp.: Lawrence K. Richards, M.D.
Co-Chp.: Karen T. Carey, Ph.D.

A Noticing National Problems Through Study of California Juvenile Incarceration Data
Lawrence K. Richards, M.D., Allison Granter, M.S.

B The Fresno-Controlled Prevention Study for Children
Philip F. Kader, B.A., Merle Canfield, Ph.D., Lawrence K. Richards, M.D.

C The Fresno-Controlled Study: Data Analysis, Conclusions, and Predictions
Merle Canfield, Ph.D., Adrianna Shoji, M.A., Kader Philip, Lawrence K. Richards, M.D.

D Preventing Incarceration: Early Prevention for Preschoolers
Karen T. Carey, Ph.D., David Barnett, Ph.D.

E Short- and Long-Term Effects of Risperidone on Conduct Problems in Children
Michael G. Aman, Ph.D., Robert L. Findling, M.D.

F Courts as Case Managers: An End to Transinstitutionalization?
Patrick H. Gardner, J.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 26  2:00 p.m.-5:00 p.m.
Salons 12 & 13, Lower B-2 Level, Marriott

PSYCHIATRY AND THE POWER OF ADVOCACY

Chp.: William M. Glazer, M.D.
Co-Chp.: Patrice A. Harris, M.D.

A Inspiring Psychiatrists to Empower Their Patients
Elizabeth A. Baxter, M.D.

B Understanding the Process of Advocating to Policy Makers
Patrice A. Harris, M.D.

C A Model Presentation: Access to Medications
Andrew J. McLean, M.D.

D Is Advocacy Required in Correctional Systems?
Charles A. Buscema, M.D.

E Forging Alliances Outside of the Point of Care
David Nelson, M.P.P.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 27  2:00 p.m.-5:00 p.m.
Salons 14 & 15, Lower B-2 Level, Marriott

APPLYING DECISION SCIENCE AND GAME
THEORY TO CLINICAL PSYCHIATRY

Chp.: Laurence V. Amsel, M.D.
Co-Chp.: Serge M. Sevy, M.D.

A Toward a Mathematical Psychiatry: The Use and
Limitations of Formal Decision Models
Laurence V. Amsel, M.D.

B Decision Modes and Psychiatry Therapy: The
Importance of Knowing How Patients Decide
Elke V. Weber, Ph.D.

C The Neurocognitive Mechanisms of Decision Making
Antoine Bechara, M.D.

D The Neuromodulation of Emotional Cues in Human
Choice
Robert D. Rogers, M.D.

E Ethnic Differences in Estimating Utilities of Symptom
Reduction in Psychosis
Leslie L. Lenert, M.D.

THIS SESSION WILL BE AUDIOTAPEO.

SYMPOSIUM 28  2:00 p.m.-5:00 p.m.
Golden Gate Hall A, B-2 Level, Marriott

SCHIZOPHRENIA: CURRENT GUIDELINES,
PRACTICES, AND EFFECTIVENESS RESEARCH

Chp.: John S. McIntyre, M.D.
Co-Chp.: Darrel A. Regier, M.D.

A Overview of Best Practices: Current Treatment
Guidelines and Protocols for Schizophrenia
Anthony F. Lehman, M.D.

B Research Gaps and Current Research Initiatives to
Improve the Treatment of Schizophrenia
Jeffrey A. Lieberman, M.D.

C Factors Affecting the Effectiveness of Clinical Decisions
in Treating Schizophrenia
Mark Olfson, M.D., Joyce C. West, Ph.D., Joshua E.
Wilk, Ph.D., Steve Marcus, Ph.D.

D The Treatment of Schizophrenia in Routine Psychiatric
Practice
Joyce C. West, Ph.D., Joshua E. Wilk, Ph.D., Mark
Olfson, M.D., Steve Marcus, Ph.D., Donald S. Rae, M.A.,
William E. Narrow, M.D., Darrel A. Regier, M.D.

Discussant: Samuel J. Keith, M.D.
THIS SESSION WILL BE AUDIOTAPEO.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Hall D, Exhibit Level, Moscone Center

PSYCHOPHARMACOLOGY

For further information on New Research Sessions, please refer
to the New Research Program and Abstracts Book included in your
registration packet.

6:00 p.m. Session

CONVOCATION OF DISTINGUISHED
FELLOWS
6:00 p.m. - 7:30 p.m.
Hall E, Exhibit Level, Moscone Center

All Distinguished Fellows, Fellows, members, and
registered guests are invited.

Presiding: Paul S. Appelbaum, M.D., President

Grand Marshals: Donald J. Scherl, M.D., Lenore C.
Terr, M.D.

Marshals: Renee L. Binder, M.D., Bruce S. Victor, M.D.

INTRODUCTION OF DISTINGUISHED LIFE
FELLOWS
Marcia K. Goin, M.D., President-Elect

INDUCTION OF DISTINGUISHED FELLOWS
Marcia K. Goin, M.D.

INTRODUCTION OF FIFTY-YEAR
DISTINGUISHED LIFE FELLOWS, FIFTY-
YEAR LIFE MEMBERS, AND
INTERNATIONAL FELLOWS
Paul S. Appelbaum, M.D.

INTRODUCTION OF FELLOWS
Paul S. Appelbaum, M.D.

PRESENTATION OF SPECIAL
PRESIDENTIAL COMMENDATIONS
Paul S. Appelbaum, M.D.

PRESENTATION OF DISTINGUISHED
SERVICE AWARDS
Paul S. Appelbaum, M.D.

(Continued on next page)
MONDAY

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS
Paul S. Appelbaum, M.D.

PRESENTATION OF AWARDS
Paul S. Appelbaum, M.D.

APA/Lilly Resident Research Awards
APIRE/Kempf Fund Awards for Research Development in Psychobiological Psychiatry
Human Rights Awards
Blanche F. Ittelson Award for Research in Child Psychiatry
Agnes Purcell McGavin Awards
Isaac Ray Award
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
Charles Krauthammer, M.D.

LECTURE 8
6:00 p.m.-7:00 p.m.
Hall E, Exhibit Level, Moscone Center

WILLIAM C. MENNINGER MEMORIAL LECTURE
Charles Krauthammer, M.D.

Horsemen of the Apocalypse: Terror, Nihilism, and Science

Charles Krauthammer, M.D., is a syndicated columnist for the Washington Post, an essayist for Time Magazine, a political analyst for “Fox News,” and a contributing editor to The Weekly Standard and The New Republic. A psychiatrist by training, Dr. Krauthammer received his medical degree in 1975 from Harvard Medical School and completed his residency in psychiatry at Massachusetts General Hospital. His scientific papers, including his codiscovery of a form of bipolar disease, are still frequently cited in the psychiatric literature. In 1978 he left the practice of psychiatry and came to Washington to serve as a science advisor to the Carter administration. He joined the staff of The New Republic as an essayist and editor in 1981. In 1987, his first full year as a syndicated columnist, he won the Pulitzer Prize for Distinguished Commentary. Among the numerous other awards he has received for his writing are the National Magazine Award for Essays and Criticism, the Champion/Tuck Award for Economic Understanding, and the People for the American Way First Amendment Award. Dr. Krauthammer was appointed to the President’s Council on Bioethics in 2001.

THIS SESSION WILL BE AUDIOTAPED.
PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 28-34

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2
7:00 a.m. - 8:30 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

IMPAIRMENT OF STRUCTURAL PLASTICITY IN SEVERE MOOD DISORDERS: CASUAL OR COLLATERAL?
Supported by Abbott Laboratories

Chp.: Pierre N. Tariot, M.D.
Co-Chp.: Husseini K. Manji, M.D.

A Reduced Hippocampal Volume in Adult Major Depression: The Role of Childhood Trauma
Meena Vythilingham, M.D.

B Targeting Structural Plasticity for Optimal Treatment of Severe Mood Disorders
Husseini K. Manji, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2
7:00 a.m. - 8:30 a.m.
Metropolitan, Second Level, Argent

IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS
Supported by Solvay Pharmaceuticals, Inc.

Chp.: Eric Hollander, M.D.

A Lithium Treatment of Patients With Suicidal Affective Disorder: Risk Factors and Mediators
Jan A. Fawcett, M.D.

B Effects of Lithium on Impulsivity, Aggression, and Suicide
Frederick K. Goodwin, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

BIPOLAR DISORDER IN WOMEN: SPECIAL CONSIDERATIONS AND EVOLVING TREATMENT
Supported by GlaxoSmithKline

Chp.: Lee S. Cohen, M.D.
Co-Chp.: Martha J. Morrell, M.D.
A Evidence-Supportive Therapies for GAD and Social Anxiety Disorder  
Jack M. Gorman, M.D.

B Evidence-Based ECT and Transcranial Magnetic Stimulation  
Sarah H. Lisanby, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 2  
7:00 a.m. - 8:30 a.m.  
Grand Ballroom, Mezzanine Level, Westin St. Francis

MANAGING ANXIETY AND SLEEP: A NEW ERA FOR GAMMA-AMINOBUTYRIC ACID  
Supported by Cephalon Inc.  
Chp.: Philip T. Ninan, M.D.

A Novel Gamma-aminobutyric acid Treatments in Neuropsychiatric Disorders  
Stephen M. Stahl, M.D.

B In Vivo Measurements of Gamma-aminobutyric acid in Neuropsychiatric Disorders  
Linda Chang, M.D.

8:00 a.m. Sessions

COURSES 60-68  
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 60 8:00 a.m. - 12 noon  
Franciscan Room B, Ballroom Level, Hilton

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO  
APA Committee on Psychiatric Dimensions of Disaster

Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfeld, M.D., V. Alex Kehayan, Ed.D.

COURSE 61 8:00 a.m. - 12 noon  
Franciscan Room D, Ballroom Level, Hilton

SELF-REGULATION: THE BRAIN AND THE POWER OF HEALING RELATIONSHIPS

Director: Daniel J. Siegel, M.D.
Faculty: Allan N. Schore, Ph.D.

COURSE 62 8:00 a.m. - 12 noon  
Imperial Ballroom A, Ballroom Level, Hilton

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 63 8:00 a.m. - 12 noon  
Yosemite Room C, Ballroom Level, Hilton

INTEGRATING PSYCHOTHERAPY AND PHARMACOTHERAPY  
APA Committee on Psychotherapy by Psychiatrists

Director: Barton J. Binder, M.D.
Faculty: Bernard D. Beitman, M.D., Michelle B. Riba, M.D.

COURSE 64 8:00 a.m. - 12 noon  
Union Square 5 & 6, Fourth Floor, Hilton

SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS

Director: Gail E. Robinson, M.D.
Faculty: Renee L. Binder, M.D., Sharyn A. Lenhart, M.D., Michael F. Myers, M.D.

COURSE 65 8:00 a.m. -12 noon  
Union Square 13, Fourth Floor, Hilton

EXPANDING HEALTH CARE DELIVERY? LET TELEPSYCHIATRY HELP!

Director: Steven E. Hyler, M.D.
Faculty: Gerald Segal, M.S., William M. Tucker, M.D.

COURSE 66 8:00 a.m. - 12 noon  
Union Square 14, Fourth Floor, Hilton

DOING RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Michelle T. Pato, M.D., Edward K. Silberman, M.D.

COURSE 67 8:00 a.m. - 12 noon  
Union Square 15 & 16, Fourth Floor, Hilton

THE CLINICAL APPLICATION OF CULTURAL PSYCHIATRY

Director: Wen-Shing Tseng, M.D.
Faculty: J. David Kinzie, M.D., Keh-Ming Lin, M.D., Jon M. Strelzter, M.D., Joseph J. Westermeyer, M.D.
TUESDAY

COURSE 68  
8:00 a.m. - 12 noon
Union Square 19 & 20, Fourth Floor, Hilton

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Director: Jesse H. Wright, M.D.
Faculty: Monica A. Basco, Ph.D., Michael E. Thase, M.D.

9:00 a.m. Sessions

CLINAL CASE CONFERENCE 2
9:00 a.m. - 10:30 a.m.
Room 121, Exhibit Level, Moscone Center

DYSKINESIAS IN A SOMATICALLY PREOCCUPIED PATIENT AFTER TREATMENT WITH ATYPICAL ANTIHYPOTICS

Moderator: Curley L. Bonds, M.D.
Discussant: Joseph M. Pierre, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINAL CASE CONFERENCE 1: PART 2
9:00 a.m. - 12 noon
Room 120, Exhibit Level, Moscone Center

TREATMENT OF THE VIP PATIENT: TWO PATIENTS, TWO THERAPISTS

Moderator: Richard L. Munich, M.D.
Presenter: Efram Bleiberg, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 69-74
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 69  
9:00 a.m. - 4:00 p.m.
Imperial Ballroom B, Ballroom Level, Hilton

MED-PHYSICAL DRUG-DRUG INTERACTIONS: AN UPDATE

Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.
Faculty: David M. Benedek, M.D., Jessica R. Oesterheld, M.D.,
Neil B. Sandson, M.D., Gary H. Wynn, M.D.

COURSE 70  
9:00 a.m. - 4:00 p.m.
Yosemite Room B, Ballroom Level, Hilton

PSYCHOTHERAPY OF BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: Eve Caligor, M.D., John F. Clarkin, Ph.D.

COURSE 71  
9:00 a.m. - 4:00 p.m.
Union Square 1 & 2, Fourth Floor, Hilton

PERSONALITY AND POLITICAL BEHAVIOR

Director: Jerrold M. Post, M.D.

COURSE 72  
9:00 a.m. - 4:00 p.m.
Union Square 21, Fourth Floor, Hilton

MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE

Director: Cecilia M. Mikalac, M.D.

COURSE 73  
9:00 a.m. - 4:00 p.m.
Union Square 23 & 24, Fourth Floor, Hilton

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 74  
9:00 a.m. - 4:00 p.m.
Union Square 25, Fourth Floor, Hilton

BASIC HYMNOSIS: PRINCIPLES AND APPLICATIONS

Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D.
DISCUSSION GROUPS 10-13

9:00 a.m. - 10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

10 Lauren B. Marangell, M.D., on Practical Psychopharmacology for the Busy Clinician (Meet the Authors)
   Pacific Conference Suite B, 4th Floor, Marriott

11 Rodrigo A. Munoz, M.D., on Protecting Clinical Autonomy
   Pacific Conference Suite C, 4th Floor, Marriott

12 Dilip V. Jeste, M.D., on Schizophrenia and Aging
   Pacific Conference Suite E, 4th Floor, Marriott

13 Chowallut D. Chacko, M.D., on an Introduction to Starting a Forensic Psychiatric Practice
   Pacific Conference Suite F, 4th Floor, Marriott

FOCUS LIVE SESSION 1

9:00 a.m. – 10:30 a.m.
Room 106, Exhibit Level, Moscone Center

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: James W. Jefferson, M.D., on Bipolar Disorder

Expert clinicians, who served as the guest editors of the first two issues of Foots will lead lively multiple-choice, question-based discussions. This session covers bipolar disorder and the second session at 11:00 a.m. covers substance abuse. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 9-10

LECTURE 9
9:00 a.m. - 10:30 a.m.
Room 101, Exhibit Level, Moscone Center
Andrea Grubb Barthwell, M.D.
Current Perspectives on Our National Drug Control Strategy

Chp.: Patricia I. Ordonces, M.D.
Co-Chp.: Teresita Sanjurjo, M.D.

Andrea Grubb Barthwell, M.D., was nominated to serve as Deputy Director of Demand Reduction for the Office of National Drug Control Policy by President George W. Bush in December 2001 and confirmed by the United States Senate on January 28, 2002. Dr. Barthwell serves as a principal advisor to ONDCP Director John P. Walters on priorities, objectives and goals pertaining to demand reduction policies within the National Drug Control Strategy. As incumbent, Dr. Barthwell provides executive leadership of the Office of Demand Reduction and is responsible for oversight of demand reduction aspects of the Strategy. Dr. Barthwell received a Bachelor of Arts in Psychology from Wesleyan University in Connecticut and a Doctor of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. In 1997, Dr. Barthwell was selected by her peers as one of the “Best Doctors in America” in Addiction Medicine.

THIS SESSION WILL BE AUDIOTAPE.
MASTER EDUCATOR CLINICAL CONSULTATION 5
9:00 a.m. - 10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

T. Byram Karasu, M.D., on Psychotherapeutic Diagnoses and Treatment Planning
Room 218, Mezzanine Level, Moscone Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

RESEARCH ADVANCES IN MEDICINE
9:00 a.m. - 11:00 a.m
Room 300, Esplanade Level, Moscone Center

UNDERSTANDING THE LATEST DEVELOPMENTS IN DEPRESSION: ITS RELATIONSHIP TO THE BRAIN, HEART, AND IMMUNE RESPONSE
Chp.: David M. McDowell, M.D.

Participants: Robert G. Robinson, M.D., on Strokes
Margaret E. Kemeny, Ph.D., on Depression and the Immune Response
David B. Buchholz, M.D., on New and Improved Understanding of Headaches
K. Ranga R. Krishnan, M.D., on Vascular Depression

REVIEW OF PSYCHIATRY: SECTION 1
9:00 a.m. - 12:30 p.m.
Room 104, Exhibit Level, Moscone Center

2003 PSYCHIATRY UPDATE: TRAUMA AND DISASTER RESPONSES AND MANAGEMENT
Co-Chps.: Robert J. Ursano, M.D., Ann E. Norwood, M.D.

1 Terrorism With Weapons of Mass Disruption: Chemical, Biological, Nuclear, Radiological, and Explosive
Robert J. Ursano, M.D.

2 Early Intervention for Trauma-Related Problems
Patricia J. Watson, Ph.D.

3 Neurobiological Mechanisms of Psychological Trauma
Omer Bonne, M.D.

4 Children, Disasters, and the September 11th World Trade Center Attack
Roy H. Lubit, M.D.

5 The Psychiatric Epidemiology of Disaster Responses
Carol S. North, M.D.

WORKSHOPS

COMPONENTS 10-17

COMPONENT WORKSHOP 10 9:00 a.m. - 10:30 a.m.
Room 105, Exhibit Level, Moscone Center

PRACTICAL TIPS ON HOW TO BE A SUCCESSFUL AUTHOR
American Psychiatric Publishing Inc. Editorial Board

Chp.: Robert E. Hales, M.D.
Participants: Glen O. Gabbard, M.D., John M. Oldham, M.D.,
Alan F. Schatzberg, M.D., Donna E. Stewart, M.D.

COMPONENT WORKSHOP 11 9:00 a.m. - 10:30 a.m.
Salons 3 & 4, Lower B-2 Level, Marriott

HOW TO PROVIDE GERIATRIC PSYCHIATRY DURING RESIDENCY
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Chp.: Colleen J. Northcott, M.D.
Participants: Barbara J. Justice, M.D., Iqbal Ahmed, M.D.,
Joseph A. Cheong, M.D.

COMPONENT WORKSHOP 12 9:00 a.m. - 10:30 a.m.
Salons 5 & 6, Lower B-2 Level, Marriott

PSYCHIATRIC MANAGEMENT OF HIV, HEPATITIS C, AND SUBSTANCE ABUSE
APA Committee on AIDS

Chp.: Milton L. Wainberg, M.D.
Participants: Karl Goodkin, M.D., Steven L. Batki, M.D.

COMPONENT WORKSHOP 13 9:00 a.m. - 10:30 a.m.
Salons 12 & 13, Lower B-2 Level, Marriott

IMGS: CHALLENGES AND SOLUTIONS
APA Committee on International Medical Graduates

Co-Chps.: Josie L. Olympia, M.D., Godehard Oepen, M.D.
Participants: Moitri N. Datta, M.D., Elizabeth J. Santos, M.D.,
Rolando R. Velasquez, L.L.B.

COMPONENT WORKSHOP 14 9:00 a.m. - 10:30 a.m.
Salons 14 & 15, Lower B-2 Level, Marriott

NEW APA ETHICS PROCEDURES: IMPLICATIONS FOR THE PROFESSION, PART 1
APA Ethics Appeal Board

Co-Chps.: Richard D. Milone, M.D., Pedro Ruiz, M.D.
Participants: JoAnn Macbeth, J.D., Alfred Herzog, M.D.,
Alan A. Stone, M.D.
COMPONENT WORKSHOP 15 9:00 a.m. - 10:30 a.m.
Golden Gate Hall A, B-2 Level, Marriott

CAREER CHOICES IN PSYCHIATRY EXPLORING FELLOWSHIP TRAINING
APA Assembly Committee of Area Member-in-Training Representatives

Chp.: Caroline E. Fisher, M.D.
Participants: Mathieu Bermingham, M.D., John R. Chamberlain, M.D., Maria I. Fernandez, M.D., Joshua A. Israel, M.D., John C. Furman, M.D.

COMPONENT WORKSHOP 16 9:00 a.m. - 10:30 a.m.
Pacific Conference Suite H, 4th Floor, Marriott

IT DOESN'T HAPPEN TO US: INSIDER'S VIEW OF TRAUMA IN MINORITY COMMUNITIES
APA Center for Mental Health Services and APA/AstraZeneca Minority Fellows

Chp.: Napoleon B. Higgins, Jr., M.D.
Participants: Laresha L. Hall, M.D., Aruna S. Rao, M.D., Jean-Marie Alves-Bradford, M.D., Eric R. Williams, M.D.

COMPONENT WORKSHOP 17 9:00 a.m. - 10:30 a.m.
Pacific Conference Suite J, 4th Floor, Marriott

RACISM: DIAGNOSTIC AND TREATMENT CONSIDERATIONS
APA Committee of Black Psychiatrists

Chp.: Michelle O. Clark, M.D.
Participants: Carl C. Bell, M.D., George L. Mallory, M.D.

ISSUES 35-53

ISSUE WORKSHOP 35 9:00 a.m. - 10:30 a.m.
Room 110, Exhibit Level, Moscone Center

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY OF PANIC: A LEARNING-STRATEGY APPROACH

Co-Chps.: Bryan K. Touchet, M.D., Kim A. Coon, L.P.C.

ISSUE WORKSHOP 36 9:00 a.m. - 10:30 a.m.
Room 111, Exhibit Level, Moscone Center

CONSENT EVALUATIONS: ASSESSING CAPACITY FOR DECISION MAKING AND FOR VOLUNTARISM

Chp.: Laura W. Roberts, M.D.

ISSUE WORKSHOP 37 9:00 a.m. - 10:30 a.m.
Room 112, Exhibit Level, Moscone Center

ARTISTIC USE OF THE CREATIVE UNCONSCIOUS IN THE THERAPEUTIC ALLIANCE

Co-Chps.: Ian E. Alger, M.D., Ferruccio A. di Cori, M.D.

ISSUE WORKSHOP 38 9:00 a.m. - 10:30 a.m.
Room 113, Exhibit Level, Moscone Center

PSYCHIATRY TRAINING FOR PRIMARY CARE PHYSICIANS: WHAT, HOW MUCH, AND HOW?

Chp.: Hoyle Leigh, M.D.
Participants: Deborah C. Stewart, M.D., Tara A. Grady-Weliky, M.D., Don R. Lipsitt, M.D., Seth M. Pownier, M.D.

ISSUE WORKSHOP 39 9:00 a.m. - 10:30 a.m.
Room 114, Exhibit Level, Moscone Center

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINE PATIENTS

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 40 9:00 a.m. - 10:30 a.m.
Room 122, Exhibit Level, Moscone Center

THE DEVELOPMENT, IMPLEMENTATION, AND OPERATION OF DIVERSE TELEPSYCHIATRY PROGRAMS

Chp.: Norman E. Alessi, M.D.
Participants: Donald M. Hilty, M.D., Beverly N. Jones, M.D.

ISSUE WORKSHOP 41 9:00 a.m. - 10:30 a.m.
Room 123, Exhibit Level, Moscone Center

CHALLENGING BEHAVIOR, MENTAL ILLNESS, AND DEVELOPMENTAL DISABILITIES

Co-Chps.: Earl L. Loschen, M.D., Robert J. Pary, M.D.
Participant: Josefina M. Baluga, M.D.

ISSUE WORKSHOP 42 9:00 a.m. - 10:30 a.m.
Room 124, Exhibit Level, Moscone Center

TREATMENT OF SCHIZOPHRENIA: ANTIPSYCHOTIC POLYPHARMACY VERSUS MONOTHERAPY

Chp.: Andre Tapp, M.D.
Participants: Donald C. Goff, M.D., William G. Honer, M.D., Alexander L. Miller, M.D., Robert A. Rosenheck, M.D.

ISSUE WORKSHOP 43 9:00 a.m. - 10:30 a.m.
Room 125, Exhibit Level, Moscone Center

RELEVANT DATA FOR THE PRACTICING PSYCHIATRIST: COMORBIDITIES/COMBINED TREATMENT

Chp.: Daniel A. Deutschman, M.D.
Participants: Terence L. Witham, M.D., John S. Lloyd, Ph.D., Robert J. Ronis, M.D., Stephen M. Goldfinger, M.D., Rebecca S. Bierman, D.O.
TUESDAY

ISSUE WORKSHOP 44  9:00 a.m. - 10:30 a.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

THE BENZODIAZEPINE CONTROVERSY

Co-Chps.: Christopher K. Chung, M.D., Dean M. De Crisce, M.D.
Participants: Stephen B. Seager, M.D., Ricardo P. Mendoza, M.D., John W. Tsuang, M.D.

ISSUE WORKSHOP 45  9:00 a.m. - 10:30 a.m.
Room 301, Esplanade Level, Moscone Center

SURGEON GENERAL'S REPORT ON CULTURE, RACE, AND ETHNICITY: CLINICAL IMPLICATIONS

Chp.: Theresa M. Miskimen, M.D.
Participants: Nang Du, M.D., James W. Thompson, M.D.

ISSUE WORKSHOP 46  9:00 a.m. - 10:30 a.m.
Room 302, Esplanade Level, Moscone Center

THE PSYCHIATRIC CARE OF SURVIVORS OF TORMTURE

Chp.: Asher D. Aladjem, M.D.
Participants: Kimberly A. Busi, M.D., Sophia Banu, M.D., Hawthorne Smith, Ph.D.

ISSUE WORKSHOP 47  9:00 a.m. - 10:30 a.m.
Room 304, Esplanade Level, Moscone Center

DEVELOPMENT OF THE SCHOOL-BASED ADOLESCENT DEPRESSION AWARENESS PROGRAM

Co-Chps.: Karen L. Swartz, M.D., Todd S. Cox, M.D.
Participants: Elizabeth A. Kastelic, M.D., Sallie Mink, R.N.

ISSUE WORKSHOP 48  9:00 a.m. - 10:30 a.m.
Room 306, Esplanade Level, Moscone Center

DEVELOPMENTS IN COGNITIVE THERAPY FOR SCHIZOPHRENIA

Chp.: David G. Kingdon, M.D.
Participant: Douglas Turkington, M.B.

ISSUE WORKSHOP 49  9:00 a.m. - 10:30 a.m.
Room 308, Esplanade Level, Moscone Center

PSYCHIATRIC ILLNESS AND THE WORKPLACE

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 50  9:00 a.m. - 10:30 a.m.
Room 309, Esplanade Level, Moscone Center

PSYCHIATRIC PERSPECTIVES ON THE EXECUTION PROCESS: A CONTINUING CONUNDRUM

Chp.: Howard J. Osofsky, M.D.
Participants: Rahn K. Bailey, M.D., Alfred M. Freedman, M.D., Abraham L. Halpern, M.D., Donna M. Mancuso, M.D., Michael J. Osofsky, Ira D. Glick, M.D.

ISSUE WORKSHOP 51  9:00 a.m. - 10:30 a.m.
Room 310, Esplanade Level, Moscone Center

FROM NEUROPATHOLOGY TO TREATMENT: EMERGING TREATMENT STRATEGIES FOR ALZHEIMER'S DISEASE

Chp.: Jacobo E. Mintzer, M.D.
Participants: Gary L. Wenk, Ph.D., David Snowdon, Ph.D., Rachelle S. Doody, M.D.

ISSUE WORKSHOP 52  9:00 a.m. - 10:30 a.m.
Salons 1 & 2, Lower B-2 Level, Marriott

THE EMERGING ROLE OF PSYCHIATRY IN A BIOTERRORISM RESPONSE

Chp.: Anthony T. Ng, M.D.
Participants: Robert DeMartino, M.D., Kenneth S. Thompson, M.D.

ISSUE WORKSHOP 53  9:00 a.m. - 10:30 a.m.
Salons 10 & 11, Lower B-2 Level, Marriott

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 1

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 14-17

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

14 Raphael J. Leo, M.D., on An Update on Pain Management (Meet the Authors)
Pacific Conference Suite B, 4th Floor, Marriott

(Continued on next page)
TUESDAY

15 Anita L.H. Clayton, M.D., on Clinical Implications of Sexual Dysfunction in Depression  
Pacific Conference Suite C, 4th Floor, Marriott

16 Steven S. Sharfstein, M.D., on Psychiatric Leadership in the Medical Marketplace  
Pacific Conference Suite E, 4th Floor, Marriott

17 Glen O. Gabbard, M.D., on Maintaining and Developing Family Relationships During Residency (For Residents Only)  
Pacific Conference Suite I, 4th Floor, Marriott

FOCUS LIVE SESSION 2

9:00 a.m. – 10:30 a.m.  
Room 106, Exhibit Level, Moscone Center

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.  
Presenter: Kathleen T. Brady, M.D., on Substance Abuse

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. The first session at 9:00 a.m. covers bipolar disorder and this session covers substance abuse. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 11-12

LECTURE 11

11:00 a.m. - 12:30 p.m.  
Rooms 130/131, Exhibit Level, Moscone Center

Christopher A. Ross, M.D.  
Neurogenetics: Insights Into Neurodegeneration and Approaches to Schizophrenia

Chp.: Anand Pandurangi, M.D.  
Co-Chp.: K. Roy MacKenzie, M.D.

Christopher A. Ross, M.D., will discuss how modern molecular genetic and neurobiologic techniques have led to great advances in our understanding of neurodegenerative diseases, and are beginning to provide insights into psychiatric diseases such as schizophrenia. Many neurodegenerative diseases, including Huntington’s Disease, Parkinson’s Disease, and also Alzheimer’s Disease, are now appreciated to involve protein misfolding and abnormal protein interactions. Huntington’s Disease is an autosomal dominant genetic disorder caused by a triplet repeat expansion in the HD gene, resulting in a huntington protein with an abnormally long polyglutamine stretch and altered conformation. Abnormal interactions with other proteins within the cell then cause neuronal cell death in selective regions of the brain, resulting in motor, cognitive, and emotional changes. Neuroimaging studies indicate that individuals with the HD gene mutation begin to have basal ganglia atrophy well before the clinically diagnostic syndrome, suggesting that when treatments are available they should begin in presymptomatic mutation-positive individuals. Parkinson’s Disease, by contrast, had long been considered to be mostly sporadic, but rare families with genetic forms of the disease are yielding insight into a pathogenic pathway involved in all patients with the disease. Abnormal interactions involving parkin and alpha-synuclein contribute to the formation of the Lewy bodies, the characteristic neuropathology of the disease. The same kinds of techniques that have been so powerful in studying these neurodegenerative diseases are now being applied to schizophrenia. These techniques are beginning to provide cell biological evidence in favor of the hypothesis that schizophrenia involves abnormalities in cerebral cortical development.

Frontiers of Science Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 12

11:00 a.m. - 12:30 p.m.  
Rooms 132/133, Exhibit Level, Moscone Center

Julien Mendlewicz, M.D.  
The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets

Chp.: Lewis L. Judd, M.D.  
Co-Chp.: Paul J. Goodnick, M.D.

Julien Mendlewicz, M.D., is Professor of Psychiatry at the Faculties of Medicine, Psychology, and Law at the University of Brussels, Chairman of the Department of Psychiatry at Erasme Hospital in Brussels, and Director of the Laboratory of Psychiatric Research of the Faculty of Medicine at the Free University of Brussels, Belgium. Professor Mendlewicz’s research interests include molecular neurobiology and behavioral genetics, particularly of affective disorders, chronobiology and sleep; and neuropharmacology. The author of more than 600 scientific articles, Professor Mendlewicz is the Founding and Principal Editor of Neuropsychopharmacology and Editor of the international series Advances in Biological Psychiatry. An active member of many international scientific societies, Professor Mendlewicz is President-Elect of the European College of Neuropsychopharmacology. He has received numerous honors, including the A.E. Bennett Research Award from the American Society of Biological Psychiatry, the Anna Monika International Foundation Prize for Research in Depression, the Lieber Prize from the National Alliance for Research
TUESDAY

MASTER EDUCATOR CLINICAL CONSULTATIONS 6-7
11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

6 Stephen M. Goldfinger, M.D., on Engaging the Disengaged: Connecting With Marginalized Patients Room 218, Mezzanine Level, Moscone Center

7 Philip R. Muskin, M.D., on Rational or Rationalized Suicide? An Ethical/Clinical Dilemma Room 220, Mezzanine Level, Moscone Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 2
11:00 a.m. - 12:30 p.m.
Room 300, Esplanade Level, Moscone Center

MENOPAUSE: WHAT PSYCHIATRISTS NEED TO KNOW

Chp.: Natalie L. Rasgon, M.D.
Presenter: Louann Brizendine, M.D.

RESEARCH CONSULTATION WITH
11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

1 J. Raymond DePaulo, Jr., M.D., on the Genetics of Bipolar Disorder and Other Psychiatric Phenotypes Sierra Conference Suite E, 5th Floor, Marriott

SCIENTIFIC AND CLINICAL REPORT SESSIONS 8-18

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m. - 12:30 p.m.
Room 110, Exhibit Level, Moscone Center

MOOD AND ANXIETY DISORDERS IN CHILDREN AND ADOLESCENTS

Chp.: Elizabeth B. Weller, M.D.
Co-Chp.: Eric R. Williams, M.D.

11:00 a.m.
23 Management of Adolescent Mania
Melissa P. DelBello, M.D.

11:30 a.m.
24 Exploratory Factor Analysis of BPD Criteria in Hospitalized Adolescents
Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D., Thomas H. McGlashan, M.D.

12 noon
25 Gender Differences in Comorbidities in Child and Adolescent GAD
Atilla Turgay, M.D., Mansoor Zafar, M.D., Rubaba Ansari, M.A., Khalid M. Jat, M.D., Eyup S. Ercan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m. - 12:30 p.m.
Room 111, Exhibit Level, Moscone Center

DEPRESSIVE DISORDERS

Chp.: Harvey Stabinsky, M.D.
Co-Chp.: Katherine G. Mellott, M.D.

11:00 a.m.
26 Continuation Cognitive-Behavioral Therapy Maintains Attributional Style Improvement in Depressed Patients Responding Acutely to Fluoxetine.
Timothy J. Petersen, Ph.D., Yasmin Mahal, B.A., Joel A. Pava, Ph.D., Ella L. Masson, B.A., Maurizio Fava, M.D., Andrew A. Nierenberg, M.D., Amy H. Farabaugh, Ph.D.

11:30 a.m.
27 The Potential Relationship Between Levels of Perceived Stress and Specific Subtypes of Major Depression
Amy H. Farabaugh, Ph.D., Pamela A. Roffi, B.S., Ella L. Masson, B.A., Dost Ongur, M.D., Timothy J. Petersen, Ph.D., Rebecca Harley, Ph.D., Maurizio Fava, M.D.

12 noon
28 Symptom Severity and Exclusion From Antidepressant Efficacy Trials
Mark Zimmerman, M.D., Michael A. Posternak, M.D., Iwona Chelminski, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m. - 12:30 p.m.
Room 112, Exhibit Level, Moscone Center

NEUROPSYCHIATRY
Chp.: Goderdz Oepen, M.D.
Co-Chp.: David A. Casey, M.D.

11:00 a.m.
29 Dyslexia as a Potential Index of Neurocognitive Impairments in Patients With Schizophrenia
Giuseppe Bersani, M. Laura Maneschi, Carlo Leone, M. Maddalena Cacioppo

11:30 a.m.
30 Previous Head Injuries in Psychiatric Inpatients
Edward Kari, M.D., Michael Gara, Ph.D., Shula Minsky, Ed.D.

12 noon
31 Neurofeedback to Increase Remission Rates in Depression
Leo I. Jacobs, M.D., Shannon Doyle, Ph.D., Dan McDonnell, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m. - 12:30 p.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

ADULT ADHD
Chp.: Gordon D. Strauss, M.D.
Co-Chp.: Keith McBurnett, Ph.D.

11:00 a.m.
32 Efficacy and Safety of Atomoxetine in Adults With ADHD
Thomas J. Spencer, M.D.

11:30 a.m.
33 Adderall XR Dosed Once Daily in Adult Patients With ADHD
Richard H. Weisler, M.D., Allan K. Chrisman, M.D., Timothy E. Wilens, M.D.

12 noon
34 Alpha-1 Agonist Prazosin for ADHD: The Role of Norepinephrine in ADHD Pathology
Fletcher B. Taylor III, M.D., Nancy Allison, P.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m. - 12:30 p.m.
Room 302, Esplanade Level, Moscone Center

TREATMENT OPTIONS IN ADHD
Chp.: Roger M.Y. Wu, M.D.
Co-Chp.: Kiki D. Chang, M.D.

11:00 a.m.
35 Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting
Christopher J. Kratochvil, M.D.

11:30 a.m.
36 Modafinil Improves ADHD Symptoms in Children in a Randomized, Double-Blind, Placebo-Controlled Study
Joseph Biederman, M.D., James M. Swanson, M.D., Frank A. Lopez, M.D.

12 noon
37 Safety and Efficacy of OROS MPH in Adolescents With ADHD
Laurence L. Greenhill, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m. - 12:30 p.m.
Room 308, Esplanade Level, Moscone Center

PHARMACOTHERAPY OF DEPRESSION
Chp.: John J. Schwab, M.D.
Co-Chp.: William A. James, M.D.

11:00 a.m.
38 Onset and Maintenance of Antidepressant Efficacy for Duloxetine 60 mg QD
Stephen K. Brannan, M.D., Craig H. Mallinckrodt, Ph.D., Gary D. Tollefson, M.D., Michael J. Detke, M.D., John G. Watkin, Ph.D.

11:30 a.m.
39 Depressive Subtypes and Response to Augmentation or Dose Increase Among Outpatients Resistant to Fluoxetine 20 mg a Day
Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Julie L. Ryan, B.A., Jessica L. Murakami, B.A., Andrew A. Nierenberg, M.D., Jerrold F. Rosenbaum, M.D., Maurizio Fava, M.D.

12 noon
40 Treatment-Related Adverse Events in a 20 mg Open-Trial of Fluoxetine: Predictors of Emergence and Impact on the Course of Treatment
George I. Papakostas, M.D., Timothy J. Petersen, Ph.D., Heidi D. Montoya, B.A., Yasmin Mahal, B.A., Andrew A. Nierenberg, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m. - 12:30 p.m.
Salons 3 & 4, Lower B-2 Level, Marriott

MOOD DISORDERS AND SOMATIC ILLNESS
Chp.: David K. Gittelman, M.D.
Co-Chp.: Mahmoud A. Mohamed, M.D.
11:00 a.m.
41 Cardiovascular Risk Factors Predict Treatment Outcome in MDD
Dan V. Ioosescu, M.D., Nicoleta Clementi-Craven, M.D., Julie L. Ryan, B.A., Andrew A. Nierenberg, M.D., George I. Papakostas, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.
42 Prevalence and Characteristics of Patients With Depression and/or Chronic Pain
Bruce A. Arnow, Ph.D., Enid M. Hunkeler, M.A., Christine Blasey, Ph.D., Bruce Fireman, Ph.D., Janelle Lee, Ph.D., Rebecca Robinson, M.S., Chris Hayward, M.D.

12 noon
43 Effectiveness of Collaborative Care in a Depressed, Poor, Primary Care Sample
Lawson R. Wulsin, M.D., Shelley A. Evans, M.S., Terrance J. Wade, Ph.D., Orson Austin, M.D., Martha McCarthy, B.A., Heidi Meyer, B.A., Victoria E. Wells, M.D.

11:00 a.m.
44 Modafinil in Children With ADHD: A Randomized, Placebo-Controlled Study
James M. Swanson, M.D., Laurence L. Greenhill, M.D., Joseph Biederman, M.D.

11:30 a.m.
45 Quetiapine Use in Children and Adolescents: A Literature Review
Brian J. McConville, M.D.

12 noon
46 Clinical Review of OROS MPH in Children, Adolescents, and Adults With ADHD
Timothy E. Wilens, M.D.

11:00 a.m.
47 Personality Traits as Predictors of Suicidality in Young Women
Joel F. Paris, M.D., Gustavo Turecki, M.D., Mark Zoccolillo, M.D., Richard Tremblay, Ph.D.

11:30 a.m.
48 Suicidal Behavior in Violent and Nonviolent Psychiatric Patients
Menahem I. Krakowski, M.D.

12 noon
49 Obstetric Complications and Suicide Risk in Adolescence and Young Adulthood
Richard Neugebauer, Ph.D., M. Lynne Reuss, M.D.

11:00 a.m.
50 Elevated Maternal Cytokine Levels and Adult Schizophrenia Patients in Offspring
Alan S. Brown, M.D., Jonathan Hooton, Ph.D., Eva Petkova, Catherine A. Schaefer, Ph.D., Vicki Babulas, M.P.H., Jack M. Gorman, M.D., Ezra S. Susser, M.D.

11:30 a.m.
51 Association Between Psychotic Symptoms and Seizures in a Community Sample
Christine L. Baker, M.P.H., Richard Neugebauer, Ph.D., Robert Kohn, M.D.

12 noon
52 Biological Mechanisms in Schizophrenic Thought Disorder and Delusions
Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Ellen S. Herbener, Ph.D., Linda S. Grossman, Ph.D.

11:00 a.m.
53 Predictors of Suicide
Chp.: Kathleen B. Unger, M.D.
Co-Chp.: Barbara J. Justice, M.D.

(Continued on next page)
TUESDAY

11:00 a.m.
53 Diagnoses in Behavioral Health Clinics: Impact on Perceived Burden of Mental Health
Abigail L. Garvey-Wilson, M.D., Charles W. Hoge, M.D., Stephen C. Messer, Ph.D., Sandra E. Lesikar, Ph.D., Karen M. Eaton, M.S.

11:30 a.m.
54 The Treatment Gap in Mental Health Care
Robert Kohn, M.D., Shekhar Saxena, M.D., Itzhak Levav, M.D., Benedetto Saraceno, M.D.

12 noon
55 Projecting National Survey Prevalences to Populations of Interest
Stephen C. Messer, Ph.D., Xian Liu, Ph.D., Charles W. Hoge, M.D., David N. Cowan, Ph.D., Charles C. Engel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENT 18-22

COMPONENT WORKSHOP 18 11:00 a.m. - 12:30 p.m.
Room 309, Esplanade Level, Moscone Center

ENCOUNTERING THE SPIRITUAL IN PSYCHIATRIC (PSYCHOTHERAPY) PRACTICE
APA Northern California Psychiatric Society

Chp.: Kalpana I. Nathan, M.D.
Participants: Randall Weingarten, M.D., Bruce Linenberg, Ph.D., Steven Fisdel, M.A.

COMPONENT WORKSHOP 19 11:00 a.m. - 12:30 p.m.
Room 310, Esplanade Level, Moscone Center

SEXUAL HARASSMENT: VICTIMS FACE CONFIDENTIALITY ISSUES IN PSYCHIATRIC CARE
APA Committee on Women

Co-Chps.: Rita R. Newman, M.D., Annette J. Hollander, M.D.
Participants: Maria T. Lymberis, M.D., David W. Garland, Esq., Francine Weiss, Esq.

COMPONENT WORKSHOP 20 11:00 a.m. - 12:30 p.m.
Salons 1 & 2, Lower B-2 Level, Marriott

PATIENT SAFETY IN PSYCHIATRY: REDUCING INPATIENT SUICIDE
APA Committee on Quality Indicators

Co-Chps.: Miles F. Shore, M.D., Alfred Herzog, M.D.
Participant: Paul Quinnett, M.D.

COMPONENT WORKSHOP 21 11:00 a.m. - 12:30 p.m.
Salons 14 & 15, Lower B-2 Level, Marriott

NEW APA ETHICS PROCEDURES: IMPLICATIONS FOR THE PROFESSION, PART 2
APA Ethics Committee and APA Ethics Appeal Board

Chp.: Wade C. Myers, M.D.
Participants: William Arroyo, M.D., Harriet C. Stern, M.D., Donald G. Langsley, M.D., Spencer Eth, M.D.

COMPONENT WORKSHOP 22 11:00 a.m. - 12:30 p.m.
Golden Gate Hall A, B-2 Level, Marriott

AIDSISM, AGEISM, RACISM: PSYCHIATRIST'S ROLE IN THE GERIATRIC AIDS EPIDEMIC
APA New York County District Branch's AIDS Committee

Co-Chps.: Kenneth B. Ashley, M.D., Mary Ann Cohen, M.D.
Participants: Kristina L. Jones, M.D., John A.R. Grimaldi, Jr., M.D.

ISSUES 54-63

ISSUE WORKSHOP 54 11:00 a.m. - 12:30 p.m.
Room 105, Exhibit Level, Moscone Center

SPIRITUAL AND RELIGIOUS ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: James L. Griffith, M.D.

ISSUE WORKSHOP 55 11:00 a.m. - 12:30 p.m.
Room 113, Exhibit Level, Moscone Center

CAREER DEVELOPMENT AND RISK MANAGEMENT

Co-Chps.: Joseph M. Schwartz, M.D., George A. Fouras, M.D.
Participants: Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D.

ISSUE WORKSHOP 56 11:00 a.m. - 12:30 p.m.
Room 114, Exhibit Level, Moscone Center

THERAPEUTIC ISSUES IN SELF-INJURIOUS BEHAVIOR

Co-Chps.: Jose A. Yaryura-Tobias, M.D., Fugen Neziroglu, Ph.D.

ISSUE WORKSHOP 57 11:00 a.m. - 12:30 p.m.
Room 121, Exhibit Level, Moscone Center

TECHNOLOGY SERVES THE PATIENT: ALGORITHMS, MONITORING, AND DECISION SUPPORT

Chp.: Daniel A. Deutschman, M.D.
Participants: Naresh A. Dewan, M.D., Joshua E. Freedman, M.D., Seth M. Powsner, M.D.
TUESDAY

ISSUE WORKSHOP 58  11:00 a.m. - 12:30 p.m.
Room 122, Exhibit Level, Moscone Center

WOMEN IN ACADEMIC PSYCHIATRY: OPPORTUNITIES, OBSTACLES, AND STRATEGIES
Co-Chps.: Carolyn B. Robinowitz, M.D., Carol C. Nadelson, M.D.
Participants: Lynn C. Epstein, M.D., Joan A. Lang, M.D., Donna E. Stewart, M.D.

ISSUE WORKSHOP 59  11:00 a.m. - 12:30 p.m.
Room 123, Exhibit Level, Moscone Center

THE ART OF THE UNCONSCIOUS: SHAKESPEARE, POETRY, FILM, AND PSYCHIATRY
Chp.: Steven E. Pflanz, M.D.
Participant: Charles R. Joy, M.D.

ISSUE WORKSHOP 60  11:00 a.m. - 12:30 p.m.
Room 124, Exhibit Level, Moscone Center

ASIAN INDIANS IN INTERFAITH MARRIAGES: CHALLENGES, CONFLICTS, AND COMPROMISES
Indo-American Psychiatric Association
Chp.: jagannahthi Srinivasaraghavan, M.D.
Participants: Surinder S. Nand, M.D., Bala Sarma, M.D., Mina S. Bobdey, M.R.C., Iqbal Ahmed, M.D.

ISSUE WORKSHOP 61  11:00 a.m. - 12:30 p.m.
Room 125, Exhibit Level, Moscone Center

THE ROLE OF THE SOUL: THE IMPACT OF SPIRITUAL BELIEF SYSTEMS OF HEALING
Chp.: Walter R. Byrd, Jr., M.D.

ISSUE WORKSHOP 62  11:00 a.m. - 12:30 p.m.
Room 304, Esplanade Level, Moscone Center

POST-GENOCIDE PSYCHOLOGICAL TRAUMA IN FILM: UNDER THE DOMIN TREE
Co-Chps.: Maurice Preter, M.D., Harold J. Bursztajn, M.D.

ISSUE WORKSHOP 63  11:00 a.m. - 12:30 p.m.
Salons 10 & 11, Lower B-2 Level, Marriott

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 2
Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

12 noon Sessions

FORUMS 4-7

FORUM 4  12 noon - 1:30 p.m.
Room 301, Esplanade Level, Moscone Center

NEUROBIOLOGY OF PARENT-CHILD RELATIONSHIPS: APPLICATIONS TO PSYCHOTHERAPY
APA Committee on Psychotherapy by Psychiatrists
Chp.: Bernard D. Beitman, M.D.
Co-Chp.: Eva M. Szegedy, M.D.
Participants: Robert J. Waldinger, M.D., David Reiss, M.D., Jill M. Hooley, Ph.D.

FORUM 5  12 noon - 1:30 p.m.
Room 306, Esplanade Level, Moscone Center

TERRORISM AND PSYCHOSOCIAL PREPAREDNESS
Chp.: Howard J. Osofsky, M.D.
Participants: Harold S. Kopklewicz, M.D., Joy D. Osofsky, Ph.D., Betty Pfefferbaum, M.D., Robert J. Ursano, M.D.

FORUM 6  12 noon - 1:30 p.m.
Room 307, Esplanade Level, Moscone Center

PROZAC ON THE COUCH
Chp.: Jonathan M. Metzl, M.D.
Participants: David M. McDowell, M.D., Joel T. Braslow, M.D.

FORUM 7  12 noon - 1:30 p.m.
Golden Gate Hall B, B-2 Level, Marriott

INTIMATE PARTNER VIOLENCE AND ABUSE: IDENTIFICATION AND INTERVENTION WITHIN A BEHAVIORAL HEALTH STUDY
Chp.: Penny K. Randall, M.D.
Participants: Carole L. Warshaw, M.D., Patricia Salber, M.D., Robin A. Dea, M.D., Bridged MaCaw, M.D.

NEW RESEARCH POSTER SESSION 6
12 noon - 2:00 p.m.
Hall D, Exhibit Level, Moscone Center

THERAPEUTICS; BIOLOGICAL, GERIATRIC, CONSULTATION, AND EMERGENCY PSYCHIATRY

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.
TUESDAY

1:00 p.m. Sessions

COURSES 75-81
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 75 1:00 p.m. - 5:00 p.m.
Franciscan Room B, Ballroom Level, Hilton

PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM

Director: Shaila Misri, M.D.
Faculty: Diana Carter, M.B., Maria Corall, M.D., Deirdre M. Ryan, M.B., Kristin S. Sivert2, M.D.

COURSE 76 1:00 p.m. - 5:00 p.m.
Imperial Ballroom A, Ballroom Level, Hilton

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE

Director: Karl Doghramji, M.D.
Faculty: Thomas D. Hurwitz, M.D., John W. Winkelman, M.D.

COURSE 77 1:00 p.m. - 5:00 p.m.
Yosemite Room A, Ballroom Level, Hilton

THE COMPLEXITIES OF CHRONIC PAIN: MULTIDISCIPLINARY TREATMENT APPROACHES

Co-Directors: Allen Lebovits, Ph.D., Matthew B. Smith, M.D.
Faculty: Robert Cancro, M.D., Michael R. Clark, M.D., Michel Dubois, M.D., Jeffrey D. Rome, M.D.

COURSE 78 1:00 p.m. - 5:00 p.m.
Union Square 5 & 6, Fourth Floor, Hilton

THE JUVENILE JUSTICE CLINIC: ADMINISTRATIVE ISSUES AND TREATMENT OPTIONS

Director: Gabriel Kaplan, M.D.
Faculty: Denise M.W. Johnson, Ph.D., Michael Swerdlow, Ph.D.

COURSE 79 1:00 p.m. - 5:00 p.m.
Union Square 14, Fourth Floor, Hilton

WRITING ABOUT CLINICAL EXPERIENCES

Director: John S. Strauss, M.D.

2:00 p.m. Sessions

LECTURES 13-15

LEcTure 13
2:00 p.m. - 3:30 p.m.
Rooms 130/131, Exhibit Level, Moscone Center

Carolyn B. Robinowitz, M.D.

Psychiatric Organized Leadership: Reflections, Predictions, and Proposals

Chp.: David A. Baron, D.O.
Co-Chp.: Patricia I. Ordorica, M.D.

The American Psychiatric Association has worked to enhance the science and the art of psychiatric care and to improve access to care for psychiatric patients. Yet, in recent years many psychiatrists have chosen not to join their specialty organization. Carolyn B. Robinowitz, M.D., discusses the current and future roles of organized medicine in general, and organized psychiatry in particular. A delegate from APA to the American Medical Association, Dr. Robinowitz is Clinical Professor of Psychiatry at Georgetown University School of Medicine and is in the private practice of general and child and adolescent psychiatry in Washington, D.C. From 1998 to 2000, she was Dean for Academic Affairs at Georgetown University School of Medicine. Previously she was Senior Deputy Medical Director at APA. She has served as President of several specialty organizations, including the American College of Psychiatrists and the American Board of Psychiatry and Neurology. Her many awards include the Distinguished Service Award and the Seymour D. Vestermark Award from APA. A graduate of Washington University School of Medicine in St.
Louis, MO, Dr. Robinowitz completed residency training in pediatrics and general psychiatry at the Bronx Municipal Hospital Center in New York and a fellowship in child psychiatry at Children's Hospital National Medical Center in Washington, D.C. Distinguished Psychiatrist Lecture Series THIS SESSION WILL BE AUDIOTAPED.

LECTURE 14

2:00 p.m. - 3:30 p.m.
Rooms 132/133, Exhibit Level, Moscone Center

Rachel Naomi Remen, M.D.

The Healer's Art: Undergraduate Education For Meaning And Commitment

Chp.: Catherine C. Crone, M.D.
Co-Chp.: Susan Stabinsky, M.D.

Rachel N. Remen, M.D., one of the pioneers of the mind-body health movement, is Clinical Professor of Family and Community Medicine at the University of California San Francisco School of Medicine. She is Co-Founder and Medical Director of the Commonweal Cancer Help Program and Founder and Director of the Institute for the Study of Health and Illness at Commonweal in Bolinas, CA. She also is in the private practice of psycho-oncology. Dr. Remen has a 48-year personal history of chronic illness, and she blends the perspectives of patient and physician in her work. She is the recipient of numerous awards, among them the Rollo May Award from Saybrook Institute in recognition of her contribution to the field of health psychology. The author of numerous publications in professional journals, Dr. Remen also wrote the bestselling books "Kitchen Table Wisdom: Stories That Heal," winner of the 1996 Willbur Award for best work of spiritual nonfiction, and "My Grandfather's Blessings: Stories of Strength, Refuge, and Belonging." Dr. Remen received her medical degree from Cornell University School of Medicine, completed her residency in pediatrics at the New York Hospital-Cornell Medical Center in New York City, and completed a fellowship in pediatric endocrinology at Stanford Medical Center in Palo Alto, CA.

This lecture will be audiorecorded.

LECTURE 15

2:00 p.m. - 3:30 p.m.
Room 300, Esplanade Level, Moscone Center

Robert L. Okin, M.D.

Mental Illness, Human Rights, Science, and Culture: A Videotaped Documentation of Conditions in Mexican Psychiatric Hospitals

Chp.: David H. Taylor, M.D.
Co-Chp.: Harvey Stabinsky, M.D.

Robert L. Okin, M.D., will discuss attempts to place the needs of people with mental disabilities on the international human rights agenda so they can receive the advocacy and protections similar to other vulnerable populations. As an example of the need for such advocacy, he will describe the conditions of Mexican psychiatric hospitals and present a videotaped documentation of these conditions. Strategies to improve this situation will be described along with the concrete results of these strategies. He will then confront the questions of (1) whether psychiatrists from one nation which neglects its mentally ill citizens, have the responsibility, much less the right, to criticize the conditions experienced by the mentally ill in other nations; and (2) whether governments can mitigate their responsibilities to the mentally ill in all nations is an issue at the frontiers of science and culture.

This session will be audiorecorded.

PRESIDENTIAL SYMPOSIUM 2

2:00 p.m. - 5:00 p.m.
Room 301, Esplanade Level, Moscone Center

THE FOUNDATION OF MEDICAL ETHICS/INFORMED CONSENT

Chp.: William T. Carpenter, Jr., M.D.
Co-Chp.: Dilip V. Jeste, M.D.

Participants: William T. Carpenter, Jr., M.D., Dilip V. Jeste, M.D., Thomas Grisso, M.D., Charles Lidz, Ph.D., Scott Y. Kim, M.D.

Discussant: Paul S. Appelbaum, M.D.

This session will be audiorecorded.

REVIEW OF PSYCHIATRY: SECTION 2

2:00 p.m. - 5:30 p.m.
Room 104, Exhibit Level, Moscone Center

MOLECULAR NEUROBIOLOGY FOR THE CLINICIAN

Chp.: Dennis S. Charney, M.D.

6 Molecular Neurobiology and Substance Abuse
Lisa Monteggia, M.D.

7 Molecular Neurobiology and New Drug Targets for Mood and Anxiety Disorders
Husseini K. Manji, M.D.

(Continued on next page)
8 Molecular Neurobiology and Schizophrenia: Implications for Etiology and Treatment
TBA

9 Molecular Neurobiology and Neuropsychiatric Disorders in Children: Present and Future
Jeremy Veenstra-VanderWeele, M.D.

10 Molecular Genetics and Psychiatric Disorders: A Role in Diagnosis and Treatment?
Francis J. McMahon, M.D.

SYMPOSIA 29-59

SYMPOSIUM 29 2:00 p.m. - 5:00 p.m.
Room 100, Exhibit Level, Moscone Center

INTEGRATED TREATMENT: PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY

Chp.: Hans Steiner, M.D.

A Integrated Treatment: From Adolescence to Young Adulthood
Hans Steiner, M.D.

B Integrated Treatment of BPD
Glen O. Gabbard, M.D.

C Integrated Treatment of Eating Disorders
Kathryn J. Zerbe, M.D.

D Psychiatric and Medical Illness
David Spiegel, M.D.

E Integrated Treatment of Juvenile Bipolar Disorder
Kiki D. Chang, M.D., Jaqueline Martin, Ph.D., Maureen Hawkins, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m. - 5:00 p.m.
Room 101, Exhibit Level, Moscone Center

RECENT DEVELOPMENTS IN GAY AND LESBIAN MENTAL HEALTH: A GLOBAL PERSPECTIVE
APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Gene A. Nakajima, M.D.
Co-Chp.: Jack Drescher, M.D.

A From Long Yong and Dui Shi to Tongzhi: Homosexuality in China
Jin Wu, M.A.

B Look to Norway? Gay Issues and Mental Health Across the Atlantic Ocean
Reidar Kjaer, M.D.

C Voices From the Past: Treatments of Homosexuality in the United Kingdom Since 1950
Michael B. King, M.D., Annie Bartlett, M.D., Glen Smith, Ph.D.

D Emergence of Lesbian and Gay Issues in International Psychiatry
Gene A. Nakajima, M.D.

Discussant: Melvin Sabshin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m. - 5:00 p.m.
Room 105, Exhibit Level, Moscone Center

NEW RESEARCH IN GAY, LESBIAN, AND BISEXUAL MENTAL HEALTH MORBIDITY

Chp.: Robert M. Kertzner, M.D.
Co-Chp.: Dan H. Karasic, M.D.

A Estimates of Mental Health Morbidity Among Lesbian, Gay, and Bisexual Adults
Susan D. Cochran, Ph.D., Vicki M. Mays, Ph.D., Heather Corliss, M.P.H.

B Sexual Orientation and Health: New Findings From a Dutch General-Population Survey
Theodorus G.M. Sandfort, Ph.D., Ine Vanwesenbeeck, Ph.D., Floor Bakker

C Minority Stress and Mental Health in Lesbians, Gay Men, and Bisexuals
Ilan H. Meyer, Ph.D.

D Depressive Distress in a Community Sample of Women: The Role of Sexual Orientation
Alicia K. Matthews, Ph.D., Towda L. Hughes, Ph.D., Timothy Johnson, Ph.D., Lisa A. Razzano, Ph.D., Roberta Cassidy, Ph.D.

E Sexual Minority Status and Its Association With Suicidality and Depression
Jay P. Paul, Ph.D., Joseph A. Catania, Ph.D., Thomas C. Mills, M.D., Ron D. Stull, Ph.D., Lance Pollack, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m. - 5:00 p.m.
Room 106, Exhibit Level, Moscone Center

AN UPDATE ON PARKINSON'S DISEASE AND ITS PSYCHIATRIC COMPLICATIONS

Chp.: Matthew A. Menza, M.D.

A Parkinson's Disease: Update on Treatment, Etiology, and Pathogenesis
Margery Mark, M.D.
B Depression in Parkinson's Disease
Jeffrey L. Cummings, M.D.

C Psychosis in Parkinson's Disease
Laura Marsh, M.D.

D Cognitive Impairment, Dementia, and Parkinson's Disease
Constantine Lyketsos, M.D.

E Anxiety, Fatigue, and Sleep in Patients With Parkinson's Disease
Matthew A. Menza, M.D.

THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 33
2:00 p.m. - 5:00 p.m.
Room 110, Exhibit Level, Moscone Center

COPING WITH CATASTROPHE

Chp.: John W. Barnhill, M.D.
Co-Chp.: Valentine Raiteri

A Psychotherapy of the Dying Patient
John W. Barnhill, M.D.

B Illness in the Training Psychiatrist
Gregory C. Dillon, M.D.

C Treating Firefighters in the Aftermath of 9/11
Kevin V. Kelly, M.D.

Discussant: Robert Michels, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 34
2:00 p.m. - 5:00 p.m.
Room 111, Exhibit Level, Moscone Center

STRATEGIES TO OVERCOME RESISTANCE

Chp.: Joseph DiGiacomo, M.D.

A Resistance and Psychodynamics
R. Rao Gogineni, M.D.

B Overcoming Resistance: Techniques From Cognitive Therapy
Donna M. Sudak, M.D.

C Resistance by Families and Children in Psychotherapy
G. Pirooz Sholevar, M.D.

D Diagnostic and Treatment Algorithms for Refractory Depression
Jay D. Amsterdam, M.D.

THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 35
2:00 p.m. - 5:00 p.m.
Room 112, Exhibit Level, Moscone Center

DEVELOPING CULTURALLY COMPETENT SERVICES FOR MINORITY POPULATIONS
APA Assembly Committee of Representatives of Minority/Underrepresented Groups

Chp.: James C.Y. Chou, M.D.

A Psychiatric Care of Hispanic Americans: Problems and Solutions
Pedro Ruiz, M.D.

B Developing Services for African Americans
William B. Lawson, M.D.

C Developing Culturally Competent Mental Health Services for Asian Americans
Evelyn Lee, Ph.D.

D New Approaches for Developing Mental Health Services for Native Americans
R. Dale Walker, M.D.

Discussant: Francis G. Lu, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 36
2:00 p.m. - 5:00 p.m.
Room 113, Exhibit Level, Moscone Center

THE ETHNICITY FACTOR IN PSYCHIATRIC RESEARCH: IDENTITY AND METHODOLOGY ISSUES
American Society of Hispanic Psychiatry

Chp.: Renato D. Alarcon, M.D.
Co-Chp.: Andres Heerlein, M.D.

A Cultural Variables and Controversies: The Identity Issue
Renato D. Alarcon, M.D.

B Cultural Issues Among Hispanics: A Portrait of Heterogeneity
Andres Heerlein, M.D.

C Methodological Issues in Ethnicity Research
Javier I. Escobar, M.D.

D The Inclusion of Race and Ethnicity in Current Psychiatric Literature
Roberto Lewis-Fernandez, M.D., Maria A. Oquendo, M.D., Naelys Diaz, M.S.W., Dana Wachtel, M.S.W., Renato D. Alarcon, M.D.

(Continued on next page)
SYMPOSIUM 37
2:00 p.m. - 5:00 p.m.
Room 114, Exhibit Level, Moscone Center

WHAT THE GENERAL PSYCHIATRIST NEEDS TO KNOW ABOUT ADDICTION PSYCHIATRY

APACouncil on Addiction Psychiatry and American Academy of Addiction Psychiatry

Chp.: Sheila B. Blume, M.D.
Co-Chp.: Bryon H. Adinoff, M.D.

A Neuroscience of Addictions
Bryon H. Adinoff, M.D.

B Treatment of Addictions
Charles P. O'Brien, M.D.

C Dual Diagnosis
Douglas M. Ziedonis, M.D., Sylvia Atidjan, M.D., Jon Kriegl, M.D., Jeffrey A. Berman, M.D.

D Consultation Psychiatrists: Frontline Observers of New Trends in Addiction
Joel E. Dimsdale, M.D.

E Current Issues in Addiction Medicine: Club Drugs
Alvaro Camacho, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 38
2:00 p.m. - 5:00 p.m.
Room 120, Exhibit Level, Moscone Center

EARLY TRAUMA: STRATEGIES FOR INTERVENTION AND TREATMENT

Chp.: Howard J. Osofsky, M.D.

A The Early Trauma Treatment Network: Assessing and Treating Trauma in Young Children
Alicia F. Lieberman, Ph.D.

B Treatment of PTSD in Infants and Young Children
Theodore J. Gaensbauer, M.D.

C Prevention and Intervention for Young Children Exposed to Violence
Joy D. Osofsky, Ph.D.

Discussants: Harry H. Wright, M.D., Robert S. Pynoos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39
2:00 p.m. - 5:00 p.m.
Room 121, Exhibit Level, Moscone Center

EARLY INTERVENTION IN PSYCHOSIS: WHERE SCIENCE MEETS COMMUNITY PSYCHIATRY

American Association of Community Psychiatrists

Chp.: William R. McFarlane, M.D.
Co-Chp.: David A. Pollack, M.D.

A Early Detection and Management of Psychiatric Disorder in Young People in Melbourne, Australia

B Intervention in the Schizophrenic Prodrome: The Prevention Through Risk Identification, Management, and Education Initiative
Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Robert B. Zipursky, M.D., Scott W. Woods, M.D., Diana O. Perkins, M.D., Keith A. Hawkins, Ph.D., Jean M. Addington, Ph.D.

C Portland Identification and Early Referral: First-Year Outcomes in a Community-Wide Psychosis Prevention Program
William R. McFarlane, M.D., William L. Cook, Ph.D., Donna Downing, O.T.R.

D A Comprehensive Approach to Early Intervention in Psychosis: The Prevention and Early Intervention Program for Psychosis Project (PEPP)
Ashok K. Malla, M.D., Ross M.G. Norman, Ph.D., Rahud Manchanda, M.D., Terry S. McLean, M.Ed., Derek J. Scholten, M.Sc., Laurel Townsend, Ph.D.

E The Tips Project: Clinical and Organizational Prerequisites for Early Intervention in Psychosis
Jan O. Johannessen, M.D.

F Implementing Early Psychosis Intervention in the Public Mental Health System
Robert M. Wolf, M.D., Tamara Sale, M.A.

Discussant: David A. Pollack, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 40
2:00 p.m. - 5:00 p.m.
Room 122, Exhibit Level, Moscone Center

DEHYDROEPIANDROSTERONE: NEUROTOSTEROID MECHANISMS, EPIDEMIOLOGY, AND APPLICATIONS IN PSYCHIATRY

Chp.: Stephen J. Ferrando, M.D.

A Dehydroepiandrosterones: Neurosteroid Modulator of Brain Excitability, Mood, Cognition, and Drug Dependence
Maria Majewska, M.D.

B Dehydroepiandrosterone Treatment of Alzheimer's Disease and Major Depression
Victor I. Reus, M.D., Owen M. Wolkowitz, M.D.

C Dehydroepiandrosterone Effects on Mood in HIV and Depressed Patients
Judith G. Rabkin, Ph.D., Martin McElhinney, Ph.D., Richard Rabkin, M.D., Judy Chiu, B.A., Stephen J. Ferrando, M.D.

SYMPOSIUM 41
2:00 p.m. - 5:00 p.m.
Room 123, Exhibit Level, Moscone Center

SCIENCE AND PSYCHIATRIC PARTICIPATION IN DISASTER RESPONSE

Chp.: Lee McCabe, Ph.D.
Co-Chp.: Michael J. Kaminsky, M.D.

A Psychiatry and Somatic Medicine in Disaster Response: Carved Out Again?
Michael J. Kaminsky, M.D.

B What You Need to Know to Get Yourself and Your Organization Ready to Respond to Disasters
George Everly, Jr., Ph.D.

C Current Science About Best Practices in Disaster Psychiatry and a Proposed Research Agenda
Michael C. Heitt, Psy.D.

D Post-Disaster Science of Therapeutic Healing
Everett R. Siegel, M.D., Michael C. Heitt, Psy.D.

Discussant: Clete DiGiovanni, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42
2:00 p.m. - 5:00 p.m.
Room 124, Exhibit Level, Moscone Center

RECOVERY FROM SCHIZOPHRENIA: A CHALLENGE FOR THE 21ST CENTURY

Chp.: Alex J. Kopelowicz, M.D.

A Operational Criteria and Factors Related to Recovery From Schizophrenia
Robert P. Liberman, M.D., Alex J. Kopelowicz, M.D., Joseph Ventura, Ph.D.

B Recovery in First-Episode Schizophrenia
Delbert G. Robinson, M.D., Margaret Woerner, Ph.D., Marjorie McMeniman, Ph.D.

C Schizophrenia and Capacity for Vocational Recovery
Zlatka L. Russinova, Ph.D., Nancy J. Wewiorski

D The Process of Recovery From Schizophrenia
LeRoy Spaniol, Ph.D., Nancy Wewiorski, Ph.D., Cheryl Gagne, M.S., William Anthony, Ph.D.

E Multiple Dimensions of Recovery in Early Psychosis
David Whitehorn, Ph.D., Jocelyn Brown, Heather Miliken, M.D., Julie Richard, B.A., Lili Kopala, M.D., Qing Rui, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43
2:00 p.m. - 5:00 p.m.
Room 125, Exhibit Level, Moscone Center

THE INVISIBLE PLAGUE: SEVERE MENTAL ILLNESS

Chp.: Nigel M. Bark, M.D.
Co-Chp.: Richard Neugebauer, Ph.D.

A Evidence for the Existence of Schizophrenia Before 1750 and What That May Mean
Nigel M. Bark, M.D.

B Management of the Mad in 17th-Century England: The Rise of Confinement
Richard Neugebauer, Ph.D.

C Political Influence on Psychiatry: Malevolent or Benevolent?
Nasser F. Loza, M.B., Waleed A.R. Fawzi, M.S.C.

D The Increasing Incidence of Psychoses From 1750 to the Present
E. Fuller Torrey, M.D.

E Criminalization of Persons With Mental Illness in the 20th and 21st Centuries
H. Richard Lamb, M.D.

Discussant: Norman Dain, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

53
TUESDAY

SYMPOSIUM 44
2:00 p.m. - 5:00 p.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

THE EVIL STANDARD: MILESTONES AND CHALLENGES
Chp.: Michael M. Welner, M.D.

A Undefined Evil: The Legal, Psychiatric, and Societal Consequences of Avoidance
Michael M. Welner, M.D.

B Researching the Depravity Standard: Reliability in Defining a Distinctive Crime
James Seward, Ph.D.

C The Depravity Scale in Relation to the Histories of 430 Convicted Killers
Michael H. Stone, M.D.

D The Civil Employment Depravity Scale: Preliminary Items and Research
Michael M. Welner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45
2:00 p.m. - 5:00 p.m.
Room 302, Esplanade Level, Moscone Center

BEREAVEMENT AFTER VIOLENT DEATH
Chp.: Edward K. Rynearson, M.D.

A The Effects of Violent Death on Bereavement
Beverley Raphael, M.D.

B Community-Based Interventions With Child and Adolescent Survivors of Homicide Victims
Alison A. Salloum, M.S.W.

C Survivors of Violent Loss Program
Stephen R. Shuchter, M.D., Connie A. Saindon, M.A.

D Terrorism Factors That Exacerbate the Experience of Victims
Kathryn M. Turman

E The Long-Term Psychological Effects of the World Trade Center Disaster: Community Strategies for Support
Vilma Torres, M.S.W.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46
2:00 p.m. - 5:00 p.m.
Room 304, Esplanade Level, Moscone Center

DIVERSE APPROACHES TO ALZHEIMER'S SCREENING
Chp.: John W. Ashford, Jr., M.D.
Co-Chp.: Frederick A. Schmitt, Ph.D.

A Mini-Cog
Soo Borson, M.D., James M. Scanlan, Ph.D.

B Memory Impairment Screen
Herman Buschke, M.D.

C Brief Alzheimer's Screen
Marta S. Mendiondo, Ph.D., John W. Ashford, Jr., M.D., Frederick A. Schmitt, Ph.D., Richard J. Kryscio, Ph.D.

Jane B. Tomatore, Ph.D., Emory Hill, Ph.D., Jo A. Laboff, B.S.

E Bowles-Langley Technology/Ashford Memory Test Online Version
John W. Ashford, Jr., M.D., Jon Livingston, Henry Bowles, Ted Langley, Ph.D., Paul Costa

F Statistical Issues in Evaluating Alzheimer's Screening Tests
Helena C. Kraemer, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47
2:00 p.m. - 5:00 p.m.
Room 306, Esplanade Level, Moscone Center

PERSONAL IDENTITY AND BIPOLAR DISORDER
Chp.: Deborah Spitz, M.D.

A Creating Narrative From Disjunction: The Clinical Picture
Deborah Spitz, M.D.

B Bipolar Disorder and Partitian Successive Selves
Jennifer Radden, Ph.D.

C Narrative Selves, Relations of Trust, and Bipolar Disorder
Nancy Potter, Ph.D.

D Values and the Nature of Bipolar Disorder
Kenneth Fulford, D.Phil.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 48
2:00 p.m. - 5:00 p.m.
Room 307, Esplanade Level, Moscone Center

THE SPECTRUM OF SEXUAL VIOLENCE: CLINICAL AND CULTURAL IMPACT
American Academy of Child and Adolescent Psychiatry

Chp.: Larry K. Brown, M.D.

A Childhood Sexual Abuse and Later Adolescent Risk Behavior
Larry K. Brown, M.D., Celia M. Lescano, Ph.D., Kelsey M. Latimer, B.A.

B Perspectives on Sexual Molestation of Boys by Roman Catholic Priests
Lynn E. Ponton, M.D.

C Sexual Violence on the Internet
Norman E. Alessi, M.D.

D Dating Violence and African-American Adolescent Females' Sexual Health
Ralph DiClemente, Ph.D., Gina M. Wingood, Sc.D.

E Adolescent Dating Violence: Screening Practices of Child and Adolescent Psychiatrists
Kristie Puster, Ph.D., Celia M. Lescano, Ph.D., Kelsey M. Latimer, B.A.

SYMPOSIUM 49
2:00 p.m. - 5:00 p.m.
Room 308, Esplanade Level, Moscone Center

ADVANCES IN UNDERSTANDING AND TREATING CHRONIC DEPRESSION
Chp.: John C. Markowitiz, M.D.
Co-Chp.: James H. Kocsis, M.D.

A Classification and Natural History of Chronic Depression
Daniel N. Klein, Ph.D.

B Cognitive-Behavioral Analysis System of Psychotherapy
Bruce A. Arnow, Ph.D.

C Treating Chronic Depression: Psychosocial Outcomes
James H. Kocsis, M.D.

D Continuation, Maintenance, and Crossover Results of Clinical Trials
Alan J. Gelenberg, M.D.

E Interpersonal Psychotherapy for Chronic Depression
John C. Markowitiz, M.D.

SYMPOSIUM 50
2:00 p.m. - 5:00 p.m.
Room 309, Esplanade Level, Moscone Center

BOUNDARY CROSSINGS: CREATIVE THERAPY OR SLIPPERY SLOPES?
Chp.: Gail E. Robinson, M.D.

A Boundary Violations Versus Boundary Crossings
Gail E. Robinson, M.D.

B Creative Moments and Challenging Events in Therapy: Bending Rules to Help
Gary R. Schoener, Psy.D.

C Is Physical Touch Still a Taboo in Psychodynamic Psychotherapy?
Howard E. Book, M.D.

D Professional Boundaries: Navigating Gray Areas and Avoiding Legal Trouble
Linda M. Jorgenson, J.D.

Discussant: Gail E. Robinson, M.D.

SYMPOSIUM 51
2:00 p.m. - 5:00 p.m.
Room 310, Esplanade Level, Moscone Center

WOMEN PSYCHIATRISTS USING SCIENCE TO HEAL
Chp.: Marian I. Butterfield, M.D.
Co-Chp.: Sylvia W. Olarte, M.D.

A Psychological Issues and Women Athletes: In a League of Their Own
Altha J. Stewart, M.D.

B Catholic and Jewish Women Survivors of the Nazi Camps: Insights
Leah J. Dickstein, M.D.

C Pursing Genetics Studies in Homogenous Portuguese Populations
Michelle T. Pato, M.D., Emanuela Mundo, M.D., Carlos N. Pato, M.D.

D Outreach to the Indigent Mentally Ill in Rural India
Geetha Jayaram, M.D.

E Innovative Models for Mental Health Services to Women in Hawaii
Leslie H. Gise, M.D.

Discussant: Michael E. Thase, M.D.

(Continued on next page)
**TUESDAY**

**F** From Bench to Bedside: Neurosteroids and Gender Differences in Psychiatry  
Christine E. Marx, M.D.

**G** HIV and Mental Illness Education Initiative in Sub-Saharan Africa  
Mary Kay Smith, M.D.

**Discussant:** Nada L. Stotland, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 52**  
2:00 p.m. - 5:00 p.m.  
Salons 1 & 2, Lower B-2 Level, Marriott

**DARWINIAN EVOLUTION AND PSYCHOPATHOLOGY**

Chp.: Daniel R. Wilson, M.D.  
Co-Chp.: Hagop S. Akiskal, M.D.

A Evolutionary Epidemiology and the Neuropsychiatry of Mania and Depression  
Daniel R. Wilson, M.D.

B Evolutionary Developmental Psychopathology  
Ian Pitchford, Ph.D.

C Clinical Equivalents in Phenotypic Expression: Implications for Research and Care  
Susan L. McElroy, M.D.

D Evolutionary Psychiatry: The End of the Beginning  
Hagop S. Akiskal, M.D.

**Discussant:** Hagop S. Akiskal, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 53**  
2:00 p.m. - 5:00 p.m.  
Salons 3 & 4, Lower B-2 Level, Marriott

**COMORBID CONDITIONS IN SCHIZOPHRENIA: NEW TREATMENT TARGET OR NEW ILLNESS MODEL?**

Chp.: Stefano Pallanti, M.D.  
Co-Chp.: Eric Hollander, M.D.

A Clinical Correlates and Chronology of Anxiety Comorbidity in Psychotic Disorders  
Giovanni B. Cassano, M.D., Liliana Dell’Osso, M.D., Marco Sacco, Alessandra Papasogli, M.D., Concetta Mastrocinque, M.D., Serena Vignoli, Stefano Pini, M.D.

B Comorbid Schizophrenia Syndromes: New Therapy Target or New Illness Model?  
Samuel G. Siris, M.D., Paul C. Bermanzohn, M.D.

C Assessment and Characterization of Social Anxiety in Schizophrenia  
Stefano Pallanti, M.D., Leonardo Quercioli, M.D., Eric Hollander, M.D.

D Impulsivity and Aggression in Schizophrenia: New Treatment Target  
Eric Hollander, M.D., Stefano Pallanti, M.D., Nicolo Baldini-Rossi, M.D.

**Discussant:** Nancy C. Andreasen, M.D.

**SYMPOSIUM 54**  
2:00 p.m. - 5:00 p.m.  
Salons 5 & 6, Lower B-2 Level, Marriott

**ADHD: LONGER-TERM TREATMENT FOR A CHRONIC DISORDER**

Chp.: Timothy E. Wilens, M.D.

A ADHD Treatment With a Once-Daily Formulation of Methylphenidate: A Two-Year Study  
Timothy E. Wilens, M.D.

B Preliminary Results of a Six-Month Trial of Methylphenidate in Adults With ADHD  
Thomas J. Spencer, M.D.

C Longer-Term Effectiveness of Various Treatments for ADHD: Results From the Multimodal Treatment Study of ADHD  
Laurence L. Greenhill, M.D.

D A Ten-Year Follow-Up of ADHD Subjects  
Joseph Biederman, M.D.

E Does the Treatment of ADHD With Stimulant Medication Contribute to Illicit Drug Use and Abuse in Adulthood? Results From a Fifteen-Year Prospective Study  
Russell A. Barkley, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 55**  
2:00 p.m. - 5:00 p.m.  
Salons 10 & 11, Lower B-2 Level, Marriott

**HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 3**

Chp.: William E. Callahan, Jr., M.D.  
Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice  
William E. Callahan, Jr., M.D.

B Office Location and Design for Efficiency and Success  
Keith W. Young, M.D.
C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 56
2:00 p.m. - 5:00 p.m.
Salons 12 & 13, Lower B-2 Level, Marriott

ETHICAL ISSUES IN THE U.S. AND FRANCE: VIVE LA DIFFERENCE

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois C. Petitjean, M.D.

A From One Culture to Another
Charles De Brito, M.D.

B Impact of Culture on Ethics
Ezra E.H. Griffith, M.D.

C About Patients' Information in France: Is Electronic Medical Record Part of the Solution?
Denis H. Chino, M.D., Veronique A. Olivier, M.D., Xavier Moine, Agnes Lemoux, Nartechnist Velut-Chino, M.D., Mordka Szpirko, M.D., Isabelle Teillet, M.D.

D Patients Reading Their Own Records: Survey of the U.S. and Comment
Thomas G. Gutheil, M.D.

E Psychiatric Treatment for Women of Child-Bearing Age: Ethical Aspects
Christine Germain, M.D., Francois C. Petitjean, M.D.

F What Is a Psychiatrist Doing Here?
Kathleen M. Mogul, M.D.

Discussants: Alexandra MacLean, M.D., Francois C. Petitjean, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 57
2:00 p.m. - 5:00 p.m.
Salons 14 & 15, Lower B-2 Level, Marriott

PSYCHIATRISTS WITH PSYCHIATRIC DISORDERS: THE FEAR OF STIGMA

Chp.: Sylvia P. Emmerich, M.D.
Co-Chp.: Philip R. Muskin, M.D.

A Psychiatric Residents in Manhattan: A Survey of Personal Psychiatric Treatment
Sylvia P. Emmerich, M.D.

B Stigma Against the Mentally Ill and Its Effects on Treatment
Paul J. Fink, M.D.

C The Role of the Training Director in Resident Mental Health: Strategies for Encouraging Treatment and Reducing Stigma
Elizabeth Auchincloss, M.D.

D A Psychiatrist's Personal Encounter With Stigma
Francine Cournos, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 58
2:00 p.m. - 5:00 p.m.
Golden Gate Hall A, B-2 Level, Marriott

ADDITIONS: CUTTING-EDGE TREATMENTS

Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

A Treatment of Cocaine Dependence
Adam M. Bisaga, M.D.

B Treatments for Heroin Dependence
Herbert D. Kleber, M.D.

C Office-Based Treatment of Opioid Addiction
Laura F. McNicholas, M.D.

D Update on Marijuana and Club Drugs: Current and Potential Treatments
David M. McDowell, M.D.

E Treatment of Comorbid Conditions
Frances R. Levin, M.D., Suzette M. Evans, Herbert D. Kleber, M.D.

Discussant: Edward V. Nunes, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 59
2:00 p.m. - 5:00 p.m.
Golden Gate Hall B, B-2 Level, Marriott

INTERNET: TECHNICAL, CLINICAL, AND SOCIETAL

American Association for Social Psychiatry and American Association for Technology in Psychiatry

Chp.: Lawrence Hartmann, M.D.
Co-Chp.: Ronnie S. Stangler, M.D.

A Addictions and the Internet
Richard N. Rosenthal, M.D.

B Sex and the Internet
Zebulon C. Taintor, M.D.

(Continued on next page)
C Pseudocommunities on the Internet
    Steven E. Hyler, M.D.

D Internet Support: Self-Help Groups
    Robert C. Hsiung, M.D.

E Eating Disorders Meet the Internet: What Patients and
Clinicians Encounter
    Joel Yager, M.D.

Discussant: Thomas A.M. Kramer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7
3:00 p.m. - 5:00 p.m.
Hall D, Exhibit Level, Moscone Center

MOOD DISORDERS

For further information on New Research Sessions, please refer
to the New Research Program Book included in your registration
packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUMS 35-41

INDUSTRY-SUPPORTED SYMPOSIUM 35
7:00 p.m. - 10:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

FACING UNMET NEEDS: ATYPICAL
ANTIPSYCHOTICS FOR MOOD AND ANXIETY
Supported by Janssen Pharmaceuticals

Chp.: Mark Pollack, M.D.

A Mechanism of Action of Atypical Antipsychotics in
Mood and Anxiety Disorders
Pierre Blier, M.D., Steven T. Szabo, Ph.D., Peter Berqvist,
Jianning Dong, Ph.D.

B Use of Atypical Antipsychotics in Mood Disorders
Charles B. Nemeroff, M.D.

C Treatment of Anxiety Disorders: Therapeutic
Challenges of the Future
Olga Brawman-Mintzer, M.D.

D Atypical Antipsychotics in PTSD: Rationale and Role
Murray B. Stein, M.D.

E Working With the Patient as a Co-Therapist: Strategies
to Enhance Treatment Adherence
Michael W. Otto, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m. - 10:00 p.m.
Hall E, Exhibit Level, Moscone Center

BIPOLAR DISORDER ACROSS THE LIFE CYCLE
Supported by Abbott Laboratories

Chp.: Charles L. Bowden, M.D.

A Reproductive Health and Metabolic Correlates in
Women Receiving Treatment for Bipolar Disorder
Natalie L. Rasgon, M.D.

B Bipolar Disorders in Adulthood
John M. Zajecka, M.D.

C Secondary Manias and Comorbid Conditions
James C.Y. Chou, M.D.

D Combination Treatments: What to Use and When
Joseph R. Calabrese, M.D.

E Management of Side Effects and Treating to Wellness
Charles L. Bowden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37
7:00 p.m. - 10:00 p.m.
Metropolitan, Second Level, Argent

SHOWING DISEASE PROGRESSION AND THE
LONG-TERM MANAGEMENT OF DEMENTIA
Supported by Novartis Pharmaceuticals Corporation

Chp.: Steven G. Potkin, M.D.

A Mechanism of Disease Progression in Dementia
Nigel Greig, Ph.D.

B Targeting Cholinergic Therapy to Slow Disease
Progression
Steven G. Potkin, M.D.

C Brain Imaging and CSF Cholinesterase Inhibition:
Long-Term Data
Agneta Nordberg, M.D.

D A Critical Review of the Long-Term Data With
Cholinesterase
P. Murali Doraiswamy, M.D.

Discussants: Nigel Greig, Ph.D., P. Murali Doraiswamy, M.D.
TUESDAY

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m. - 10:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

OPTIMIZING TREATMENTS FOR PATIENTS WITH SCHIZOPHRENIA: TARGETING POSITIVE PATIENT OUTCOMES
Supported by Pfizer Inc.

Chp.: Daniel E. Casey, M.D.

A The Science of Antipsychotics: Mechanistic Insight
Daniel E. Casey, M.D.

B Management of Acute Psychosis From Emergency to Stabilization
Daniel L. Zimbroff, M.D.

C Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes
Herbert Y. Meltzer, M.D.

D Factors in Antipsychotic Drug Selection: Tolerability Considerations
Henry A. Nasrallah, M.D.

E Obesity, Diabetes, and Metabolic Syndrome: New Challenges in Antipsychotic Drug Therapy
Enrique Caballero, M.D.

F Long-Term Treatment Goals: Enhancing Healthy Outcomes
Carol A. Tamminga, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 39
7:00 p.m. - 10:00 p.m.
Continental Ballroom, Ballroom Level, Hilton

BIOLOGICAL AND PSYCHOLOGICAL ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA: REVISITING AND UPDATING MEYER'S PSYCHOBIOLOGY FOR THE 21ST CENTURY
Supported by Bristol-Myers Squibb Company

Chp.: Peter J. Weiden, M.D.

A Psychological Mechanisms of Psychosis: Implications for Psychotherapeutic Intervention
Douglas Turkington, M.B.

B Biologic Mechanisms of Psychosis: From Dopamine Excess to Dopamine Stabilization
Bryan L. Roth, M.D.

C What Is an Adequate Treatment Response? Establishing Therapeutic Goals in Schizophrenia
Peter J. Weiden, M.D.

D Long-Term Treatment of Schizophrenia: Moving From a Relapse-Prevention Model to a Recovery Model
John M. Kane, M.D.

E Diagnostic Boundaries Between Bipolar Disorder and Schizophrenia: Implications for Pharmacological Intervention
Stephen M. Strakowski, M.D.

Discussant: Nina R. Schooler, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 40
7:00 p.m. - 10:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

REAL-WORLD CHALLENGES IN DEPRESSION AND ANXIETY
Supported by GlaxoSmithKline

Chp.: David L. Dunner, M.D.

A Long-Term Consequences of Social Anxiety Disorder: Breaking the Cycle
Karen D. Wagner, M.D.

B Depression and Anxiety in Medical Illness: The Brain-Body Interface
Prakash S. Masand, M.D.

C Overcoming Stigma and Optimizing Outcome in Late-Life Depression
Lori J. Birdsong, M.D.

D The Clinical Challenge of Depression in Bipolar Disorder
David L. Dunner, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 41
7:00 p.m. - 10:00 p.m.
Salon 9, Lower B-2 Level, Marriott

WOMEN AND PSYCHIATRIC DISORDERS: DOES GENDER MATTER FOR TREATMENT?
Supported by Wyeth Pharmaceuticals

Chp.: Jerrold F. Rosenbaum, M.D.
Co-Chp.: Lee S. Cohen, M.D.

A Hormones and the Brain
Meir Steiner, M.D.

B Sex, Hormones, and Depression: The Impact of Sex Steroids on Mood Across the Reproductive Life Cycle
Claudio N. Soares, M.D.

C Trauma and PTSD in Women
Shamsah B. Sonawalla, M.D.

D Women and Alcohol Use Disorders
Shelly F. Greenfield, M.D.

E Does Gender Matter to Treatment?
Jerrold F. Rosenbaum, M.D.
Institute Objectives:

At the conclusion of the 2003 Institute on Psychiatric Services, participants will:

1. Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;

2. Better understand how the current health care system affects patient care;

3. Gain new knowledge and skills useful in public psychiatry settings;

4. Understand the importance of gaining access to integrated mental health care for all patients; and

5. Recognize the important role the physician plays in helping the patient gain access to integrated mental health care.

For further information, please call or write to our new address:

Institute on Psychiatric Services
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901

Telephone: 1 (888) 357-7924 (Toll Free)
Fax: (703) 907-1090
E-Mail: apa@psych.org
Web: http://www.psych.org

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 42-45

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1
7:00 a.m. - 8:30 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

NEUROPSYCHIATRY IN THE AGE OF POLYPHARMACY
Supported by Janssen Pharmaceutics

Chp.: Prakash S. Masand, M.D.

A An Evidence-Based Approach to Rational Polypharmacy in Schizophrenia
Prakash S. Masand, M.D.

B Polypharmacy in the Treatment of Bipolar Disorder
Andrew L. Stoll, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 1
7:00 a.m. - 8:30 a.m.
Hall E, Exhibit Level, Moscone Center

TREATING ADHD ACROSS THE LIFE CYCLE
Supported by Novartis Pharmaceuticals Corporation

Chp.: Thomas J. Spencer, M.D.
Co-Chp.: Joseph Biederman, M.D.

A Pathophysiology of ADHD
Stephen V. Faraone, Ph.D.

B ADHD From Childhood to Adolescence: Developmental Issues in Clinical Presentations
Russell A. Barkley, Ph.D.

Discussants: Betty Jo Salmeron, M.D., Michael Sanders, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44, PART 1
7:00 a.m. - 8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

INSOMNIA IN TODAY'S SOCIETY: CONSEQUENCES AND TREATMENTS
Supported by Sanofi-Synthelabo, Inc.

Chp.: Gregory M. Asnis, M.D.
Co-Chp.: Shari Kohn, Ph.D.

A The Importance of Identifying and Treating Insomnia
David N. Neubauer, M.D.

B Pharmacotherapy of Insomnia
Gregory M. Asnis, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 45, PART 1
7:00 a.m. - 8:30 a.m.
Salons 7 & 8, Lower B-2 Level, Marriott

OBESITY IN PSYCHIATRIC PRACTICE: RECOGNITION AND TREATMENT
Supported by Ortho-McNeil Pharmaceuticals

Chp.: B. Timothy Walsh, M.D.

A Obesiy Update
Robert Kushner, M.D.

B Psychotropic Medication and Weight Gain
David B. Allison, Ph.D.

C Obesity and Psychiatric Disorders
Laurel Mayer, M.D.

8:00 a.m. Sessions

COURSES 82-89
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 82 8:00 a.m. - 12 noon
Franciscan Room B, Ballroom Level, Hilton

PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE
APA Committee on Psychiatric Dimensions of Disaster

Director: Carol S. North, M.D.
Faculty: Betty Pfefferbaum, M.D., Phebe M. Tucker, M.D.

COURSE 83 8:00 a.m. - 12 noon
Franciscan Room C, Ballroom Level, Hilton

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 84 8:00 a.m. - 12 noon
Yosemite Room A, Ballroom Level, Hilton

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: John L. Black, M.D., Brett A. Koplin, M.D.
WEDNESDAY

COURSE 85  8:00 a.m. - 12 noon
Union Square 1 & 2, Fourth Floor, Hilton

MEDITATION FOR PSYCHOTHERAPISTS AND THE PARADIGM OF HEALTH
Director: James T. Sacamano, M.D.
Faculty: Ira Rechtshaffen, Ph.D.

COURSE 86  8:00 a.m. - 12 noon
Union Square 13, Fourth Floor, Hilton

A PSYCHODYNAMIC APPROACH TO TREATMENT REFRAC'TORY MOOD DISORDERS
Director: Eric M. Plakun, M.D.
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

COURSE 87  8:00 a.m. - 12 noon
Union Square 14, Fourth Floor, Hilton

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION
Director: Nashaat N. Boutros, M.D.
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 88  8:00 a.m. - 12 noon
Union Square 15 & 16, Fourth Floor, Hilton

ASSESSING THE RISK OF VIOLENCE IN BOTH FORENSIC AND SEX OFFENDER SETTINGS
Director: Bradley R. Johnson, M.D.
Faculty: Judith V. Becker, Ph.D.

COURSE 89  8:00 a.m. - 5:00 p.m.
Imperial Ballroom B, Ballroom Level, Hilton

OFFICE-BASED BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENT PATIENTS
American Academy of Addiction Psychiatry and APA Council on Addiction Psychiatry

Co-Directors: Eric C. Strain, M.D., Thomas R. Kosten, M.D.
Faculty: Herbert D. Kleber, M.D., Laura F. McNicholas, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 3
9:00 a.m. - 10:30 a.m.
Room 121, Exhibit Level, Moscone Center

TREATING THE CHRONICALLY MEDICALLY ILL ADOLESCENT: A CASE STUDY
Moderator: Gia M. Crecelius, M.D.
Discussant: Margaret L. Stuber, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1
9:00 a.m. - 12 noon
Room 120, Exhibit Level, Moscone Center

A CASE OF MURDER AND DISSOCIATIVE IDENTITY DISORDER: REAL OR MALINGERED MENTAL ILLNESS?
Moderator: Britta Ostermeyer, M.D.
Presenters: Thomas G. Cobb, M.D., Renee M. Sorrentino, M.D., Richard P. Kluft, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 90-94
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 90  WITHDRAWN

COURSE 91  9:00 a.m. - 4:00 p.m.
Yosemite Room B, Ballroom Level, Hilton

ALZHEIMER'S DISEASE: ADVANCED APPROACHES TO TREATMENT
Director: William E. Reichman, M.D.
Faculty: Peter M. Aupperle, M.D., Constantine Lyketsos, M.D., Jacobo E. Mintzer, M.D., David L. Sultzer, M.D., Pierre N. Tarot, M.D.
WEDNESDAY

COURSE 92
9:00 a.m. - 4:00 p.m.
Yosemite Room C, Ballroom Level, Hilton

BACK TO THE FUTURE: THE EVOLUTIONARY FRAMEWORK FOR PSYCHIATRY
Director: John R. Evaldson, M.D.
Faculty: Mark T. Erickson, M.D., Annette J. Hollander, M.D.,
David Mullen, M.D., Daniel R. Wilson, M.D.

COURSE 93
9:00 a.m. - 4:00 p.m.
Union Square 19 & 20, Fourth Floor, Hilton

ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY
Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D.

COURSE 94
9:00 a.m. - 4:00 p.m.
Union Square 23 & 24, Fourth Floor, Hilton

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT
Director: Robert P. Granacher, Jr., M.D.

DISCUSSION GROUPS 18-20
9:00 a.m. - 10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

18 Stephen C. Scheiber, M.D., on the Core Competencies: What It Means for Residents and Faculty (Meet the Authors)
Pacific Conference Suite B, 4th Floor, Marriott

19 Anthony F. Lehman, M.D., on Evidence-Based Psychiatry: The Promise and Pitfall of Translating Science Into Practice
Pacific Conference Suite C, 4th Floor, Marriott

20 Carolyn B. Robinowitz, M.D., on Women in Leadership: Problems, Prospects, and Proposals
Pacific Conference Suite E, 4th Floor, Marriott

LECTURES 16-17

LECTURE 16
9:00 a.m. - 10:30 a.m.
Rooms 130/131, Exhibit Level, Moscone Center

APA'S GEORGE TARJAN AWARD LECTURE
Prakash N. Desai, M.D.
Health, Culture, and South-Asian Indians in North America
Chp: Godehard Oepen, M.D.

(Continued on next page)
WEDNESDAY

Master Educator Clinical Consultation 8

9:00 a.m. - 10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

Carol C. Nadelson, M.D., on Women in Leadership: Understanding Achievement Obstacles
Room 218, Mezzanine Level, Moscone Center

This session is open to APA members only. Blue registration badge or APA membership card required for admittance.

Review of Psychiatry: Section 3

9:00 a.m. - 10:30 a.m.
Room 104, Exhibit Level, Moscone Center

Standardized Evaluation in Clinical Practice

Chp.: Michael B. First, M.D.

13. Use of Structured Assessment for the Diagnosis of Childhood Disorders in Clinical Settings
   Christopher Lucas, M.D.

   Maria A. Oquendo, M.D., Batsheva Halberstam, B.A., J. John Mann, M.D.

15. Nationwide Implementation of Global Assessment of Functioning as an Indicator of Patient Severity and Service Outcomes
   William W. Van Stone, M.D., Kathy Henderson, M.D., Rudolf H. Moos, Ph.D., Robert Rosenheck, M.D., Mary Schon, M.D.

Workshops

Component 23-29

Component Workshop 23 9:00 a.m. - 10:30 a.m.
Salons 3 & 4, Lower B-2 Level, Marriott

Women's Leadership 101
APA Committee on Women

Co-Chps.: Caroline E. Fisher, M.D., Jodi E. Star, M.D.
Participants: Leslie H. Gise, M.D., Donna M. Norris, M.D., Marcia K. Goin, M.D.

Component Workshop 24 9:00 a.m. - 10:30 a.m.
Salons 5 & 6, Lower B-2 Level, Marriott

Great Expectations: Integrating Mind and Brain in Resident Training
APA/GlaxoSmithKline Fellows

Co-Chps.: Jodi J. Gold, M.D., Rebecca Brendel, M.D.
Participants: Abigail B. Schlesinger, John W. Grace, Alec O. Oskin

Component Workshop 25 9:00 a.m. - 10:30 a.m.
Salons 10 & 11, Lower B-2 Level, Marriott

Patient Safety in Psychiatry: Reducing Adverse Medication Events
APA Task Force on Patient Safety

Co-Chps.: Alfred Herzog, M.D., Miles F. Shore, M.D.
Participant: John W. Goethe, M.D.
COMPONENT WORKSHOP 26  9:00 a.m. - 10:30 a.m.
Salons 12 & 13, Lower B-2 Level, Marriott

WHAT IS THE ETHICAL STANCE? ISSUES RELATED TO WORLD PSYCHIATRY AND COURTS
*APA Council on Psychiatry and Law and APA Committee on Judicial Action*

Chp.: Jeffrey L. Metzner, M.D.
Participants: Alan A. Stone, M.D., Renee L. Binder, M.D., Richard Bonnie, L.L.B.

COMPONENT WORKSHOP 27  9:00 a.m. - 10:30 a.m.
Salons 14 & 15, Lower B-2 Level, Marriott

TEACHING COMPETENCE IN PSYCHOTHERAPY TO RESIDENTS: ARE FACULTY COMPETENT?
*APA Committee on Psychotherapy by Psychiatrists*

Chp.: Lisa A. Mellman, M.D.
Participants: Jerald Kay, M.D., David A. Goldberg, M.D., Joanna E. Steinglass, M.D., Jennifer K. Coffman, M.D.

COMPONENT WORKSHOP 28  9:00 a.m. - 10:30 a.m.
Golden Gate Hall A, B-2 Level, Marriott

GLOBAL TRAUMA: EXPERIENCE AND IMPLICATIONS FOR DSM-V
*APA Council on Global Psychiatry*

Co-Chps.: Arthur M. Kleinman, M.D., Harold I. Eist, M.D.
Participants: Robert J. Ursano, M.D., Lars Weisaeth, M.D., Arieh Y. Shalev, M.D., Elie G. Karam, M.D., Raphael Beverley, M.D.

COMPONENT WORKSHOP 29  9:00 a.m. - 10:30 a.m.
Golden Gate Hall C, B-2 Level, Marriott

TRAUMA AND HOMELESSNESS: PSYCHIATRIC ASPECTS OF A SOCIOECONOMIC PROBLEM
*APA Northern California Psychiatric Society*

Co-Chps.: Adam P. Nelson, M.D., Byron J. Wittlin, M.D.
Participants: Mary K. Connor, Jean A. Marsters, M.D., Robert A. Rosenheck, M.D.

ISSUES 64-82

ISSUE WORKSHOP 64  9:00 a.m. - 10:30 a.m.
Room 110, Exhibit Level, Moscone Center

CULTURE, RACE, ETHNICITY, AND PSYCHOPHARMACOLOGY: RECENT RESEARCH ADVANCES

Co-Chps.: Pedro Ruiz, M.D., Keh-Ming Lin, M.D.
Participants: Edmond H.T. Pi, M.D., Ricardo P. Mendoza, M.D., William B. Lawson, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 65  9:00 a.m. - 10:30 a.m.
Room 111, Exhibit Level, Moscone Center

REVISION OF THE APA ETHICS ANNOTATIONS: FOSTERING DIALOGUE

Co-Chps.: Laura W. Roberts, M.D., Scott Y. Kim, M.D.
Participants: S. Nassir Ghaemi, M.D., Richard D. Milone, M.D., Michael R. Arambula, M.D., Jennifer Radden, Ph.D.

ISSUE WORKSHOP 66  9:00 a.m. - 10:30 a.m.
Room 112, Exhibit Level, Moscone Center

THE DISRUPTIVE PHYSICIAN AND HOSPITAL CULTURE

Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

ISSUE WORKSHOP 67  9:00 a.m. - 10:30 a.m.
Room 113, Exhibit Level, Moscone Center

THE UNWRITTEN RULES FOR SUCCESS AS A COMMUNITY PSYCHIATRIST

Co-Chps.: Stephen M. Goldfinger, M.D., Charles W. Huffine, Jr., M.D.
Participants: Stuart A. Anfang, M.D., Kenneth S. Thompson, M.D.

ISSUE WORKSHOP 68  9:00 a.m. - 10:30 a.m.
Room 114, Exhibit Level, Moscone Center

THE MONTGOMERY COUNTY EMERGENCY SERVICE DIVERSION MODEL: A COMPREHENSIVE CONTINUUM OF FORENSIC INTERVENTIONS

Chp.: Rocio Nell, M.D.
Participant: Donald S. Kline, Ph.D.

ISSUE WORKSHOP 69  9:00 a.m. - 10:30 a.m.
Room 123, Exhibit Level, Moscone Center

ELECTRONIC MEDICAL RECORDS ENHANCE QUALITY AND PRODUCTIVITY: THE TIME HAS COME

Chp.: Daniel A. Deutschman, M.D.
Participants: Robert C. Hsiung, M.D., Andrea I. Glasser, M.Ed., Jaskaran Singh, M.D., Jesse H. Wright, M.D.

ISSUE WORKSHOP 70  9:00 a.m. - 10:30 a.m.
Room 124, Exhibit Level, Moscone Center

INDIVIDUAL PSYCHOTHERAPY WITH MEN SUFFERING FROM FATHER LOSS

Chp.: Lawrence L. Kennedy, M.D.
WEDNESDAY

ISSUE WORKSHOP 71  9:00 a.m. - 10:30 a.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

MATCHMAKER, MATCHMAKER MAKE ME A MATCH

Chp.: Lawrence Bryskin, M.D.
Participants: Abba E. Borowich, M.D., Esther Jungreis, Maurice Stein, Rabbi Zvi Schachtel, B.A., Rena Hirsch, B.A.

ISSUE WORKSHOP 72  9:00 a.m. - 10:30 a.m.
Room 300, Esplanade Level, Moscone Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 73  9:00 a.m. - 10:30 a.m.
Room 301, Esplanade Level, Moscone Center

WHEN PSYCHIATRISTS HAVE A MENTAL ILLNESS: THE STORIES OF THEIR LOVED ONES
National Alliance for the Mentally Ill

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Jane Baxter, Marian Fireman, M.D., Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D., Andrew Vogel-Scibilia

ISSUE WORKSHOP 74  9:00 a.m. - 10:30 a.m.
Room 302, Esplanade Level, Moscone Center

CUTTING-EDGE ISSUES IN CROSS-CULTURAL PSYCHIATRY

Chp.: Albert C. Gaw, M.D.
Participants: Desmond S. Fung, M.D., Alice C. Tso, M.D., Phuong-Thuy Le, M.D.

ISSUE WORKSHOP 75  9:00 a.m. - 10:30 a.m.
Room 304, Esplanade Level, Moscone Center

THE PSYCHIATRIST’S NIGHTMARE: A MALPRACTICE LAWSUIT

Chp.: David W. Preven, M.D.
Participants: Susan Stabinsky, M.D., Jacqueline M. Melonas, J.D., Harvey Stabinsky, M.D.

ISSUE WORKSHOP 76  9:00 a.m. - 10:30 a.m.
Room 306, Esplanade Level, Moscone Center

COUNSELING COMMITTED COUPLES: RETHINKING THERAPEUTIC NEUTRALITY

Chp.: Scott D. Haltzman, M.D.
Participants: Jack Drescher, M.D., Janice R. Levine, Ph.D., Dorianna F. Morar, M.D.

ISSUE WORKSHOP 77  9:00 a.m. - 10:30 a.m.
Room 308, Esplanade Level, Moscone Center

INTERGENERATIONAL TRANSMISSION OF TRAUMA IN PREVENTION OF LONG-TERM CONSEQUENCES OF TRAUMATIC STRESS

Chp.: Andrei Novac, M.D.
Participants: Rita R. Newman, M.D., Charles W. Portney, M.D.

ISSUE WORKSHOP 78  9:00 a.m. - 10:30 a.m.
Room 309, Esplanade Level, Moscone Center

INDIVIDUAL PSYCHOTHERAPY FOR MARITAL PROBLEMS

Co-Chps.: Michael C. Hughes, M.D., Eva C. Ritvo, M.D.

ISSUE WORKSHOP 79  9:00 a.m. - 10:30 a.m.
Room 310, Esplanade Level, Moscone Center

HEPATITIS C INFECTION: THE NEXT PSYCHIATRIC EPIDEMIC

Chp.: Andrew F. Angelino, M.D.
Participant: Glenn J. Treisman, M.D.

ISSUE WORKSHOP 80  9:00 a.m. - 10:30 a.m.
Salons 1 & 2, Lower B-2 Level, Marriott

FAMILY THERAPY TRAINING FOR PSYCHIATRY RESIDENTS

Chp.: Steven J. Wolin, M.D.
Participants: Ellen M. Berman, M.D., John S. Rolland, M.D., John Sargent, M.D., Peter J. Steinglass, M.D.

ISSUE WORKSHOP 81  9:00 a.m. - 10:30 a.m.
Pacific Conference Suite H, 4th Floor, Marriott

FAMILY THERAPY FOR ANOREXIA NERVOSA

Chp.: James D. Lock, M.D.
Participant: Daniel Legrange, Ph.D.

ISSUE WORKSHOP 82  9:00 a.m. - 10:30 a.m.
Pacific Conference Suite J, 4th Floor, Marriott

HELPING THE HEALERS: PROVIDING IMPAIRMENT EDUCATION TO PHYSICIANS

Chp.: Karen E. Broquet, M.D.
11:00 a.m. Sessions

**DISCUSSION GROUPS 21-24**

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

21 Robert G. Robinson, M.D., on Controversies in Vascular and Post-Stroke Depression  
Pacific Conference Suite B, 4th Floor, Marriott

22 Arnold E. Andersen, M.D., on Eating Disorders in Males: A Rising Tide  
Pacific Conference Suite C, 4th Floor, Marriott

23 Kathryn J. Zerbe, M.D., on Women's Mental Health  
Pacific Conference Suite E, 4th Floor, Marriott

24 Carl C. Bell, M.D., on Cross-Cultural Issues: When the Patient Is Different From You (For Residents Only)  
Pacific Conference Suite I, 4th Floor, Marriott

**LECTURES 18-19**

**LECTURE 18**
11:00 a.m. - 12:30 p.m.  
Rooms 130/131, Exhibit Level, Moscone Center

Marshal F. Folstein, M.D.

The Meaning of Cognitive Impairment

Chp.: Thomas N. Wise, M.D.  
Co-Chp.: Paul J. Goodnick, M.D.

A low score on a measure of cognitive impairment can point to a variety of syndromes and pathological states, and accurate diagnosis is highly important for making use of the new opportunities for treatment on the horizon. Marshal F. Folstein, M.D., presents a plan for systematic assessment of cognitive impairment and discusses the range of clinical conditions associated with this impairment. Dr. Folstein is Dr. Frances S. Arkin Professor and Chair in the Department of Psychiatry at Tufts University School of Medicine and Psychiatrist-in-Chief in the Department of Psychiatry at New England Medical Center in Boston, MA. His research interests include the causes and treatment of cognitive disorders associated with aging. He is currently investigating the effects of micronutrients on cognition. The author or co-author of more than 225 research articles and book chapters, Dr. Folstein serves on the editorial boards of several journals, including the American Journal of Geriatric Psychiatry and Alzheimer's Disease and Related Disorders. He is a Fellow of the American Psychiatric Association, the American College of Physicians, and the Gerontological Society of America. A graduate of Georgetown University School of Medicine, Dr. Folstein completed his residency in neurology at Cleveland Metropolitan General Hospital and his residency in psychiatry at the New York Hospital, Westchester Division. Distinguished Psychiatrist Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

**LECTURE 19**
11:00 a.m. - 12:30 p.m.  
Rooms 132/133, Exhibit Level, Moscone Center

Samuel H. Barondes, M.D.

Better Than Prozac: Creating New Psychiatric Drugs

Chp.: Peter D. Kramer, M.D.

Samuel H. Barondes, M.D., is the Jeanne and Sanford Robertson Professor of Neurobiology and Psychiatry and Director of the Center for Neurobiology and Psychiatry at the University of California, San Francisco. A leading authority on the application of molecular biology to psychiatry, Dr. Barondes is author of more than 200 original research articles, editor of the books Cellular Dynamics of the Neuron and Neuronal Recognition, and author of Molecules and Mental Illness and Mood Genes: Hunting for Origins of Mania and Depression. His book, Better Than Prozac: Creating the Next Generation of Psychiatric Drugs, is scheduled for publication by Oxford University Press in the spring of 2003. Dr. Barondes is a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American College of Neuropsychopharmacology. A graduate of Columbia University College of Physicians and Surgeons in New York City, Dr. Barondes received his clinical training in medicine and psychiatry at Boston-area hospitals affiliated with Harvard Medical School (Peter Bent Brigham Hospital, McLean Hospital, and Massachusetts General Hospital) and received his training in molecular biology at the National Institutes of Health in Bethesda, MD. Frontiers of Science Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

**MASTER EDUCATOR CLINICAL CONSULTATION 9**

11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

David V. Sheehan, M.D., on Anxiety Disorders  
Room 218, Mezzanine Level, Moscone Center

This session is open to APA members only. Blue registration badge or APA membership card required for admittance.
MEDICAL UPDATE 3
11:00 a.m. - 12:30 p.m.
Room 300, Esplanade Level, Moscone Center

YOGIC BREATHING: NEUROPHYSIOLOGIC
THEORY AND CLINICAL APPLICATIONS FOR
TREATMENT OF STRESS RELATED
DISORDERS, DEPRESSION, AND AGGRESSION

Chp.: Philip R. Muskin, M.D.
Presenter: Richard P. Brown, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

RESEARCH CONSULTATION WITH

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-
come, first-served basis.

2 Katherine L. Wisner, M.D., on Depression During
Pregnancy and the Postpartum Period
Sierra Conference Suite E, 5th Floor, Marriott

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 19-28

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m. - 12:30 p.m.
Room 110, Exhibit Level, Moscone Center

DIAGNOSTIC ISSUES

Chp.: Sophia Vinogradov, M.D.
Co-Chp.: Michael J. Pratts, M.D.

11:00 a.m.
56 The Development of a Brief Adult Mental Health
Screening Tool for Jails
Robert L. Trestman, M.D., Julian Foro, Ph.D., Janelle Mallet,
Valerie Hogan, M.A.

11:30 a.m.
57 Diagnosing and Treating Infants and Toddlers in
Public Mental Health Settings
Harry H. Wright, M.D., Rosetta H. Penny, M.S.W., Kristin M.
Wieduwilt, M.S.

12 noon
58 Psychiatric Nomenclature
Roger Peele, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m. - 12:30 p.m.
Room 111, Exhibit Level, Moscone Center

BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

Chp.: Anton C. Trinidad, M.D.
Co-Chp.: Caroline E. Fisher, M.D.

11:00 a.m.
59 TAK-375 Is a Highly Selective Agonist at the ML-1
Receptor
Keisuke Hirai, Ph.D., Kelli Nishiyama, Koki Kato, Ph.D.,
Shui Hinuma, Ph.D., Osamu Uchikawa, Ph.D., Shigenori
Ohkawa, Ph.D., Masaomi Miyamoto, Ph.D.

11:30 a.m.
60 Safety, Pharmacokinetics, and Pharmacodynamics of
TAK-375 in Healthy Adults
Charlene M. Stubbs, Ph.D., Aziz Karim, Ph.D.

12 noon
61 Selectivity of the ML-1 Agonist TAK-375: Lack of
Binding to NON-ML-1 Targets
Masaomi Miyamoto, Ph.D., Keisuke Hirai, Ph.D., Koki
Kato, Ph.D., Osamu Uchikawa, Ph.D., Shigenori
Ohkawa, Ph.D.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m. - 12:30 p.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

PEDIATRIC ADHD

Chp.: Mohammad Shafii, M.D.
Co-Chp.: Duru Sakhrani M.D., M.D.

11:00 a.m.
62 An Open-Label Trial of Adderall XR: Quality-of-Life
Assessments
Floyd R. Sallee, M.D., Paul J. Ambrosini, M.D., Frank A.
Lopez, M.D., J. Jordan Storlazzi, M.D., Simon J. Tulloch, M.D.,
M. Alex Michaels, M.D.

11:30 a.m.
63 Long-Term Safety and Efficacy of Adderall XR in
Children With ADHD
Mark C. Chandler, M.D., Frank A. Lopez, M.D., Joseph
Biederman, M.D.

12 noon
64 An Open-Label, Community-Assessment Trial of
Adderall XR in Pediatric ADHD
Paul J. Ambrosini, M.D., Frank A. Lopez, M.D., Mark C.
Chandler, M.D., Simon J. Tulloch, M.D., M. Alex
Michaels, M.D.

THIS SESSION WILL BE AUDIOTAPEED.
SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m. - 12:30 p.m.
Room 302, Esplanade Level, Moscone Center

GERIATRIC PSYCHIATRY

Chp.: Paul P. Yeung, M.D.
Co-Chp.: Mohammad Shafii, M.D.

11:00 a.m.
65 NIMH Atypical Antipsychotic Effectiveness Trial In Alzheimer’s CATIE-AD
M. Saleem Ismail, M.D., Ge A. Donker, M.D., Karen S. Dagerman, M.S., Sonia Davis, D.P.H., Pierre N. Tariot, M.D.

11:30 a.m.
66 Meta-Analysis of Risperidone for Dementia: The Price Paid for Efficacy
Ge A. Donker, M.D., Karen S. Dagerman, M.S.

12 noon
67 Switching Elderly Chronic Schizophrenia Patients to Olanzapine: A Prospective Study
Yoram Barak, M.D., Eyal Z. Shamir, M.D., Ronit Weizman, M.D., Dov Aizenberg

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m. - 12:30 p.m.
Room 308, Esplanade Level, Moscone Center

THE PROMISE OF SCIENCE: THE POWER OF HEALING

Chp.: David H. Taylor, M.D.
Co-Chp.: Barbara A. Fitzgerald, M.D.

11:00 a.m.
68 Serum Lipid Fractions in Clozapine-Treated Patients Over a Two-Year Period
Charles F. Caley, Pharm.D., Stephen B. Woolley, M.P.H., John W. Goethe, M.D.

11:30 a.m.
69 The Influence of Group Psychoeducation on Quality of Life in Schizophrenia Patients and Their Relatives
Lucie Motlova, M.D., Eva Dragomirecka, Ph.D., Filip Spaniel, M.D., Pavla Selepova, Richard Zalesky, M.D., Eva Goppoldova

12 noon
70 HIV-Related Stigma: Disclosure, Depression, and Social Support
Rachel Power, Ph.D., Cheryl Koopman, Ph.D., Dennis M. Israeliski, M.D., Ron Duran, Ph.D., David Spiegel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m. - 12:30 p.m.
Salons 3 & 4, Lower B-2 Level, Marriott

TOPICS IN SUICIDE AND VIOLENCE

Chp.: Stephanie Z. Hall, M.D.
Co-Chp.: Rahil Jummani, M.D.

11:00 a.m.
71 Impulsivity, Suicide, and Prefrontal Hypometabolism in Borderline Personality
Paul H. Soloff, M.D., Carolyn Meltzer, M.D., Carl Becker, B.A., Phil J. Greer, M.A., Thomas M. Kelly, Ph.D., Doreen Constantine, M.Ed.

11:30 a.m.
72 Suicide Rates Over the Decade Across Civilian and Military Populations
Abigail L. Garvey-Wilson, M.D., Karen M. Eaton, M.S., Charles W. Hoge, M.D., Stephen C. Messer, Ph.D., Sandra E. Lesikar, Ph.D.

12 noon
73 Clozapine Reduces Violent Behavior in Heterogeneous Diagnostic Groups
John E. Kraus, Jr., M.D., Brian B. Sheitman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m. - 12:30 p.m.
Salons 12 & 13, Lower B-2 Level, Marriott

ISSUES IN PSYCHIATRY

Chp.: Tanya R. Anderson, M.D.
Co-Chp.: Darrin L. Bailey, M.D.

11:00 a.m.
74 Children Excluded From Primary School: Randomized, Controlled Trial of a Team Intervention
Christos Panayiotopoulos, Ph.D., Michael J. Kerfoot, Ph.D.

11:30 a.m.
75 Malpractice Liability and Managed Care: Is a Resolution in Sight?
Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

12 noon
76 The Power of Humor in Psychotherapy
William F. Fry, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m. - 12:30 p.m.
Golden Gate Hall C, B-2 Level, Marriott

PSYCHOPHARMACOLOGY OF HEADACHE AND ANXIETY DISORDERS

Chp.: Barbara L. Yates, M.D.
Co-Chp.: Ann M. Bogan, M.D.

11:00 a.m.
77 Clinical Experiments With Sertraline in Panic Disorder
Matig R. Mavissakalian, M.D.

11:30 a.m.
78 Double-Blind Oral Morphine in Treatment-Resistant OCD
Lorrin M. Koran, M.D., Kim D. Bullock, M.D., Bettina E. Franz, M.D., Nona Gamel, M.S.W., Michael A. Elliott, M.A.

12 noon
79 Treatment of Tension Headache With Mirtazapine
Isin B. Kulaksizoglu, M.D., Sibel Gakir, M.D., Mustafa Ertas

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m. - 12:30 p.m.
Sierra Conference Suite H, 5th Floor, Marriott

INTERNATIONAL PSYCHIATRY

Chp.: Dilip V. Jeste, M.D.
Co-Chp.: Rose M. Pham, M.D.

11:00 a.m.
80 Excess Mortality in Schizophrenia in Stockholm County, Sweden
Massimo di Giannantonio, M.D., Nestor Correia, Lena Brandt, B.S.C., Anders Ekbom, M.D., Par Sparen, Ph.D.

11:30 a.m.
81 Sex Differences in Health Service Use and Functioning Associated With Depressive Symptoms: Findings From the Utrecht Health Project
Mirjam I. Geerlings, Ph.D., Huib Burger, Ph.D., Johan M. Havenaar, M.D., Mattijs E. Numans, M.D., Diederic E. Grobbee, Ph.D.

12 noon
82 Binge Eating Disorder in Fiji, A Small-Scale, Indigenous Society
Anne E. Becker, M.D., Rebecca A. Burwell, M.Phil., Kesaia Navara, Stephen E. Gilman, Sc.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 30-38

COMPONENT WORKSHOP 30 11:00 a.m. - 12:30 p.m.
Room 124, Exhibit Level, Moscone Center

UNITED WE STAND: DEVELOPING PARTNERSHIPS FOR PATIENT ADVOCACY
APA Committee on Public Affairs and APA Committee on Government Relations

Chp.: Mary H. Davis, M.D.
Participants: Jeffrey Akaka, M.D., John Bush, Judith F. Kashtan, M.D.

COMPONENT WORKSHOP 31 11:00 a.m. - 12:30 p.m.
Room 125, Exhibit Level, Moscone Center

CPT CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements

Co-Chps.: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
Participants: Ronald A. Shellow, M.D., Gerald Rogan, M.D., Joseph M. Schwartz, M.D.
WEDNESDAY

COMPONENT WORKSHOP 32  11:00 a.m. - 12:30 p.m.
Room 309, Esplanade Level, Moscone Center

RETIREMENT ISSUES FOR PSYCHIATRISTS AND THEIR SPOUSES
APA Lifers and APA Task Force on Senior Psychiatrists

Chp.: Hugh C. Hendrie, M.D.
Participants: Irvin M. Cohen, M.D., Mary Austrom, Ph.D., Captane P. Thomson, M.D.

COMPONENT WORKSHOP 33  11:00 a.m. - 12:30 p.m.
Room 310, Esplanade Level, Moscone Center

STATE OF THE STATES FOR STATE HOSPITAL PSYCHIATRISTS
APA Caucus of State Hospital Psychiatrists

Co-Chps.: Beatrice M. Kovasznay, M.D., Yadollah M. Jabbarpour, M.D.
Participants: Thomas W. Hester, M.D., Perry B. Bach, M.D., Anita Everett, M.D., Wayne F. Brown, M.D.

COMPONENT WORKSHOP 34  11:00 a.m. - 12:30 p.m.
Salons 1 & 2, Lower B-2 Level, Marriott

DEPRESSIVE DISORDERS AND HISPANICS: A DEVELOPMENTAL PERSPECTIVE
APA Committee of Hispanic Psychiatrists

Co-Chps.: Ana E. Campo, M.D., Oscar E. Perez, M.D.
Participants: Daniel Castellanos, M.D., Sayonara Baez, M.D.

COMPONENT WORKSHOP 35  11:00 a.m. - 12:30 p.m.
Salons 5 & 6, Lower B-2 Level, Marriott

WHY PSYCHIATRY? SAYS MOM
APA Committee of Asian-American Psychiatrists

Co-Chps.: John S. Luo, M.D., Surinder S. Nand, M.D.
Participants: Mona H. Gill, M.D., Sue Y. Lee, M.D., Mary Ann Barnovitz

COMPONENT WORKSHOP 36  11:00 a.m. - 12:30 p.m.
Salons 10 & 11, Lower B-2 Level, Marriott

CLINICAL ISSUES OF ETHNIC DIVERSITY IN LONG-TERM CARE FACILITIES
APA Committee on Ethnic Minority Elderly

Co-Chps.: Ronald Brenner, M.D., Josepha A. Cheong, M.D.
Participants: Iqbal Ahmed, M.D., Warachal E. Faison, M.D., Mia J. Robinson, Ella Brodsky, M.D.

COMPONENT WORKSHOP 37  11:00 a.m. - 12:30 p.m.
Salons 14 & 15, Lower B-2 Level, Marriott

IMPLICATIONS OF FINANCING OF HEALTH CARE FOR PSYCHIATRIC EDUCATION AND PRACTICE
APA Council on Healthcare Systems and Financing

Chp.: Barry F. Chaitin, M.D.
Participants: Nyapati R. Rao, M.D., Bruce J. Schwartz, M.D., Frederick J. Stoddard, Jr., M.D., Allison M. Wehr, M.D., Rebecca Brendel, M.D., Joyce A. Tinsley, M.D.

COMPONENT WORKSHOP 38  11:00 a.m. - 12:30 p.m.
Golden Gate Hall A, B-2 Level, Marriott

INTERSEX CONDITIONS: CONTROVERSIES AND NEW APPROACHES TO TREATMENT
APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Richard O. Hire, M.D.
Participants: Jack Drescher, M.D., Benjamin H. McCommon, Jr., M.D., Vernon A. Rosario, M.D.

ISSUES 83-88

ISSUE WORKSHOP 83  11:00 a.m. - 12:30 p.m.
Room 112, Exhibit Level, Moscone Center

DO I NEED AN MBA TO TRANSFORM MY CAREER?
Chp.: Arthur L. Lazarus, M.D.

ISSUE WORKSHOP 84  11:00 a.m. - 12:30 p.m.
Room 113, Exhibit Level, Moscone Center

THE BEGINNING STAGES OF COUPLES' THERAPY: VIDEO CASE STUDIES
Chp.: Ian E. Alger, M.D.

ISSUE WORKSHOP 85  11:00 a.m. - 12:30 p.m.
Room 114, Exhibit Level, Moscone Center

HEALING THE HURT CHILD: TREATING FETAL ALCOHOL SYNDROME SPECTRUM DISORDER CHILDREN
Chp.: Peter D. Ganime, M.D.
Participants: Denise Aloia, M.D., Grace Hickey, Psy.D., Joanne Dunnigan, M.S.W., Jennifer Smith, Ph.D.

ISSUE WORKSHOP 86  11:00 a.m. - 12:30 p.m.
Room 122, Exhibit Level, Moscone Center

GOING PUBLIC OVER PATIENT PRIVACY
Chp.: Rodrigo A. Munoz, M.D.
Participants: Pamela J. Wright-Etter, M.D., Kevin M. Etter, M.D.

71
WEDNESDAY

ISSUE WORKSHOP 87  11:00 a.m. - 12:30 p.m.
Room 123, Exhibit Level, Moscone Center

CHILDREN OF PSYCHIATRISTS: INSIGHTS AND RECOMMENDATIONS FROM THOSE WHO KNOW

Co-Chps.: Leah J. Dickstein, M.D., Michelle B. Riba, M.D.
Participants: Cory Butterfield, David Robinowitz, M.D., Barbara Kamholz, M.D.

ISSUE WORKSHOP 88  11:00 a.m. - 12:30 p.m.
Room 304, Esplanade Level, Moscone Center

INTERNATIONAL PSYCHIATRIC/ PSYCHOPHARMACOLOGICAL ORGANIZATIONS' COLLABORATION

College of International Neuropsychopharmacology, European College of Neuropsychopharmacology, World Federation of Societies of Biological Psychiatry, and World Psychiatric Association

Chp.: Marcia K. Goin, M.D.
Participants: Paul S. Appelbaum, M.D., Herbert Y. Meltzer, M.D., Yves LeCrubier, M.D., Ahmed Okasha, M.D., Carlos R. Hojat, M.D.

12 noon Sessions

FORUMS 8-10

FORUM 8  12 noon - 1:30 p.m.
Room 301, Esplanade Level, Moscone Center

ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION

Chp.: Stephen C. Scheiber, M.D.
Participants: Michael H. Ebert, Larry R. Faulkner, M.D., Glen C. Davis, M.D., Nalene N. Andrade, M.D., David A. Mrazek, M.D., Burton V. Reifler, M.D., James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D.

FORUM 9  12 noon - 1:30 p.m.
Room 306, Esplanade Level, Moscone Center

MEANINGFUL ACTIVITIES AND STRUCTURE MATTER: HOW A PREVOCATIONAL PROGRAM HELPS SEVERELY MENTALLY ILL CLIENTS

Chp.: Amelia Truman
Participant: Israel Katz, M.D.

FORUM 10  12 noon - 1:30 p.m.
Golden Gate Hall B, B-2 Level, Marriott

APA AND THE PHARMACEUTICAL INDUSTRY: CONTROVERSIES AND APPROACHES

Chp.: Stephen M. Goldfinger, M.D.
Participants: Charles R. Goldman, M.D., Geetha Jayaram, M.D., David M. McDowell, M.D., Daniel K. Winstead, M.D.

NEW RESEARCH POSTER SESSION 8
12 noon - 2:00 p.m.
Hall D, Exhibit Level, Moscone Center

SCHIZOPHRENIA, SYSTEMS ISSUES, STIGMA, TECHNOLOGY, AND CREATIVELY

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m. Sessions

COURSES 95-99
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 95  1:00 p.m. - 5:00 p.m.
Franciscan Room B, Ballroom Level, Hilton

MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENT

Director: Murray D. Schane, M.D.
Faculty: Howard Fradkin, Ph.D., Richard Gartner, Ph.D., William Holmes, M.D., Larry A. Morris, Ph.D.

COURSE 96  1:00 p.m. - 5:00 p.m.
Yosemite Room A, Ballroom Level, Hilton

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

COURSE 97  1:00 p.m. - 5:00 p.m.
Union Square 14, Fourth Floor, Hilton

PSYCHIATRY AND THE INTERNET

Director: Robert S. Kennedy, M.A.
Faculty: Robert C. Hsuang, M.D., Thomas A.M. Kramer, M.D.
WEDNESDAY

COURSE 98 1:00 p.m. - 5:00 p.m.
Union Square 15 & 16, Fourth Floor, Hilton

UPDATE ON SLEEP MEDICINE: ADVANCED TOPICS

Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirshkowitz, Ph.D., Lois E. Krahn, M.D.

COURSE 99 1:00 p.m. - 5:00 p.m.
Union Square 21, Fourth Floor, Hilton

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

2:00 p.m. Sessions

LECTURES 20-22

LECTURE 20
2:00 p.m. - 3:30 p.m.
Room 114, Exhibit Level, Moscone Center

APA'S ALEXANDRA SYMONDS AWARD LECTURE
Donna E. Stewart, M.D.

International Determinants of Women's Mental Health

Chp.: Sylvia W. Olarte, M.D.
Co-Chair: Deborah Spitz, M.D.

Donna E. Stewart, M.D., is the Lillian Love Chair in Women's Health at the University Health Network and the University of Toronto, where she is responsible for research, education, policy, and health service delivery for women's health. She is also Professor in the Faculty of Medicine in the Departments of Psychiatry, Obstetrics/Gynecology, Medicine, Anesthesia, Family and Community Medicine, and Surgery at the University of Toronto. Her research interests are in women's health and mental health, women's health education, psychological aspects of reproductive health, and psychological reactions to physical illness. She is active also in medical education and career development for women health care professionals. She has served as a consultant to Health Canada, the Population Health Council, the National Institutes of Health, and U.S. Public Health Service. A Distinguished Fellow of the American Psychiatric Association, Dr. Stewart formerly chaired the APA Committee on Women and currently chairs the Section of Women's Mental Health for the World Psychiatric Association. She is the author of more than 200 peer-reviewed publications and co-editor of three books on women's mental health, including *A Clinician's Guide to Menopause*. In 2001 she was appointed Deputy Editor for American Psychiatric Publishing, Inc.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 21
2:00 p.m. - 3:30 p.m.
Rooms 130/131, Exhibit Level, Moscone Center

APA AWARD FOR RESEARCH IN PSYCHIATRY
Ming T. Tsuang, M.D.

Searching for Etiological Risk Factors of Schizophrenia

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Darrel A. Reiger, M.D.

Ming T. Tsuang, M.D., is Stanley Cobb Professor of Psychiatry and Psychobiology in the Departments of Psychiatry and Epidemiology at Harvard University and Director of the Harvard Institute of Psychiatric Epidemiology and Genetics. His current research aim is to advance the prevention of psychiatric disorders, particularly schizophrenia, by identifying traits that predispose a person to the disorder from both genetic and environmental perspectives. Dr. Tsuang has received numerous awards for his research in schizophrenia, manic-depressive illness, and substance abuse, including the Stanley Dean Award for Research in Schizophrenia, the Noyes Award for Research in Schizophrenia, the National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award, the Lifetime Achievement Award from the International Society of Psychiatric Genetics, and the Gold Medal Award from the Society of Biological Psychiatry. He is the author or coauthor of more than 400 publications and serves as Editor of *Neuropsychiatric Genetics*, a section of the *American Journal of Medical Genetics*. A Distinguished Life Fellow of the American Psychiatric Association and a Member of the Institute of Medicine, Dr. Tsuang is President-Elect of the American Psychopathological Association. He received his medical degree from National Taiwan University and his doctoral degrees in psychiatric epidemiology and genetics from the University of London.

THIS SESSION WILL BE AUDIOTAPED.
The Revolution in Mouse Molecular Genetics: New Approaches for Psychiatric Research

Laurence H. Tecott, M.D.

A remarkable degree of homology exists between the human and mouse genomes, and humans and mice share many features of brain organization, as well as many similar responses to pharmacological agents and to gene mutations. Laurence H. Tecott, M.D., describes the state of the art in the use of mouse molecular genetic technologies to discern mammalian neural gene function and to model the phenomenology of psychiatric diseases. Dr. Tecott is Associate Professor of Psychiatry and Associate Director of the Center for Neurobiology and Psychiatry at the University of California, San Francisco. He is the author of numerous scientific articles and book chapters and coauthor of the book Atlas of the Developing Rat Brain. He has received the March of Dimes Basil O'Connor Scholar Award and both the Young Investigator Award and Independent Investigator Award of the National Alliance for Research on Schizophrenia and Depression. Dr. Tecott received his medical degree from the University of California, San Francisco, where he also completed his residency in psychiatry and a fellowship in psychiatry and pharmacology. He received his doctoral degree in neuroscience from Stanford University in Stanford, California.

REVIEW OF PSYCHIATRY: SECTION 4
2:00 p.m. - 5:30 p.m.
Room 104, Exhibit Level, Moscone Center

GERIATRIC PSYCHIATRY

Chp.: Alan M. Mellow, M.D.

16 Depression and Anxiety in Late Life
Alan M. Mellow, M.D.

17 Dementia
Myron F. Weiner, M.D.

18 Late-Life Psychoses
George T. Grossberg, M.D.

19 Late-Life Addictions
Frederic C. Blow, Ph.D.

20 Geriatric Psychiatry at the Crossroads of Public Policy and Clinical Practice
Christine M. deVries, M.A.

SYMPOSIA 60-82

SYMPOSIUM 60 2:00 p.m. - 5:00 p.m.
Room 110, Exhibit Level, Moscone Center

WORLD PSYCHIATRIC ASSOCIATION'S INTERNATIONAL GUIDELINES FOR DIAGNOSTIC ASSESSMENT

Chp.: Juan E. Mezzich, M.D.
Co-Chp.: T. Bedirhan Ustun, M.D.

A Interviewing and Extended Sources of Information
Carlos E. Berganza, M.D.

B Evaluation of Symptoms and Mental Status
Andrew E. Skodol II, M.D.

C Standardized and Idiographic Diagnostic Formulation
Juan E. Mezzich, M.D.

D Linking Diagnosis to Treatment
Ahmed Okasha, M.D.

E A Case Formulation According to the International Guidelines for Diagnostic Assessment
Miguel R. Jorge, M.D.

Discussants: Francis G. Lu, M.D., Iguent Kuey, M.D.

SYMPOSIUM 61 2:00 p.m. - 5:00 p.m.
Room 111, Exhibit Level, Moscone Center

DIMENSIONALITY IN PSYCHIATRIC DISORDERS

Chp.: Stephen B. Shanfield, M.D.

A A Diagnostic Versus a Dimensional View of Delusions: A 20-Year Follow-Up
Martin Harrow, Ph.D., Ellen S. Herbener, Ph.D., Kalman J. Kaplan, Ph.D., Joseph F. Goldberg, M.D., Eileen M. Martin, Ph.D.

B Dimensions of Depression and Differential Sensitivity to Antidepressants
Martin M. Katz, Ph.D., Alan Frazer, Ph.D., Charles L. Bowden, M.D.

C Behavioral Dimensions of Bipolar Disorder
Charles L. Bowden, M.D.
WEDNESDAY

D Dimensions of Personality Disorder
Larry J. Siever, M.D.

Discussant: Stephen B. Shanfield, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62 2:00 p.m. - 5:00 p.m.
Room 112, Exhibit Level, Moscone Center

WORKPLACE ISSUES IN PSYCHOTHERAPY
APA Committee on Psychotherapy by Psychiatrists and APA Committee on APA/Business Relationships

Chp.: Norman A. Clemens, M.D.

A Workplace Issues Are Vital in Psychotherapy
Norman A. Clemens, M.D.

B Disability and Psychotherapy
Marcia A. Scott, M.D.

C A Psychodynamic Model for Sexual and Other Forms of Workplace Harassment and Violence
Stuart W. Twemlow, M.D.

D Psychotherapy and Vocational Rehabilitation in Community Psychiatry
Linda G. Gochfeld, M.D.

Discussant: Daniel B. Borenstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63 2:00 p.m. - 5:00 p.m.
Room 113, Exhibit Level, Moscone Center

THE NATURE AND TREATMENT OF BDD FROM CLINICIANS' AND PATIENTS' PERSPECTIVES

Chp.: Fugen Neziroglu, Ph.D.

A An Overview of the Phenomenology and Diagnostic Issues in BDD
James Claiborn, Ph.D.

B New Cognitive Interventions for BDD
Sabine Wilhelm, Ph.D.

C Behavioral Treatment of BDD
Fugen Neziroglu, Ph.D.

D Addiction to Plastic Surgeries in People With BDD
Eda E. Gorbis, Ph.D.

E Biological Treatment for BDD
Jose A. Yaryura-Tobias, M.D.

Discussants: Deborah Lowgren, Arie Winograd, M.A.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m. - 5:00 p.m.
Room 120, Exhibit Level, Moscone Center

CLINICAL MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID CONDITIONS

Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Leslie L. Citrome, M.D.

A Clinical Management of Depression in Schizophrenia
Samuel G. Siris, M.D.

B Management of Schizophrenia With Comorbid Anxiety Disorders
Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.

C Schizophrenia and PTSD
Lewis A. Opler, M.D., Mary Jane Alexander, Kristina H. Muenzenmaier, M.D., Anne-Marie Shelley, Ph.D.

D Persistent Aggressive Behavior in Schizophrenia: Update 2003
Leslie L. Citrome, M.D., Jan Volavka, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 65 2:00 p.m. - 5:00 p.m.
Room 121, Exhibit Level, Moscone Center

NEW RESEARCH AND NOVEL THERAPEUTIC STRATEGIES FOR OCD

Chp.: Brian A. Fallon, M.D.

A Pharmacologic Strategies for Refractory OCD
Brian A. Fallon, M.D., Suzanne Feinstein, Ph.D., Franklin R. Schneier, M.D., Raphael Campeas, M.D., Carlos Blanco-Jerez, M.D., Michael R. Liebowitz, M.D.

B Neurosurgical Approaches to Treatment-Intractable OCD
Steven A. Rasmussen, M.D., Benjamin D. Greenberg, M.D., George Noren, M.D., Richard Marslano, R.N., Jane L. Eisen, M.D.

C The Role of Cognitive-Behavioral Therapy in the Treatment of OCD
H. Blair Simpson, M.D., Michael R. Liebowitz, M.D.

D Effects of Cognitive Therapy for OCD
Gail Stikettee, Ph.D., Sabine Wilhelm, Ph.D.

E Kundalini Yoga Meditation for the Treatment of OCD
David Shannahoff-Khalsa, B.S.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 66 2:00 p.m. - 5:00 p.m.
Room 122, Exhibit Level, Moscone Center

E- THERAPY, TELEPSYCHIATRY, AND VIRTUAL ENVIRONMENTS: THE EVOLUTION OF CYBERPSYCHIATRY

Chp.: Henry J. Moller, M.D.

A Frontiers in Psychiatric Computerology
James E. Swain, M.D.

B Overcoming Impediments to Technological Advances in Psychiatry
Norman E. Alessi, M.D.

C Measuring Consciousness: Virtual Environments in the Assessment of Human Performance
Henry J. Moller, M.D.

D Virtual Environment for the Assessment of Attention and Memory Processes
Albert A. Rizzo, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67 2:00 p.m. - 5:00 p.m.
Room 123, Exhibit Level, Moscone Center

REPLENISHING OURSELVES: SUPPLY OF PSYCHIATRISTS FOR THE PRESENT AND THE FUTURE

Chp.: Nyapati R. Rao, M.D.
Co-Chp.: Frederick S. Sierles, M.D.

A Current Status of the Psychiatry Workforce in the U.S.
Darrel A. Regier, M.D., Joshua E. Wilk, Ph.D., Joyce C. West, Ph.D., Fanifteh F. Duffy, Ph.D.

B Implications of a Need-Based Approach to Psychiatric Workforce
Larry R. Faulkner, M.D.

C Child and Adolescent Psychiatry Workforce: A Critical Shortage and National Challenge
Wun-Jung Kim, M.D.

D School by School Trends in Medical Student Career Choice of Psychiatry, 1999-2001
Frederick S. Sierles, M.D., Stephen H. Dinwiddie, M.D., Delia Patroi, M.D., Nutan Atre-Vaidya, M.D., Michael J. Schnift, D.O.

E Departments of Psychiatry With High Recruitment Into Psychiatry From 1999-2001: Implication for Medical Student Education
Darlene Shaw, Ph.D., Frederick S. Sierles, M.D., Joshua T. Thornhill IV, M.D., Kathleen A. Clegg, M.D., Lowell D. Tong, M.D.

F An Analysis of Recent Trends in Program Size, Program Type, and Demographics in Psychiatric Residency Training and Its Workforce
Nyapati R. Rao, M.D.

Discussant: Richard A. Cooper, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m. - 5:00 p.m.
Room 124, Exhibit Level, Moscone Center

PTSD: A LATIN-AMERICAN NIGHTMARE
American Society of Hispanic Psychiatry

Chp.: Luis F. Ramirez, M.D.
Co-Chp.: Renato D. Alarcon, M.D.

A Trauma and PTSD: Some New Concepts
Jose M. Canive, M.D.

B Neurobiological Findings on PTSD
Gerardo Villareal, M.D.

C Resilience: A New Concept
Dora Cardona, M.D.

D Trauma and Debriefing in the Colombian Army
Daniel Toledo, M.D.

E PTSD and PET: The Malvinas Trauma
Roxana Galeno, M.D.

F Comprehensive Management of the Patient With PTSD
Renato D. Alarcon, M.D.

G Psychopharmacology and PTSD
Luis F. Ramirez, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m. - 5:00 p.m.
Room 125, Exhibit Level, Moscone Center

MANAGING SUICIDALITY IN BPD

Chp.: Joel F. Paris, M.D.

A Long-Term Outcome and Suicide in BPD
Joel F. Paris, M.D.

B Suicide Prediction in BPD
Donald W. Black, M.D.

C Chronic Suicidality and BPD
Randy A. Sansone, M.D.

D Liability Issues in Litigation After Suicide
Thomas G. Gutheil, M.D.
E The Application of Dialectical Behavior Therapy to Chronic Suicidality in BPD
Marsha M. Linehan, Ph.D.
Discussant: Thomas H. McGlashan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m. - 5:00 p.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

TERRORISM, WAR, AND REFUGEES: PSYCHIATRIC EFFECTS AND PREVENTION?

Chp.: Nigel M. Bark, M.D.
Co-Chp.: Hamid Ghodse, Ph.D.

A New York City Childrens' Reactions to Terrorism After 9/11
Christina Hoven, D.P.H., Cristiane Duarte, Ph.D., Ping Wu, Ph.D., Donald Mandell, Cecille Bimer, Julia Mooney, B.A.

B Terrorism in Nairobi and New York: The Lessons Learned
Frank G. Njenga, M.D.

C Violence Against Civilians: A Historical Perspective
Nasser F. Loza, M.B., Waleed A.R. Fawzi, M.S.C.

D Mental Health Sequelae of the Lebanon Wars
Elie G. Karam, M.D., Aimee N. Karam, Ph.D., John A. Fayyad, M.D., Caroline E. Cordahi, DEA, Zeina W. Mneimneh, M.P.H., Nadine Melhem, Ph.D.

E Transgenerational Transmission of Aggression
Sam Tyano, M.D.

F Not Traumatized but Demoralized: Mental Health Needs of Asylum Seekers in Britian
Patrick J. Bracken, M.D.
Discussant: Ezra S. Susser, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m. - 5:00 p.m.
Room 300, Esplanade Level, Moscone Center

NEUROPSYCHIATRIC ASPECTS OF HIV/AIDS: AN OVERVIEW, PART 1
Chp.: Francine Cournos, M.D.

A HIV Treatment Update
Paul Volberding, M.D.

B CNS Manifestations
Marshall Forstein, M.D.

C Case Discussion and Clinical Panel
Warren M. Liang, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m. - 5:00 p.m.
Room 301, Esplanade Level, Moscone Center

UNMET NEEDS IN BIPOLAR DISORDER: REDEFINING THE SPECTRUM AND ITS BOUNDARIES

Chp.: Joseph R. Calabrese, M.D.
Co-Chp.: Elie G. Hantouche, M.D.

A OCD-Bipolar Comorbidity Redefined: Place of Cyclothymia
Elie G. Hantouche, M.D.

B The Atypical Depression: Bipolar II Borderline Connection
Giulio Perugi, M.D., Hagop S. Akiskal, M.D.

C Early Recognition of Soft-Spectrum Bipolar Disorder in Children
Eric A. Youngstrom, Ph.D.

D Eating Disorders and Bipolarity: Clinical and Treatment Issues
Susan L. McElroy, M.D.

E Contrasting Early Treatment of Bipolar Disorder With the 2002 APA Guidelines
Joseph R. Calabrese, M.D., Robert M.A. Hirschfeld, M.D.
Discussant: Hagop S. Akiskal, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m. - 5:00 p.m.
Room 302, Esplanade Level, Moscone Center

GLUTAMATE: AN EXCITING NEUROTRANSMITTER

Chp.: Jerrold F. Rosenbaum, M.D.

A Neuroimaging of Human Glutamatergic Systems
John H. Krystal, M.D., Graeme Mason, Ph.D., Aysenul Belger, Ph.D.

B The Role of Glutamate in Psychiatric Disorders
Dennis S. Charney, M.D.

C Glutamate in Preclinical Models of Anxiety
Darryle Schoepp, Ph.D.

D The Experience With a Glutamate Agonist in GAD
Jerrold F. Rosenbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 74  2:00 p.m. - 5:00 p.m.
Room 304, Esplanade Level, Moscone Center

COGNITIVE DYSFUNCTION IN BIPOLAR DISORDER

Chp.: Joseph F. Goldberg, M.D.
Co-Chp.: Katherine E. Burdick, Ph.D.

A Neuropsychological Functioning in Bipolar Disorder
   Eduard Vieta, M.D., Anabel Martinez-Aran, Ph.D.

B Psychomotor and Attentional Impairment in Bipolar Disorder
   Katherine E. Burdick, Ph.D.

C Working Memory in Bipolar Disorder: Neurocognitive and Functional Imaging Findings
   Caleb M. Adler, M.D., Stephen M. Strakowski, M.D.

D Differentiating Bipolar Disorder and ADHD: Comorbidity Versus Single Diagnosis
   Joseph Biederman, M.D., Janet Wozniak, M.D., Eric Mick, Sc.D., Stephen V. Farone, Ph.D.

E Cognitive Side Effects of Mood Stabilizers
   Joseph F. Goldberg, M.D., Katherine E. Burdick, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75  2:00 p.m. - 5:00 p.m.
Room 306, Esplanade Level, Moscone Center

ROLES FOR PSYCHIATRY IN END-OF-LIFE CARE

Chp.: Maurice D. Steinberg, M.D.
Co-Chp.: Joseph S. Weiner, M.D.

A Depression at the End-of-Life: Is That all There Is?
   Michael A. Weizneter, M.D.

B Meaning-Centered Group Psychotherapy in Advanced Cancer Patients
   William Breitbart, M.D., Christopher Gibson, Ph.D., Hayley Pessin, Ph.D., Mindy Greenstein, Ph.D., Barry D. Rosenfeld, Ph.D., Alexis Tomarken, M.S.W., Michael Kramer, Ph.D.

C Complicated Grief: Conceptual Issues, Epidemiology, and Evidence-Based Clinical Implications
   Holly G. Prigerson, Ph.D.

D Emotional Barriers to End-of-Life Communication: An Innovative Training for Physicians
   Joseph S. Weiner, M.D., Debra L. Roter, Ph.D., Steven A. Cole, M.D.

E Oregon's Death With Dignity Act: Who Chooses Physician-Assisted Suicide?
   Linda K. Ganzini, M.D., Elizabeth E. Goy, Ph.D.

Discussant: Edwin H. Cassem, M.D.

SYMPOSIUM 76  2:00 p.m. - 5:00 p.m.
Room 307, Esplanade Level, Moscone Center

NEW AND PRACTICAL WAYS TO EFFECTIVELY TREAT BORDERLINE PATIENTS

Chp.: John G. Gunderson, M.D.
Co-Chp.: James A. Chu, M.D.

A A Psychoeducation Program for Borderline Patients
   Mary C. Zanarini, Ed.D., John G. Gunderson, M.D.

B Effectiveness of Inpatient Dialectical Behavioral Therapy for BPD: A Controlled Trial
   Martin Bohus, M.D.

C An Attachment-Theory-Based, Mentalization-Focused Psychotherapy for BPD: Theory and Practice
   Peter Fonagy, Ph.D.

D Split Treatments: From Problem to Asset
   John G. Gunderson, M.D.

E Boundaries, Liability, and Countertransference in the Treatment of BPD
   Glen O. Gabbard, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77  2:00 p.m. - 5:00 p.m.
Room 308, Esplanade Level, Moscone Center

THE DUAL-DIAGNOSIS CHALLENGE: ASSESSMENT AND TREATMENT

Chp.: Michael B. First, M.D.

A Using the Psychiatric Research Interview for Substance and Mental Disorders to Diagnose Psychotic Disorders in Substance Users
   Deborah S. Hasin, Ph.D.

B Application of the Lead Standard in Dual-Diagnosis Patients
   Michael B. First, M.D.

C Differentiating Primary Versus Drug-Induced Persisting Psychosis: Biological Markers
   Nashaat N. Boutros, M.D.

D Course of Substance Abuse Among Comorbid Psychotic Patients: Two-Year Follow-Up in First Admission Patients
   Mark J. Sedler, M.D., Evelyn J. Bromet, Ph.D., Joseph E. Schwartz, Ph.D.

E Peer Support for the Treatment Resistant: Will It Help?
   Carol L.M. Caton, Ph.D., Sam Tsemberis, Ph.D., Robert E. Drake, M.D., Mindy J. Follilove, M.D., Carlos E. Almeida, Jr., M.D., Henry L. McMurtry, M.D., Frederic I. Kass, M.D.

THIS SESSION WILL BE AUDIOTAPED.
<table>
<thead>
<tr>
<th>SYMPOSIUM 78</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 309, Esplanade Level, Moscone Center</td>
<td></td>
</tr>
</tbody>
</table>

IS THIS AN ACT OR AN ACT? APPROACHES TO ASSERTIVE COMMUNITY TREATMENT

Chp.: Hunter L. McQuistion, M.D.

A Adapting the Assertive Community Treatment Model to Work With Forensic MICA Population in Supported Apartments
Michelle Des Roches, M.S.W.

B Assertive Community Treatment With Homeless Individuals
Ann L. Hackman, M.D.

C Pathways to Housing: From Streets to Homes: Housing People With Dual Diagnosis Directly From the Streets
Sam Tsemberis, Ph.D.

D Assertive Community Treatment in New York: A Platform for Implementing Evidence-Based Practices
Linda Rosenberg, M.S.W.

Discussant: Ronald J. Diamond, M.D.

THIS SESSION WILL BE AUDIOTAPED.

<table>
<thead>
<tr>
<th>SYMPOSIUM 79</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 310, Esplanade Level, Moscone Center</td>
<td></td>
</tr>
</tbody>
</table>

THE ESSENCE OF LEARNING PSYCHIATRY: CLINICAL SUPERVISION

Chp.: Pete M. Ellis, B.M.

A Models of Clinical Supervision
Peter Burnett, B.M., Alexandra M. Cockram, M.Ed., Pete M. Ellis, B.M., David Burke, Brian Kelly, B.M.

B Evidence for the Efficacy: Effectiveness of Supervision in Clinical Practice
Alexandra M. Cockram, M.Ed., Pete M. Ellis, B.M., Brian Kelly, B.M., David Burke, Peter Burnett, B.M.

C Supervision in Psychiatry Training: Current Status and Limitations
Brian Kelly, B.M.

D The Development of a Model for Training and Accrediting Supervisors
David Burke, Alexandra M. Cockram, M.Ed., Pete M. Ellis, B.M., Brian Kelly, B.M., Peter Burnett, B.M.

THIS SESSION WILL BE AUDIOTAPED.

<table>
<thead>
<tr>
<th>SYMPOSIUM 80</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golden Gate Hall A, B-2 Level, Marriott</td>
<td></td>
</tr>
</tbody>
</table>

META-ANALYSES OF THE EFFICACY OF SECOND VERSUS FIRST-GENERATION ANTIPSYCHOTICS

Chp.: Ira D. Glick, M.D.
Co-Chp.: John M. Davis, M.D.

A Systematic Reviews of Randomized Trials: The Example of the Atypical Antipsychotics
John R. Geddes, M.R.C.

B The Effects of Olanzapine on the Five Dimensions of Schizophrenia Derived by Factor Analysis
John M. Davis, M.D., Nancy Chen, M.S.

C Examples of How Meta-Analyses Can Inform Clinical Practice
Stefan Leucht, M.D., Thomas Barnes, M.D., John M. Kane, M.D., Rolf Engel, Ph.D., Werner Kissling, M.D., Johannes Haman, M.D., Kristian Wahlbeck, M.D.

D A Meta-Analysis of the Efficacy of Second-Generation Antipsychotics
Ira D. Glick, M.D., John M. Davis, M.D., Nancy Chen, M.S.

Discussant: Stephen R. Marder, M.D.

THIS SESSION WILL BE AUDIOTAPED.

<table>
<thead>
<tr>
<th>SYMPOSIUM 81</th>
<th>2:00 p.m. - 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golden Gate Hall B, B-2 Level, Marriott</td>
<td></td>
</tr>
</tbody>
</table>

THE PSYCHOLOGICAL IMPACT OF 9/11: RESULTS FROM FIVE MAJOR STUDIES

Chp.: Lisa D. Butler, Ph.D.

A Findings From the National Study of Americans’ Reactions to 9/11
William E. Schlenker, Ph.D., Juesta M. Caddell, Ph.D., Lori Ebert, Ph.D., John A. Fairbank, Ph.D., Richard A. Kulka, Ph.D.

B A National Longitudinal Study of Psychological Consequences of 9/11
Bradley D. Stein, M.D., Marc N. Elliott, Ph.D., Lisa H. Jaycox, Ph.D., Rebecca L. Collins, Ph.D., Sandra H. Berry, M.A., Mark A. Schuster, M.D.

C PTSD in New York City After 9/11
Sandro Galea, M.D., Heidi S. Resnick, Ph.D., Dean Kilpatrick, Ph.D., Jennifer Aern, M.P.H., Joel Gold, M.D., Jennifer Stuber, Ph.D., David Vlahov, Ph.D.

D Prior Tragedy Matters: Cross Community Responses to 9/11
E. Alison Holman, Ph.D., Roxane Silver, Ph.D., Daniel McIntosh, Ph.D., Michael Poulin, B.A., Virginia Gilrivas, M.A.

(Continued on next page)
WEDNESDAY

E Psychosocial Predictors of Resiliency in Coping With the Tragedy of 9/11
Lisa D. Butler, Ph.D., Jay Azarow, Ph.D., Juliette C. Desjardins, M.D., Cheryl Koopman, Ph.D., Sue DiMiceli, B.A., David Spiegel, M.D.

Discussant: David Spiegel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 46-52

INDUSTRY-SUPPORTED SYMPOSIUM 46
7:00 p.m. - 10:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

COMPASSIONATE AND SAFE EMERGENT CARE: BEST PRACTICES IN ANTIPSYCHOTIC USE
Supported by Janssen Pharmaceuticals

Chp.: Glenn W. Currier, M.D.

A Can Acute Care Be Compassionate?
Michael H. Allen, M.D.

B Can Acute Care Be Compassionate? Provider/Nurse’s Perspective
Grad Green, M.S.N.

C Evaluating Equivalence of Antipsychotics: Oral Versus IM Administration for Acute Disorders
Glenn W. Currier, M.D.

D Evidence-Based Medicine and the Evolving Standard of Care: Developing the Treatment Alliance
Frederick Veser, M.D., Joseph J. Zealberg, M.D., Belynda D. Veser, M.D.

E Transitioning Patients for Long-Term Success
Robert R. Conley, M.D.

Discussant: Ira D. Glick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 47
7:00 p.m. - 10:00 p.m.
Hall E, Exhibit Level, Moscone Center

JUVENILE BIPOLAR DISORDER: CONTEMPORARY ISSUES IN RESEARCH
Supported by Novartis Pharmaceuticals Corporation

Chp.: Timothy E. Wilens, M.D.

A Diagnostic and Treatment Implications of Psychiatric Comorbidity in Juvenile Bipolar Disorder
Timothy E. Wilens, M.D.

B Pediatric Mania: A Developmental Subtype of Bipolar Disorder?
Joseph Biederman, M.D., Eric Mick, Sc.D., Stephen V. Faraone, Ph.D., Thomas J. Spencer, M.D., Timothy E. Wilens, M.D., Janet Wozniak, M.D.

C The Therapeutic Role of Atypical Antipsychotic Medications in Pediatric-Onset Bipolar Disorder
Janet Wozniak, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9
3:00 p.m. - 5:00 p.m.
Hall D, Exhibit Level, Moscone Center

EPIDEMIOLOGY; ADDICTIONS; EATING,ATTENTION SPECTRUM, AND PERSONALITY DISORDERS; CULTURAL, DIAGNOSTIC, CHILD/ADOLESCENT, AND GENDER ISSUES

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.
D Treatment of Pediatric Bipolar Disorder With Anticonvulsant Mood Stabilizers
Joseph M. Gonzalez-Heydrich, M.D.

E Genetics of Early-Onset Bipolar Disorder
Stephen V. Faraone, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 48
7:00 p.m. - 10:00 p.m.
Metropolitan, Second Level, Argent

CHALLENGES IN DEMENTIA: EVIDENCE-BASED CONSIDERATIONS FROM EARLY DIAGNOSIS TO LONG-TERM MANAGEMENT
Supported by Eisai Inc., Pfizer Inc.

Chp.: John H. Greist, M.D.

A Validated Screening Tools for Dementia
John H. Greist, M.D.

B Real World Assessment and Management of Mild Cognitive Impairment: A Case Study
M. Saleem Ismail, M.D.

C Issues and Practical Lessons in Clinical Trials in Dementia
Rachelle S. Doody, M.D.

D Cholinesterase Inhibitors in Vascular Dementia: A New Treatment Model?
Stephen P. Salloway, M.D.

E Strategies for Keeping the Brain Young
Gary W. Small, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 49
7:00 p.m. - 10:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

COMBINED PHARMACOTHERAPY FOR BIPOLAR DISORDERS
Supported by GlaxoSmithKline

Chp.: Frederick K. Goodwin, M.D.

A The Rationale for Combined Pharmacotherapy
Frederick K. Goodwin, M.D.

B Potential Synergies in the Mechanisms of Actions of Mood Stabilizers
L. Trevor Young, M.D.

C Mood-Stabilizer Combinations: Multimodal Therapy or Polypharmacy?
Terence A. Ketter, M.D.

D Antidepressants in Combination Therapy of Bipolar Disorder
S. Nassir Ghaemi, M.D.

E Atypical Antipsychotics Combined With Standard Mood Stabilizers for Bipolar Disorder
Joseph F. Goldberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 50
7:00 p.m. - 10:00 p.m.
Continental Ballroom, Ballroom Level, Hilton

NOVEL THERAPEUTIC OPTIONS FOR PSYCHOTIC DISORDERS
Supported by Bristol-Myers Squibb Company

Chp.: Rajiv Tandon, M.D.

A The Evolution of Antipsychotic Therapy: A Mechanism-Based Evaluation
W. Wolfgang Fleischhacker, M.D.

B Limitations of Existing Antipsychotic Therapies
Rajiv Tandon, M.D.

C Developments in Antipsychotic Therapy: Real-World Clinical Experience
Susan M. Maixner, M.D.

D Emerging Clinical Developments in Schizophrenia and Psychotic Disorders Research
T. Scott Stroup, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 51
7:00 p.m. - 10:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

BIPOLAR DISORDER: CLINICAL AND PUBLIC HEALTH IMPLICATIONS OF MEDICAL AND PSYCHIATRIC COMORBIDITY
Supported by Ortho-McNeil Pharmaceuticals

Chp.: Paul E. Keck, Jr., M.D.

A Treatment Approaches for Managing Anxiety Disorder in the Bipolar Patient
Patricia Suppes, M.D.

B The Challenge of Treating Bipolar Disorder and Substance Abuse
Mark A. Frye, M.D.

C New Treatment Options for Eating Disorders and Obesity With Comorbid Bipolar Disorder
Shishuka Malhotra, M.D.

D Influence of Medical Comorbidities on Treatment Approaches in Bipolar Patients
John L. Beyer, M.D.

E Gender and Bipolar Disorder
Lori L. Alshuler, M.D., Mark A. Frye, M.D.
WEDNESDAY

INDUSTRY-SUPPORTED SYMPOSIUM 52
7:00 p.m. - 10:00 p.m.
Salon 9, Lower B-2 Level, Marriott

STRIVING TO HEAL THE MIND: THE CHALLENGE OF PTSD
Supported by Wyeth Pharmaceuticals

Chp.: Martin B. Keller, M.D.

A The Global Burden of PTSD: Results From the World Health Organization International Consortium on Psychiatric Epidemiology
Ronald C. Kessler, Ph.D.

B Exposure to Stress and Trauma Across the Life Span: Neurobiological Consequences
Linda L. Carpenter, M.D.

C Early Intervention for PTSD Prophylaxis in Trauma Survivors: Emerging Evidence
Arieh Y. Shalev, M.D.

D Healing the Mind: Therapeutic Approaches for Chronic PTSD
Barbara O. Rothbaum, Ph.D.

E Medicines That Heal the Mind: Pharmacological Approaches for PTSD
Jonathan R.T. Davidson, M.D.
THURSDAY, MAY 22, 2003

156TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 42-45

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2
7:00 a.m. - 8:30 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

NEUROPSYCHIATRY IN THE AGE OF POLYPHARMACY
Supported by Janssen Pharmaceuticals

Chp.: Prakash S. Masand, M.D.

A Polypharmacy in the Treatment of Major Depression
Mark H. Rapaport, M.D.

B Combination Therapy for Alzheimer's Disease: What Are We Waiting for?
P. Murali Doraiswamy, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 2
7:00 a.m. - 8:30 a.m.
Hall E, Exhibit Level, Moscone Center

TREATING ADHD ACROSS THE LIFE CYCLE
Supported by Novartis Pharmaceuticals Corporation

Chp.: Thomas J. Spencer, M.D.
Co-Chp.: Joseph Biederman, M.D.

A ADHD in Adults: Developmental Issues in Clinical Presentations
Thomas J. Spencer, M.D.

B Treatment Options: Evolving Treatments for a Changing Disease
Joseph Biederman, M.D.

Discussants: Michael Sanders, M.D., Betty Jo Salmeron, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44, PART 2
7:00 a.m. - 8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

INSOMNIA IN TODAY'S SOCIETY: CONSEQUENCES AND TREATMENTS
Supported by Sanofi-Synthelabo, Inc.

Chp.: Gregory M. Asnis, M.D.
Co-Chp.: Shari Kohn, Ph.D.

A Cognitive-Behavioral Therapy of Insomnia
Shari Kohn, Ph.D.

B When to Refer a Patient With Insomnia to a Sleep Specialist Laboratory
Michael Thorpy, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 45, PART 2
7:00 a.m. - 8:30 a.m.
Salons 7 & 8, Lower B-2 Level, Marriott

OBESITY IN PSYCHIATRIC PRACTICE: RECOGNITION AND TREATMENT
Supported by Ortho-McNeil Pharmaceuticals

Chp.: B. Timothy Walsh, M.D.

A Psychological Treatment of Obesity and Binge Eating
Denise E. Wilfley, Ph.D.

B Pharmacotherapy of Obesity and Binge Eating
Susan L. McElroy, M.D.

8:00 a.m. Sessions

COURSES 100-102
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 100 8:00 a.m. - 12 noon
Franciscan Room D, Ballroom Level, Hilton

RECOVERY FROM MENTAL ILLNESS AND STIGMA: INTEGRATION OF MEDICINE AND RECOVERY

Director: Eugene A. Oulvey, Ph.D.
Faculty: Shyam K. Bhat, M.D., Thomas O. Osinowo, M.D., Denise Sommers, M.A., Karen L. Lee, M.A., Vivek Jain, M.D.

COURSE 101 8:00 a.m. - 12 noon
Yosemite Room C, Ballroom Level, Hilton

SEXUAL DISORDERS: DIAGNOSIS AND TREATMENT

Director: Waguih W. Ishak, M.D.
Faculty: Marina Busset, M.D., Richard N. Chenik, J.D., Sofia M. Encarnacion, M.D., Maria D.M. Leonido-Yee, M.D., Uni P. Peles, M.D., Henrik Zakari, M.D.
THURSDAY

COURSE 102  8:00 a.m. - 12 noon
Union Square 14, Fourth Floor, Hilton

ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS

Co-Directors: Herman M. Van Praag, M.D., Jaap B. Bakker, Ph.D.
Faculty: Anton J.M. Loonen, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 4
9:00 a.m. - 10:30 a.m.
Room 121, Exhibit Level, Moscone Center

DEALING WITH DIAGNOSTIC AMBIGUITY: WHEN SOMATIC MEMORY AND ANXIETY SYMPTOMS CONFUSE

Moderator: Jayne M. Stevenson, M.D.
Discussant: Joel Yager, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2:
PART 2
9:00 a.m. - 12 noon
Room 120, Exhibit Level, Moscone Center

A CASE OF MURDER AND DISSOCIATIVE IDENTITY DISORDER: REAL OR MALINGERED MENTAL ILLNESS?

Moderator: Britta Ostermeyer, M.D.
Presenters: Thomas G. Cobb, M.D., Renee M. Sorrentino, M.D., Richard P. Kluft, M.D., Phillip J. Resnick, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

DISCUSSION GROUP 25
9:00 a.m. - 10:30 a.m.
This session is limited to 25 participants on a first-come, first-served basis.
A. John Rush, M.D., on Relevance of Treatment Algorithms in Clinical Care
Pacific Conference Suite C, 4th Floor, Marriott

LECTURE 23
9:00 a.m. - 10:30 a.m.
Rooms 132/133, Exhibit Level, Moscone Center

APA'S KUN-PO SOO AWARD LECTURE
Masahisa Nishizono, M.D.
Remembering the Past and Living in the Now: Modernization in East Asian Countries and Psychotherapy
Chp.: John Luo, M.D.

Masahisa Nishizono, M.D., is Professor of Psychiatry and former Dean at Fukuoka University School of Medicine in Fukuoka, Japan. A pioneer in integrating community mental health care with hospital-based treatment in Japan, Dr. Nishizono is the author of more than 250 scientific articles and book chapters and the author or editor of several books. He has held several leadership positions in Japanese and international psychiatric and psychoanalytic societies, including the Presidency of the Japanese Society of Psychiatry and Neurology, the Japanese Psychoanalytical Association, the Japanese Psychoanalytical Society, and the Japanese Association for Emergency Psychiatry. Dr. Nishizono has been an active proponent of international collaboration in psychiatry and has served as President of the Pacific Rim College of Psychiatrists, the Association for Medical Education in the Western Pacific Region, and the Asian Society for Child and Adolescent Psychiatry and Allied Professions. A Corresponding Fellow of the American Psychiatric Association and a Fellow of the American Academy of Psychoanalysis, Dr. Nishizono has received numerous awards for his contributions to medical education and biopsychosocial treatment, including the Alexander Gran Nick Award from the American Association for Psychosocial Rehabilitation. THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENT 39-42

COMPONENT WORKSHOP 39  9:00 a.m. - 10:30 a.m.
Room 308, Esplanade Level, Moscone Center

NEVER- TAUGHT DILEMMAS: WHEN WORK AND DISABILITY ISSUES IMPACT PATIENT CARE
APA Corresponding Committee on Psychiatry in the Workplace

Co-Chps.: Steven E. Pflanz, M.D., Marcia A. Scott, M.D.
Participants: Daniel B. Borenstein, M.D., Jacquelyn B. Chang, M.D., Harry Prosen, M.D.
THURSDAY

COMPONENT WORKSHOP 40 9:00 a.m. - 10:30 a.m.
Salons 14 & 15, Lower B-2 Level, Marriott

SUMMARY OF THE SURGEON GENERAL'S MEETING ON HEALTH OF THE MENTALLY RETARDED
APA Committee on Children with Mental or Developmental Disorders

Chp.: Roxanne C. Dryden-Edwards, M.D.
Participants: Carl B. Feinstein, M.D., Paula J. Lockhart, M.D.,
Stephen B. Corbin, D.D.S., Timothy Shriver, Ph.D.

COMPONENT WORKSHOP 41 9:00 a.m. - 10:30 a.m.
Golden Gate Hall A, B-2 Level, Marriott

THE ADMINISTRATIVE PSYCHIATRY CREDENTIAL
APA Committee on Psychiatric Administration and Management

Chp.: Stuart B. Silver, M.D.
Participants: Paul Rodenhauser, M.D., S. Atezaz Saeed, M.D.,
Veena Garyali, M.D., Beth Ann Brooks, M.D.

COMPONENT WORKSHOP 42 9:00 a.m. - 10:30 a.m.
Pacific Conference Suite H, 4th Floor, Marriott

PRACTICING REWARDING PSYCHIATRY IN JAILS AND PRISONS: A PRACTICUM
APA Caucus of Psychiatrists Working in Correctional Settings

Chp.: Henry C. Weinstein, M.D.
Participants: Kathryn A. Burns, M.D., Kenneth G. Gilbert, M.D.,
Annette L. Hanson, M.D., John S. Zil, M.D.

ISSUES 89-110

ISSUE WORKSHOP 89 9:00 a.m. - 10:30 a.m.
Room 110, Exhibit Level, Moscone Center

TEACHING PSYCHIATRIC ETHICS ENGAGINGLY, EFFECTIVELY
Association for Academic Psychiatry

Chp: Laura W. Roberts, M.D.

ISSUE WORKSHOP 90 9:00 a.m. - 10:30 a.m.
Room 111, Exhibit Level, Moscone Center

NEUROBIOLOGY OF LEARNING: MOVING FROM THE IVORY TOWER INTO THE CLASSROOM

Chp.: Janet E. Osterman, M.D.

ISSUE WORKSHOP 91 9:00 a.m. - 10:30 a.m.
Room 112, Exhibit Level, Moscone Center

THE USES AND ABUSES OF PSYCHIATRIC INDEPENDENT MEDICAL EXAMINATIONS: AN ETHICAL DILEMMA?

Chp.: Landy F. Sparr, M.D.
Participant: Michael D. Freeman, Ph.D.

ISSUE WORKSHOP 92 9:00 a.m. - 10:30 a.m.
Room 113, Exhibit Level, Moscone Center

BEYOND THE CHALK BOARD: USING COMPUTERS TO ENHANCE PSYCHIATRIC EDUCATION

Chp.: Sudha Prathikanti, M.D.
Participant: Lee A. Rawitscher, M.D.

ISSUE WORKSHOP 93 9:00 a.m. - 10:30 a.m.
Room 114, Exhibit Level, Moscone Center

SPECIFIC PSYCHOTHERAPEUTIC TECHNIQUES FOR ADOLESCENTS

Chp.: Eva M. Szigethy, M.D.
Participants: Barbara L. Milrod, M.D., Lena Verdelli, Ph.D.

ISSUE WORKSHOP 94 9:00 a.m. - 10:30 a.m.
Room 122, Exhibit Level, Moscone Center

PSYCHIATRIC TREATMENT AND PERSONAL GROWTH: WHAT ABOUT US?

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Francine Cournos, M.D., Carl C. Bell, M.D.,
Margery S. Sved, M.D.

ISSUE WORKSHOP 95 9:00 a.m. - 10:30 a.m.
Room 123, Exhibit Level, Moscone Center

A PROGRAM TO ENHANCE CULTURAL COMPETENCY IN RESIDENCY TRAINING

Chp.: Hinda F. Dubin, M.D.
Participants: Lisa D. Green-Paden, M.D., Theodora G. Balis, M.D.

ISSUE WORKSHOP 96 9:00 a.m. - 10:30 a.m.
Room 124, Exhibit Level, Moscone Center

CLINICAL MANAGEMENT OF DIFFICULT SCHIZOPHRENIA

Co-Chps.: Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.
Participants: Samuel G. Sims, M.D., Faq A. Hameed, M.D.,
Naveed Iqbal, M.D.
THURSDAY

ISSUE WORKSHOP 97  9:00 a.m. - 10:30 a.m.
Room 125, Exhibit Level, Moscone Center

CD-ROMS FOR DUMMIES: A STEP-BY-STEP GUIDE FOR DEVELOPING EDUCATIONAL CDs
Chp.: Kristi S. Williams, M.D.
Participants: Marijo B. Tamburrino, M.D., Cindy J. Stengle, B.B.A.

ISSUE WORKSHOP 98  9:00 a.m. - 10:30 a.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

MAKING THE MEDIA WORK FOR YOU
Chp.: Nada L. Stotland, M.D.

ISSUE WORKSHOP 99  9:00 a.m. - 10:30 a.m.
Room 300, Esplanade Level, Moscone Center

THE EMPATHIC HEALER: ARTIST OR SCIENTIST?
Chp.: Michael J. Bennett, M.D.

ISSUE WORKSHOP 100  9:00 a.m. - 10:30 a.m.
Room 301, Esplanade Level, Moscone Center

TREATING ADDICTION: MEETING NEW NEEDS IN A NEW WORLD
Chp.: Richard J. Frances, M.D.
Participants: Sheila B. Blume, M.D., Sheldon I. Miller, M.D., Marc Galanter, M.D., Robert B. Millman, M.D., Lionel P. Solursh, M.D., Frances R. Levin, M.D.

ISSUE WORKSHOP 101  9:00 a.m. - 10:30 a.m.
Room 302, Esplanade Level, Moscone Center

PSYCHODYNAMICS IN TREATMENT-REFRACTORY DEPRESSION
Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.
Participant: David L. Mintz, M.D.

ISSUE WORKSHOP 102  9:00 a.m. - 10:30 a.m.
Room 304, Esplanade Level, Moscone Center

BRIDGES FOR HEALING: INTEGRATING FAMILY THERAPY AND PSYCHOPHARMACOLOGY
Chp.: Roy O. Resnikoff, M.D.

ISSUE WORKSHOP 103  9:00 a.m. - 10:30 a.m.
Room 306, Esplanade Level, Moscone Center

MAKING TELPSYCHIATRY MEDIA WORK FOR YOU
Co-Chps.: Debra A. Katz, M.D., Rob Sprang, M.B.A.
Participants: Timothy S. Allen, M.D., Shari G. Sistrunk, M.D.

ISSUE WORKSHOP 104  9:00 a.m. - 10:30 a.m.
Room 309, Esplanade Level, Moscone Center

DYSMORPHOLOGIES: RECOGNITION AND TREATMENT
Co-Chps.: Syed S. A. Naqvi, M.D., Jeremy E. Revell, M.D.
Participant: Robb Saito, M.D.

ISSUE WORKSHOP 105  9:00 a.m. - 10:30 a.m.
Room 310, Esplanade Level, Moscone Center

PSYCHIATRIC DISABILITY: THE ROLE OF PSYCHIATRIC ASSESSMENT
Chp.: Edward A. Volkman, M.D.
Participant: Janice Volkman, J.D.

ISSUE WORKSHOP 106  9:00 a.m. - 10:30 a.m.
Salons 1 & 2, Lower B-2 Level, Marriott

THE MEANING OF THE PACIFIC RIM FOR WORLD AND AMERICAN PSYCHIATRY
Pacific Rim College of Psychiatrists
Co-Chps.: Francis G. Lu, M.D., Bruce Singh, M.D.
Participants: Ching-Piao Chien, M.D., Robert O. Pasnau, M.D., Milton H. Miller, M.D.

ISSUE WORKSHOP 107  9:00 a.m. - 10:30 a.m.
Salons 3 & 4, Lower B-2 Level, Marriott

AN UPDATE ON MANAGEMENT OF SUICIDE ATTEMPTS: A REVIEW FOR CLINICIANS
Co-Chps.: Jose de Leon, M.D., Maria A. Oquendo, M.D.
Participants: Jeronimo Saiz-Ruiz, M.D., Enrique Baca-Garcia, M.D.

ISSUE WORKSHOP 108  9:00 a.m. - 10:30 a.m.
Salons 5 & 6, Lower B-2 Level, Marriott

ADHERENCE TO HIV MEDICATIONS IN THE PSYCHIATRICALLY ILL: NEW FINDINGS
Chp.: Dan H. Karasic, M.D.
Participants: David Bangsberg, M.D., Joshua Bamberger, M.D., James L. Sorensen, Ph.D.

ISSUE WORKSHOP 109  9:00 a.m. - 10:30 a.m.
Salons 10 & 11, Lower B-2 Level, Marriott

INPATIENT VIOLENCE: LESSONS FROM THE INNER-CITY PSYCHIATRY HOSPITAL
Chp.: Jeffrey M. Levine, M.D.
Participants: Ali Khadivi, Ramon C. Patel, M.D., Merrill R. Rotter, M.D.
ISSUE WORKSHOP 110  
9:00 a.m. - 10:30 a.m.  
Golden Gate Hall C, B-2 Level, Marriott  

PSYCHIATRIC CARE OF MUSLIM PATIENTS: A U.S. PERSPECTIVE  

Co-Chps.: Arif M. Shoaib, M.D., Pedro Ruiz, M.D.  
Participants: Syed A. Husain, M.D., Ayesha Mian, M.D., Mohammad F. Danish, M.D.  

11:00 a.m. Sessions  

DISCUSSION GROUP 26  
11:00 a.m. - 12:30 p.m.  
This session is limited to 25 participants on a first-come, first-served basis.  

Larry E. Tune, M.D., on Delirium and Dementia  
Pacific Conference Suite C, 4th Floor, Marriott  

LECTURE 24  
11:00 a.m. - 12:30 p.m.  
Rooms 130/131, Exhibit Level, Moscone Center  

APA'S SOLOMON CARTER FULLER AWARD LECTURE  
James H. Carter, M.D.  

Culture/Racism and Ethnic Diversity With Past Corrective Actions, Successes, and Failures  
Chp.: Michelle O. Clark, M.D.  

James H. Carter, M.D., is Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine in Durham, North Carolina. He is also Senior Consulting Psychiatrist and Co-Founder of the Social Work-Mental Health Unit at Lincoln Community Health Center in Durham and Medical Director of the judicial substance abuse program South Light in Raleigh, North Carolina. He has written numerous scientific papers and is the author of two books, *Psychosocial Intervention With Aged African Americans and Death and Dying Among African Americans*. A Distinguished Life Fellow of the American Psychiatric Association, Dr. Carter is a recipient of the Order of the Long Leaf Pine, the highest honor given to North Carolina citizens for service to the people of the state. In 1994, the annual James H. Carter, Sr., Lecture Series, which provides a forum for cross-cultural issues, was endowed in his honor at Duke University. Dr. Carter received his medical degree from Howard University.  

MEDICAL UPDATE 4  
11:00 a.m. - 12:30 p.m.  
Room 300, Esplanade Level, Moscone Center  

CLUB DRUGS: A PRIMER FOR MENTAL HEALTH PROFESSIONALS  
Chp.: Julie K. Schulman, M.D.  
Presenter: David Smith, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SCIENTIFIC AND CLINICAL REPORT SESSIONS 29-40  

SCIENTIFIC AND CLINICAL REPORT SESSION 29  
11:00 a.m. - 12:30 p.m.  
Room 110, Exhibit Level, Moscone Center  

SECONDARY OUTCOMES IN ADHD  
Chp.: Lois T. Flaherty, M.D.  
Co-Chp.: Nang Du, M.D.  

11:00 a.m.  
86 Consistency of ADHD Parent/Teacher Symptom Reports: Results of OROS MPH Studies  
Stephen V. Faraone, Ph.D.  

11:30 a.m.  
87 Patient and Parent Satisfaction of Once-Daily OROS MPH Formulation for ADHD  
Mark A. Stein, Ph.D.  

12 noon  
88 Driving Performance Among Adolescents With ADHD: Medication Effects  
Daniel J. Cox, Larry Merkel  
THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m. - 12:30 p.m.
Room 111, Exhibit Level, Moscone Center

ETHICAL ISSUES IN THE TREATMENT OF PSYCHOSIS

Chp.: Scott Y. Kim, M.D.
Co-Chp.: David Y. Kan, M.D.

11:00 a.m.
89 Factors Associated With Determining Competence to Consent in Acute Psychoses
Nicholas A. Keks, M.D., Vivienne Howe, Kellie M. Feister, Kym Jenkins, M.D., David L. Copolov, M.D.

11:30 a.m.
90 Ethical Challenges of Managing Pregnant Patients Who Have Schizophrenia
John H. Coverdale, M.D., Laurence B. McCullough, Ph.D., Frank A. Chervenak, M.D.

12 noon
91 Schizophrenia and Suicide in the Managed Care Era
Bentson H. McFarland, M.D., Lara Davis, B.S., Jo Mahler, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m. - 12:30 p.m.
Room 125, Exhibit Level, Moscone Center

ALCOHOL AND DRUG-RELATED DISORDERS

Chp.: Petros Levounis, M.D.
Co-Chp.: Kewchang Lee, M.D.

11:00 a.m.
92 Impulsivity, Sensation Seeking, and Coping Styles Among Substance Abusers
Kevin P. Hill, M.D., Ashwin A. Patkar, M.D., Charles C. Thornton, Ph.D., Edward Gottheil, M.D., Anup M. Desai, M.D., Heather W. Murray, B.A., Michael J. Vergare, M.D.

11:30 a.m.
93 Substance Abuse Disorders and History of Childhood Sexual Abuse in a Population of U.S. Veterans
Jehangir B. Bastani, M.D., Martin Mellstrom, Ph.D., Vicki A. Albers, M.D.

12 noon
94 Attachments for In-Treatment Alcoholics and Teens Predicted to Be Addicts
Marc A. Lindberg, Ph.D., Stuart Thomas, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m. - 12:30 p.m.
Rooms 272/274/276, Mezzanine Level, Moscone Center

AIDS AND HIV-RELATED DISORDERS

Chp.: Frederick N. Parris, M.D.
Co-Chp.: Lishan Workeneh, M.D.

11:00 a.m.
95 Psychiatric Effects Associated With Efavirenz: A Retrospective Study
Talia Puzantian, Pharm.D., Jeannie Lee, Pharm.D., Regina J. Lee, Pharm.D., Janice Wong, Pharm.D., Li Liu, M.D., Dan H. Karasic, M.D.

11:30 a.m.
96 PTSD and Acute Stress Reactions to Recent Life Events Among HIV Positive Persons
Cheryl Koopman, Ph.D., Cheryl Gore-Felton, Ph.D., Negar Azmi, B.A., Kristian O'Shea, Rachel Power, Ph.D., Dennis M. Israelksi, M.D., David Spiegel, M.D.

12 noon
97 Use of Marijuana to Manage Distress Symptoms Among HIV-Infected Persons
Diane Prentiss, M.A., Rachel Power, Ph.D., Gladys Balmas, M.P.H., Dennis M. Israelski, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:00 a.m. - 12:30 p.m.
Room 302, Esplanade Level, Moscone Center

ADJUNCTIVE TREATMENTS IN SCHIZOPHRENIA

Chp.: Charles S. Price, M.D.
Co-Chp.: Susan I. Hobbins

98 -WITHDRAWN

11:00 a.m.
99 Rivastigmine and Glantamine Treatment for Schizophrenic Cognitive Impairment
Mohammad Z. Hussain , M.D., Zubaida A. Chaudhry, M.D.

11:45 a.m.
100 Modafinil as Adjunct Treatment in Schizophrenia: An Open-Label Study
Murray H. Rosenthal, D.O., Sharon Bryant, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m. - 12:30 p.m.
Room 308, Esplanade Level, Moscone Center

WOMEN'S HEALTH

Chp.: Susan Stabinsky, M.D.
Co-Chp.: Caroline E. Fisher, M.D.

11:00 a.m.
101 Sertraline Prevents Postpartum Depression
   Katherine L. Wisner, M.D., Kathleen S. Peindl, Ph.D.,
   James M. Perel, Ph.D., Barbara H. Hanusa, Ph.D.,
   Catherine M. Plontek, M.D., Robert L. Findling, M.D.

11:30 a.m.
102 Depressed Women Have Elevated Coagulation Factors
   in Mid Life
   Ruby Castilla-Puentes, M.D., Zhang Yangang, M.S., Joyce T.
   Bromberger, Ph.D., James M. Perel, Ph.D., Karen A.
   Matthews, Ph.D.

12 noon
103 HRT With Androgens as a Strategy to Treat
   Postmenopausal Depression
   Rodrigo Dias, M.D., Florence Kerr-Correa, M.D., Luzia A.
   Trinca, Ph.D., Ricardo A. Moreno, M.D., Anagloria
   Pontes, M.D., Hans W. Halbe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m. - 12:30 p.m.
Salons 3 & 4, Lower B-2 Level, Marriott

BIPOLAR DISORDERS

Chp.: Patricia Suppes, M.D.
Co-Chp.: Neha Bahadur, M.D.

11:00 a.m.
104 Bipolar Disorder Treatment: Critical Synthesis of
   Guidelines and Algorithms
   Heinz C. Grunze, M.D.

11:30 a.m.
105 Rapid-Cycling Bipolar Disorder: Focus on Treatment
   Joseph F. Goldberg, M.D., S. Nassir Ghaemi, M.D., Martin
   Harrow, Ph.D.

12 noon
106 Mood Stabilizers: Standard, New, and Putative
   Eduard Vieta, M.D., Anabel Martinez-Aran, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 36
11:00 a.m. - 12:30 p.m.
Salons 5 & 6, Lower B-2 Level, Marriott

VIOLENCE, TRAUMA, AND VICTIMIZATION

Chp.: Jeffrey M. Friend, M.D.
Co-Chp.: Keith McBurnett, Ph.D.

11:00 a.m.
107 Treatment Outcome for Sexually Abused Children at
   One-Year Follow-Up
   Judith A. Cohen, M.D., Anthony P. Mannarino, Ph.D.,
   Kraig Knudson, M.P.H.

11:30 a.m.
108 Psychological Symptoms Six Years After a Plane
   Crash
   Christoffel J. Yzermans, Ph.D., Ge A. Donker, M.D.,
   Hiske E. Becker, M.D.

12 noon
109 San Francisco Third Graders After 9/11: Three
   Windows to Healing
   Lenore C. Terr, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 37
11:00 a.m. - 12:30 p.m.
Salons 12 & 13, Lower B-2 Level, Marriott

ISSUES IN THE TREATMENT OF DEPRESSION
   AND SEXUAL DYSFUNCTIONS

Chp.: Thomas N. Wise, M.D.
Co-Chp.: Eric R. Williams, M.D.

11:00 a.m.
110 Maintaining Compliance and Remission in MDD
   With Sildenafil Prescription for SSRI-SD
   H. George Nurnberg, M.D., Paula L. Hensley, M.D.

11:30 a.m.
111 Efficacy and Safety of Sildenafil Citrate in Men With
   Serotonergic-Antidepressant-Associated Erectile
   Dysfunction: Results of a Prospective, Multicenter,
   Randomized, Double-Blind, Placebo-Controlled
   Trial
   Maurizio Fava, M.D., H. George Nurnberg, M.D., Stuart N.
   Seidman, M.D., Willis Holloway, Jr., M.D., Mildred
   Farmer, M.D., Susan Nicholas, Vera Stecher, Ph.D.

12 noon
112 Pretreatment Characteristics of Placebo Response in
   Major Depression
   Andrew F. Leuchter, M.D., Melinda Morgan, Ph.D., Ian A.
   Cook, M.D., Michelle Abrams, R.N., Jennifer Dunkin, Ph.D.,
   Elise Witte, Ph.D., Scott D. Greenwald, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 38
11:00 a.m. - 12:30 p.m.
Golden Gate Hall B, B-2 Level, Marriott

COGNITIVE BEHAVIORAL THERAPY

Chp.: Anton C. Trinidad, M.D.
Co-Chp.: Denise M. Richardson

113 WITHDRAWN

(Continued on next page)
11:00 a.m.
114 The Effective Delivery of Cognitive-Behavioral Therapy for Panic Disorder: An International Multicenter Trial
Justin A. Kenardy, Ph.D., Michael G. Dow, Ph.D., Craig G. Taylor, M.D., Derek W. Johnston, Ph.D., Michelle G. Newman, Ph.D.

11:45 a.m.
115 Efficacy of Self-Administered Cognitive-Behavior Therapy and Sertraline in Panic Disorder
Jacques Bradwejn, M.D., Diana Koszycki, Ph.D., Zindel V. Segal, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 39
11:00 a.m. - 12:30 p.m.
Sierra Conference Suite H, 5th Floor, Marriott

OUTCOMES IN DEPRESSION

Chp.: Emily K. Lee, M.D.
Co-Chp.: Elena F. Swartz, M.D.

11:00 a.m.
116 Problem-Solving Ability and Comorbid Personality Disorders in Depressed Outpatients
Rebecca Harley, Ph.D., Megan E. Hughes, B.A., Heidi D. Montoya, B.A., George I. Papakostas, M.D., Albert Yeung, M.D., Paolo Cassano, M.D., Amy H. Farbaugh, Ph.D., Maurizio Fava, M.D.

11:30 a.m.
117 A Comparison of Weight Changes Associated With Different Augmentation Strategies
Christina M. Dording, M.D., Megan E. Hughes, B.A., Pamela A. Roffi, B.S., Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Dan V. losifescu, M.D., Maurizio Fava, M.D.

12 noon
118 Depression Disease Management Improves Depression and QOL
Ron Aubert, Ph.D., Fang Xia, Ph.D., Cindy Woo, M.P.H., George Fulop, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 40
11:00 a.m. - 12:30 p.m.
Pacific Conference Suite J, 4th Floor, Marriott

SLEEP DISORDERS

Chp.: Thomas C. Neylan, M.D.
Co-Chp.: Richard A. Nathanson, M.D.

11:00 a.m.
119 Modafinil Improves Cognition in Narcolepsy Patients With Excessive Sleepiness
Jonathan R. L. Schwartz, M.D., Michael T. Nelson, Rod J. Hughes, Ph.D., Chris A. Veit, M.S.W., Kenneth C. Cobb, Elliott R. Schwartz, D.O.
THURSDAY

COMPONENT WORKSHOP 47  11:00 a.m. - 12:30 p.m.
Golden Gate Hall A, B-2 Level, Marriott

DADDY AND PAPA: A PSYCHOSOCIAL PROFILE OF GAY PARENTING
APA Committee on Gay, Lesbian, and Bisexual Issues
Chp.: Jack Drescher, M.D.
Participants: Daniel W. Hicks, M.D., Diana C. Miller, M.D., Susan A. Turner, M.D.

ISSUES 111-118

ISSUE WORKSHOP 111  11:00 a.m. - 12:30 p.m.
Room 113, Exhibit Level, Moscone Center
THE POWER OF HEALING: SPIRITUALITY GROUP WORK WITH PSYCHIATRY STAFF
Chp.: C. Paul Yang, M.D.
Participants: Hendry Ton, M.D., Heather M. Hall, M.D.

ISSUE WORKSHOP 112  11:00 a.m. - 12:30 p.m.
Room 114, Exhibit Level, Moscone Center
HARM REDUCTION: A CRITICAL REVIEW
Co-Chps.: Jeffrey N. Wilkins, M.D., Jack Kuo, M.D.
Participants: Glenn Backef, Maria Chavez

ISSUE WORKSHOP 113  11:00 a.m. - 12:30 p.m.
Room 122, Exhibit Level, Moscone Center
PARENTING WITH THE BRAIN IN MIND: ATTACHMENT AND SELF-UNDERSTANDING
Chp.: Daniel J. Siegel, M.D.
Participant: Mary Hartzell, M.Ed.

ISSUE WORKSHOP 114  11:00 a.m. - 12:30 p.m.
Room 123, Exhibit Level, Moscone Center
SERVICE INTEGRATION AND CONTINUITY IN CALIFORNIA: PROGRAMS FROM HARBOR-UCLA
Chp.: Mary E. Read, M.D.
Participants: Michael W. Smith, M.D., Paul G. Arns, Ph.D., Leslie Groenewold, R.N.

ISSUE WORKSHOP 115  11:00 a.m. - 12:30 p.m.
Room 124, Exhibit Level, Moscone Center
BRIDGING THE GAP BETWEEN MENTAL HEALTH AND PRIMARY CARE FOR ASIAN AMERICANS
Co-Chps.: Francis G. Lu, M.D., Henry Chung, M.D.
Participants: Sue S. Chan, M.D., Teddy Chen, M.D., Albert Yeung, M.D.

ISSUE WORKSHOP 116  11:00 a.m. - 12:30 p.m.
Room 310, Esplanade Level, Moscone Center
COMPUTER-ASSISTED PSYCHOTHERAPY IN CLINICAL PRACTICE
Chp.: Jesse H. Wright, M.D.

ISSUE WORKSHOP 117  11:00 a.m. - 12:30 p.m.
Salons 10 & 11, Lower B-2 Level, Marriott
RACIAL, ETHNIC, AND CULTURAL BIAS IN PSYCHOTHERAPY
Chp.: Edmundo J. Ruiz, M.D.
Participant: Homero R. Sanchez, M.D.

ISSUE WORKSHOP 118  11:00 a.m. - 12:30 p.m.
Pacific Conference Suite A, 4th Floor, Marriott
ESSENTIAL SKILLS 101: WRITING MANUSCRIPTS FOR PUBLICATION
Chp.: Laura W. Roberts, M.D.

12 noon Session

NEW RESEARCH POSTER SESSION 10
12 noon - 2:00 p.m.
Hall D, Exhibit Level, Moscone Center

VIOLENCE, TRAUMA, STRESS, ANXIETY, FORENSICS, COGNITION, AND OTHER TOPICS
For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 83-104

SYMPOSIUM 83  2:00 p.m. - 5:00 p.m.
Room 110, Exhibit Level, Moscone Center

THE EFFECT OF PERSONALITY DISORDERS ON THE TREATMENT OF AXIS I DISORDERS
Association for Research in Personality Disorders
Chp.: James H. Reich, M.D.

A The Anxious Personality Disorder Cluster and Outcome of Treatment of Axis 1 Disorders
James H. Reich, M.D.  
(Continued on next page)
B The Effect of Axis II Diagnosis and Treatment of Axis I Disorders
   Cesare Maffei, M.D., Francesca Biondini, Ph.D.

C Interventions for Axis II Patients With Comorbid Axis I Disorders
   David P. Bernstein, Ph.D.

D Personality Disorders Predict Completion of Substance Abuse Treatment
   Per Vaglum, M.D., Edle Raundal, Ph.D.

E Dialectic Behavior Therapy in Borderline Substance Abusers
   Wim Van Den Brink, M.D.

F Emotional Dysregulation and Treatment of Axis I Disorders
   John Livesley, M.D.

Discussant: Joel F. Paris, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84  2:00 p.m. - 5:00 p.m.
Room 111, Exhibit Level, Moscone Center

THE DIFFICULT-TO-TREAT PSYCHIATRIC PATIENT

Chp.: Mantosh J. Dewan, M.D.

A The Difficult-to-Treat Eating-Disordered Patient
   Katherine A. Halmi, M.D., Wendy A. Harris, M.D., Claire Wiseman, Ph.D.

B Working With the Difficult-to-Treat DID Patient
   Richard P. Kluft, M.D.

C The Difficult-to-Treat PTSD Patient
   Randall D. Marshall, M.D., Elizabeth A. Hembree, Ph.D., Lee A. Fitzgibbons, Ph.D., Edna B. Foa, Ph.D.

SYMPOSIUM 85  2:00 p.m. - 5:00 p.m.
Room 112, Exhibit Level, Moscone Center

QUALITY MEASUREMENT IN A CANADIAN INNER-CITY ACADEMIC ENVIRONMENT

Chp.: Ian C. Dawe, M.D.
   Co-Chp.: Paul S. Links, M.D.

A Quality Measurement in Mental Health Care
   Ian C. Dawe, M.D.

B Evaluation of a Mobile Crisis Service in the Inner City
   Nancy E. Read, M.S.C., Joanne C. Walsh, B.S.C.N., Sean B. Rourke, Ph.D., Ian C. Dawe, M.D.
A Correlates of Serious Suicidal Ideation Among Central-American Youths
Lenn Murrelle, Ph.D., Leo Russo, Ph.D., Enrique Warner, M.P.H.,
Luis Sandi, M.D., Alfredo Moreno, M.D.

B Phenomenology and Treatment of Psychosis in Children
Rosa E. Ulloa, M.D.

C Diagnosis and Treatment of Children With ADHD: A
Chilean Experience
Arturo Grau, M.D.

D A Study of Risperidone in the Treatment of Children With
Tourette's Syndrome
Carolina Remedi, M.D., Carlos Soria, M.D., Nestor
Edelstein, M.D.

E Anxiety, Depression, and Somatic Complaints in
Traumatized Children
Ruby Castilla-Puentes, M.D., Miguel Habeych, M.D., Ivan
Gomez, M.D., Sandra Castilla-Puentes, M.D., Wilma Castilla-
Puentes, M.D., Maria C. Caballero, R.N.,
Gilmareosa De Conteras, M.S.W.

Discussants: Viviana J. Chiappe, M.D., Roberto Yunes, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m. - 5:00 p.m.
Room 121, Exhibit Level, Moscone Center

POLYPHARMACY: EVIDENCE BASIS VERSUS
CLINICAL EXPERIENCE

Chp.: James M. Ellison, M.D.
Co-Chp.: David N. Osser, M.D.

A Polypharmacy: Extent of the Problem and the
Massachusetts Response
Annette Hanson, M.D.

B The Placebo Effect in the Assessment of Polypharmacy
Walter A. Brown, M.D.

C Coprescribing Antidepressants: Dual or Dueling
Treatment?
James M. Ellison, M.D.

D Combination Treatment in Schizophrenia
Donald C. Goff, M.D.

E Treatment of Insomnia in the Psychiatric Patient
John W. Winkelman, M.D.

Discussants: Olivia I. Okereke, M.D., David N. Osser, M.D.
THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SYMPOSIUM 91  2:00 p.m. - 5:00 p.m.
Room 124, Exhibit Level, Moscone Center

CONCEPTUALIZATIONS OF JEONG AND ITS
APPLICATION TO THE HEALING PROCESS

Chp.: Christopher K. Chung, M.D.
Co-Chp.: Samson J. Cho, M.D.

A Attachment and Jeong: Are They Connected?
David S. Rue, M.D.

B A Comparative Analysis of Jeong of Korea and Amae of
Japan
Byung Kun Min, M.D.

C Restoring of Jeong Through the Use of Healing Rituals in
Bereavement Periods
Soo Kyung Chang, M.D., Christopher K. Chung, M.D.

D From We-Ness Perspectives: Dynamics of BPD and
Hwabyung
Christopher K. Chung, M.D., Samson J. Cho, M.D., Tawnya L.
Christiansen, M.D.

E Psychotherapeutic Applications of Jeong and Haan
Luke Kim, M.D.

Discussant: Edmond H.T. Pi, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92  2:00 p.m. - 5:00 p.m.
Room 125, Exhibit Level, Moscone Center

BOUNDARIES EDUCATION: AN EXPERT UPDATE
ON DIVERSE APPROACHES AND SETTINGS

Chp.: Gregg E. Gorton, M.D.

A Effective Boundaries Education
Gregg E. Gorton, M.D., Steven E. Samuel, Ph.D., Gail
Zivin, Ph.D.

B Tools for Preventive and Remedial Boundaries Training
Gary R. Schoener, Psy.D.

C Supervision of Intense Affective Reactions to Patients and
Construction of Optimal Boundaries
Nancy A. Bridges, L.C.S.W.

D Teaching Boundaries to Physicians of All Kinds
Werner Tschan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93  2:00 p.m. - 5:00 p.m.
Room 300, Esplanade Level, Moscone Center

SCHIZOPHRENIA WITH COMORBIDITY:
DIAGNOSES OR DIMENSIONS?

Chp.: Lewis A. Opler, M.D.
Co-Chp.: Michael Y. Hwang, M.D.

A Clinical and Research Evidence for Comorbidity in
Schizophrenia
Michael Y. Hwang, M.D.

B Toward a Dimensional Approach to Psychiatric
Nosology
Robert F. Krueger, Ph.D.

C Using Symptom Dimensions to Guide Treatment
Lewis A. Opler, M.D., Anne-Marie Shelley, Ph.D., Joseph
Battaglia, M.D., Jeffrey Lucey, M.D.

D Diagnostic Models and Subjectivity
John S. Strauss, M.D.

Discussants: Ming T. Tsuang, M.D., Michael B. First, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94  2:00 p.m. - 5:00 p.m.
Room 301, Esplanade Level, Moscone Center

DELIRIUM SUBTYPES: DIAGNOSIS AND
TREATMENT

Chp.: Stephen M. Saravay, M.D.
Co-Chp.: Paula T. Trzepacz, M.D.

A Delirium After Post-Traumatic Brain Injury
Paula T. Trzepacz, M.D.

B The Delirium Experience
William Breitbart, M.D., Christopher Gibson, Ph.D., Annie
Tremblay, M.D.

C Motoric Subtypes of Delirium: The Limerick Delirium
Study
David J. Meagher, M.D., Maria Moran, M.B., Sinead
Donnelly, M.D., Bangaru Raju, M.D.

D Cholinesterase Inhibitors in the Intervention and
Treatment of Delirium
Benjamin Liptzin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95  2:00 p.m. - 5:00 p.m.
Room 302, Esplanade Level, Moscone Center

A TERRORIST'S COMPETENCY TO STAND TRIAL:
ASSESSING AMNESIA

Chp.: Stuart B. Kleinman, M.D.
A A Historical Approach to Assessing Recollection of an Alleged Terrorist
Stuart B. Kleinman, M.D.

B Prosecuting and Defending an Amnesic Individual Accused of Participating in Terrorism
Andrew A. Rubin, J.D.

C Competency in a Defendant Who Claims Amnesia
Eric D. Goldsmith, M.D.

D Assessing Competence to Stand Trial in an Alleged Terrorist: The Role of Psychological Testing
Barry D. Rosenfeld, Ph.D.

SYMPOSIUM 96 2:00 p.m. - 5:00 p.m.
Room 304, Esplanade Level, Moscone Center

NEW EVIDENCE ON EXPOSURE AND PRESENT-FOCUSED TREATMENTS FOR COMPLEX PTSD
Chp.: Catherine Classen, Ph.D.

A Trauma-Focused Versus Present-Focused Group Therapy for Survivors of Childhood Sexual Abuse
Catherine Classen, Ph.D., Cheryl Koopman, Ph.D., David Spiegel, M.D.

B Emotional Regulation and Interpersonal Skill as a Prerequisite to Emotional Processing of Traumatic Memories
Marylene Clotire, Ph.D.

C Development and Initial Evaluation of Brief Integrative Therapy for PTSD in Female Childhood Sexual Abuse Survivors
Annmarie McDonagh-Coyle, M.D., Julian Ford, Ph.D., Christine Demment, Ph.D.

D Outcome of Trauma Treatment With Comorbid Substance Abuse
Julian Ford, Ph.D., Linda Frisman, Ph.D.

Discussant: David Spiegel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97 2:00 p.m. - 5:00 p.m.
Room 306, Esplanade Level, Moscone Center

THE NEUROPSYCHIATRIC ASPECTS OF HIV/AIDS: EVALUATION AND TREATMENT, PART 2
Chp.: Marshall Forstein, M.D.

A Evaluating the Neuropsychiatric Patient
Karl Goodkin, M.D.

B Six Things You Need to Know: Drug-Drug Interactions
Marshall Forstein, M.D.

C Managing Depression and Anxiety: Assessment and Treatment
Stephen J. Ferrando, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98 2:00 p.m. - 5:00 p.m.
Room 307, Esplanade Level, Moscone Center

NEW RESEARCH IN THE BIOLOGY AND TREATMENT OF BULIMIA NERVOSA
Chp.: Allan S. Kaplan, M.D.
Co-Chp.: David C. Jimerson, M.D.

A Impaired Satiety in Bulimia Nervosa: State Versus Trait
David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Erand D. Metzger, M.D.

B Disturbances in Satiety in Bulimia Nervosa
B. Timothy Walsh, M.D., Michael J. Devlin, M.D., Ellen Zinner, Ph.D., Harry Kissileff, Ph.D., Janet L. Guss, M.A., Robyn Sysko, B.A.

C Alterations of 5HT 1A and 2A Receptors Persist After Recovery From Bulimia Nervosa
Walter H. Kaye, M.D., Guido K.W. Frank, M.D., Carolyn Meltzer, M.D., Julie Price, Ph.D., Wayne C. Drevets, M.D., Chester Mathis, Ph.D.

D Pharmacotherapy of Bulimia Nervosa: A Review of Established Medications and Promising New Agents
Allan S. Kaplan, M.D.

E New Models for Disseminating Psychotherapy for Eating Disorders
James E. Mitchell, M.D., Stephen A. Wonderlich, Ph.D., James L. Roerig, Ph.D., Martina de Zwaan, M.D., Ross D. Crosby, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 99 2:00 p.m. - 5:00 p.m.
Room 308, Esplanade Level, Moscone Center

TERRORISM AND POLITICAL VIOLENCE IN THE 21ST CENTURY: NEW FORMS AND RESPONSES
Chp.: Jerrold M. Post, M.D.
Co-Chp.: Stevan M. Weine, M.D.

A The Violent True Believer: Homicidal and Suicidal States of Mind
J. Reid Meloy, Ph.D.

B The Psychology of Murder-Suicide: Relation to Suicidal Terrorism
Melvyn M. Nizny, M.D.

C Differentiating the Motivations and Constraints for Weapons of Mass-Destruction Terrorism
Jerrold M. Post, M.D.

(Continued on next page)
D Terror and War: Literary Perspectives
Tvrtko Kulenovic, Ph.D.

E Paths and Obstacles to Reconciliation in Kosovo
Stevan M. Weine, M.D., Ferid Agami, M.D.

Discussant: David A. Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 100 2:00 p.m. - 5:00 p.m.
Room 309, Esplanade Level, Moscone Center

BIPOLAR SPECTRUM OR BORDERLINE PERSONALITY? A RELEVANT DISTINCTION?

Chp.: Joseph F. Goldberg, M.D.
Co-Chp.: S. Nassir Ghaemi, M.D.

A Borderline Personality or Bipolar II?
Hagop S. Akiskal, M.D.

B Borderline, Bipolar, and Beyond: Affective Illness as Precursor to Borderline Personality
Michael H. Stone, M.D.

C Dimensional Versus Categorical Psychopathology: Genetic Correlates
Joseph F. Goldberg, M.D.

D Differential Pharmacotherapy of Bipolar Spectrum and BPD
S. Nassir Ghaemi, M.D.

E Nosology and DSM-V: Lessons From the Bipolar-Borderline Controversy
Paul R. McHugh, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 101 2:00 p.m. - 5:00 p.m.
Room 310, Esplanade Level, Moscone Center

NEW INTRAVENOUS TREATMENTS: A NEW TOOL TO OVERCOME DIFFICULTIES AND RESISTANCE

Chp.: Stefano Pallanti, M.D.
Co-Chp.: Lorrin M. Koran, M.D.

A Intravenous Antidepressants: A Pharmacokinetic Perspective on Response and Resistance in Major Depression and OCD
Emanuela Mundo, M.D., Sâvio R. Bareggi, M.D., Carlo A. Altamura, M.D.

B Intravenous Citalopram and Clomipramine in Major Depression: A Double-Blind Study
Stefano Pallanti, M.D., Leonardo Quercioli, M.D.

C Intravenous Antidepressant Therapy With Mirtazapine and Citalopram
Siegfried Kasper, M.D., Anastasios Konstantinidis, M.D., Diethar Winkler, M.D., Jueren Stastny, M.D., Christian Bamas, M.D., Eva Hilger-Assem, M.D., Franz Muller-Spahn, M.D.

D Pulse-Loaded Intravenous Clomipramine for Refractory OCD
Lorrin M. Koran, M.D.

E Intravenous Clomipramine in Adolescents With Treatment-Resistant OCD and Depression
Floyd R. Sallee, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 102 2:00 p.m. - 5:00 p.m.
Salons 3 & 4, Lower B-2 Level, Marriott

INTERESTS AND VULNERABILITIES OF HEALTH CARE PRACTITIONERS

Chp.: John O. Beahrs, M.D.

A Beneficence and Nonreciprocity in Contemporary Health Care
John O. Beahrs, M.D.

B Psychiatry’s Internal Dissension
Michael T. McGuire, M.D.

C Duties to Others: Medicolegal Aspects
Thomas G. Gutheil, M.D.

D Managed Care and the Dilemmas of Psychiatric Education
Seymour L. Halleck, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 103 2:00 p.m. - 5:00 p.m.
Golden Gate Hall A, B-2 Level, Marriott

COMORBIDITY WITH SUBSTANCE ABUSE

Chp.: Marc Galanter, M.D.
Co-Chp.: Kathleen T. Brady, M.D.

A Substance Abuse and Depression
Edward V. Nunes, M.D.

B Substance Abuse and PTSD
Kathleen T. Brady, M.D., Susan Sonne, Ph.D., Therese Killeen, Ph.D., Aimee McRae, Ph.D.

C Substance Abuse and ADD
Timothy E. Wilens, M.D.
D Substance Abuse and Social Phobia
  Hugh Myrick, M.D.

Discussants: Richard N. Rosenthal, M.D., Michael H. Gendel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104  2:00 p.m. - 5:00 p.m.
Golden Gate Hall C, B-2 Level, Marriott

LOVE FROM PATHOLOGY TO NORMALITY:
FRENCH AND AMERICAN STYLE, PART 2

Chp.: Richard Rechtman, M.D.
Co-Chp.: John A. Talbott, M.D.

A Broken Hearts, Heavy Hearts: Narrative, Distress, and
  Compliance After an Infarct
  Danielle Groleau, Ph.D., Evelyne Hudon, M.D., Laurence J.
  Kirmayer, M.D., Francois Lesperance, M.D., Zeev
  Rosberger, Ph.D.

B From Erotomania to Stalking
  Francois C. Petitjean, M.D., Natacha Fouilhoux, M.D., Agop
  Kaveoian, M.D.

C The Love Life of Melancholics
  Peter D. Kramer, M.D.

D The Medical Marriage
  Michael Myers, M.D.

E The Clinical Meaning of Love
  Richard Rechtman, M.D., Eric J. Marcel, M.D.

F Transcultural Aspects of Love
  James K. Boehnlein, M.D.

Discussant: Yves G. Thoret, M.D.
THIS SESSION WILL BE AUDIOTAPED.
CALL FOR PAPERS

PRESIDENT'S THEME:
Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier

Marcia K. Goin, M.D.
President

Geetha Jayaram, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported Symposium</td>
<td>June 2, 2003</td>
</tr>
<tr>
<td>Course</td>
<td>September 3, 2003</td>
</tr>
<tr>
<td>Reports</td>
<td>September 3, 2003</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 3, 2003</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue: September 3, 2003</td>
</tr>
<tr>
<td></td>
<td>Component: September 17, 2003</td>
</tr>
<tr>
<td>New Research</td>
<td>December 5, 2003</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Jayaram at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
2003 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Dissociative Disorders
7. Eating Disorders
8. Mental Retardation (Child/Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Schizophrenia and Other Psychotic Disorders
12. Sexual and Gender Identity Disorders
13. Sleep Disorders
14. Somatoform Disorders

PRACTICE AREAS/SETTINGS
15. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Child and Adolescent Psychiatry and Disorders
19. Consultation-Liaison and Emergency Psychiatry
20. Cross-Cultural and Minority Issues
21. Diagnostic Issues
22. Epidemiology
23. Ethics and Human Rights
24. Forensic Psychiatry
25. Genetics
26. Geriatric Psychiatry
27. Neuropsychiatry
28. Psychiatric Education
29. Psychiatric Rehabilitation
30. Psychoanalysis
31. Research Issues
32. Social and Community Psychiatry
33. Stress
34. Suicide
35. Violence, Trauma, and Victimization

TREATMENTS
36. Behavior and Cognitive Therapies
37. Combined Pharmacotherapy and Psychotherapy
38. Couple and Family Therapies
39. Group Therapy
40. Individual Psychotherapies
41. Psychopharmacology
42. Other Somatic Therapies
43. Treatment Techniques and Outcome Studies

OTHER ISSUES
44. Computers
45. Creativity and the Arts
46. Gender Issues
47. Health Services Research
48. Historical Questions
49. Information Technology
50. Internet
51. Lesbian/Gay/Bisexual/Transgender Issues
52. Managed Care and Health Care Funding
53. Political Questions
54. Professional and Personal Issues
55. Religion, Spirituality, and Psychiatry
56. Resident and Medical Student Concerns
57. Presidential Theme: The Promise of Science – The Power of Healing
58. Stigma/Advocacy
59. Telepsychiatry
60. Virtual Reality
61. Women’s Health Issues

GUIDE TO USING THE TOPIC INDEX
Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
TOPIC INDEX

DISORDERS Page #

TOPIC 1: AIDS AND HIV-RELATED DISORDERS

SCIENTIFIC AND CLINICAL REPORTS
95 Psychiatric Effects Associated With Efavirenz: A Retrospective Study
96 PTSD and Acute Stress Reactions to Recent Life Events Among HIV Positive Persons
97 Use of Marijuana to Manage Distress Symptoms Among HIV-Infected Persons

SYMPOSIA
71 Neuropsychiatric Aspects of HIV/AIDS: An Overview, Part 1
77 The Neuropsychiatric Aspects of HIV/AIDS: Evaluation and Treatment, Part 2

WORKSHOPS - COMPONENT
12 AIDSism, Ageism, Racism: Psychiatrist's Role in the Geriatric AIDS Epidemic

WORKSHOP - ISSUE
108 Adherence to HIV Medications in the Psychiatrically Ill: New Findings

TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS

COURSE
39 Integrated Model for Treatment of Co-Occurring Psychiatric and Substance Disorders

FOCUS LIVE
2 Substance Abuse

LECTURE
9 Current Perspectives on Our National Drug Control Strategy

SCIENTIFIC AND CLINICAL REPORTS
4 Effect of Modafinil on Cocaine Abstinence and Treatment Retention in Cocaine Dependence: Preliminary Results From an Open-Label Study
92 Impulsivity, Sensation Seeking, and Coping Styles Among Substance Abusers
93 Substance Abuse Disorders and History of Childhood Sexual Abuse in a Population of U.S. Veterans
94 Attachments for In-Treatment Alcoholics and Teens Predicted to Be Addicts

SYMPOSIA
5 Compulsive Buyers: Treating the Casualties of Consumerism
21 Update on Treatment of Stimulant Abuse
58 Addictions: Cutting-Edge Treatments
86 The Veterans Administration Experience: Treating Comorbid Hepatitis C and Substance Use Disorders/Psychiatric Illness
103 Comorbidity With Substance Abuse

WORKSHOP - COMPONENT
4 Ambulatory Detoxification From Opioids: Doing It Well and Getting Paid Too

TOPIC 3: ANXIETY DISORDERS

INDUSTRY-SUPPORTED SYMPOSIA
3 Anxiety Disorders: Sources, Signs, and Solutions
6 Beyond Benzodiazepines: New Molecules for the Treatment of Anxiety
52 Striving to Heal the Mind: The Challenge of PTSD

WORKSHOP - COMPONENT
4 Ambulatory Detoxification From Opioids: Doing It Well and Getting Paid Too

TOPIC 4: ATTENTION SPECTRUM DISORDERS

COURSES
1 ADD in Children and Adolescents
16 ADD in Adults
37 Advanced Assessment and Treatment of ADD

INDUSTRY-SUPPORTED SYMPOSIA
43 Treating ADHD Across the Life Cycle, Part 1
43 Treating ADHD Across the Life Cycle, Part 2

SCIENTIFIC AND CLINICAL REPORTS
32 Efficacy and Safety of Atomoxetine in Adults With ADHD
33 Adderall XR Dosed Once Daily in Adult Patients With ADHD
34 Alpha-1 Agonist Prazosin for ADHD: The Role of Norepinephrine in ADHD Pathology
63 Long-Term Safety and Efficacy of Adderall XR in Children With ADHD
64 An Open-Label, Community-Assessment Trial of Adderall XR in Pediatric ADHD

SYMPOSIUM
54 ADHD: Longer-Term Treatment for a Chronic Disorder

TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)

ADVANCES IN RESEARCH
Advances in the Treatment of Alzheimer's Disease

COURSES
91 Alzheimer's Disease: Advanced Approaches to Treatment
96 The Evaluation and Identification of the Major Dementias

DISCUSSION GROUP
26 Delirium and Dementia

INDUSTRY-SUPPORTED SYMPOSIA
37 Slowing Disease Progression and the Long-Term Management of Dementia
48 Challenges in Dementia: Evidence-Based Considerations From Early Diagnosis to Long-Term Management

LECTURE
18 The Meaning of Cognitive Impairment

MASTER EDUCATOR CLINICAL CONSULTATION Page #
9 Anxiety Disorders

SCIENTIFIC AND CLINICAL REPORTS
11 The Prevalence of PTSD in Canada
12 A New Self-Report Screening Tool for DSM-IV Axis I Diagnosis
13 Sexual Aversion Disorders in Primary Anxiety Disorders
77 Clinical Experiments With Sertraline in Panic Disorder
78 Double-Blind Oral Methylphenidate in Treatment-Resistant OCD

SYMPOSIA
12 OCD Spectrum Illnesses: What Does It Mean? Does It Help Our Treatment?
19 Novel Clinical Perspectives on the Pathophysiology and Treatment of PTSD
65 New Research and Novel Therapeutic Strategies for OCD
68 PTSD: A Latin-American Nightmare
75 Glutamate: An Exciting Neurotransmitter
96 New Evidence on Exposure and Present-Focused Treatments for Complex PTSD

WORKSHOP - COMPONENT
46 Update on Practice Guidelines: PTSD/Acute Stress Disorder
RESEARCH ADVANCES IN MEDICINE

STrokes

SCIENTIFIC AND CLINICAL REPORTS

5 Quetiapine Treatment of Hallucinations and Agitation of Lewy Body Disease
29 Dyslexia as a Potential Index of Neurocognitive Impairments in Patients With Schizophrenia

SYMPOSIUM

16 Cognitive Therapy in Novel Clinical Situations: Rationale, Issues, and Controversies
46 Diverse Approaches to Alzheimer's Screening

TOPIC 6: DISSOCIATIVE DISORDERS

CONTINUOUS CLINICAL CASE CONFERENCES

1 A Case of Murder and Dissociative Identity Disorder: Real or Malingered Mental Illness? Part I
2 A Case of Murder and Dissociative Identity Disorder: Real or Malingered Mental Illness? Part II

SYMPOSIUM

95 A Terrorist's Competency to Stand Trial: Assessing Amnesia

TOPIC 7: EATING DISORDERS

COURSES

5 Integrated Treatment of Eating Disorders
21 Therapeutic Interventions in Eating Disorders: Basic Principles

DISCUSSION GROUP

22 Eating Disorders in Males: A Rising Tide

INDUSTRY-SUPPORTED SYMPOSIA

15 New Challenges in the Management of Depression
45 Obesity in Psychiatric Practice: Recognition and Treatment, Part 1
45 Obesity in Psychiatric Practice: Recognition and Treatment, Part 2

SCIENTIFIC AND CLINICAL REPORT

82 Binge Eating Disorder in Fiji, A Small-Scale, Indigenous Society

SYMPOSIUM

4 Pathological Body Sculpting in the Athlete
17 Eating Disorders 2003: From Laboratory to Practice
98 New Research in the Biology and Treatment of Bulimia Nervosa

WORKSHOPS - ISSUES

14 Innovative Treatment in Bulimia Nervosa
81 Family Therapy for Anorexia Nervosa

TOPIC 8: MENTAL RETARDATION (CHILD/adolescent/ADULT)

WORKSHOP - COMPONENT

40 Summary of the Surgeon General's Meeting on Health of the Mentally Retarded

WORKSHOPS - ISSUES

41 Challenging Behavior, Mental Illness, and Developmental Disabilities
104 Dysmorphologies: Recognition and Treatment

TOPIC 9: MOOD DISORDERS

ADVANCES IN RESEARCH

The Latest Developments in the Genetics of Mood Disorders

COURSES

11 Neuroendocrinology in Mood Disorders: Dysregulation and Treatment
34 Evidence-Based Management of SAD: Focus on Light Therapy
38 ECT Practice Update
50 The Conceptual Basis of Psychiatry

DISCUSSION GROUP

21 Controversies in Vascular and Post-Stroke Depression

INDUSTRY-SUPPORTED SYMPOSIA

2 Bipolar Disorder: Strategies for Stabilizing Patients Over the Long Term
4 New Strategies for Managing Bipolar Disorder
12 An Integrated Approach to the Management of Bipolar Disorder: An Alliance of Science and Medicine
16 Issues in Treating Mania: Acute and Continuation Phase
17 Tricks of the Trade in the Long-Term Treatment of Depression
21 Peptides and Hormones as Targets in Antidepressant Treatment
22 A Comprehensive Approach to Managing Bipolar Disorder: Bench to bedside and Beyond
34 Managing Anxiety and Sleep: A New Era for Gamma-Aminobutyric Acid, Part 1
34 Managing Anxiety and Sleep: A New Era for Gamma-Aminobutyric Acid, Part 2
35 Facing Unmet Needs: Atypical Antipsychotics for Mood and Anxiety
36 Bipolar Disorder Across the Life Cycle
40 Real-World Challenges in Depression and Anxiety
49 Combined Pharmacotherapy for Bipolar Disorders
51 Bipolar Disorder: Clinical and Public Health Implications of Medical and Psychiatric Comorbidity

MASTER EDUCATOR CLINICAL CONSULTATION

3 Treating Bipolar Depression

RESEARCH ADVANCES IN MEDICINE

Vascular Depression
Depression and the Immune Response

RESEARCH CONSULTATION

1 The Genetics of Bipolar Disorder and Other Psychiatric Phenotypes

SCIENTIFIC AND CLINICAL REPORTS

17 Tridimensional Personality Questionnaire and Anxiety Disorder Comorbidity in MDD
18 Difference in Subjective/Objective Sadness Predicts Drug Response
19 Identifying Depression in Older Inpatients With the Geriatric Depression Scale and Structured Clinical Interview
26 Continuation Cognitive-Behavioral Therapy Maintains Attributional Style Improvement in Depressed Patients Responder Acutely to Fluoxetine
27 The Potential Relationship Between Levels of Perceived Stress and Specific Subtypes of Major Depression
28 Symptom Severity and Exclusion From Antidepressant Efficacy Trials
41 Cardiovascular Risk Factors Predict Treatment Outcome in MDD
42 Prevalence and Characteristics of Patients With Depression and/or Chronic Pain
43 Effectiveness of Collaborative Care in a Depressed, Poor, Primary Care Sample
45 Effectiveness and Tolerability of Newer Antidepressants Among Depressed Chinese-American Patients

(Continued on next page)
## TOPIC 12: SEXUAL AND GENDER IDENTITY

### COURSES
- 101 Sexual Disorders: Diagnosis and Treatment 83

### DISCUSSION GROUP
- 15 Clinical Implications of Sexual Dysfunction in Depression 42

### SYMPOSIUM
- 24 Sexual and Gender Identity Disorders: Questions for DSM-V 32

## TOPIC 13: SLEEP DISORDERS

### COURSES
- 12 Dream Translation: One Empirically-Based Approach 2
- 31 Irresistible Sleep: Narcolepsy Update 8
- 53 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders 24
- 76 Overview and Update of Sleep Disorders Medicine 48
- 98 Update on Sleep Medicine: Advanced Topics 73

### INDUSTRY-SUPPORTED SYMPOSIA
- 44 Insomnia in Today's Society: Consequences and Treatments, Part 1 61
- 44 Insomnia in Today's Society: Consequences and Treatments, Part 2 83

### SCIENTIFIC AND CLINICAL REPORTS
- 119 Modafinil Improves Cognition in Narcolepsy Patients With Excessive Sleepiness 90
- 120 Modafinil as Adjunctive Therapy Improves Quality of Life in Sleep Apnea 90
- 121 Modafinil Improves Quality of Life as Adjunct Treatment of Obstructive Sleep Apnea 90

## TOPIC 14: SOMATOFORM DISORDERS

### COURSE
- 77 The Complexities of Chronic Pain: Multidisciplinary Treatment Approaches 48

### SYMPOSIUM
- 63 The Nature and Treatment of BDD From Clinicians' and Patients' Perspectives 75

## TOPIC 15: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

### COURSES
- 8 Basic Concepts in Administrative Psychiatry I: Theory, Human Resources, and Fiscal Management 1
- 22 Basic Concepts in Administrative Psychiatry II: Care Management, Law, and Ethics 7

### DISCUSSION GROUP
- 16 Psychiatric Leadership in the Medical Marketplace 42

### SYMPOSIA
- 41 Science and Psychiatric Participation in Disaster Response 53
- 55 How to Launch a Successful Private Practice, Part 3 56

### WORKSHOPS - COMPONENTS
- 31 CPT Coding and Documentation Update 70
- 33 State of the States for State Hospital Psychiatrists 71
- 41 The Administrative Psychiatry Credential 85

### WORKSHOPS - ISSUES
- 53 How to Launch a Successful Private Practice, Part 1 41
- 55 Career Development and Risk Management 46
- 58 Women in Academic Psychiatry: Opportunities, Obstacles, and Strategies 47
- 63 How to Launch a Successful Private Practice, Part 2 47
- 66 The Disruptive Physician and Hospital Culture 65
- 67 The Unwritten Rules for Success as a Community Psychiatrist 65
- 105 Psychiatric Disability: The Role of Psychiatric Assessment 86

## TOPIC 16: ADDICTION PSYCHIATRY

### COURSES
- 20 Achieving Effective Dual Diagnosis Treatment 5
- 89 Office-Based Buprenorphine Treatment for Opioid Dependent Patients 62

### DISCUSSION GROUP
- 8 New Developments in Substance Dependence: Genetics, Criteria, and Treatment 20

### SCIENTIFIC AND CLINICAL REPORT
- 2 Differences in Peripheral Noradrenergic Function Among Actively Drinking and Recently Abstinent Alcohol-Dependent 21

### SYMPOSIUM
- 37 What the General Psychiatrist Needs to Know About Addiction Psychiatry 52

### WORKSHOPS - ISSUES
- 100 Treating Addiction: Meeting New Needs in a New World 86
- 112 Harm Reduction: A Critical Review 91

## TOPIC 17: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

### COURSES
- 9 Introduction to Transcranial Magnetic Stimulation 2
- 18 Behavioral Neuroanatomy: An Introduction 5
- 87 Behavioral Neuroanatomy: An Introduction 62
- 92 Back to the Future: The Evolutionary Framework for Psychiatry 63

### REVIEW OF PSYCHIATRY: SECTION 2
- Molecular Neurobiology for the Clinician 49

### SCIENTIFIC AND CLINICAL REPORTS
- 3 Changes in Peripheral Noradrenaline and 5HT Levels and Craving During Alcohol Withdrawal 21
- 102 Depressed Women Have Elevated Coagulation Factors in Mid Life 89

### SYMPOSIA
- 2 Mineral/Vitamin Modification of Mental Disorders and Brain Function 27
- 22 Interferon-Induced Neuropsychiatric Side Effects: New Data and Treatments 31

### WORKSHOP - ISSUE
- 19 Ethnic Biodiversity in Substance Abuse and Mental Health Disorders 19
## TOPIC INDEX

### TOPIC 18: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

#### CLINICAL CASE CONFERENCES
1. Diagnostic and Treatment Issues in the Care of an Adolescent With Comorbid Bipolar Disorder and ADHD 15
3. Treating the Chronically Medically Ill Adolescent: A Case Study 62

#### INDUSTRY-SUPPORTED SYMPOSIAS
26. Treatment of Comorbidity in Neuropsychiatric Disorders in Children and Adolescents 12
47. Juvenile Bipolar Disorder: Contemporary Issues in Research 80

#### LECTURE
3. The Neurobiological Consequences of Child Abuse 16

#### SCIENTIFIC AND CLINICAL REPORTS
23. Management of Adolescent Mania 43
24. Exploratory Factor Analysis of BPD Criteria in Hospitalized Adolescents 43
25. Gender Differences in Comorbidities in Child and Adolescent GAD 43
35. Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting 44
36. Modafinil Improves ADHD Symptoms in Children in a Randomized, Double-Blind, Placebo-Controlled Study 44
37. Safety and Efficacy of OROS MPH in Adolescents With ADHD 44
44. Modafinil in Children With ADHD: A Randomized, Placebo-Controlled Study 45
45. Quetiapine Use in Children and Adolescents: A Literature Review 45
46. Clinical Review of OROS MPH in Children, Adolescents, and Adults With ADHD 45

#### SYMPOSIA
6. Quality of Care for Children and Adolescents 28
25. Confronting Crises in Education, Mental Health, and Juvenile Justice 32

#### WORKSHOPS - ISSUES
85. Healing the Hurt Child: Treating Fetal Alcohol Syndrome Spectrum Disorder Children 71
93. Specific Psychotherapeutic Techniques for Adolescents 85
113. Parenting With the Brain in Mind: Attachment and Self-Understanding 91

### TOPIC 19: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

#### COURSES
13. Psychiatric Consultations in Medical Settings: The Basics 5
41. Families Coping With Medical Illness: An Integrative Treatment Model 15
60. Med-Psych Drug-Drug Interactions: An Update 37

#### DISCUSSION GROUP
14. An Update on Pain Management (Meet the Authors) 41

### TOPIC 20: CROSS-CULTURAL AND MINORITY ISSUES

#### COURSES
46. DSM-IV-TR Cultural Formulations: Diagnosis and Therapy 15
67. The Clinical Application of Cultural Psychiatry 36

#### DISCUSSION GROUPS
24. Cross-Cultural Issues: When the Patient Is Different From You (For Residents Only) 67

#### LECTURES
15. Mental Illness, Human Rights, Science, and Culture: A Videotaped Documentation of Conditions in Mexican Psychiatric 49
16. Health, Culture, and South-Asian Indians in North America 63
23. Remembering the Past and Living in the Now: Modernization in East Asian Countries and Psychotherapy 84
24. Culture/Racism and Ethnic Diversity With Past Corrective Actions, Successes, and Failures 87

#### MASTER EDUCATOR CLINICAL CONSULTATION
4. Cross-Cultural Issues in Psychiatric Care 21

#### SCIENTIFIC AND CLINICAL REPORT
84. When the Poetry No Longer Rhymes: Somalis in the American Psychiatric Clinic 70

#### SYMPOSIA
8. Challenges in Cross-Cultural Psychiatry: Focus on Depression and Ethnopsychopharmacology 28
23. Roads to Healing in Mental Health in the Americas 32
35. Developing Culturally Competent Services for Minority Populations 51
87. Children at Risk for Mental Illness in Latin America 92
91. Conceptualizations of Jeong and Its Application to the Healing Process 94
### TOPIC INDEX

#### WORKSHOPS - COMPONENTS
- It Doesn't Happen to Us: Insider's View of Trauma in Minority Communities 40
- Racism: Diagnostic and Treatment Considerations 40
- Why Psychiatry? Says Mom 71
- Clinical Issues of Ethnic Diversity in Long-Term Care Facilities 71
- Biracial or Bicultural Americans: Issues and Insights for Therapy 90

#### WORKSHOPS - ISSUES
- Mind-Body Connection in Traditional Chinese Medicine 24
- Surgeon General's Report on Culture, Race, and Ethnicity: Clinical Implications 41
- Asian Indians in Interfaith Marriages: Challenges, Conflicts, and Compromises 47
- Culture, Race, Ethnicity, and Psychopharmacology: Recent Research Advances 65
- Fitmaker, Matchmaker Make Me a Match 66
- Cutting-Edge Issues in Cross-Cultural Psychiatry 66
- A Program to Enhance Cultural Competency in Residency Training 85
- The Meaning of the Pacific Rim for World and American Psychiatry 86
- Care of Muslim Patients: A U.S. Perspective 91
- Bridging the Gap Between Mental Health and Primary Care for Asian Americans 91
- Racial, Ethnic, and Cultural Bias in Psychotherapy 91

#### TOPIC 21: DIAGNOSTIC ISSUES

#### CLINICAL CASE CONFERENCE
- Dealing With Diagnostic Ambiguity: When Somatic Memory and Anxiety Symptoms Confuse 84

#### REVIEW OF PSYCHIATRY: SECTION 3
- Standardized Evaluation in Clinical Practice 84

#### SCIENTIFIC AND CLINICAL REPORTS
- Diagnosing and Treating Infants and Toddlers in Public Mental Health Settings 68
- Psychiatric Nomenclature 68

#### SYMPOSIA
- Evaluating Clinical Competence: Current Options, Future Directions 29
- World Psychiatric Association's International Guidelines for Diagnostic Assessment 74
- Dimensionality in Psychiatric Disorders 74
- The Dual-Diagnostic Challenge: Assessment and Treatment 78

#### WORKSHOP - COMPONENT
- The Research Base for New Diagnostic Criteria for Depression 23

#### WORKSHOP - ISSUE
- The Uses and Abuses of Psychiatric Independent Medical Examinations: An Ethical Dilemma? 85

#### TOPIC 22: EPIDEMIOLOGY

#### SCIENTIFIC AND CLINICAL REPORTS
- Diagnoses in Behavioral Health Clinics: Impact on Perceived Burden of Mental Health 46
- The Treatment Gap in Mental Health Care 46
- Projecting National Survey Prevalences to Populations of Interest 46
- Sex Differences in Health Service Use and Functioning Associated With Depressive Symptoms: Findings From the Utrecht Health Project 70

#### TOPIC 23: ETHICS AND HUMAN RIGHTS

#### COURSES
- Medical Ethics 101 7
- The Juvenile Justice Clinic: Administrative Issues and Treatment Options 48

#### FORUM
- APA and the Pharmaceutical Industry: Controversies and Approaches 72

#### PRESIDENTIAL SYMPOSIUM
- Moral and Philosophical Issues in Psychiatry 26
- The Foundation of Medical Ethics/Informed Consent 49

#### SCIENTIFIC AND CLINICAL REPORTS
- Factors Associated With Determining Competence to Consent in Acute Psychoses 88
- Ethical Challenges of Managing Pregnant Patients Who Have Schizophrenia 88

#### SYMPOSIUM
- Ethical Issues in the U.S. and France: Vivre La Difference 57

#### WORKSHOPS - COMPONENTS
- New APA Ethics Procedures: Implications for the Profession, Part 1 39
- New APA Ethics Procedures: Implications for the Profession, Part 2 46
- What Is the Ethical Stance? Issues Related to World Psychiatry and Courts 65

#### WORKSHOPS - ISSUES
- Moral Aspects of Clinical Practice: A Functional Approach 17
- Nonssexual Boundary Violations 18
- Content Evaluations: Assessing Capacity for Decision Making and for Voluntarism 40
- The Psychiatric Care of Survivors of Torture 41
- Psychiatric Perspectives on the Execution Process: A Continuing Conundrum 41
- Revision of the APA Ethics Annotations: Fostering Dialogue 65
- Going Public Over Patient Privacy 71
- Teaching Psychiatric Ethics Engagingly, Effectively 85

#### TOPIC 24: FORENSIC PSYCHIATRY

#### COURSES
- Contemporary Malpractice Liability: A Practical Guide 5
- The Psychiatrist as Expert Witness 14
- The Detection of Malingered Mental Illness 36
- Insanity Defense Evaluations 61

#### DISCUSSION GROUPS
- Infanticide: Psychosocial and Legal Perspectives of Mothers Who Kill (Meet the Authors) 16
- An Introduction to Starting a Forensic Psychiatric Practice 38

#### LECTURES
- Expert Testimony in the Age of Daubert 10
- Labeling the Dissenter as Mad: Forensic Psychiatry in China and Its Political Abuses 16

#### SCIENTIFIC AND CLINICAL REPORT
- Malpractice Liability and Managed Care: Is a Resolution in Sight? 69

#### SYMPOSIUM
- The Evil Standard: Milestones and Challenges 54

#### WORKSHOP - COMPONENT
- Practicing Rewarding Psychiatry in Jails and Prisons: A Practicum 85
### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 Distinguishing Mental Illness From Bad Behavior in Prisoners</td>
<td>19</td>
</tr>
<tr>
<td>23 Restorative Justice and Therapeutic Jurisprudence: An Enjoyable Exchange of Ideas</td>
<td>19</td>
</tr>
<tr>
<td>32 Discussing the Concept of Mental Health Courts</td>
<td>24</td>
</tr>
<tr>
<td>34 Patient Responsibility for Addiction to Prescribed Substances</td>
<td>24</td>
</tr>
<tr>
<td>68 The Montgomery County Emergency Service Diversion Model: A Comprehensive Continuum of Forensic Interventions</td>
<td>65</td>
</tr>
<tr>
<td>75 The Psychiatrist's Nightmare: A Malpractice Lawsuit</td>
<td>66</td>
</tr>
</tbody>
</table>

### TOPIC INDEX

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOPIC 25: GENETICS</td>
<td></td>
</tr>
<tr>
<td>COURSE</td>
<td></td>
</tr>
<tr>
<td>84 Psychiatric Genomics: Applications for Clinical Practice</td>
<td>61</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>5 Genetics and Psychiatry: Real Genes, Real Progress</td>
<td>3</td>
</tr>
<tr>
<td>LECTURES</td>
<td></td>
</tr>
<tr>
<td>10 Genes, Family Relationships, and DSM-V</td>
<td>38</td>
</tr>
<tr>
<td>12 The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets</td>
<td>42</td>
</tr>
<tr>
<td>22 The Revolution in Mouse Molecular Genetics: New Approaches for Psychiatric Research</td>
<td>74</td>
</tr>
<tr>
<td>MEDICAL UPDATE</td>
<td></td>
</tr>
<tr>
<td>1 Ethnicity and Pharmacogenetics</td>
<td>21</td>
</tr>
<tr>
<td>TOPIC 26: GERIATRIC PSYCHIATRY</td>
<td></td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4</td>
<td></td>
</tr>
<tr>
<td>74 Geriatric Psychiatry</td>
<td>74</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>7 Hyponatremia Associated With the Use of Antidepressants in Geriatric Patients</td>
<td>21</td>
</tr>
<tr>
<td>65 NIMH Appraisal Antipsychotic Effectiveness Trial In Alzheimer's CATIE-AD</td>
<td>69</td>
</tr>
<tr>
<td>66 Meta-Analysis of Risperidone for Dementia: The Price Paid for Efficacy</td>
<td>69</td>
</tr>
<tr>
<td>67 Switching Elderly Chronic Schizophrenia Patients to Olanzapine: A Prospective Study</td>
<td>69</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
<td></td>
</tr>
<tr>
<td>15 Management of Disinhibition in Dementia</td>
<td>18</td>
</tr>
<tr>
<td>51 From Neuropathology to Treatment: Emerging Treatment Strategies for Alzheimer's Disease</td>
<td>41</td>
</tr>
<tr>
<td>TOPIC 27: NEUROPSYCHIATRY</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>4 Determining Medical Fitness to Drive: Relevant Issues for Psychiatrists</td>
<td>1</td>
</tr>
<tr>
<td>17 Psychiatric Disorders Related to Epilepsy</td>
<td>5</td>
</tr>
<tr>
<td>43 Update in Neuropsychiatry: Delirium, Traumatic Brain Injury, and Post-Stroke Depression</td>
<td>15</td>
</tr>
<tr>
<td>44 Advances in Neuropsychiatry</td>
<td>15</td>
</tr>
<tr>
<td>94 Traumatic Brain Injury: Neuropsychiatric Assessment</td>
<td>63</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>11 Enhancing Skill Treating Comorbid Depression and Neurological Illness</td>
<td>6</td>
</tr>
<tr>
<td>20 Depression, Apathy, and Fatigue in Neuropsychiatric Disorders</td>
<td>10</td>
</tr>
<tr>
<td>28 Impairment of Structural Plasticity in Severe Mood Disorders: Causal or Collateral? Part 1</td>
<td>13</td>
</tr>
<tr>
<td>28 Impairment of Structural Plasticity in Severe Mood Disorders: Causal or Collateral? Part 2</td>
<td>35</td>
</tr>
<tr>
<td>TOPIC 28: PSYCHIATRIC EDUCATION</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>33 Integrative Psychotherapy Supervision: Basic Tools</td>
<td>8</td>
</tr>
<tr>
<td>40 Teaching Psychiatry? Let Hollywood Help!</td>
<td>14</td>
</tr>
<tr>
<td>FORUM</td>
<td></td>
</tr>
<tr>
<td>8 ABPN Update: Requirements for ABPN Examination</td>
<td>72</td>
</tr>
<tr>
<td>LECTURE</td>
<td></td>
</tr>
<tr>
<td>14 The Healer's Art: Undergraduate Education for Meaning and Commitment</td>
<td>49</td>
</tr>
<tr>
<td>MEDICAL UPDATE</td>
<td></td>
</tr>
<tr>
<td>4 Club Drugs: A Primer for Mental Health Professionals</td>
<td>87</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
</tr>
<tr>
<td>20 Psychiatry Training in Primary Care: Current Status and Satisfaction</td>
<td>22</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>9 Core Competencies: How They Fit Into Certification and Recertification</td>
<td>28</td>
</tr>
<tr>
<td>13 Evolution of the Social Brain: Implications for Medical Education and Treatment</td>
<td>29</td>
</tr>
<tr>
<td>67 Replenishing Ourselves: Supply of Psychiatrists for the Present and the Future</td>
<td>76</td>
</tr>
<tr>
<td>92 Boundaries Education: An Expert Update on Diverse Approaches and Settings</td>
<td>94</td>
</tr>
<tr>
<td>WORKSHOPS - COMPONENTS</td>
<td></td>
</tr>
<tr>
<td>10 Practical Tips on How to Be a Successful Author</td>
<td>39</td>
</tr>
<tr>
<td>11 How to Provide Geriatric Psychiatry During Residency</td>
<td>39</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
<td></td>
</tr>
<tr>
<td>8 Institute of Medicine Study: Incorporating Research Into Residency Training</td>
<td>18</td>
</tr>
<tr>
<td>29 Psychotherapy With African-American Patients: Training Perspectives</td>
<td>23</td>
</tr>
<tr>
<td>38 Psychiatry Training for Primary Care Physicians: What, How Much, and How?</td>
<td>40</td>
</tr>
<tr>
<td>90 Neurobiology of Learning: Moving From the Ivory Tower Into the Classroom</td>
<td>85</td>
</tr>
<tr>
<td>TOPIC 29: PSYCHIATRIC REHABILITATION</td>
<td></td>
</tr>
<tr>
<td>COURSE</td>
<td></td>
</tr>
<tr>
<td>100 Recovery From Mental Illness and Stigma: Integration of Medicine and Recovery</td>
<td>83</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>42 Recovery From Schizophrenia: A Challenge for the 21st Century</td>
<td>53</td>
</tr>
<tr>
<td>WORKSHOP - COMPONENT</td>
<td></td>
</tr>
<tr>
<td>39 Never-Taught Dilemmas: When Work and Disability Issues Impact Patient Care</td>
<td>84</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
<td></td>
</tr>
<tr>
<td>114 Service Integration and Continuity in California: Programs From Harbor-UCLA</td>
<td>91</td>
</tr>
</tbody>
</table>
### TOPIC 30: PSYCHOANALYSIS

**SYMPOSIUM**
- 33 COPING WITH CATASTROPHE 51
- 104 LOVE FROM PATHOLOGY TO NORMALITY: FRENCH AND AMERICAN STYLE, PART 2 97

### TOPIC 31: RESEARCH ISSUES

**COURSES**
- 66 DOING RESEARCH ON A SHOESTRING BUDGET 36
- 102 ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS 84

**NEW RESEARCH SESSIONS**
- 1 young investigators' poster session 17
- 2 young investigators' oral/slide session 25
- 3 young investigators' oral/slide session 25
- 4 young investigators' oral/slide session 25
- 5 poster session 33
- 6 poster session 47
- 7 poster session 58
- 8 poster session 72
- 9 poster session 80
- 10 poster session 91

**SYMPOSIUM**
- 36 THE ETHNICITY FACTOR IN PSYCHIATRIC RESEARCH: IDENTITY AND METHODOLOGY ISSUES 51
- 40 DEHYDROEPIANDROSTERONE: NEUROSTEROID MECHANISMS, EPIDEMIOLOGY, AND APPLICATIONS IN PSYCHIATRY 53

### TOPIC 32: SOCIAL AND COMMUNITY PSYCHIATRY

**COURSES**
- 28 ORGANIZATIONAL AND GROUP INTERVENTIONS FOLLOWING DISASTERS 7
- 60 DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO 36
- 82 PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE 61

**FORUM**
- 9 MEANINGFUL ACTIVITIES AND STRUCTURE MATTER: HOW A PREVOCATIONAL PROGRAM HELPS SEVERELY MENTALLY ILL CLIENTS 72

**LECTURES**
- 5 COMMUNITY PSYCHIATRY: 1963-2003 20
- 17 CAN PSYCHIATRY IMPROVE COMMUNITY WELFARE? NEW RESEARCH AND PRACTICE PARADIGM 63

**SYMPOSIUM**
- 78 IS THIS AN ACT OR AN ACT? APPROACHES TO ASSERTIVE COMMUNITY TREATMENT 79

**WORKSHOP - COMPONENT**
- 29 TRAUMA AND HOMELESSNESS: PSYCHIATRIC ASPECTS OF A SOCIOECONOMIC PROBLEM 65

**WORKSHOPS - ISSUES**
- 16 PREPARING PSYCHIATRISTS FOR MASS-CASUALTY EVENTS 19
- 21 LESSONS LEARNED FROM SEPTEMBER 11 19
- 25 LONG-TERM STRUCTURED CARE: A FAMILY PERSPECTIVE 23
- 47 DEVELOPMENT OF THE SCHOOL-BASED ADOLESCENT DEPRESSION AWARENESS PROGRAM 41

### TOPIC 33: STRESS

**COURSE**
- 54 CHILD MURDER BY PARENTS 24

**INDUSTRY-SUPPORTED SYMPOSIUM**
- 19 STRESS, PSYCHOPATHOLOGY, AND THE BRAIN: NOVEL INTERVENTION STRATEGIES 9

### MEDICAL UPDATE

- 3 YOGIC BREATHING: NEUROPHYSIOLOGIC THEORY AND CLINICAL APPLICATIONS FOR TREATMENT OF STRESS RELATED DISORDERS, DEPRESSION, AND AGGRESSION 68

**WORKSHOPS - ISSUES**
- 49 PSYCHIATRIC ILLNESS AND THE WORKPLACE 41
- 77 INTERGENERATIONAL TRANSMISSION OF TRAUMA IN PREVENTION OF LONG-TERM CONSEQUENCES OF TRAUMATIC STRESS 66

### TOPIC 34: SUICIDE

**INDUSTRY-SUPPORTED SYMPOSIUM**
- 27 REDUCING SUICIDALITY IN SCHIZOPHRENIA AND BIPOLAR DISORDER 12
- 29 IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS, PART 1 13
- 29 IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS, PART 2 35

**MASTER EDUCATOR CLINICAL CONSULTATION**
- 7 RATIONAL OR RATIONALIZED SUICIDE? AN ETHICAL/Clinical DILEMMA 43

**SCIENTIFIC AND CLINICAL REPORTS**
- 47 PERSONALITY TRAITS AS PREDICTORS OF SUICIDALITY IN YOUNG WOMEN 45
- 48 SUICIDAL BEHAVIOR IN VIOLENT AND NONVIOLENT PSYCHIATRIC PATIENTS 45
- 49 OBSTETRIC COMPLICATIONS AND SUICIDE RISK IN ADOLESCENCE AND YOUNG ADULTHOOD 45
- 71 IMPULSIVITY, SUICIDE, AND PREFRONTAL HYPOMETABOLISM IN BORDERLINE PERSONALITY 69
- 72 SUICIDE RATES OVER THE DECADE ACROSS CIVILIAN AND MILITARY POPULATIONS 69

**WORKSHOP - COMPONENT**
- 20 PATIENT SAFETY IN PSYCHIATRY: REDUCING INPATIENT SUICIDE 46

**WORKSHOPS - ISSUES**
- 26 IMMINENT RISK OF SUICIDE IN CORRECTIONAL FACILITIES 23
- 27 THE IMPACT OF SUICIDE ON CLINICIANS 23
- 107 AN UPDATE ON MANAGEMENT OF SUICIDE ATTEMPTS: A REVIEW FOR CLINICIANS 86

### TOPIC 35: VIOLENCE, TRAUMA, AND VICTIMIZATION

**COURSES**
- 15 RISK ASSESSMENT FOR VIOLENCE 5
- 64 SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS 36
- 71 PERSONALITY AND POLITICAL BEHAVIOR 37
- 88 ASSESSING THE RISK OF VIOLENCE IN BOTH FORENSIC AND SEX OFFENDER SETTINGS 62
- 95 MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENT 72

**FORUMS**
- 5 TERRORISM AND PSYCHOSOCIAL PREPAREDNESS 47
- 7 INTIMATE PARTNER VIOLENCE AND ABUSE: IDENTIFICATION AND INTERVENTION WITHIN A BEHAVIORAL HEALTH STUDY 47

**REVIEW OF PSYCHIATRY: SECTION 1**
- 2003 PSYCHIATRY UPDATE: TRAUMA AND DISASTER RESPONSES AND MANAGEMENT 39

**SCIENTIFIC AND CLINICAL REPORTS**
- 73 CLOZAPINE REDUCES VIOLENT BEHAVIOR IN HETEROGENEOUS DIAGNOSTIC GROUPS 69
- 107 TREATMENT OUTCOME FOR SEXUALLY ABUSED CHILDREN AT ONE-YEAR FOLLOW-UP 89
- 108 PSYCHOLOGICAL SYMPTOMS SIX YEARS AFTER A PLANE CRASH 89
### SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advances in the Treatment of Childhood</td>
<td>30</td>
</tr>
<tr>
<td>Treatment of Traumatic Grief</td>
<td></td>
</tr>
<tr>
<td>Early Trauma: Strategies for Intervention</td>
<td>52</td>
</tr>
<tr>
<td>and Treatment</td>
<td></td>
</tr>
<tr>
<td>Bereavement After Violent Death</td>
<td>54</td>
</tr>
<tr>
<td>The Spectrum of Sexual Violence: Clinical</td>
<td>55</td>
</tr>
<tr>
<td>and Cultural Impact</td>
<td></td>
</tr>
<tr>
<td>Terrorism, War, and Refugees: Psychiatric</td>
<td>77</td>
</tr>
<tr>
<td>Effects and Prevention?</td>
<td></td>
</tr>
<tr>
<td>The Psychological Impact of 9/11: Results</td>
<td>79</td>
</tr>
<tr>
<td>From Five Major Studies</td>
<td></td>
</tr>
<tr>
<td>Terrorism and Political Violence in the</td>
<td>95</td>
</tr>
<tr>
<td>21st Century: New Forms and Responses</td>
<td></td>
</tr>
</tbody>
</table>

### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Intervention Following Mass Violence</td>
<td>17</td>
</tr>
<tr>
<td>Designing an Effective Approach</td>
<td></td>
</tr>
<tr>
<td>Sexual Harassment: Victims Face</td>
<td>46</td>
</tr>
<tr>
<td>Confidentiality Issues in Psychiatric</td>
<td></td>
</tr>
<tr>
<td>Care</td>
<td></td>
</tr>
<tr>
<td>Global Trauma: Experience and Implications</td>
<td>65</td>
</tr>
<tr>
<td>for DSM-V</td>
<td></td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Youth Violence: Principles of Prevention</td>
<td>19</td>
</tr>
<tr>
<td>The Emerging Role of Psychiatry in a</td>
<td>41</td>
</tr>
<tr>
<td>Bioterrorism Response</td>
<td></td>
</tr>
<tr>
<td>Post-Genocide Psychological Trauma in Film</td>
<td>47</td>
</tr>
<tr>
<td>Under the Dome</td>
<td></td>
</tr>
<tr>
<td>Inpatient Violence: Lessons From the</td>
<td>86</td>
</tr>
<tr>
<td>Inner-City Psychiatry Hospital</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 36: BEHAVIOR AND COGNITIVE THERAPIES

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive Therapy for Schizophrenia</td>
<td>8</td>
</tr>
<tr>
<td>Cognitive Therapy: The Basics</td>
<td>24</td>
</tr>
<tr>
<td>Engaging Resistant and Hostile Patients</td>
<td>25</td>
</tr>
<tr>
<td>Into Participatory Treatment</td>
<td></td>
</tr>
<tr>
<td>Integrating Psychotherapy and Pharmacotherapy</td>
<td>36</td>
</tr>
<tr>
<td>Cognitive Therapy for Severe Mental</td>
<td>37</td>
</tr>
<tr>
<td>Disorders</td>
<td></td>
</tr>
<tr>
<td>Introduction to Cognitive-Behavioral</td>
<td>37</td>
</tr>
<tr>
<td>Therapy</td>
<td></td>
</tr>
<tr>
<td>Basic Hypnosis: Principles and Applications</td>
<td>37</td>
</tr>
<tr>
<td>Advanced Hypnosis: Applications in</td>
<td>63</td>
</tr>
<tr>
<td>Psychiatry</td>
<td></td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Power of Humor in Psychotherapy</td>
<td>69</td>
</tr>
<tr>
<td>The Effective Delivery of Cognitive-Behavioral Therapy for Panic Disorder: An International Multicenter Trial</td>
<td>90</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teaching Cognitive-Behavior Therapy:</td>
<td>17</td>
</tr>
<tr>
<td>Effective Training in Unexpected Settings</td>
<td></td>
</tr>
<tr>
<td>Developments in Cognitive Therapy for</td>
<td>41</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td></td>
</tr>
<tr>
<td>Therapeutic Issues in Self-Injurious</td>
<td>46</td>
</tr>
<tr>
<td>Behavior</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 37: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Psychodynamic Approach to Treatment</td>
<td>62</td>
</tr>
<tr>
<td>Refractory Mood Disorders</td>
<td></td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacological Treatment of Chronic Pain</td>
<td>9</td>
</tr>
<tr>
<td>Comorbidity With Depression and Other</td>
<td></td>
</tr>
<tr>
<td>Psychotic Disorders</td>
<td></td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect of Self-Administered Cognitive-Behavioral Therapy and Sertraline in Panic Disorder</td>
<td>90</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrated Treatment: Psychopharmacology</td>
<td>50</td>
</tr>
<tr>
<td>and Psychotherapy</td>
<td></td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychological Management of Psychosis</td>
<td>18</td>
</tr>
<tr>
<td>Psychodynamics in Treatment-Refractory</td>
<td>86</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
</tr>
<tr>
<td>Bridges for Healing: Integrating Family</td>
<td>86</td>
</tr>
<tr>
<td>Therapy and Psychopharmacology</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 38: COUPLE AND FAMILY THERAPIES

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Counseling Committed Couples: Rethinking</td>
<td>66</td>
</tr>
<tr>
<td>Therapeutic Neutrality</td>
<td></td>
</tr>
<tr>
<td>The Beginning Stages of Couples' Therapy:</td>
<td>71</td>
</tr>
<tr>
<td>Video Case Studies</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 39: GROUP THERAPY

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group Therapy for People With Chronic</td>
<td>2</td>
</tr>
<tr>
<td>Mental Illness</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 40: INDIVIDUAL PSYCHOTHERAPIES

### COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotic-Induced Movement Disorders:</td>
<td>1</td>
</tr>
<tr>
<td>Assessment and Treatment</td>
<td></td>
</tr>
<tr>
<td>Interpersonal Psychotherapy</td>
<td>1</td>
</tr>
<tr>
<td>Interpersonal Psychotherapy</td>
<td>5</td>
</tr>
<tr>
<td>Davanloo's Intensive Short-Term Dynamic</td>
<td>7</td>
</tr>
<tr>
<td>Psychotherapy in Clinical Practice</td>
<td></td>
</tr>
<tr>
<td>Brief Psychodynamic Psychotherapy: The Core</td>
<td>7</td>
</tr>
<tr>
<td>Conflictual Relationship Theme Method</td>
<td></td>
</tr>
<tr>
<td>Psychiatry Update: In Spanish</td>
<td>15</td>
</tr>
<tr>
<td>Advanced Interviewing Techniques</td>
<td>15</td>
</tr>
<tr>
<td>The Advanced Practice of Psychotherapy</td>
<td>25</td>
</tr>
<tr>
<td>An Integrative Approach to Facilitate the</td>
<td>48</td>
</tr>
<tr>
<td>Working-Through Process</td>
<td></td>
</tr>
</tbody>
</table>

### FORUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurobiology of Parent-Child Relationships:</td>
<td>47</td>
</tr>
<tr>
<td>Applications to Psychotherapy</td>
<td></td>
</tr>
</tbody>
</table>

### SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boundary Crossings: Creative Therapy or</td>
<td>55</td>
</tr>
<tr>
<td>Slippery Slopes?</td>
<td></td>
</tr>
<tr>
<td>Workplace Issues in Psychotherapy</td>
<td>75</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meditation: Theory, Therapy, Research, and</td>
<td>18</td>
</tr>
<tr>
<td>Practice</td>
<td></td>
</tr>
<tr>
<td>Working Through in Psychotherapy</td>
<td>18</td>
</tr>
<tr>
<td>Brief Psychodynamic Psychotherapy of Panic:</td>
<td>40</td>
</tr>
<tr>
<td>A Learning-Strategy Approach</td>
<td></td>
</tr>
<tr>
<td>Dynamic Therapy With Self-Destructive</td>
<td>40</td>
</tr>
<tr>
<td>Borderline Patients</td>
<td></td>
</tr>
<tr>
<td>Individual Psychotherapy for Matal</td>
<td>66</td>
</tr>
<tr>
<td>Problems</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 41: PSYCHOPHARMACOLOGY

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Treatment of Schizophrenia</td>
<td>14</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUPS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Some Recent Advancements in Psychopharmacology</td>
<td>16</td>
</tr>
<tr>
<td>Practical Psychopharmacology for the Busy</td>
<td>38</td>
</tr>
<tr>
<td>Clinician (Meet the Authors)</td>
<td></td>
</tr>
</tbody>
</table>

### FORUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prozac on the Couch</td>
<td>47</td>
</tr>
</tbody>
</table>

### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizophrenia Treatment in the Community:</td>
<td>1</td>
</tr>
<tr>
<td>The Role of Long-Acting Antipsychotics</td>
<td></td>
</tr>
<tr>
<td>Diagnosis and Treatment: Mood Stabilizers</td>
<td>5</td>
</tr>
<tr>
<td>Across the Psychiatric Spectrum</td>
<td></td>
</tr>
<tr>
<td>Neuropsychiatry in the Age of Polypharmacy</td>
<td>61</td>
</tr>
<tr>
<td>Part 1</td>
<td></td>
</tr>
<tr>
<td>Neuropsychiatry in the Age of Polypharmacy</td>
<td>83</td>
</tr>
<tr>
<td>Part 2</td>
<td></td>
</tr>
</tbody>
</table>
LECTURE
19 Better Than Prozac: Creating New Psychiatric Drugs 67

SCIENTIFIC AND CLINICAL REPORTS
15 A Three-Week Comparison of Olanzapine Versus Risperidone in the Treatment of Bipolar Mania: Improvement in Manic and Depressive Symptoms and Treatment Adherence 22
16 Olanzapine/Fluoxetine Combination and Olanzapine in the Treatment of Bipolar Depression 22
38 Onset and Maintenance of Antidepressant Efficacy for Duloxetine 60 mg QD 44
39 Depressive Subtypes and Response to Augmentation or Dose Increase Among Outpatients Resistant to Fluoxetine 20 mg a Day 44
40 Treatment-Related Adverse Events in a 20 mg Open-Trial of Fluoxetine: Predictors of Emergence and Impact on the Course of Treatment 44
59 TAK-375 Is a Highly Selective Agonist at the ML-1 Receptor 68
60 Safety, Pharmacokinetics, and Pharmacodynamics of TAK-375 in Healthy Adults 68
61 Selectivity of the ML-1 Agonist TAK-375: Lack of Binding to NON-ML-1 Targets 68
68 Serum Lipid Fractions in Clozapine-Treated Patients Over a Two-Year Period 69
79 Treatment of Tension Headache With Mirtazapine 70
99 Rivastigmine and Glantamine Treatment for Schizophrenic Cognitive Impairment 88
111 Efficacy and Safety of Sildenafil Citrate in Men With Serotonergic-Antidepressant-Associated Erectile Dysfunction: Results of a Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial 89
112 Pretreatment Characteristics of Placebo Response in Major Depression 89

SYMPOSIA
88 Polypharmacy: Evidence Basis Versus Clinical Experience 93
101 New Intravenous Treatments: A New Tool to Overcome Difficulties and Resistance 96

WORKSHOPS - ISSUES
28 Evidence-Based Medicine: An Application in Child and Adolescent Psychopharmacology 23
42 Treatment of Schizophrenia: Antipsychotic Polypharmacy Versus Monotherapy 40
44 The Benzodiazepine Controversy 41

TOPIC 42: OTHER SOMATIC THERAPIES

COURSE
42 Using Neurofeedback in Your Practice: Latest Trends and Hands-On Experience 15

TOPIC 43: TREATMENT TECHNIQUES AND OUTCOME STUDIES

CLINICAL CASE CONFERENCE
2 Dyskinesias in a Somatically Preoccupied Patient After Treatment With Atypical Antipsychotics 37

CONTINUOUS CLINICAL CASE CONFERENCES
1 Treatment of the VIP Patient: Two Patients, Two Therapists: Part 1 15
2 Treatment of the VIP Patient: Two Patients, Two Therapists: Part 2 37

DISCUSSION GROUP
25 Relevance of Treatment Algorithms in Clinical Care 84

FORUM
2 The Placebo Effect: Science, Belief, and Clinical Practice 24

INDUSTRY-SUPPORTED SYMPOSIA
13 Remission in Psychiatric Disorders: Definitions, Issues, and Treatments 6
14 Barriers to Optimal Outcome in Anxiety and Depression 8
23 A Rational Algorithm for Selecting Atypicals in Schizophrenia and Bipolar Disorders 11
33 Evidence-Based Treatment of Psychiatric Disorders, Part 1 14
33 Evidence-Based Treatment of Psychiatric Disorders, Part 2 35

MASTER EDUCATOR CLINICAL CONSULTATION
5 Psychotherapeutic Diagnoses and Treatment Planning 39

SCIENTIFIC AND CLINICAL REPORTS
56 The Development of a Brief Adult Mental Health Screening Tool for Jails 68
69 The Influence of Group Psychoeducation on Quality of Life in Schizophrenia Patients and Their Relatives 69

SYMPOSIA
34 Strategies to Overcome Resistance 51
84 The Difficult-to-Treat Psychiatric Patient 92

WORKSHOP - COMPONENT
3 Patient Safety in Psychiatry: Minimizing the Use of Restraint and Seclusion 17

OTHER ISSUES

TOPIC 44: COMPUTERS

COURSES
24 Build Your Own Relational Database Electronic Medical Record 7
32 Computer-Assisted Diagnostic Interview 8

WORKSHOPS - ISSUES
43 Relevant Data for the Practicing Psychiatrist: Comorbidities/Combined Treatment 40
57 Technology Serves the Patient: Algorithms, Monitoring, and Decision Support 46
69 Electronic Medical Records Enhance Quality and Productivity: The Time Has Come 65
92 Beyond The Chalk Board: Using Computers to Enhance Psychiatric Education 85
116 Computer-Assisted Psychotherapy in Clinical Practice 91

TOPIC 45: CREATIVITY AND THE ARTS

COURSE
79 Writing About Clinical Experiences 48

FORUM
3 Music and the Mind: George Greenhwin 24

LECTURE
8 Honesmen of the Apocalypse: Terror, Nihilism, and Science 34

WORKSHOPS - ISSUES
22 A Psychiatrist’s View on Artists and the Arts 19
37 Artistic Use of the Creative Unconscious in the Therapeutic Alliance 40
59 ‘The Art of the Unconscious: Shakespeare, Poetry, Film, and Psychiatry 47
72 The Portrayal of Psychiatry in Recent American Film 66
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 46: GENDER ISSUES</strong> Page #</td>
</tr>
<tr>
<td>DISCUSSION GROUPS</td>
</tr>
<tr>
<td>6 Gender and Cultural Issues in Diagnosis and Treatment</td>
</tr>
<tr>
<td>20 Women in Leadership: Problems, Prospects, and Proposals</td>
</tr>
<tr>
<td>MASTER EDUCATOR CLINICAL CONSULTATION</td>
</tr>
<tr>
<td>8 Women in Leadership: Understanding Achievement Obstacles</td>
</tr>
<tr>
<td>WORKSHOPS - COMPONENTS</td>
</tr>
<tr>
<td>23 Women's Leadership 101</td>
</tr>
<tr>
<td>38 Intersex Conditions: Controversies and New Approaches to Treatment</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
</tr>
<tr>
<td>70 Individual Psychotherapy With Men Suffering From Father Loss</td>
</tr>
<tr>
<td><strong>TOPIC 47: HEALTH SERVICES RESEARCH</strong></td>
</tr>
<tr>
<td>SYMPOSIA</td>
</tr>
<tr>
<td>43 The Invisible Plague: Severe Mental Illness</td>
</tr>
<tr>
<td>85 Quality Measurement in a Canadian Inner-City Academic Environment</td>
</tr>
<tr>
<td>89 Truth and Expectations in Psychopharmacology Research</td>
</tr>
<tr>
<td><strong>TOPIC 48: HISTORICAL QUESTIONS</strong></td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>7 The Commitment of Psychiatrists: Lessons From Al-Andalus</td>
</tr>
<tr>
<td><strong>TOPIC 49: INFORMATION TECHNOLOGY</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>48 Evidence-Based Medicine: An Introduction for Psychiatrists</td>
</tr>
<tr>
<td>52 How to Use Your Palm OS PDA in Psychiatric Practice: Basic</td>
</tr>
<tr>
<td>80 How to Use Your Palm OS PDA in Psychiatric Practice: Advanced</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
</tr>
<tr>
<td>17 Implementing Web-Based Psychopharmacology Algorithms: Problems and Solutions</td>
</tr>
<tr>
<td>97 CD-ROMs for Dummies: A Step-by-Step Guide for Developing Educational CDs</td>
</tr>
<tr>
<td>98 Making the Media Work for You</td>
</tr>
<tr>
<td><strong>TOPIC 50: INTERNET</strong></td>
</tr>
<tr>
<td>COURSE</td>
</tr>
<tr>
<td>97 Psychiatry and the Internet</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>59 Internet: Technical, Clinical, and Societal</td>
</tr>
<tr>
<td><strong>TOPIC 51: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES</strong></td>
</tr>
<tr>
<td>SYMPOSIA</td>
</tr>
<tr>
<td>30 Recent Developments in Gay and Lesbian Mental Health: A Global Perspective</td>
</tr>
<tr>
<td>31 New Research in Gay, Lesbian, and Bisexual Mental Health Morbidity</td>
</tr>
<tr>
<td>82 Gay and Lesbian Parenting</td>
</tr>
<tr>
<td>WORKSHOP - COMPONENT</td>
</tr>
<tr>
<td>47 Daddy and Papa: A Psychosocial Profile of Gay Parenting</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
</tr>
<tr>
<td>2 Understanding Transgendered Youth: Treatment and Service Strategies</td>
</tr>
<tr>
<td><strong>TOPIC 52: MANAGED CARE AND HEALTH CARE FUNDING</strong></td>
</tr>
<tr>
<td>COURSE</td>
</tr>
<tr>
<td>59 Current Coding and Documentation Requirements</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
</tr>
<tr>
<td>91 Schizophrenia and Suicide in the Managed Care Era</td>
</tr>
<tr>
<td>WORKSHOP - COMPONENT</td>
</tr>
<tr>
<td>37 Implications of Financing of Health Care for Psychiatric Education and Practice</td>
</tr>
<tr>
<td><strong>TOPIC 53: POLITICAL QUESTIONS</strong></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>10 Psychiatry and the Pharmaceutical Industry: Where Is the Boundary?</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
</tr>
<tr>
<td>88 International Psychiatric/Psychopharmaceutical Organizations' Collaboration</td>
</tr>
<tr>
<td><strong>TOPIC 54: PROFESSIONAL AND PERSONAL ISSUES</strong></td>
</tr>
<tr>
<td>COURSE</td>
</tr>
<tr>
<td>72 Money Matters: Using Theory in Clinical Practice</td>
</tr>
<tr>
<td>DISCUSSION GROUPS</td>
</tr>
<tr>
<td>11 Protecting Clinical Autonomy</td>
</tr>
<tr>
<td>19 Evidence-Based Psychiatry: The Promise and Pitfall of Translating Science Into Practice</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>13 Psychiatric Organizational Leadership: Reflections, Predictions, and Proposals</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>7 Practicing Psychiatry in 2003</td>
</tr>
<tr>
<td>102 Interests and Vulnerabilities of Health Care Practitioners</td>
</tr>
<tr>
<td>WORKSHOPS - COMPONENTS</td>
</tr>
<tr>
<td>8 Medicare Update 2003</td>
</tr>
<tr>
<td>13 IMGs Challenges and Solutions</td>
</tr>
<tr>
<td>32 Retirement Issues for Psychiatrists and Their Spouses</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
</tr>
<tr>
<td>6 Risk-Management Issues in Psychiatric Practice</td>
</tr>
<tr>
<td>13 Depression and the Physician: When Being a &quot;Good&quot; Doctor Is Not Enough</td>
</tr>
<tr>
<td>33 Learning Psychotherapy in Private Practice</td>
</tr>
<tr>
<td>73 When Psychiatrists Have a Mental Illness: The Stories of Their Loved Ones</td>
</tr>
<tr>
<td>82 Helping the Healers: Providing Impairment Education to Physicians</td>
</tr>
<tr>
<td>83 Do I Need an MBA to Transform My Career?</td>
</tr>
<tr>
<td>87 Children of Psychiatrists: Insights and Recommendations From Those Who Know</td>
</tr>
<tr>
<td>94 Psychiatric Treatment and Personal Growth: What About Us?</td>
</tr>
<tr>
<td>118 Essential Skills 101: Writing Manuscripts for Publication</td>
</tr>
<tr>
<td><strong>TOPIC 55: RELIGION, SPIRITUALITY, AND PSYCHIATRY</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>25 Clinical Applications and Research in Transpersonal Psychiatry</td>
</tr>
<tr>
<td>47 Transpersonal Psychiatry: Clinical Applications</td>
</tr>
<tr>
<td>85 Meditation for Psychotherapists and the Paradigm of Health</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>15 Spirituality and World View in Clinical Practice</td>
</tr>
<tr>
<td>90 Model Psychiatry Residency Programs on Religion and Spirituality</td>
</tr>
</tbody>
</table>
TOPIC INDEX

WORKSHOP - COMPONENT Page #
18 Encountering the Spiritual in Psychiatric (Psychotherapy) Practice 46

WORKSHOPS - ISSUES
5 Santeria as a Religion in Mental Health Patients 18
54 Spiritual and Religious Assessment in Clinical Practice 46
61 The Role of the Soul: The Impact of Spiritual Belief Systems of Healing 47
111 The Power of Healing: Spirituality Group Work With Psychiatry Staff 91

TOPIC 56: RESIDENT AND MEDICAL STUDENT CONCERNS

COURSE
99 Treating Medical Students and Physicians 73

DISCUSSION GROUPS
9 Borderline Personality Disorder (For Residents Only) 20
17 Maintaining and Developing Family Relationships During Residency (For Residents Only) 42
18 The Core Competencies: What It Means for Residents and Faculty (Meet the Authors) 63

RESIDENT’S SESSION
Meet the Experts: Sunny-Side Up 14

SCIENTIFIC AND CLINICAL REPORT
22 What Increases the Frequency at Which Medical Students Ask Addiction Questions? 22

WORKSHOPS - COMPONENTS
5 Practice Settings for Early Career Psychiatrists: A Primer 23
15 Career Choices in Psychiatry Exploring Fellowship Training 40
24 Great Expectations: Integrating Mind and Brain in Resident Training 64
27 Teaching Competence in Psychotherapy to Residents: Are Faculty Competent? 65
44 Transition Into the Postresidency Period 90
45 Combined Residency Training: Now What Are You Doing? 90

WORKSHOPS - ISSUES
4 Multiculturality Squared: Training Multicultural Residents to Treat Multicultural Patients 18
80 Family Therapy Training for Psychiatry Residents 66

TOPIC 57: PRESIDENTIAL THEME: "THE PROMISE OF SCIENCE - THE POWER OF HEALING"

COURSE
61 Self-Regulation: The Brain and the Power of Healing Relationships 36

INDUSTRY-SUPPORTED SYMPOSIUM
46 Compassionate and Safe Emergent Care: Best Practices in Anti-psychotic Use 80

SCIENTIFIC AND CLINICAL REPORT
109 San Francisco Third Graders After 9/11: Three Windows to Healing 89

SYMPOSIUM
20 Integrating Interpersonal Neurobiology in Psychiatric Training and Practice 31
27 Applying Decision Science and Game Theory to Clinical Psychiatry 33
79 The Essence of Learning Psychiatry: Clinical Supervision 79

WORKSHOP - ISSUE
99 The Empathic Healer: Artist or Scientist? 86

TOPIC 58: STIGMA/ADVOCACY Page #

SCIENTIFIC AND CLINICAL REPORT SESSION
70 HIV-Related Stigma: Disclosure, Depression, and Social Support 69

SYMPOSIUM
26 Psychiatry and the Power of Advocacy 32
57 Psychiatrists With Psychiatric Disorders: The Fear of Stigma 57

WORKSHOPS - COMPONENTS
9 Using Radio to Combat Stigma and Improve the Image of Psychiatry 23
30 United We Stand: Developing Partnerships for Patient Advocacy 70

TOPIC 59: TELEPSYCHIATRY

COURSE
65 Expanding Health Care Delivery? Let Telepsychiatry Help! 36

SCIENTIFIC AND CLINICAL REPORT
21 Retrospective Evaluation of Telemental Health Care Services for Remote Military Populations 22

WORKSHOPS - ISSUES
9 Expanding Telepsychiatry Beyond Patient Care: Opportunities and Challenges 18
18 Telepsychiatry With Developmentally Disabled: Teaching, Training, and Treating 19
40 The Development, Implementation, and Operation of Diverse Telepsychiatry Programs 40
103 Making Telepsychiatry Work for You 86

TOPIC 60: VIRTUAL REALITY

SYMPOSIUM
66 E-Therapy, Telepsychiatry, and Virtual Environments: The Evolution of Cyberpsychiatry 76

TOPIC 61: WOMEN’S HEALTH ISSUES

COURSES
30 Treatment Issues for Women in Minority Groups 8
75 Psychiatric Disorders in Pregnancy and Postpartum 48

DISCUSSION GROUPS
2 Depression in Perimenopausal Women 16
23 Women’s Mental Health 67

INDUSTRY-SUPPORTED SYMPOSIUM
10 Moods, Cycles, and Motherhood 6
30 Bipolar Disorder in Women: Special Considerations and Evolving Treatment, Part 1 13
30 Bipolar Disorder in Women: Special Considerations and Evolving Treatment, Part 2 35
41 Women and Psychiatric Disorders: Does Gender Matter for Treatment? 59

LECTURE
20 International Determinants of Women’s Mental Health 73

MEDICAL UPDATE
2 Menopause: What Psychiatrists Need to Know 43

RESEARCH CONSULTATION
2 Depression During Pregnancy and the Postpartum Period 68
# TOPIC INDEX

## SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>Predictors of First Depressive Episode in Black and White Women in Mid Life</td>
</tr>
<tr>
<td>101</td>
<td>Sertraline Prevents Postpartum Depression</td>
</tr>
<tr>
<td>103</td>
<td>HRT With Androgens as a Strategy to Treat Postmenopausal Depression</td>
</tr>
<tr>
<td>110</td>
<td>Maintaining Compliance and Remission in MDD With Sildenafil Prescription for SSRI-SD</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Abortion: Scientific Data to Inform Clinical Care</td>
</tr>
<tr>
<td>51</td>
<td>Women Psychiatrists Using Science to Heal</td>
</tr>
</tbody>
</table>

## SYMPOSIA

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Abortion: Scientific Data to Inform Clinical Care</td>
</tr>
<tr>
<td>55</td>
<td>Women Psychiatrists Using Science to Heal</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

APA 156TH ANNUAL MEETING

A
Abegg, Susan E. .............................. 21
Abi, Jorgey, Ahmad A .......................... 27
Aboujia, Eliaa .................................. 27
Abrams, Michael T ............................. 18
Abramson, Ronald D ......................... 28
Addington, Jean M ............................ 52
Adinoff, Bryon H .............................. 52
Adityanjan, K ................................. 27
Adler, Caleb M .................................. 78
Agami, Fimri ................................. 96
Agans, W. Stewart ........................... 30
Ahern, Jennifer ............................... 79
Ahmed, Aqbal ................................ 39, 47, 71
Aziz, Khaleel .................................. 69
Akeke, Camilo B ............................... 70
Alkhatib, Hassan K ............................ 90
Alkhalaf, Hagey S ............................. 56, 77, 96
Aladjem, Asster D ............................ 41
Alarcon, Renato D ......................... 32, 51, 76
Alberto, Monchbach .......................... 32
Alberts, Vicki A ............................... 88
Albright, Annette .............................. 90
Allesi, Norman E ......................... 23, 40, 55, 76
Alexander, Mary Jane ...................... 75
Alger, Ian E .................................. 18, 40, 71
Allen, Michael H .............................. 9, 80
Allen, Timothy S ............................. 86
Allison, David B .............................. 61
Allison, Nancy ................................. 44
Almeida, Jr., Carlos E ........................ 78
Alonso, Donie ................................. 71
Alpert, Jonathan E ............................ 44, 45, 70, 90
Altamura, Carlo A ........................... 96
Altshuler, Steven I ......................... 8, 17
Altshuler, Lorin L ......................... 20, 35, 81
Alves-Bradford, Jean-Marie ............... 40
Aman, Michael G ............................. 32
Ambrosini, Paul J ............................ 68
Ansel, Laurence V ........................... 33
Amsterdam, David A ........................ 51
Andersen, Arnold E .......................... 30, 67
Anderson, Peter D .......................... 19
Anderson, Tanya R ........................... 69
Andrade, Naiteen N .......................... 72
Andreaten, Nancy C .......................... 56
Andrews, Linda B ............................ 28
Anfang, Susan A .............................. 65
Angelino, Andrew F ........................... 66
Anserts, Rubaia .............................. 43
Anthony, William ........................... 53
Appelbaum, Paul S ................................ 7, 10, 14, 16, 20, 33, 38, 49, 72
Arab, Michael R .............................. 65
Arciniegas, David B ......................... 6
Armstrong, Scott C ........................... 37
Arnold, Paul D ............................... 29
Arnoult, Bruce A ............................. 45, 55
Arns, Paul G ................................. 91
Atkins, Romoal A ............................. 21
Avon, Stephen C .............................. 22
Arroyo, William .............................. 46
Aman, Bonna ................................. 30
Ashford, J. V. ............................... 40
Ashley, Kenneth B .......................... 46
Arias, Gregory M ............................ 31, 61, 83
Ardalan, Sofia ................................. 52
Atre-Vadha, Nutan ............................ 76
Avlart, Ron .................................. 90
Auchincloss, Elizabeth ...................... 57
Auger, David M .............................. 62
Austin, Linda S .............................. 23
Austin, Ornson ............................... 45
Austrom, Mary ............................... 71
Avram, Ron B .................................. 21
Aziz, Najeeb ................................. 88
B
Babula, Vicki ................................ 45
Baca-Garcia, Enrique ....................... 86
Bach, Perry B .................................. 71
Backer, Glen .................................. 71
Baez, Sayonara ................................ 71
Bahadur, Neha ................................. 89
Baldassano, Claudia F ........................ 11
Baldessari, Ross J ............................ 12
Balducci, Nicola .............................. 56
Balts, Theodora G ............................ 85
Balmes, Gladys ............................... 88
Balsera, Sandra ............................... 22
Balgu, Josefine M ............................. 40
Bamberger, Joshua ........................... 86
Bangert, David ............................... 22
Banu, Sophia ................................. 41
Barak, Yoram ................................. 69
Bareghi, Salvo R ............................. 96
Bark, Nigel M ................................. 53, 77
Barley, Russell A ............................. 56, 61
Barnes, Christian ............................ 96
Barnes, Thomas .............................. 79
Barnett, David ............................... 32
Barsh, John W ................................. 51
Barnes, Mary Ann ............................ 71
Barron, David A .............................. 38, 48
Barrodes, Samuel H .......................... 67
Barr, John ..................................... 5
Barlow, Andrea Grubbs ..................... 38
Barlett, Anne ................................ 50
Barsoum, Monica A ........................... 37
Basys, Andrias ............................... 21
Bastani, Jelodie B ............................ 88
Batki, Steven L ............................... 31, 39
Battaglia, Joseph ............................ 94
Battista, John R .............................. 27
Bauer, Antonia L ............................. 27
Baxter, Elizabeth A ........................... 32
Baxter, Jane ................................. 66
Beauch, John O ............................... 29, 96
Beauchorn, Gabrielle F ........................ 15
Becher, Antonia .............................. 33
Beck, Aaron T .................................. 30
Beck, Judith S ............................... 17, 24
Becker, Anne E .............................. 70
Becker, Carl ................................ 69
Becker, Daniel F ............................. 43
Becker, Hulie E .............................. 89
Becker, Judith V .............................. 62
Beeler, Alan R ................................ 7
Beeler, Lee R ................................ 28
Beinman, Bernard D ........................... 47
Belger, Ayenonc ................................ 77
Bell, Carl C ................................. 19, 20, 40, 67, 85, 90
Bender, Donna S ............................. 21, 26
Benedek, David M ............................ 37
Benedek, Elisa P ............................. 10, 18
Bennett, Michael J ........................... 86
Benor, Marilyn B ............................. 31
Benton, David ................................. 27
Berne, Eugene V .............................. 31
Berganza, Carlos E ............................ 74
Bergen, Andrew .............................. 30
Berlant, Jeffrey L ............................. 31
Berman, Ellen M ............................. 66
Berman, Jeffrey A ............................. 31, 52
Bermorson, Paul C ............................ 56
Bermingham, Mathieu ........................ 40
Bens, Gregory S ............................. 31
Berner, Carol A ............................... 7, 14, 28
Berner, David P .............................. 92
Berny, Peter .................................. 58
Berrinetti, Wade H .......................... 6, 30
Berry, Sandra H .............................. 79
Bersani, Giuseppe ............................. 44
Beverley, Raphael ........................... 65
Beyer, John L .................................. 81
Bhat, Shyam K ............................... 83
Biederman, Joseph .......................... 44, 45, 56, 61, 68, 78, 80, 83
Bierman, Rebecca S ........................... 40
Binder, Renee L .............................. 53, 36, 65, 80
Bodnari, Francesca ........................... 92
Biedong, Lor L ................................ 59
Bimer, Cecile ................................. 77
Bisag, Adam M ............................... 57
Blacks, Donald W ............................ 27, 76
Black, Jed E ................................. 14
Black, John L ................................. 61
Blanco-Jerez, Carlos .......................... 75
Blain, Ima J ................................. 23
Blaew, Christine ............................. 45
Bliesberg, Erfran ............................. 15, 37
Bliesberg, Pierre ............................. 58
Blinder, Barton J ............................. 36
Blow, Frederic C ............................. 74
Blume, Sheila B ............................... 52, 86
Blumenfeld, Michael .......................... 23, 36
Blumen, Dietrich P ........................... 5
Bobey, Mina S ............................... 47
Boehnlein, James K .......................... 97
Bogden, Ann M ............................... 70
Bogonove, Oliver J ........................... 21
Boluus, Martin ............................... 78
Bonds, Orgy L ............................... 37
Bonnie, Ormer ............................... 39
Bonnin, Richard ............................. 65
Book, Howard E .............................. 7, 55
Book, Jonathan D ............................ 23
Boothe, Semaire .............................. 7
Boorenstein, Daniel B .......................... 75, 84
Borowich, Abba E ........................... 30, 66
113
Caligor, Eve ........................................... 37
Callahan, Jr., William E ... 41, 47, 56, 57
Camacho, Alvaro .................. 52
Campas, Rafael .................. 75
Campo, Ana E ..................... 26, 71
Cannon, Robert ................. 48
Canfield, Merle ................. 32
Canino, Gloria .................. 28
Canive, Jose M .................. 76
Capuron, Lucile ................. 31
Cardona, Dora ................. 76
Cary, Karen T .................. 32
Carfagno, Jessica .............. 32
Carpenter, Linda L ............. 82
Carpenter, Jr., William T ..... 1, 49
Carter, Diana .................. 30
Carter, James H ................. 87
Casey, Daniel E .................. 50
Casey, David A ................. 22, 44
Cassano, Giovanni B ........... 56
Cassano, Paola ................. 59
Cassam, Edwin H ............... 78
Cassidy, Roberta ............... 50
Castellanos, Daniel ............ 71
Castilla-Puente, Ruby .......... 89, 92, 93
Castilla-Puente, Sandra ...... 93
Catania, Joseph A .............. 50
Caton, Carol L.M ............... 78
Cerra, Kenneth M ............... 24
Chacko, Chowdhar D .......... 38
Chainer, Mary F ............... 71
Chamberlain, John R ........... 23, 40
Chan, Carlyle K ............... 24, 48
Chan, Sue S .................. 91
Chandler, Mark C ............... 68
Chann, Andrew ................. 52
Chang, Jaquelyn B ............. 84, 90
Chang, Ki K .................. 6, 44, 50
Chang, Linda .................. 36
Chang, Soo Kyung .............. 94
Chapman, Daniel P ............ 18
Charat, Valerie .................. 30
Charney, Dennis S .............. 23, 49, 77
Chaskel, Roberto E ............ 32
Chaudhry, Zubaida A ........... 88
Chavez, Mary .................. 91
Chelmifska, Ivona .............. 43
Chen, Guang .................. 11
Chen, Nancy .................. 79
Chen, Shirley .................. 29
Chen, Terry .................. 91
Chen, R. Nandi ................. 83
Cheong, Joseph A .............. 39, 71
Chervenak, Frank A ........... 88
Chester, Adam R ............... 23
Chester, Jane G ................. 28
Chiappe, Viviana J ............. 93
Chien, Ching-Piao .............. 86
Chin, Allan B .................. 7
Chino, Dennis H ............... 57
Choi, Charles .................. 8
Choi, Judy .................. 53
Choi, Samson J .................. 94
Choi, James C.Y ............... 51, 58
Choy, Yukjun ................. 22
Christensen, Allan K .......... 44
Christian, Tawnya L ........... 94
Chu, James A .................. 78
Chung, Christopher K ........ 41, 94
Chung, Henry .................. 91
Chung, Hellen W ............... 27
Citrome, Leslie L .............. 3, 75
Claborn, James ............... 75
Clark, David L .................. 5, 62
Clark, Marlene ................. 18
Clark, Michael R .............. 48
Clark, Michael O ............... 40, 87
Clarkin, John F ............... 26, 37
Cleary, Catherine .............. 29, 95
Clausen, Bente ................. 15
Clayton, Anita L.H ............ 9, 42
Cogg, Kathleen A .............. 76
Clements, Norman A ........... 75
Clemente-Craven, Nicoletta ... 45, 70
Cloitre, Marylene .............. 95
Cobb, Kenneth C ............... 90
Cobb, Thomas G ............... 62, 84
Cochez, Susan D ............... 50
Cocorea, Alexandra M ........ 79
Coffey, C. Edward ............. 15
Coffman, Jennifer K ........... 65
Cohn, Geoffrey ................. 27
Cohen, Ivan M .................. 71
Cohen, Judah A ............... 31, 89
Cohen, Lee S ............... 12, 13, 35, 39
Cohen, Mary Ann .............. 46
Cole, Steven A ................. 78
Collin, Rebecca L .............. 79
Conley, Robert R ............. 80
Connor, Mary K ............... 65
Constantinou, Doreen ........ 69
Contreras, Virginia .......... 18
Conti, Stephen ............... 52
Cook, Ian A .................. 89
Cook, William L ............... 52
Cooke, Edith .................. 18
Cookson, John .................. 6
Coon, Kim A .................. 40
Cooper, Richard A ............. 76
Copolov, David L .............. 88
Corell, Maria ................. 48
Corbin, Stephen B ............. 85
Cordahi, Caroline E ........... 77
Cordova, Matthew J ........... 29
Cortisi, Heather ............... 50
Correia, Nestor ............... 70
Cortese, Leonardo ............. 1
Costa, Paul .................. 71
Cournima, Francine ........... 57, 77, 85
Coverdale, John H ............ 18, 88
Covington, Jr., Edward C ...... 9
Coward, David N ............... 46
Cox, Dan J .................. 87
Cox, Todd S .................. 41
Cusack, Michael ............... 31
Cotz, David .................. 57
Cromby, Graeme ............... 62
Croft, Harry A ................. 27
Cron, Catherine C ............ 21, 49
Crosby, Ross D ................. 95
Crow, Scott J .................. 30
Crowder, Martin J ............ 27
Crowley, Brian ............... 28
Culpepper, Larry ............. 8, 11
Cummins, Jeffrey L ........... 6, 10, 15, 51
Currier, Glenn W ............... 80

D

Dackis, Charles A ............... 21
Dagerman, Karen S ........... 69
Dain, Norman ................. 53
D'Alli, Richard E .............. 45

C

Calabrea, Joseph R .............. 2, 22, 58, 77
Calabrese, Loretta ............ 8
Caley, Charles F ............... 69
Caliguri, Michael ............. 114

B

Boursot, Nazhasa . N. ........ 5, 62, 78
Bowen, Charles L .................. 2, 58, 74
Bowen, Jr., Theran C ........... 18
Boyle, Henry .................. 54
Bracken, Patrick J .............. 77
Bradwein, Jacques ............. 90
Brady, Kathleen T .............. 42, 96
Brandt, Lena ................. 70
Brannan, Stephen K ........... 44
Bray, Joel T .................. 47
Brawman-Minter, Olga ........ 58
Breitbart, William .......... 10, 78, 94
Brendel, David H .............. 16
Brendel, Rebecca ............... 64, 71
Brenner, Ronald ............... 71
Bridges, Nancy A ............... 94
Brizendine, Louise ............ 43
Bro, Thomas M .................. 15
Brodkin, Amy C ............... 28
Bredekamp, Elia ............... 71
Bromberg, Joyce T .............. 70, 89
Bromet, Evelyn J ............... 78
Brooks, Beth Ann ............. 85
Broquet, Karen E ............... 66
Brown, Alan S ............... 45
Brown, Charlotte ............... 70
Brown, Eileen ............... 22
Brown, Jocelyn ................. 53
Brown, Larry K ................. 55
Brown, Richard P ............... 68
Brown, Thomas E ............... 1, 5, 14
Brown, Walter A ............... 93
Brown, Wayne F ............... 71
Bryant, Sharon ................. 88
Bryan, Lawrence ............... 66
Buchholz, David ............... 39
Buchbaum, Monte S ............. 27
Buhk, Cynthia M ............... 30
Bullock, Kim D ................. 27, 70
Burdick, Katherine E ........... 78
Burgard, Melissa A ............ 30
Burger, Hub ............... 70
Burke, David .................. 79
Burlingame, Gary .............. 30
Burnett, Peter ............... 79
Burns, Kathryn A ............... 85
Bursztain, Harold J .......... 24, 47
Burwell, Rebecca A ............. 70
Buscema, Charles A ............ 32
Buschke, Katherine ............. 66
Butler, B. John ............... 53
Bush, John .................. 70
Buti, Kimberly A ............... 41
Bussel, Manna ............... 19, 83
Buttinger, Regina .............. 64
Butler, Lisa D ............... 29, 79, 80
Butterfield, Cory ............... 72
Butterfield, Marian I .......... 55
Byrd, Jr., Walter R ............ 47

C

Calabrese, Joseph R .............. 2, 22, 58, 77
Calabrese, Loretta ............ 8
Caley, Charles F ............... 69
Caliguri, Michael ............. 114
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eates, Karen M</td>
<td>46, 69</td>
</tr>
<tr>
<td>Ebert, Leon</td>
<td>79</td>
</tr>
<tr>
<td>Ebert, Michael H</td>
<td>72</td>
</tr>
<tr>
<td>Edelein, Nestor</td>
<td>93</td>
</tr>
<tr>
<td>Edwards, Jane</td>
<td>52</td>
</tr>
<tr>
<td>Eisen, Jane L</td>
<td>75</td>
</tr>
<tr>
<td>Eit, Harold T</td>
<td>24, 26, 65, 91</td>
</tr>
<tr>
<td>Elchom, Anders</td>
<td>70</td>
</tr>
<tr>
<td>Elliot, Mare N</td>
<td>79</td>
</tr>
<tr>
<td>Elliott, Michael A</td>
<td>70</td>
</tr>
<tr>
<td>Elliott, Richard L</td>
<td>5</td>
</tr>
<tr>
<td>Ellis, Peter M</td>
<td>79</td>
</tr>
<tr>
<td>Elston, James M</td>
<td>93</td>
</tr>
<tr>
<td>Enmenich, Sylvia P</td>
<td>57</td>
</tr>
<tr>
<td>Encarnacion, Sofia M</td>
<td>83</td>
</tr>
<tr>
<td>Engel, Charles C</td>
<td>46</td>
</tr>
<tr>
<td>Engel, Ralph</td>
<td>79</td>
</tr>
<tr>
<td>Eppersson, C. Neill</td>
<td>6</td>
</tr>
<tr>
<td>Epstein, Lynn C</td>
<td>47</td>
</tr>
<tr>
<td>Erean, Eyup S</td>
<td>43</td>
</tr>
<tr>
<td>Erickson, Mark T</td>
<td>29, 63</td>
</tr>
<tr>
<td>Eman, Milton K</td>
<td>90</td>
</tr>
<tr>
<td>Ertas, Mustafa</td>
<td>70</td>
</tr>
<tr>
<td>Eskobor, Javer S</td>
<td>15, 51</td>
</tr>
<tr>
<td>Eth, Spencer</td>
<td>46, 90</td>
</tr>
<tr>
<td>Etter, Kevin M</td>
<td>71</td>
</tr>
<tr>
<td>Evaldson, John R</td>
<td>29, 63</td>
</tr>
<tr>
<td>Evans, Angela R</td>
<td>22</td>
</tr>
<tr>
<td>Evans, Aom J</td>
<td>19</td>
</tr>
<tr>
<td>Evans, Dwight L</td>
<td>3</td>
</tr>
<tr>
<td>Evans, Shelley A</td>
<td>45</td>
</tr>
<tr>
<td>Evans, Steven M</td>
<td>52</td>
</tr>
<tr>
<td>Everett, Anita</td>
<td>71</td>
</tr>
<tr>
<td>Everly, Jr., George</td>
<td>53</td>
</tr>
<tr>
<td>Eves, Anita</td>
<td>53</td>
</tr>
<tr>
<td>F</td>
<td></td>
</tr>
<tr>
<td>Faber, Raymond A</td>
<td>72</td>
</tr>
<tr>
<td>Faber, Ronald J</td>
<td>27</td>
</tr>
<tr>
<td>Factor, Robert M</td>
<td>29</td>
</tr>
<tr>
<td>Fagoliani, Andrea</td>
<td>6</td>
</tr>
<tr>
<td>Fahner, Rodolpho D</td>
<td>32</td>
</tr>
<tr>
<td>Fairbank, John A</td>
<td>79</td>
</tr>
<tr>
<td>Faison, Waranch E</td>
<td>71</td>
</tr>
<tr>
<td>Fallon, Brian A</td>
<td>75</td>
</tr>
<tr>
<td>Farabough, Amy H</td>
<td>22, 43, 90</td>
</tr>
<tr>
<td>Faranehe, Stephen V</td>
<td>61, 78, 80, 81, 87</td>
</tr>
<tr>
<td>Faraba, Sam</td>
<td>29</td>
</tr>
<tr>
<td>Farmer, Mildred</td>
<td></td>
</tr>
<tr>
<td>Fasanello, Jo Ellen</td>
<td>23</td>
</tr>
<tr>
<td>Faulkner, Larry R</td>
<td>72, 76</td>
</tr>
<tr>
<td>Fava, Maurizio</td>
<td>9, 22, 43, 44, 45, 70, 89, 90</td>
</tr>
<tr>
<td>Fawcett, Jan A</td>
<td>12, 35</td>
</tr>
<tr>
<td>Fawzy, Waed A.R.</td>
<td>53, 77</td>
</tr>
<tr>
<td>Fayyad, John A</td>
<td>77</td>
</tr>
<tr>
<td>Feinrin, Carl B</td>
<td>5</td>
</tr>
<tr>
<td>Feurin, Suzanne</td>
<td>75</td>
</tr>
<tr>
<td>Feldman, Jacqueline M</td>
<td>1</td>
</tr>
<tr>
<td>Ferguson, Yvonne B</td>
<td>7</td>
</tr>
<tr>
<td>Fernandez, Maria I</td>
<td>40</td>
</tr>
<tr>
<td>Fernandez, Stephen J</td>
<td>53, 95</td>
</tr>
<tr>
<td>Fichter, Christopher G</td>
<td>95</td>
</tr>
<tr>
<td>Fields, Howard</td>
<td>24</td>
</tr>
<tr>
<td>Fieve, Ronald R</td>
<td>22</td>
</tr>
<tr>
<td>Findling, Robert L</td>
<td>3, 12, 32, 89</td>
</tr>
<tr>
<td>Finn, Paul J</td>
<td>19, 32, 57</td>
</tr>
<tr>
<td>Fireman, Bruce</td>
<td>45</td>
</tr>
<tr>
<td>Fireman, Christian</td>
<td>66</td>
</tr>
<tr>
<td>First, Michael B</td>
<td>14, 64, 78, 94</td>
</tr>
<tr>
<td>Fischbein, Ellen R</td>
<td>18</td>
</tr>
<tr>
<td>Fiskel, Steven</td>
<td>46</td>
</tr>
<tr>
<td>Fishbain, David</td>
<td>9</td>
</tr>
<tr>
<td>Fisher, Caroline E</td>
<td>40, 64, 68, 89</td>
</tr>
<tr>
<td>Fisher, Masaru J</td>
<td>90</td>
</tr>
<tr>
<td>Fisher, Robert S</td>
<td>5</td>
</tr>
<tr>
<td>Fitzgerald, Barbara A</td>
<td>69</td>
</tr>
<tr>
<td>Fitzgibbon, Cheslea A</td>
<td>92</td>
</tr>
<tr>
<td>Fitzmaurice, Garrett</td>
<td>28</td>
</tr>
<tr>
<td>Flaherty, Lois T</td>
<td>87</td>
</tr>
<tr>
<td>Flischacker, Wolfgang</td>
<td>81</td>
</tr>
<tr>
<td>Fleming, Candace M</td>
<td>15</td>
</tr>
<tr>
<td>Flory, Curtis</td>
<td>23</td>
</tr>
<tr>
<td>Fox, Eda B</td>
<td>92</td>
</tr>
<tr>
<td>Fochtmann, Lauren J</td>
<td>90</td>
</tr>
<tr>
<td>Forster, Kellie M</td>
<td>88</td>
</tr>
<tr>
<td>Folstein, Marshal F</td>
<td>67</td>
</tr>
<tr>
<td>Fonagy, Peter</td>
<td>78</td>
</tr>
<tr>
<td>Foote, William W</td>
<td>7, 15</td>
</tr>
<tr>
<td>Ford, Julian</td>
<td>95</td>
</tr>
<tr>
<td>For-Arend, Lisa</td>
<td>22</td>
</tr>
<tr>
<td>Foro, Julian</td>
<td>68</td>
</tr>
<tr>
<td>Forstein, Marshall H</td>
<td>77, 95</td>
</tr>
<tr>
<td>Fosbuxous, Natacha</td>
<td>98</td>
</tr>
<tr>
<td>Fourns, George A</td>
<td>46</td>
</tr>
<tr>
<td>Fradkin, Howard</td>
<td>72</td>
</tr>
<tr>
<td>Frances, Richard J</td>
<td>86</td>
</tr>
<tr>
<td>Fred, E.</td>
<td>64</td>
</tr>
<tr>
<td>Frank, Ellen</td>
<td>6, 11</td>
</tr>
<tr>
<td>Frank, Guido K.W.</td>
<td>95</td>
</tr>
<tr>
<td>Frankenburg, Frances R</td>
<td>21, 27</td>
</tr>
<tr>
<td>Franko, Debra L</td>
<td>30</td>
</tr>
<tr>
<td>Fredin, Serena E</td>
<td>74</td>
</tr>
<tr>
<td>Frazer, Alan</td>
<td>74</td>
</tr>
<tr>
<td>Freedman, Alfred M</td>
<td>41</td>
</tr>
<tr>
<td>Freedman, Joshua E</td>
<td>7, 46</td>
</tr>
<tr>
<td>Freedman, Robert</td>
<td>3</td>
</tr>
<tr>
<td>Freeman, Michael D</td>
<td>85</td>
</tr>
<tr>
<td>Friedman, Matthew J</td>
<td>17</td>
</tr>
<tr>
<td>Friend, Jeffrey M</td>
<td>89</td>
</tr>
<tr>
<td>Frisman, Linda</td>
<td>95</td>
</tr>
<tr>
<td>Frotnon, John A</td>
<td>23</td>
</tr>
<tr>
<td>Fry, Jr, William F</td>
<td>69</td>
</tr>
<tr>
<td>Frye, Mark A.</td>
<td>2, 11, 35, 81</td>
</tr>
<tr>
<td>Fullbright, Robert K</td>
<td>27</td>
</tr>
<tr>
<td>Fullford, Kenneth</td>
<td>26, 54</td>
</tr>
<tr>
<td>FULLNORE, MINDY J</td>
<td>78</td>
</tr>
<tr>
<td>Fopol, George</td>
<td>22, 90</td>
</tr>
<tr>
<td>Fung, Desmond S</td>
<td>66</td>
</tr>
<tr>
<td>Furnan, John C</td>
<td>40</td>
</tr>
<tr>
<td>Furtado, James A</td>
<td>82</td>
</tr>
<tr>
<td>D'Alessio, Frances A</td>
<td>45</td>
</tr>
<tr>
<td>Dezf, Rodolphe</td>
<td>89</td>
</tr>
<tr>
<td>Diaz, Naouel</td>
<td>51</td>
</tr>
<tr>
<td>Dickstein, Leah J</td>
<td>20, 55, 66, 72, 73, 85</td>
</tr>
<tr>
<td>DiClemente, Ralph</td>
<td>55</td>
</tr>
<tr>
<td>di Cori, Ferruccio A</td>
<td>40</td>
</tr>
<tr>
<td>Diefenbark, Eric W</td>
<td>92</td>
</tr>
<tr>
<td>Di Giacomo, Joseph</td>
<td>51</td>
</tr>
<tr>
<td>di Giannantonio, Massimo</td>
<td>70</td>
</tr>
<tr>
<td>DiGiovanni, Clete</td>
<td>53</td>
</tr>
<tr>
<td>Dillon, Gregory C</td>
<td>51</td>
</tr>
<tr>
<td>DiMacedo, Joseph A</td>
<td>80</td>
</tr>
<tr>
<td>Dimsdale, Joel E</td>
<td>52</td>
</tr>
<tr>
<td>Dinwiddie, Stephen H</td>
<td>7, 76</td>
</tr>
<tr>
<td>Doghramji, Karl</td>
<td>48</td>
</tr>
<tr>
<td>Domenick, Jason A</td>
<td>92</td>
</tr>
<tr>
<td>Donacon, Nelson H</td>
<td>27</td>
</tr>
<tr>
<td>Dong, Jayming</td>
<td>51</td>
</tr>
<tr>
<td>Donker, Ge A</td>
<td>69, 89</td>
</tr>
<tr>
<td>Donnelly, Sinead</td>
<td>94</td>
</tr>
<tr>
<td>Doody, Rachelle S</td>
<td>41, 81</td>
</tr>
<tr>
<td>Dooley, Trath</td>
<td>31</td>
</tr>
<tr>
<td>Doraiswamy, P. Murali</td>
<td>58, 83</td>
</tr>
<tr>
<td>Dording, Christina M</td>
<td>90</td>
</tr>
<tr>
<td>Dorer, David J</td>
<td>30</td>
</tr>
<tr>
<td>Dow, Michael G</td>
<td>90</td>
</tr>
<tr>
<td>Dowling, Donna</td>
<td>52</td>
</tr>
<tr>
<td>Downs, Susan R</td>
<td>8</td>
</tr>
<tr>
<td>Doyle, Shannon</td>
<td>44</td>
</tr>
<tr>
<td>Dragomirecka, Eva</td>
<td>69</td>
</tr>
<tr>
<td>Drake, Robert E</td>
<td>78</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>---------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Ginsberg, David L</td>
<td>9</td>
</tr>
<tr>
<td>Gilrivas, Virginia</td>
<td>79</td>
</tr>
<tr>
<td>Gilman, Stephen E</td>
<td>70</td>
</tr>
<tr>
<td>Gillespie, Ian A</td>
<td>1</td>
</tr>
<tr>
<td>Gill, Mona H</td>
<td>71</td>
</tr>
<tr>
<td>Gilbert, Kenneth G</td>
<td>85</td>
</tr>
<tr>
<td>Gijsbers van Wijk, C. M. T.</td>
<td>19</td>
</tr>
<tr>
<td>Gibson, Christopher</td>
<td>78, 94</td>
</tr>
<tr>
<td>Goeke, John W</td>
<td>74</td>
</tr>
<tr>
<td>Goeke, John H</td>
<td>81</td>
</tr>
<tr>
<td>Gooch, Lincoln D.</td>
<td>27</td>
</tr>
<tr>
<td>Goudreau, Linda G</td>
<td>75</td>
</tr>
<tr>
<td>Gourley, John W</td>
<td>64, 69</td>
</tr>
<tr>
<td>Goff, Donald C</td>
<td>10, 40</td>
</tr>
<tr>
<td>Gogineni, R. Rao</td>
<td>51</td>
</tr>
<tr>
<td>Goff, Donald C</td>
<td>1</td>
</tr>
<tr>
<td>Goitein, Michael H</td>
<td>9</td>
</tr>
<tr>
<td>George, Elizabeth</td>
<td>8, 15</td>
</tr>
<tr>
<td>Germain, Christine</td>
<td>57</td>
</tr>
<tr>
<td>Geno, Jessica</td>
<td>21</td>
</tr>
<tr>
<td>Gochfeld, Linda G</td>
<td>77</td>
</tr>
<tr>
<td>Gibrion, Christopher</td>
<td>78, 94</td>
</tr>
<tr>
<td>Giese-Davis, Janine</td>
<td>29</td>
</tr>
<tr>
<td>Giers, John W</td>
<td>20, 31</td>
</tr>
<tr>
<td>Gil, Monika H</td>
<td>71</td>
</tr>
<tr>
<td>Gillispie, Jan C.</td>
<td>27</td>
</tr>
<tr>
<td>Gilman, Stephen E</td>
<td>70</td>
</tr>
<tr>
<td>Gilmour, Virginia J.</td>
<td>78</td>
</tr>
<tr>
<td>Ginsberg, David L</td>
<td>3, 16</td>
</tr>
<tr>
<td>Gise, Leslie H.</td>
<td>55, 64</td>
</tr>
<tr>
<td>Gittelman, David K</td>
<td>44</td>
</tr>
<tr>
<td>Glaister, Andrew L</td>
<td>65</td>
</tr>
<tr>
<td>Glaister, William M</td>
<td>32</td>
</tr>
<tr>
<td>Gluck, J. D.</td>
<td>13, 41, 79, 80</td>
</tr>
<tr>
<td>Goldfarb, Linda G</td>
<td>75</td>
</tr>
<tr>
<td>Goethe, John W</td>
<td>64, 69</td>
</tr>
<tr>
<td>Goff, Donald C</td>
<td>10, 40, 93</td>
</tr>
<tr>
<td>Gogineni, R. Rao</td>
<td>51</td>
</tr>
<tr>
<td>Goldman, Robert M</td>
<td>17, 37</td>
</tr>
<tr>
<td>Gold, Jodi J.</td>
<td>64</td>
</tr>
<tr>
<td>Gold, Joel</td>
<td>79</td>
</tr>
<tr>
<td>Gold, David A.</td>
<td>65</td>
</tr>
<tr>
<td>Goldberg, Joseph F</td>
<td>6, 74, 78, 81, 89, 96</td>
</tr>
<tr>
<td>Goldfinger, Stephen M.</td>
<td>19, 40, 43, 65, 72</td>
</tr>
<tr>
<td>Goldman, Charles R</td>
<td>72</td>
</tr>
<tr>
<td>Goldman, Morris B</td>
<td>14</td>
</tr>
<tr>
<td>Goldman, Eric D.</td>
<td>95</td>
</tr>
<tr>
<td>Gomes, Ivan</td>
<td>93</td>
</tr>
<tr>
<td>Gonzales-Heyndrich, J. M.</td>
<td>81</td>
</tr>
<tr>
<td>Goodhue, Angela D.</td>
<td>23</td>
</tr>
<tr>
<td>Goodkin, Karl</td>
<td>39, 95</td>
</tr>
<tr>
<td>Goodman, Marianne</td>
<td>27</td>
</tr>
<tr>
<td>Goodman, Robin F.</td>
<td>31</td>
</tr>
<tr>
<td>Goodnick, Paul J.</td>
<td>42, 67</td>
</tr>
<tr>
<td>Goodwin, Frederick K</td>
<td>23, 35, 81</td>
</tr>
<tr>
<td>Gopalakrishnan, Raman N.</td>
<td>21</td>
</tr>
<tr>
<td>Gopaldova, Eva</td>
<td>69</td>
</tr>
<tr>
<td>Goris, E. E.</td>
<td>75</td>
</tr>
<tr>
<td>Gordon, Edward</td>
<td>23, 28</td>
</tr>
<tr>
<td>Gordon, Tracy R.</td>
<td>47, 70</td>
</tr>
<tr>
<td>Gore, John C.</td>
<td>27</td>
</tr>
<tr>
<td>Gore-Felton, Cheryl</td>
<td>68</td>
</tr>
<tr>
<td>Gorelick, David A.</td>
<td>31</td>
</tr>
<tr>
<td>Gorman, Jack M.</td>
<td>3, 36, 45</td>
</tr>
<tr>
<td>Gorton, Greg E.</td>
<td>94</td>
</tr>
<tr>
<td>Gosselin, Blake A.</td>
<td>30</td>
</tr>
<tr>
<td>Gonthier, Edward</td>
<td>88</td>
</tr>
<tr>
<td>Goy, Elisabeth E.</td>
<td>76</td>
</tr>
<tr>
<td>Grace, John W.</td>
<td>64</td>
</tr>
<tr>
<td>Grady, Brian J.</td>
<td>22</td>
</tr>
<tr>
<td>Grady-Welkay, Tara A.</td>
<td>40</td>
</tr>
<tr>
<td>Granacher, Jr., Robert P.</td>
<td>63</td>
</tr>
<tr>
<td>Greepmeime, William L.</td>
<td>19</td>
</tr>
<tr>
<td>Grub, Arulmo</td>
<td>38, 93</td>
</tr>
<tr>
<td>Gray, Gregory E.</td>
<td>15</td>
</tr>
<tr>
<td>Gray, Kevin F.</td>
<td>72</td>
</tr>
<tr>
<td>Green, Grae</td>
<td>80</td>
</tr>
<tr>
<td>Green-Paden, Lisa D.</td>
<td>85</td>
</tr>
<tr>
<td>Greenberg, Benjamin D</td>
<td>75</td>
</tr>
<tr>
<td>Greenfield, Shelly F.</td>
<td>59</td>
</tr>
<tr>
<td>Greenhill, Laurence L.</td>
<td>44, 45, 56</td>
</tr>
<tr>
<td>Greenstein, Mindy</td>
<td>78</td>
</tr>
<tr>
<td>Greenwald, Scott D.</td>
<td>89</td>
</tr>
<tr>
<td>Greer, Phil J.</td>
<td>58</td>
</tr>
<tr>
<td>Greig, Nigel</td>
<td>58</td>
</tr>
<tr>
<td>Greit, John H.</td>
<td>81</td>
</tr>
<tr>
<td>Grice, Dorothy E.</td>
<td>30</td>
</tr>
<tr>
<td>Griffield, Ezra E.H.</td>
<td>57</td>
</tr>
<tr>
<td>Griffield, James L.</td>
<td>46, 93</td>
</tr>
<tr>
<td>Grilo, Carlos M.</td>
<td>21, 43</td>
</tr>
<tr>
<td>Grimaild, Jr., John A.R.</td>
<td>46</td>
</tr>
<tr>
<td>Grisso, Thomas</td>
<td>49</td>
</tr>
<tr>
<td>Groebner, Diederick E.</td>
<td>70</td>
</tr>
<tr>
<td>Groenewold, Leslie</td>
<td>91</td>
</tr>
<tr>
<td>Grouleau, Danielle</td>
<td>97</td>
</tr>
<tr>
<td>Grossberg, George T.</td>
<td>74</td>
</tr>
<tr>
<td>Grossman, Linda S.</td>
<td>45</td>
</tr>
<tr>
<td>Gruchenthal, Michael F.</td>
<td>11</td>
</tr>
<tr>
<td>Grunhaus, Leon J.</td>
<td>95</td>
</tr>
<tr>
<td>Grunau, Heinz C.</td>
<td>89</td>
</tr>
<tr>
<td>Gunderson, John G.</td>
<td>21, 25, 26, 78</td>
</tr>
<tr>
<td>Gupta, Sanjay</td>
<td>22</td>
</tr>
<tr>
<td>Guichard, Marianne T.</td>
<td>90</td>
</tr>
<tr>
<td>Guire, Jamie H.</td>
<td>32</td>
</tr>
<tr>
<td>Gutheil, Thomas G.</td>
<td>57, 76, 96</td>
</tr>
<tr>
<td>Grywette, McLeod F.</td>
<td>18</td>
</tr>
<tr>
<td>Habecky, Miguel</td>
<td>93</td>
</tr>
<tr>
<td>Hackman, Ann L.</td>
<td>79</td>
</tr>
<tr>
<td>Halbe, Hans W.</td>
<td>89</td>
</tr>
<tr>
<td>Haberstum, Banheva</td>
<td>11</td>
</tr>
<tr>
<td>Hales, Deborah J.</td>
<td>38, 42</td>
</tr>
<tr>
<td>Hales, Robert E.</td>
<td>13, 35, 39</td>
</tr>
<tr>
<td>Hall, Heather M.</td>
<td>91</td>
</tr>
<tr>
<td>Hall, Laresha L.</td>
<td>40</td>
</tr>
<tr>
<td>Hall, Stephanie Z.</td>
<td>69</td>
</tr>
<tr>
<td>Hallack, Seymour L.</td>
<td>96</td>
</tr>
<tr>
<td>Haller, Ellen</td>
<td>8, 89</td>
</tr>
<tr>
<td>Halm, Katherine A.</td>
<td>36, 92</td>
</tr>
<tr>
<td>Halpern, Abraham L.</td>
<td>19, 41</td>
</tr>
<tr>
<td>Hallman, Scott D.</td>
<td>66</td>
</tr>
<tr>
<td>Haman, Johannes</td>
<td>79</td>
</tr>
<tr>
<td>Hameed, Ahmad</td>
<td>22</td>
</tr>
<tr>
<td>Harmsen, Tanja A.</td>
<td>85</td>
</tr>
<tr>
<td>Hammond, Sean M.</td>
<td>27</td>
</tr>
<tr>
<td>Hanson, Sarah E.</td>
<td>27</td>
</tr>
<tr>
<td>Hansen, Mark R.</td>
<td>6</td>
</tr>
<tr>
<td>Hanso, Annette L.</td>
<td>85</td>
</tr>
<tr>
<td>Hanspach, Elie G.</td>
<td>77</td>
</tr>
<tr>
<td>Hanusa, Barbara H.</td>
<td>89</td>
</tr>
<tr>
<td>Hargreaves, Richard</td>
<td>11</td>
</tr>
<tr>
<td>Hartley, Rebecca</td>
<td>43, 90</td>
</tr>
<tr>
<td>Harper III, R. Andrew</td>
<td>18</td>
</tr>
<tr>
<td>Harris, Meredith</td>
<td>52</td>
</tr>
<tr>
<td>Harris, Patricia E.</td>
<td>32</td>
</tr>
<tr>
<td>Harris, Wendy A.</td>
<td>92</td>
</tr>
<tr>
<td>Harrow, Martin</td>
<td>45, 74, 89</td>
</tr>
<tr>
<td>Harrmann, Lawrence</td>
<td>57</td>
</tr>
<tr>
<td>Hartston, Heidi</td>
<td>27</td>
</tr>
<tr>
<td>Hartzell, Mary</td>
<td>91</td>
</tr>
<tr>
<td>Hasin, Deborah S.</td>
<td>78</td>
</tr>
<tr>
<td>Hatai, Shikumar</td>
<td>1</td>
</tr>
<tr>
<td>Hater, Peter</td>
<td>92</td>
</tr>
<tr>
<td>Havelaar, Johan M.</td>
<td>70</td>
</tr>
<tr>
<td>Hawkins, Keith A.</td>
<td>52</td>
</tr>
<tr>
<td>Hawkins, Maureen</td>
<td>50</td>
</tr>
<tr>
<td>Hayward, Chris</td>
<td>45</td>
</tr>
<tr>
<td>Heerlen, Andrea</td>
<td>31</td>
</tr>
<tr>
<td>Heim, Christine</td>
<td>2, 9</td>
</tr>
<tr>
<td>Heit, Michael C.</td>
<td>53</td>
</tr>
<tr>
<td>Hellenstein, David J.</td>
<td>21</td>
</tr>
<tr>
<td>Hemlere, Elizabeth A.</td>
<td>92</td>
</tr>
<tr>
<td>Heinen, R. E.</td>
<td>17</td>
</tr>
<tr>
<td>Hertz, Sarah E.</td>
<td>17</td>
</tr>
<tr>
<td>Hitzendra-Serrano, Ruben J.</td>
<td>32</td>
</tr>
<tr>
<td>Hess, Richard G.</td>
<td>5</td>
</tr>
<tr>
<td>Herzog, Alfred</td>
<td>17, 39, 46, 64</td>
</tr>
<tr>
<td>Herzog, David B.</td>
<td>30</td>
</tr>
<tr>
<td>Hester, Thomas W.</td>
<td>71</td>
</tr>
<tr>
<td>Hurt, John F.</td>
<td>71</td>
</tr>
<tr>
<td>Hick, Grace</td>
<td>71</td>
</tr>
<tr>
<td>Hicks, Daniel W.</td>
<td>91</td>
</tr>
<tr>
<td>Higgins, NP. Napoleon B.</td>
<td>40</td>
</tr>
<tr>
<td>Hilger-Assen, Eva</td>
<td>96</td>
</tr>
<tr>
<td>Hill, Danny B.</td>
<td>32</td>
</tr>
<tr>
<td>Hill, Jerry W.</td>
<td>54</td>
</tr>
<tr>
<td>Hill, Kevin P.</td>
<td>88</td>
</tr>
<tr>
<td>Hilly, Donald M.</td>
<td>40</td>
</tr>
<tr>
<td>Hinuma, Shuji</td>
<td>68</td>
</tr>
<tr>
<td>Hiroi, Katsuepe</td>
<td>68</td>
</tr>
<tr>
<td>Hire, Richard O.</td>
<td>71</td>
</tr>
<tr>
<td>Hirsch, Renata</td>
<td>66</td>
</tr>
<tr>
<td>Hirschfeld, Robert MA.</td>
<td>6, 8, 77</td>
</tr>
<tr>
<td>Hissink, Max</td>
<td>73</td>
</tr>
<tr>
<td>Ho, Andrew P.</td>
<td>5</td>
</tr>
<tr>
<td>Ho, Samuel</td>
<td>92</td>
</tr>
<tr>
<td>Hobbs, Susan L.</td>
<td>88</td>
</tr>
<tr>
<td>Hoffman-Riemen, Kristina</td>
<td>1</td>
</tr>
<tr>
<td>Hogenti, Valerie</td>
<td>68</td>
</tr>
<tr>
<td>Hooge, Charles W.</td>
<td>46, 69</td>
</tr>
<tr>
<td>Hoqi, Carlos R.</td>
<td>63</td>
</tr>
<tr>
<td>Hollander, Annette J.</td>
<td>46, 63</td>
</tr>
<tr>
<td>Hollander, Eric</td>
<td>5, 13, 35, 56</td>
</tr>
<tr>
<td>Hollorey, Jr., Willis</td>
<td>89</td>
</tr>
<tr>
<td>Holton, E. Alison</td>
<td>79</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

L
Laboff, Jo A. .............................................. 54
Lafer, Beny ................................................. 13
Lam, Naomi K ............................................. 90
Lam, Raymond W ........................................ 8
Larsh, H. Richard ...................................... 23, 53
Lambert, Martin ......................................... 52
Lang, Joan A .............................................. 47
Lang, Megan ............................................. 24
Langley, John H ......................................... 92
Langley, Ted ............................................ 54
Langley, Donald G ...................................... 46
Lappin, Debra R ......................................... 93
Laruelle, Marc .......................................... 27
Latimer, Kelsey M ....................................... 55
Lausterbach, Edward C ............................... 5, 62
Lawson, David ........................................... 31
Lawson, William B ..................................... 51, 65
Layne, Christopher M ................................... 30
Lazarus, Arthur L ........................................ 71
Le, Phuong-Thuy ........................................ 8
Lepe, Lucian L ........................................... 48
Lebovits, Allen ......................................... 40
LeCrubier, Yves ......................................... 72
Lee, Emily K ............................................ 50
Lee, Evelyn ............................................... 45
Lee, Janelle ............................................... 88
Lee, Karen L .............................................. 83
Lee, Kathryn A ........................................... 24
Lee, Kevin A ............................................... 88
Lee, Regina J ............................................ 88
Lee, Sue Y ................................................ 71
Legrange, Daniel ....................................... 66
Lehman, Anthony F ..................................... 33, 65
Lehman, Gwen .......................................... 24
Leigh, Hoyle ............................................ 22, 40
LeMelle, Stephanie ..................................... 20
Lemours, Agnes ........................................ 57
Lenert, Leslie ........................................... 95
Lennon, Sharyn A ....................................... 36
Lenert, Leslie L .......................................... 33
Lemoux, Agnes .......................................... 57
Leonard, John H ......................................... 92
Lexier, Francoise ...................................... 46, 69
Leslie, John ............................................. 97
Leucht, Stefan M ......................................... 79
Leonardo-Yee, Maria D.M ................................ 83
Leone, Carlo ............................................. 44
Leonard, Celia M ........................................ 55
Lesasky, Linda ........................................... 41
Leo, Raphael J ........................................... 41
Leopold, Allen .......................................... 48
Leubl-Krueger, Yves ................................. 72
Lee, Paul S ............................................... 92
Levant, Effie ............................................. 26
Leslie, John ............................................. 92
Lescano, Celia M ......................................... 55
Levin, Karen L ........................................... 83
Levy, Evelyn ............................................. 45
Levy, Arlene I ........................................... 46
Levy, Izhak ............................................... 46
Leventhal, Susan A ...................................... 48
Levensky, Philip G .................................... 37
Levinson, Alan I ........................................ 18
Levin, Frances R ......................................... 57, 86
Levine, Janice R ......................................... 66
Levine, Jeffrey M ........................................ 86
Levitt, Anthony J ........................................ 8
Levenson, Petros ....................................... 88
Lewis-Fernandez, Roberto .......................... 15, 51
Levy, Alfred ............................................. 24
Li, Zheng-Ming ........................................ 21, 36, 65
Lindberg, Marc A ....................................... 88

M
Lindsay, David C ....................................... 19
Lilienberg, Bruce ...................................... 46
Lipkin, Paul S ........................................... 92
Lipsett, Don H .......................................... 46
Lipkin, Steven H ....................................... 18, 48
Liptzin, Benjamin ..................................... 94
Lisanby, Sarah H ....................................... 2, 36
Liu, Ja .................................................... 88
Liu, Xin .................................................. 46
Livesey, John ............................................ 92
Livingston, Jon ......................................... 54
Lloyd, John S ............................................ 7, 40
Lobo-Pita, Sheila M ................................. 18
Lock, James D ........................................... 66
Lockhart, Paula J ....................................... 85
Lockwood, Kari ......................................... 22
Logan, Kathleen ....................................... 70
Loo, Anthony ............................................ 84
Lorenc, Frank A ........................................ 44, 68
Lorenzo-Borja, Juan J ............................... 26, 93
Loschen, Earl L ......................................... 40
Lorincz, Mihaly F ...................................... 75, 85
Lowenkrug, Eugene L .................................. 5, 69
Lovett, Deborah ....................................... 53, 77
Lu, Frances G .......................................... 7, 15, 46, 51, 74, 86, 91, 93
Lubin, Roy H ........................................... 39
Lux, Christopher ...................................... 64
Lucey, Jeffrey .......................................... 94
Ludwig, Marna ......................................... 18
Lu, John S ............................................... 24, 48, 71, 84
Lydiard, R. Bruce ....................................... 9
Lykesatos, Constantin .................................. 19, 51, 62
Lyubimty, Maria ......................................... 46
McAuley, JoAnn ......................................... 39
MacKenzie, K. Roy ..................................... 42
Madhusoodanan, Subramoniam .................... 21
Maffei, Cesare .......................................... 92
Mahal, Yasmin ......................................... 43, 44
Mahler, Jo ............................................... 88
Maiman, Susan M ....................................... 81
Maipoura, Mana ....................................... 53
Maldonado, Jose R ..................................... 15, 37, 63
Mallota, Shashuka ..................................... 81
Mall, Ashok K .......................................... 52
Malter, Janelle ......................................... 48
Mallick, Craig H ........................................ 48
Mallos, Ronna .......................................... 22
Malkoff, George L ...................................... 40
Malpawat, Carl P ....................................... 18
Manchanda, Rohit ..................................... 52
Mancini, Catherine L .................................. 22
Manos, Donna M ....................................... 41
Mandell, Donald ........................................ 77
Maneschi, Luisa ........................................ 44
Manjai, Huicera K ..................................... 11, 13, 35, 49
Mann, J. John .......................................... 11, 23, 64
Mannix, Anthony P .................................... 89
Manning, John .......................................... 29
Maranell, Lauren B ..................................... 12, 38
Marcel, Eric ............................................ 97
Marchant, Nestor F .................................... 32
Marcus, Eric R ......................................... 18
Marcus, Steven C ....................................... 33
Marder, Stephen R ..................................... 14, 35, 79
Martin, Robert S ........................................ 10
Mark, Margery .......................................... 50
Markowitz, John C .................................... 5, 55
Marmor, Charles R ..................................... 31
Marsh, Laura ............................................ 51
Marshall, Randall D .................................... 92
Marzano, Richard ...................................... 73
Martins, Jean A ......................................... 86
Martin, Eileen M ....................................... 74
Martin, Jaqueline ..................................... 50
Martinez-Aran, Anabel .............................. 78, 89
Marx, Christine F ..................................... 56
Mastrand, Prakash S .................................. 22, 59, 61, 83
Mason, Graeme ......................................... 77
Mason, Eva L ............................................ 43
Masters, Robert S ....................................... 90
Mastersson, James F .................................... 96
Mastrogiacoma, Concettina ......................... 56
Mathias, Chester ....................................... 95
Matorin, Ana A ......................................... 18, 23
Matthews, Alicia K .................................... 50
Matthews, Karen A ..................................... 70, 89
Matthews, Martin R.A ................................ 17
Mavrovas, Angela ...................................... 70
MaWhinney, Joseph R ............................... 28
Mayberg, Helen S ....................................... 13
Mayer, Laura ............................................ 61
Mayo, Vicki M ............................................ 50
Mccall, Keith ............................................ 44, 89
McCabe, Lee ............................................ 53
McClellan, Kathleen .................................. 14
McClarey, Martha ...................................... 94
McCarthy, Mary K ..................................... 93
Mc Care, Alicia ......................................... 31
McCaw, Bridget ........................................ 47
McCormack, Benjamin H ........................... 71
McConville, Brian J .................................... 24
McDowell, Laurence W ............................. 88
McKegg, Henry L ........................................ 18, 23, 78
McDermott, Stephen P ............................... 30
McDonagh-Coyne, Annmarie ....................... 95
McDonnell, Dan ......................................... 44
McDougall, Christopher J .......................... 12
McDowell, David M ................................... 16, 39, 47, 57, 63, 72, 74
McElhinney, Martin .................................. 53
McElroy, Susan L ........................................ 11, 56, 77, 83
McKee, Miles E .......................................... 54
McFarlane, Benson H .................................. 86
McFarlane, William R .................................. 52
McGlashan, Thomas H ............................... 21, 27, 43, 52, 77
McGorry, Patrick D ..................................... 52
McGregor, Jacqueline C ............................. 18
McGuire, Michael T .................................... 96
McHugh, Paul R ........................................... 96
McInnis, Daniel ......................................... 79
McIntyre, John S ....................................... 16, 24, 33, 90
McKay, Dennis .......................................... 29
McLean, Alexander .................................... 57
McLean, Andrew J ..................................... 32
McLean, Terry S ......................................... 52
McMahan, Francis R .................................... 50
McMeniman, Marjorie .................................. 53
McNicholas, Laura F .................................. 57, 62
McFarlane, Michelle ................................... 18
McQuistion, Hunter L .................................. 79
McRae, Anne ............................................ 96
Meagher, David J ....................................... 94
Mezey, Michael ......................................... 9
Meckstroth, Karen .................................... 29
Mee-Lee, David ......................................... 25
Meier, Andrew .......................................... 32
Mele-Madura, Lewis .................................. 7
Meltzer, Nadine ........................................... 77
PARTICIPANT INDEX
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wolin, Steven J.</td>
<td>66</td>
</tr>
<tr>
<td>Wolkowitz, Owen M.</td>
<td>53</td>
</tr>
<tr>
<td>Wonderlich, Stephen A.</td>
<td>30, 95</td>
</tr>
<tr>
<td>Wong, Janice</td>
<td>88</td>
</tr>
<tr>
<td>Woo, Cindy</td>
<td>90</td>
</tr>
<tr>
<td>Wood, William G.</td>
<td>7</td>
</tr>
<tr>
<td>Woods, Scott W.</td>
<td>52</td>
</tr>
<tr>
<td>Woods, Sherwyn M.</td>
<td>10</td>
</tr>
<tr>
<td>Woolley, Stephen B.</td>
<td>69</td>
</tr>
<tr>
<td>Workeneh, Lishan</td>
<td>88</td>
</tr>
<tr>
<td>Wozniak, Janet</td>
<td>12, 78, 80</td>
</tr>
<tr>
<td>Wright, Annette</td>
<td>52</td>
</tr>
<tr>
<td>Wright, Harry H.</td>
<td>52, 68</td>
</tr>
<tr>
<td>Wright, Jesse H.</td>
<td>8, 17, 37, 65, 91</td>
</tr>
<tr>
<td>Wright-Etter, Pamela J.</td>
<td>71</td>
</tr>
<tr>
<td>Wu, Jin</td>
<td>50</td>
</tr>
<tr>
<td>Wu, Ping</td>
<td>77</td>
</tr>
<tr>
<td>Wu, Roger M.Y.</td>
<td>44</td>
</tr>
<tr>
<td>Wulsin, Lawson R.</td>
<td>45</td>
</tr>
<tr>
<td>Wynn, Gary H.</td>
<td>37</td>
</tr>
<tr>
<td>Xia, Fang</td>
<td>90</td>
</tr>
<tr>
<td>Yager, Joel</td>
<td>6, 18, 30, 58, 84</td>
</tr>
<tr>
<td>Yang, C. Paul</td>
<td>91</td>
</tr>
<tr>
<td>Yang, Jing-Duan</td>
<td>24</td>
</tr>
<tr>
<td>Yang, Zhang</td>
<td>89</td>
</tr>
<tr>
<td>Yaryura-Tobias, Jose A.</td>
<td>29, 46, 75</td>
</tr>
<tr>
<td>Yates, Barbara L.</td>
<td>70</td>
</tr>
<tr>
<td>Yatham, Lakshmi N.</td>
<td>3</td>
</tr>
<tr>
<td>Yeomans, Frank P.</td>
<td>26, 37</td>
</tr>
<tr>
<td>Yeung, Albert</td>
<td>28, 70, 90, 91</td>
</tr>
<tr>
<td>Yeung, Paul P.</td>
<td>16, 22, 69</td>
</tr>
<tr>
<td>Yonkers, Kimberly A.</td>
<td>6</td>
</tr>
<tr>
<td>Young, Elizabeth A.</td>
<td>11</td>
</tr>
<tr>
<td>Young, Keith W.</td>
<td>41, 47, 56, 57</td>
</tr>
<tr>
<td>Young, L. Trevor</td>
<td>81</td>
</tr>
<tr>
<td>Youngstrom, Eric A.</td>
<td>77</td>
</tr>
<tr>
<td>Yudofsky, Stuart C.</td>
<td>13, 35</td>
</tr>
<tr>
<td>Yuness, Roberto</td>
<td>93</td>
</tr>
<tr>
<td>Yung, Alison B.</td>
<td>52</td>
</tr>
<tr>
<td>Yzermans, Christoffel J.</td>
<td>89</td>
</tr>
<tr>
<td>Zafar, Mansoor</td>
<td>43</td>
</tr>
<tr>
<td>Zajecka, John M.</td>
<td>58</td>
</tr>
<tr>
<td>Zafar, Henrik</td>
<td>19, 83</td>
</tr>
<tr>
<td>Zalesky, Richard</td>
<td>69</td>
</tr>
<tr>
<td>Zaraini, Mary C.</td>
<td>21, 27, 78</td>
</tr>
<tr>
<td>Zarate, Jr., Carlos M.</td>
<td>2, 22</td>
</tr>
<tr>
<td>Zealberg, Joseph J.</td>
<td>80</td>
</tr>
<tr>
<td>Zerbe, Kathryn J.</td>
<td>1, 50, 67</td>
</tr>
<tr>
<td>Ziedonis, Douglet M.</td>
<td>31, 52</td>
</tr>
<tr>
<td>Ziegler, Penelope P.</td>
<td>23</td>
</tr>
<tr>
<td>Zil, John S.</td>
<td>85</td>
</tr>
<tr>
<td>Zima, Bonnie T.</td>
<td>28</td>
</tr>
<tr>
<td>Zimbrottof, Daniel L.</td>
<td>59</td>
</tr>
<tr>
<td>Zimmerman, Ellen</td>
<td>95</td>
</tr>
<tr>
<td>Zimmerman, Mark</td>
<td>43, 64</td>
</tr>
<tr>
<td>Zimovszky, Robert B.</td>
<td>52</td>
</tr>
<tr>
<td>Zivin, Gail</td>
<td>94</td>
</tr>
<tr>
<td>Zoccolillo, Mark</td>
<td>45</td>
</tr>
</tbody>
</table>

123
THE FIRST AND LAST

At Your Annual Meeting Bookstore

APPI BOOKSTORE AT THE 2003 APA ANNUAL MEETING
Grow professionally and increase your knowledge of psychiatric practices through the extensive selection at the APPI bookstore. Our wide variety of topics allows you to pick up the titles you've always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!

Make sure to visit the APPI bookstore when you’re in San Francisco—you won’t be disappointed!

APPI Bookstore Hours during the 2003 APA Annual Meeting
Saturday, May 17 11 am-5 pm
Sunday, May 18 11 am-4:30 pm
Monday, May 19 10 am-6 pm
Tuesday, May 20 10 am-6 pm
Wednesday, May 21 10 am-3 pm

Sunrise Special!
Members-in-Training ONLY
American Psychiatric Publishing, Inc. is committed to helping APA Members-in-Training gain the knowledge needed to excel in the psychiatric profession. We are pleased to announce that we are bringing back the APPI Bookstore's Members-in-Training Sunrise Special. Between the hours of 8 am and 11 am, on Sunday, May 18, the APPI Bookstore will be open for members-in-training only, and will offer a 25% discount. Don’t miss out on this special offer!

The First and Last Word in Psychiatry
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901
Phone: 703-907-7322 or 1-800-368-5777
Fax: 703-907-1091
Email: appi@psych.org
Web: www.appi.org

Please reference priority code AH326 when ordering

CD-ROM INCLUDED

Edited by Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.

This densely informative textbook comprises 40 scholarly, authoritative chapters by 89 experts and combines junior and senior authors alike to enhance the rich diversity and quality of clinical perspectives. The editors have added a chapter on interpersonal therapy and updated all chapters to include the latest references and research findings. Selected chapters have been completely rewritten by new authors.

2003 • 1776 pages • ISBN 1-58562-032-7 • hardcover
$229.00 • Item #62032

Alan F. Schatzberg, M.D., Jonathan Cole, M.D., and Charles DeBattista, M.D.

A deeply informative yet eminently practical manual on this complex subject. Here, three senior psychopharmacologists offer a unique clinical perspective and practical advice on applying psychotropic medications to the treatment of specific psychiatric conditions.

2003 • 736 pages • ISBN 0-88048-865-4 • paperback
$59.00 • Item #8865

FOCUS
The Journal of Lifelong Learning in Psychiatry
Editors: Deborah J. Hales, M.D., and Mark Hyman Rapaport, M.D.

FOCUS is the first integrated approach to staying current in your field. Each issue focuses on a major subject in psychiatry and updates you with original clinical and review articles, and reprints of the most important articles as selected by experts. FOCUS provides a comprehensive clinical review of current practice that helps you stay abreast of developments in psychiatry—each issue is like a review course in itself.

2003 • Volume 1, 4 issues • ISSN 1541-4094
Please call for pricing information

Prices subject to change without notice.
REVIEW OF PSYCHIATRY
VOLUME 22
Series Editors: John M. Oldham, M.D., M.S., and Michelle B. Riba, M.D., M.S.

**JANUARY**
Concise Guide to Anxiety Disorders
Eric Hollander, M.D., and Daphne Simeon, M.D.
2003 • 272 pages • ISBN 1-58562-080-7 • paperback
$27.95 • Item #62080

Textbook of Family and Couples Therapy: Clinical Applications
Edited by G. Pirooz Shoever, M.D., with Linda D. Schwoeri, Ph.D.
2003 • 976 pages • ISBN 0-88048-318-3 • hardcover
$59.00 • Item #62318

The Dementias: Diagnosis, Treatment, and Research, Third Edition
Edited by Myron F. Weiner, M.D., and Susan E. Adamowski, Ed.D.
2003 • 352 pages • ISBN 1-58562-103-2 • paperback
$84.95 • Item #62043

**FEBRUARY**
Agitation in Patients With Dementia: A Practical Guide to Diagnosis and Management
Edited by Donald P. Hay, M.D., David T. Klein, Psy.D., Linda K. Hay, R.N., Ph.D., George T. Grossberg, M.D., and John S. Kennedy, M.D., F.R.C.P.
2003 • 272 pages • ISBN 0-88048-813-3 • paperback
$43.95 • Item #62043

**MARCH**
Evidence-Based Practices in Mental Health Care
American Psychiatric Association
2003 • 128 pages • ISBN 0-89042-294-X • paperback
$18.95 • Item #62294

Neuroleptic Malignant Syndrome and Related Conditions, Second Edition
Stephan C. Mann, M.D., Stanley N. Caroff, M.D., Paul E. Keck, M.D., and Arthur Lazarus, M.D., M.B.A.
2003 • 192 pages • ISBN 1-58562-011-4 • paperback
$19.95 • Item #62011

Core Competencies for Psychiatric Practice: What Clinicians Need to Know
(A Report of the American Board of Psychiatry and Neurology)
Edited by Stephen C. Scheiber, M.D., and Susan E. Adamowski, Ed.D.
2003 • 192 pages • ISBN 1-58562-112-9 • paperback
$29.00 • Item #62112

Psychoneuroendocrinology: The Scientific Basis of Clinical Practice
Edited by Owen M. Wolkowitz, M.D., and Stephen C. Mann, M.D., Stanley N. Caroff, M.D., and Jessica R. Oesterheld, M.D.
2003 • 192 pages • ISBN 1-58562-112-9 • paperback
$39.95 • Item #62119

**APRIL**
Fundamentals of Psychiatric Treatment Planning, Second Edition
James A. Kennedy, M.D.
2003 • 368 pages • ISBN 1-58562-061-0 • spiralbound
$49.00 • Item #62061

Mastering the Kennedy Axis V: A New Psychiatric Assessment of Patient Functioning
James A. Kennedy, M.D.
2003 • 350 pages • ISBN 1-58562-061-0 • spiralbound
$44.00 • Item #62092

Concise Guide to Pain Management for Psychiatricists
Raphael J. Leo, M.D.
2003 • 352 pages • ISBN 1-58562-103-2 • paperback
$27.95 • Item #62103

American Psychiatric Glossary, Eighth Edition
Edited by Nariman C. Shahrokh, and Robert E. Hales, M.D., M.B.A.
2003 • 272 pages • ISBN 1-58562-093-9 • paperback
$39.95 • Item #62101

**MAY**
Schizophrenia Into Later Life: Treatment, Research, and Policy
Edited by Carl L. Cohen, M.D.
2003 • 336 pages • ISBN 1-58562-027-8 • paperback
$36.00 • Item #62037

Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450, OGTs, P-Glycoproteins, Second Edition
Kelly L. Cozza, M.D., Scott C. Armstrong, M.D., and Jessica R. Oesterheld, M.D.
2003 • 560 pages • ISBN 1-58562-111-0 • paperback
$34.95 • Item #62111

Concise Guide to Child and Adolescent Psychiatry, Third Edition
Mina K. Dulcan, M.D., D. Richard Martini, M.D., and MaryBeth Lake, M.D.
2003 • 400 pages • ISBN 1-58562-074-2 • paperback
$37.95 • Item #62074

Network Therapy for Alcohol and Drug Abuse: Effective Office-Based Treatment
Marc Galanter, M.D.
2003 • Approx. 39 min. • ISBN 1-58562-142-0 • VHS
$49.95 • Item #62142

The Clinical Interview of the Child, Third Edition
Stanley I. Greenspan, M.D., with Nancy Thomidike Greenspan
2003 • 320 pages • ISBN 1-58562-137-4 • paperback
$39.95 until May 31, 2003, $39.95 thereafter • Item #62137

Medical Illness and Schizophrenia
Edited by Jonathan M. Meyer, M.D., and Henry A. Nasrallah, M.D.
2003 • 332 pages • ISBN 1-58562-106-4 • paperback
$39.95 • Item #62106

Autism Spectrum Disorders: A Research Review for Practitioners
Edited by Sally Ozonoff, Ph.D., Sally J. Rogers, Ph.D., and Robert L. Hendren, D.O.
2003 • 320 pages • ISBN 1-58562-119-6 • paperback
$39.95 • Item #62119

Personality Disorders Over Time: Precursors, Course, and Outcome
Joel Paris, M.D.
2003 • 240 pages • ISBN 1-58562-040-8 • paperback
$33.00 • Item #62040

Drug Interactions Casebook: The Cytochrome P450 System and Beyond
Neil B. Sandson, M.D.
2003 • 288 pages • ISBN 1-58562-091-2 • paperback
$33.00 • Item #62091
INDUSTRY-SUPPORTED SYMPOSIUM 1  
Saturday, May 17, 2003, 12:30 p.m. - 3:30 p.m.  
Gateway Ballroom, Exhibit Level, Moscone Center

Schizophrenia Treatment in the Community: 
The Role of Long-Acting Antipsychotics

Agenda
12:00 - 12:30 pm  Lunch
12:30 - 12:40 pm  Welcome and Introduction
John D. Kane, MD (Chair)  
Molloy Hospital
12:40 - 1:00 pm  Key Issues in Long-Term 
Pharmacotherapy of 
Schizophrenia
Wallace C. Carpenter, Jr., MD, MSc  
Maryland Psychiatric 
Research Center
1:00 - 1:40 pm  The Latest Advance in 
Long-Acting Antipsychotic 
Therapy
John D. Kane, MD

1:40 - 2:15 pm  Translating From 
Clinical Trials to Community 
Care of Patients 
With Schizophrenia
Jacqueline M. Friedman, MD  
University of Alabama School of Medicine
2:15 - 2:35 pm  Overcoming Obstacles to 
Patient Acceptance of 
Long-Acting Antipsychotics
David C. Henderson, MD  
Massachusetts General Hospital
2:45 - 3:30 pm  Questions and Answers

At the conclusion of this symposium, the participant should be able to:
- Evaluate the probability of poor medication adherence and understand its consequences
- Assess the role of long-acting risperidone in the treatment of schizophrenia
- Discuss key interim data and important gaps in clinical data relevant to community practice
- Effectively encourage patients to accept and adhere to pharmacologic treatment

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Support by an unrestricted educational grant from Jansen

Sponsored by the American Psychiatric Association

RS-176A

INDUSTRY-SUPPORTED SYMPOSIUM 2  
Saturday, May 17, 2003, 12:30 p.m. - 3:30 p.m.  
Salons 7 & 8, Lower B-2 Level, Marriott

BIPOLAR DISORDER: 
STRATEGIES FOR STABILIZING 
PATIENTS OVER THE LONG TERM

SUNDAY MAY 17
12:30-3:30 pm Clinical Program 
San Francisco Marriott  Salons 7 & 8 
Lower B-2 Level

Symposium Chair
Joseph R. Calabrese, MD
University Hospitals of Cleveland 
Case Western Reserve University
School of Medicine

New Results From the Stanley Bipolar 
Treatment Network
Robert M. Post, MD
Chase, Maryland

Update on Anticonvulsants in Bipolar Disorder
Charles L. Bowden, MD
The University of Texas Health Science Center
Medical School

Psychosocial Strategies to Avoid Medication-Induced 
Mood Distabilization
Carlos A. Zarate, Jr., MD
Germano, Maryland

For more information about the symposium, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-257-7925 (within the U.S. or Canada) or at 732-997-7925.

Supported by an unrestricted educational grant from Jansen
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 17, 2003, 12:30 p.m. - 3:30 p.m.
Salon 9, Lower B-2 Level, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

GENETICS AND PSYCHIATRY: REAL GENES, REAL PROGRESS

AGENDA:
5:30-6:00 pm Dinner
6:00-7:20 pm Game and Protein: Expression in Brain
It Depends on Inheritance
Joseph E. Kleinman, MD
National Institute of Mental Health

7:20-7:50 pm Genetic Engineering in Animals: New Insights About Anxiety and Antidepressants
Richard N. Shader, MD
Columbia University

7:50-8:15 pm A Schizophrenia Gene: From Linkage to Function
Richard W.ItemId
National Institute of Mental Health

8:15-9:00 pm Questions and Answer Session
All Faculty

9:00 pm Adjourn

LEARNING OBJECTIVES:
After attending this symposium, participants will be able to:
- Describe how genes and environment interact to modify behavior and contribute to psychiatric illness
- Understand the effects of psychiatric medications on gene expression and how these effects may be used to develop new drugs
- Discuss the role of genetic factors in the development of psychiatric disorders

CME STATEMENT:
This symposium is supported by the American Psychiatric Association and AstraZeneca.

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.
Continental Ballroom, Ballroom Level, Hilton

BEYOND BENZODIAZEPINES: New Targets for the Treatment of ANXIETY

Objectives:
- Recognize the frequency of childhood anxiety disorders and what is known about long-term treatment outcomes
- Assess the economic, educational, marital, social, and health care burden associated with anxiety disorders
- Recognize the burden of illness of generalized anxiety disorder (GAD) and compare and contrast the advantages and disadvantages of existing and potential new treatments for GAD
- Identify new molecular targets for potential antianxiety medications by reviewing current strategies

APA Annual Meeting
Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-200-2004 (within the United States) or 202-362-7000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity offers a maximum of 3 Category I credits towards the AMA Physician's Recognition Award and the CME requirement of the JCAH. Each physician should claim only those credits that relate directly to the educational activity.

Sponsored by the American Psychiatric Association
INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 8
Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.
Salon 9, Lower B-2 Level, Marriott
INDUSTRY-SUPPORTED SYMPOSIUM 9
Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

INDUSTRY-SUPPORTED SYMPOSIUM 10
Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton
### INDUSTRY-SUPPORTED SYMPOSIUM 11

**Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.**  
**Continental Ballroom, Ballroom Level, Hilton**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:00 - 8:10 AM | Introduction  
Steven L. Dubovsky, MD  
University of Colorado Health Sciences Center |
| 8:10 - 8:35 AM | Depression in Neurological Disorders  
Gary Tucker, MD  
University of Washington |
| 8:35 - 9:00 AM | Depression in Dementiaing Disorders  
Jeffrey L. Cummings, MD  
University of California, Los Angeles |
| 9:00 - 9:25 AM | Depression Following Traumatic Brain Injury  
David B. Arconais, MD  
University of Colorado Health Sciences Center |

**Program Chair:** Steven L. Dubovsky, MD  
University of Colorado Health Sciences Center

**Educational Objectives:** As the conclusion of this symposium, the participant should be able to understand the neurobiology of depression in patients with medical and neurological illnesses and how these comorbidities influence and affect antidepressant choices.

**Accreditation:** The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the APA Physician Recognition Award for a maximum of 75 credits every three years. Each physician should claim only those credits that reflect actual activity in the activity.

Accreditation must be registered for its CME Annual Meeting to attend the symposium. Space is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA, for more information, 800-357-9794 (United States or Canada) or 703-907-7700.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Organon Inc.

---

### INDUSTRY-SUPPORTED SYMPOSIUM 12

**Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**

**An Integrated Approach to the Management of Bipolar Disorder:**  
**An Alliance of Science and Medicine**

**Sunday, May 18, 2003**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:30 AM | Welcome and Introduction  
Robert B. Nemeroff, MD  
Program Chairperson  
University of Miami School of Medicine  
Miami, Florida |
| 9:00 AM | The Role of Genetics in Bipolar Disease  
David M. Burns, MD  
Department of Psychiatry  
University of Pennsylvania School of Medicine |
| 9:30 AM | The Importance of Mood Stabilization in the Treatment of Mania  
Gary E. Sachs, MD  
Hospital for Special Surgery  
New York, New York |
| 10:00 AM | Disease Management Strategies for Bipolar Disorder  
John L. Meltzer, MD  
Ferring Pharmaceuticals  
Marlton, New Jersey |

**Program Description:**  
The session aims to provide physicians and researchers with an overview of the management of bipolar disorder. The sessions will cover various aspects of the disease, including genetics, mood stabilization, and disease management strategies.  

**Program Goals:**  
To provide physicians with an overview of the management of bipolar disorder.  
To provide researchers with an overview of the management of bipolar disorder.

**Program Participation:**  
The session is open to all interested physicians and researchers.

**Program Accreditation:**  
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 9 credits toward the APA Physician Recognition Award for a maximum of 75 credits every three years. Each physician should claim only those credits that reflect actual activity in the activity.

Accreditation must be registered for its CME Annual Meeting to attend the symposium. Space is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA, for more information, 800-357-9794 (United States or Canada) or 703-907-7700.

Sponsored by an unrestricted educational grant from Organon Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.
Salon 9, Lower B-2 Level, Marriott

PROGRAM OBJECTIVES:
After attending the continuing medical education symposium, the psychiatrist should be able to:
• Develop and maintain better therapeutic alliances
• Appreciate the effect of medication nonadherence on therapeutic outcome in the treatment of mood and anxiety disorders
• Understand the underlying technology of controlled-release drug formulations
• Understand the need for and application of evidence-based medicine in the practice of psychiatry.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CMR requirement of the APA. Each participant should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-337-7924 (within the US or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from GlaxoSmithKline

AGENDA
1:00 PM Welcome and Introduction
1:30 PM Lunch
1:30 PM From Medication Noncompliance to Medication Interest: The Art of Discussing Medications With Patients
SHAWN C. SHA, MD
Dartmouth Medical School
1:35 PM Antidepressant Formulations: Advantages and Limitations
2:05 PM Controlled-Release
2:35 PM An Evidence-Based Approach to Clinical Trials in Anxiety and Depression
3:05 PM Case-Based Approach to Optimal Outcome in Depression and Anxiety
3:35 PM Panel Discussion With Questions and Answers
4:20 PM Closing Remarks, Adjournment

David V. Sheehan, MD, MBA
Symposium Chair
University of South Florida

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center
INDUSTRY-SUPPORTED SYMPOSIUM 15
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Metropolitan, Second Level, Argent

New Challenges in the Management of Depression

APA 2003 Annual Meeting
1:30 pm
Introduction
Karen D. Green Wagner, MD, PhD—Chair • University of Texas Medical Branch
1:40 pm
Solving the Conundrum of Childhood Depression
Karen D. Green Wagner, MD, PhD
2:00 pm
Achieving Rapid Onset of Action and Remission in Depressed Adults
Richard M. Hirschfeld, MD • University of Texas Medical Branch
2:30 pm
Tickling the Brain: Advances in Antidepressant Brain Stimulation Techniques
Mark S. George, MD • Medical University of South Carolina
2:50 pm
Enhancing Collaboration Between the Primary Care Physician and the Psychiatrist
Larry G. Galler, MD, MPH • Boston University School of Medicine
3:20 pm
Maintaining Quality of Life in the Elderly
Steven P. Rosell, MD • College of Physicians and Surgeons of Columbia University
3:45 pm
Question and Answer Session
4:00 pm
Conclusion

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from

FOREST PHARMACEUTICALS, INC.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendance at this symposium allows for the allocation of these credits. Further information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll free at 1-888-357-7804 (within the US or Canada) or 703-987-7800.

Educational Objectives:
• Demonstrate increased knowledge about managing depression across the spectrum of age ranges and treatment settings, including identifying and managing depression in children; establish collaborative relationships with primary care physicians; achieve rapid onset of antidepressant response and remission in adults; and improve quality of life in depressed elderly patients
• Discuss how primary care doctors treat depression and present a model of an effective interaction between the primary care doctor and psychiatrist for the optimal treatment of the depressed patient
• Improve onset of action of antidepressant treatment and become better able to achieve remission in the treatment of patients with depression
• Describe and evaluate brain stimulation techniques for the treatment of depression, including electroconvulsive therapy and transcranial magnetic stimulation
• Understand the challenges associated with the treatment of depression in the elderly
• Increase knowledge about the clinical presentation of depression in children and adolescents, identify effects of parental depression, and obtain information about treatment and prevention strategies for depressed youth

INDUSTRY-SUPPORTED SYMPOSIUM 16
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

ISSUES IN TREATING MANIA:
ACUTE AND CONTINUATION PHASE

SUNDAY, MAY 18, 2003 • LUNCH: 1:00–1:30 PM • SYMPOSIUM: 1:30–4:30 PM
HILTON SAN FRANCISCO, GRAND BALLROOM, SALON B, GRAND BALLROOM LEVEL • SAN FRANCISCO, CALIFORNIA

This symposium will be conducted on May 18, 2003, during the 2003 Annual Meeting of the American Psychiatric Association

AGENDA:

1:30–1:35 pm Lunch

1:35–1:45 pm Welcome and Opening Remarks
Michael R. Allen, MD (Symposium Chairperson)
University of Colorado

1:45–2:05 pm Managing Acute Mania in the Emergency Room
Michael R. Allen, MD
University of Colorado

1:45–2:45 pm Identifying Suicidal Behavior and At-Risk Patients
Gary J. Tachos, MD
Massachusetts General Hospital

2:05–2:55 pm Pharmacological Options for the Treatment of Pediatric Mania
Melissa J. Savitsky, MD
University of Cincinnati

3:00–3:15 pm Approaches to the Treatment of Mania
Amy H. Porter, MD
Massachusetts General Hospital

3:15–3:30 pm Adjourn

LEARNING OBJECTIVES:
After attending this symposium, participants will be able to:

• Describe how family psychosocial educational treatment can be used effectively with medication during the stabilization and maintenance phases of bipolar disorder, and to address symptoms associated with the condition.
• Describe and evaluate brain stimulation techniques for the treatment of depression, including electroconvulsive therapy and transcranial magnetic stimulation
• Understand the challenges associated with the treatment of depression in the elderly
• Increase knowledge about the clinical presentation of depression in children and adolescents, identify effects of parental depression, and obtain information about treatment and prevention strategies for depressed youth

CME Statement:
A报仇 报 who are not eligible for CME credit may participate in the event for information and educational purposes.

The topics presented in this symposium are not related to the products of this company, nor are any off-label or improper uses of products presented at this meeting discussed.

133
INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Continental Ballroom, Ballroom Level, Hilton

INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott
INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Salon 9, Lower B-2 Level, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 20
Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.
Grand Ballroom, Mezzanine Level, Westin St. Francis
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

INDUSTRY-SUPPORTED SYMPOSIUM 22
Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.
Metropolitan, Second Level, Argent
A Rational Algorithm for Selecting Atypicals in Schizophrenia and Bipolar Disorders

Sunday, May 18, 2003 • Dinner: 6:30–7:00 PM • Symposium: 7:00–10:00 PM

Hilton San Francisco, Grand Ballroom, Salon B, Grand Ballroom Level • San Francisco, California

This symposium will be conducted on May 18, 2003, during the 2003 Annual Meeting of the American Psychiatric Association.

AGENDA:

6:30–7:00 A.M.: Dinner
7:00–8:00 A.M.: Welcome and Opening Remarks
10:30–11:30 A.M.: Bipolar Disorders and Schizophrenia: Similarities and Differences in Susceptibilities to Side Effects
11:30–12:00 P.M.: Minimizing Specific Medical Problems by Customizing Antipsychotic Selection
12:00–1:00 P.M.: Question and Answer Session

LEARNING OBJECTIVES:

After attending this symposium, participants will be able to:

- Explain how atypical antipsychotics demonstrate a broader spectrum of efficacy than conventional agents, how they appear to be more effective in alternate treatment-refractory patients, with obsessive preoccupying the two-track record in this regard, review a comparison of “first-line” typical antipsychotics across all available clinical trial data, and explain how appropriate dosing is a constant toward optimizing efficacy.

- Demonstrate how certain populations are susceptible to certain medical side effects (e.g., EPS in the elderly), discuss in detail the selection of a specific antipsychotic for each patient, based on higher medical risk profile.

- Describe the potential increased health risks associated with atypical antipsychotics and discuss health assessment strategies and potential intervention strategies to reduce risk of cardiovascular and sedative side effects.

- Increase the risk of side effects with atypical antipsychotics in the treatment of bipolar disorder and schizophrenia.

- Discuss the current understanding of the difference between efficacy and effectiveness as it pertains to the treatment of schizophrenia.

CME STATEMENT:

At the completion of this symposium, participants should be able to:

- Understand why the management of depression in patients with cardiovascular disease (CVD) is important to initiating treatment response.

- Recognize the interrelationship between depression and cardiovascular morbidity and mortality, and understand how the depression can improve a medical patient's overall quality of life.

- Recognize the need for early identification and treatment of anxiety disorders in primary care.

- Understand the significance of long-term treatment of depression and anxiety.

- Communicate and empower the approach in treating patients with depression and medical recommendations to the psychiatric and primary care settings.

APA 150th Annual Meeting:

Hilton San Francisco, Grand Ballroom, Salon B, Grand Ballroom Level, San Francisco, California

INDUSTRY-SUPPORTED SYMPOSIUM 23

Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

INDUSTRY-SUPPORTED SYMPOSIUM 24

Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.

Continental Ballroom, Ballroom Level, Hilton
INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

Medical Considerations in the Management of Special Patient Populations

Sunday, May 18, 2003
6:30PM-7:00PM Dinner
7:00PM-10:00PM Educational Program
San Francisco Marriott
Verba Buena Ballroom, Salons 7 and 8
Lower B 2 Level

Don’t Miss This Important Educational Dinner Program!

INDUSTRY-SUPPORTED SYMPOSIUM 26
Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.
Salon 9, Lower B-2 Level, Marriott

Treatment of Comorbidity in Neuropsychiatric Disorders in Children and Adolescents

Sunday, May 18, 2003
Salon 7, San Francisco Marriott
San Francisco, CA

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis.

For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-337-7924 (within the U.S. or Canada) or at 703-977-7300.

Supported by an unrestricted educational grant from Janssen

Sponsored by the American Psychiatric Association

RS-11780
INDUSTRY-SUPPORTED SYMPOSIUM 27
Sunday, May 18, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Mezzanine Level, Westin St. Francis

Reducing Suicidality in Schizophrenia and Bipolar Disorder

Presented at the APA 156th Annual Meeting
Sunday, May 18, 2003
7:00 p.m. - 10:00 p.m.
Westin St. Francis
Mezzanine Level, Grand Ballroom
San Francisco, California

Faculty and Agenda

Reception and Dinner: 8:30 p.m. - 9:00 p.m.
8:15 p.m. Reducing Suicidality in Schizophrenia and Schizoaffective Disorder
Herbert Y. Meltzer, MD
Chair, Vanderbilt University Medical Center

7:00 p.m. Welcome and Introduction
Herbert Y. Meltzer, MD, Chair, Vanderbilt University Medical Center

7:15 p.m. Suicidality and Its Management in Schizophrenia and Bipolar Disorder
Kay R. Jamison, MD
Johns Hopkins University

7:45 p.m. A Model for Suicide Assessment
Douglas G. Baxter, MD
Substance Abuse and Mental Health Services Administration

Target Audience:
This continuing education activity is designed for psychiatrists and other clinicians who diagnose and treat schizophrenia and bipolar disorder.

Learning Objectives:
At the conclusion of this symposium, the participant should be able to recognize the patients with bipolar disorder or schizophrenia who are at greater risk for suicidality, assess the level of risk, and apply the most appropriate pharmacologic and psychotherapeutic techniques to deal with current crises and minimize future suicidality.

Accreditation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Registration Policy:
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA's Web site at www.psych.org or contact the APA toll-free at (888) 337-7924 (within the US or Canada) or (703) 973-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 28
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

Impairments of Structural Plasticity in Severe Mood Disorders: Cause or Collateral?

Learning Objectives:
- Discuss mechanisms involved in neurogenesis, cellular atrophy, and cell death.
- Discuss neurogenesis and the effects of mood stabilizers on specific molecular and cellular targets.

Credit Designation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the symposium, please visit the APA's Web site at www.psych.org or contact the APA toll-free at 1-888-337-7924 (within the US or Canada) or 703-973-7300.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

Sponsored by the American Psychiatric Association and held at the APA 2003 Annual Meeting.
INDUSTRY-SUPPORTED SYMPOSIUM 29
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS (Parts 1 & 2)

Breakfast will be served on both days from 6:30 A.M. - 7:00 A.M.

Monday, May 19 (Part 1)
- 7:00 AM - 7:30 AM  
  Treating Impulsivity in Impulse Control and Personality Disorders  
  Eric Hollander, MD; New York, NY

- 7:30 AM - 7:50 AM  
  Primary and Secondary Disorders of Aggression in Youth: Mood Stabilizers, Abyypical, and Stimulants  
  Hans Steinic, MD; Stanford, CA

- 7:50 AM - 8:10 AM  
  Strategies for Augmenting Pharmacological Intervention in Youth with Disorders of Aggression  
  Kirt Saxena, MD; Palo Alto, CA

- 8:10 AM - 8:30 AM  
  Question & Answer Session

Tuesday, May 20 (Part 2)
- 7:00 AM - 7:30 AM  
  Lithium Treatment of Patients with Suicidal Affective Disorder: Risk Factors and Predictors  
  Jan A. Fawcett, MD; Chicago, IL

- 7:30 AM - 8:00 AM  
  Effects of Lithium on Impulsivity, Aggression, and Suicide  
  Frederick K. Goodwin, MD; Washington, DC

- 8:00 AM - 8:30 AM  
  Question & Answer Session

Overall Objective: At the conclusion of this symposium, the participant should be able to recognize contributing factors to the development of impulsivity, aggression, and suicide, and adopt effective management strategies to reduce these problem behaviors.

Attendance is required for the APA 2003 Annual Meeting to attend this symposium. Seating is limited and is based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

This program is supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.

Sponsored by the American Psychiatric Association.

INDUSTRY-SUPPORTED SYMPOSIUM 30
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

APA 2003 Annual Meeting ~ Two-Part Breakfast CME Symposium
Monday & Tuesday, May 19-20
6:30-7 AM Breakfast ~ 7-8:30 AM Clinical Program
Hilton San Francisco ~ Grand Ballroom Salon B

Bipolar Disorder in Women: Special Considerations & Evolving Treatment Strategies

Lee S. Cohen, MD  Symposium Chair
Martha J. Morrell, MD  Symposium Co-Chair

Bipolar Disorder in Women: Phannacological & Gender-Related Differences
Ruta M. Nonacs, MD, PhD  Massachusetts General Hospital  Harvard Medical School

Course & Treatment of Bipolar Disorder During Pregnancy
Lee S. Cohen, MD  Massachusetts General Hospital  Harvard Medical School

Bipolar Illness & the Postpartum Period: Clinical Issues & Controversies
Adelle C. Vigueria, MD  Massachusetts General Hospital  Harvard Medical School

Use of Antiepileptic Medications in Women
Martha J. Morrell, MD  Columbia University College of Physicians & Surgeons

Two-Part Breakfast Series Agenda ~ May 19-20
6:30 AM  Breakfast  
6:30 AM  Introduction - L. Cohen, MD
7:15 AM  Speaker presentations
8:00 AM  Question & answer session
8:30 AM  Program concludes

Exemption Objective: To examine clinical management issues for bipolar women, focusing on efficacy of treatment in the impact of treatment on reproductive endocrine function.

Sponsored by the American Psychiatric Association.

For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from .

140
INDUSTRY-SUPPORTED SYMPOSIUM 31
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Continental Ballroom, Ballroom Level, Hilton

INDUSTRY-SUPPORTED SYMPOSIUM 32
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Salons 7 & 8, Lower B-2 Level, Marriott
INDUSTRY-SUPPORTED SYMPOSIUM 33
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Salon 9, Lower B-2 Level, Marriott

EVIDENCE-BASED TREATMENT OF PSYCHIATRIC DISORDERS
PARTS 1 & 2

Overview:
This symposium will focus on developing and evaluating the evidence base for the management of various psychiatric disorders. Evidence-based medicine is notcookbook medicine. It is also not a cost-cutting venture. It is the integration of best evidence with the best clinical knowledge to enhance the treatment of patients. In this symposium, Dr. Ranga Krishnan will give an overview of what evidence-based medicine is. He will discuss how it is practiced, and how to ask questions, evaluate the evidence, appraise it, and use it to make decisions. Dr. Michael Thase will then discuss the evidence for different treatment modalities in the management of unipolar depression. Dr. Jack Gorman will discuss the evidence for different treatment modalities for generalized anxiety disorders and social phobia. Dr. Richard Nemeroff will discuss what the evidence is for case management, psychosocial interventions in the acute-treatment and long-term management of schizophrenia. Dr. Sarah Lusby will discuss the evidence for the use of electroconvulsive therapy (ECT) and transcranial magnetic stimulation in mood disorders.

Target Audience:
The activity is designed specifically for psychiatrists.

Learning Objectives:
Upon completion of this symposium, the participants should be able to:
• Understand the principles of evidence-based medicine

Accreditation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Registration Policy:
Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about this meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 34
Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.
Grand Ballroom, Mezzanine Level, Westin St. Francis

Managing Anxiety and Sleep:
A New Era for Gamma-Aminobutyric Acid

Educational Council:
Chairperson:
Philip T. Niran, MD
Emory University,
Atlanta, GA

Linda Chang, MD
Brookhavens National Laboraory
Oak Ridge, TN

Ted B. Black, MD
Stanford University
Stanford, CA

Stephen M. Stahl, MD, PhD
Neuroscience Education Institute
University of California, San Diego
Canduia, CA

Educational Objectives:
At the conclusion of this symposium, the participant should be able to:
• Describe the pathophysiology of GABA and its role in anxiety disorders.
• Explain the differences between the management of anxiety disorders versus symptoms, particularly with novel GABAergic medications.

Participation:
Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Agenda
Monday, May 19, 2003
7:00 a.m. - 7:30 a.m.
Welcome & Introduction
Philip T. Niran, MD
7:30 a.m. - 7:45 a.m.
Novel Gamma-Aminobutyric Acid in the Human Brain
Philip T. Niran, MD
7:45 a.m. - 8:00 a.m.
Gamma-Aminobutyric Acid Mechanisms in Sleep Disorders
Ted B. Black, MD
8:00 a.m. - 8:30 a.m.
Questions & Answers, Panel

Tuesday, May 20, 2003
7:00 a.m. - 7:30 a.m.
Welcome & Introduction
Philip T. Niran, MD
7:30 a.m. - 7:45 a.m.
Novel Gamma-Aminobutyric Acid in the Human Brain
Philip T. Niran, MD
7:45 a.m. - 8:00 a.m.
Gamma-Aminobutyric Acid Mechanisms in Sleep Disorders
Ted B. Black, MD
8:00 a.m. - 8:30 a.m.
Questions & Answers, Panel
INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center

Facing Unmet Needs:
Atypical Antipsychotics for Mood and Anxiety

**Agenda**

- **6:30 - 7:00 pm**
  - Dinner

- **7:00 - 7:30 pm**
  - Welcome and Introduction
    - Mark Plotnick, MD (Chair)
    - Massachusetts General Hospital

- **7:30 - 8:00 pm**
  - Mechanism of Action of Atypical Antipsychotics in Mood and Anxiety Disorders
    - Pierre Bléau, MD, PhD
    - University of Florida
    - McKnight Brain Institute

- **8:00 - 8:25 pm**
  - Treatment of Anxiety Disorders: Therapeutic Challenges for the Future
    - Olya Brennan-Minder, MD
    - Medical University of South Carolina

- **8:25 - 9:00 pm**
  - Atypical Antipsychotics in PTSD: Retinada and Role
    - Murray B. Stein, MD
    - University of CA, San Diego School of Medicine

- **9:00 - 9:45 pm**
  - Working with the Patient as a Co-therapist: Strategies to Enhance Treatment Adherence
    - Michael W. Otto, PhD
    - Massachusetts General Hospital

**Questions and Answers**

At the conclusion of this symposium, the participant should be able to:

- Discuss the benefits, as well as limitations, of the current therapeutic modalities for the treatment of mood and anxiety disorders.
- Examine the potential role of atypical antipsychotics to improve patient outcomes.

---

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-337-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from JANSSEN

Sponsored by the American Psychiatric Association

RS-117BD

---

INDUSTRY-SUPPORTED SYMPOSIUM 36
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Hall E, Exhibit Level, Moscone Center

Bipolar Disorders
Across the Life Cycle

**Tuesday, May 20th, 2003**

**Agenda**

- **6:00 - 6:30 pm**
  - Dinner

- **6:30 - 7:00 pm**
  - Introduction

- **7:00 - 7:30 pm**
  - Reproductive Health and Metabolic Correlates in Women Receiving Treatment for Bipolar Disorder
    - Natalie Rustein, MD, PhD
    - Stanford University School of Medicine

- **7:30 - 8:00 pm**
  - Bipolar Disorders in Adulthood
    - John M. Zajecka, MD
    - Rush-Presbyterian-St. Luke's Medical Center

- **8:00 - 8:30 pm**
  - Secondary Manias and Comorbid Conditions
    - James C. Y. Chou, MD
    - New York University School of Medicine

- **8:30 - 9:00 pm**
  - Combination Treatments: What to Use and When
    - Joseph R. Goldberg, MD
    - Case Western Reserve School of Medicine

- **9:00 - 9:30 pm**
  - Management of Side Effects and Tolerating to Wellness
    - Charles L. Boardman, MD — Program Chairman
    - The University of Texas Health Science Center

**Q & A**

---

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

Sponsored by the American Psychiatric Association and held at the APA 2003 Annual Meeting.
INDUSTRY-SUPPORTED SYMPOSIUM 37
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Metropolitan, Second Level, Argent

INDUSTRY-SUPPORTED SYMPOSIUM 38
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton
INDUSTRY-SUPPORTED SYMPOSIUM 39
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Continental Ballroom, Ballroom Level, Hilton

BIOLIC AND PSYCHOLIC ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA:
Revisiting and Updating Meyer's Psychobiology for the 21st Century
Tuesday, May 20, 2003

Agenda
7:00 PM Welcome and Introductions: Models of the Mind and Meyer's Psychobiology
Peter J. Weiden, MD
State University of New York Health Science Center at Brooklyn
7:10 PM Biologic Mechanisms of Psychosis: From Dopaminergic Excess to Dopamine Stabilization
Brian L. Weins, MD, PhD
Case Western Reserve University School of Medicine
7:35 PM What Is an Adequate Treatment Response? Establishing Therapeutic Goals in Schizophrenia
Peter J. Weiden, MD
8:00 PM Psychologic Mechanisms of Psychosis: Implications for Psychotherapeutic Intervention
Douglas Turkington, MD
University of Newcastle-upon-Tyne
8:25 PM Long-Term Treatment of Schizophrenia: Moving from a Relapse Prevention Model to a Recovery Model
John M. Kane, MD
Albert Einstein College of Medicine
8:50 PM Diagnostic Boundaries Between Bipolar Disorder and Schizophrenia: Implications for Pharmacologic Intervention
Stephen M. Straube, MD
University of Cincinnati College of Medicine
9:15 PM Q&A Panel Discussion

Learning Objectives
After completion of this symposium, the participants should be better able to:

- State the goals and potential symptomatic benefits that can be achieved with the use of CGI as an adjunct to antipsychotic medication in the management of patients with schizophrenia.
- Understand the mechanisms of action of currently available and newer antipsychotic medications, and how these mechanisms result in both efficacy and side effects profiles.
- Understand how clinical trial data can be used to optimize care and the limitations in adaptation of such information to clinical practice.
- Discuss the barriers that exist in the pharmacologic and psychosocial management of psychiatric disorders, how they influence patients' overall health, and potential ways to overcome these barriers.

- Discuss the appropriate use of the newer antipsychotic agents, alone and in combination with other agents, in the management of a range of neurologic and psychiatric disorders.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 40
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

REAL-WORLD CHALLENGES IN DEPRESSION AND ANXIETY
A dinner symposium to be held at the American Psychiatric Association's 160th Annual Meeting
Sponsored by the American Psychiatric Association

TUESDAY, MAY 20, 2003
7:00 PM - 10:00 PM
San Francisco Marriott
Salons 7 & 8, Lower B-2 Level
San Francisco, California

Program Objectives
After attending this continuing medical education program, the psychiatrist should be able to:

- Recognize the importance of early diagnosis and treatment of social anxiety disorder
- Understand the bidirectional comorbidity of medical illnesses and mood and anxiety disorders
- Demonstrate the risk factors for late-life depression and discuss treatment strategies
- Discuss the issues associated with treating the depressive component of bipolar disorder

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

AGENDA
6:30 PM - 7:00 PM Dinner
7:00 PM Welcome and Program Introduction
DAVID L. DUNNER, MD
Symposium Chair
University of California, San Francisco
7:05 PM Long-Term Consequences of Social Anxiety Disorder: Breaking the Cycle
KAREN DENIS WAGNER, MD, PhD
University of Texas Medical Branch
7:35 PM Depression and Anxiety in Medical Illness: The Brain-Body Interface
PRAKASH S. MANAND, MD
Duke University Medical Center
8:05 PM Overcoming Stigma and Optimizing Outcome in Late-Life Depression
LORE BIRDSONG, MD
University of Washington
8:35 PM The Clinical Challenge of Depression in Bipolar Disorder
DAVID L. DUNNER, MD
9:05 PM Panel Discussion With Questions and Answers
9:50 PM Closing Remarks, Adjournment
DAVID L. DUNNER, MD
INDUSTRY-SUPPORTED SYMPOSIUM 41
Tuesday, May 20, 7:00 p.m. - 10:00 p.m.
Salon 9, Lower B-2 Level, Marriott

Women and Psychiatric Disorders
Does Gender Matter to Treatment?

Overview:
The symposium will explore gender-related differences in risk for psychiatric disorders and response to treatment. The complex interaction between female reproductive biology and other factors that may contribute to emergence of psychiatric disorders, including past history of psychiatric illness and a wide spectrum of psychosocial variables, is also being studied. This symposium will include presentations that highlight advances in previously understudied areas in women's mental health. Dr. Meri Mihalopoulos will provide a conceptual framework for understanding the role of gender-related differences in mental health and will discuss how gender-related differences in mental health may affect mental health outcomes longitudinally across the life cycle of women. Dr. Claudia Sauer will review recent findings which indicate the potential role of estrogen as a treatment for reproductive-associated mood disturbances in both younger and older populations of women. Dr. Shannon Greenfield will present an overview of recent systematic studies of trauma in women, including the psychopathology of posttraumatic stress disorder and its treatment. Dr. Sheryl Greenfield will address specific considerations with respect to the recognition and management of alcohol and substance use in women. Lastly, Dr. Jared K. Rosenbaum will discuss the various factors which may contribute to gender and culturally based differences in clinical presentation and management of psychiatric disorders in women, as well as potential mechanisms which may underlie differences in response to treatment for mood disorders across populations of women, particularly those treating with different classes of antidepressants.

Accreditation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only the credits that he/she actually spent in the educational activity.

Registration Policy:
Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-served basis.

For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-559-5300.

Sponsored by an unrestricted educational grant from JANSSEN

INDUSTRY-SUPPORTED SYMPOSIUM 42
Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.
Gateway Ballroom, Exhibit Level, Moscone Center

Neuropsychiatry in the Age of Polypharmacy

Agenda, Day 1
6:30 - 7:30 AM
Breakfast
7:00 - 7:30 AM
Welcome and Introduction
Prakash Misand, MD (Chair)
Duke University Medical Center
7:30 - 7:35 AM
An Evidence-based Approach to Rationale
Polypharmacy in Schizophrenia
Prakash Misand, MD
7:30 - 8:05 AM
Polypharmacy in the Treatment of Bipolar Disorder
Marvin A. Stohler, MD
Harvard Medical School
8:05 - 8:30 AM
Questions and Answers

Agenda, Day 2
6:30 - 7:00 AM
Breakfast
7:00 - 7:05 AM
Welcome and Introduction
Prakash Misand, MD (Chair)
Duke University Medical Center
7:05 - 7:30 AM
Polypharmacy in the Treatment of Major Depression
Mark R. Rapaport, MD
Cedars-Sinai Medical Center
7:35 - 8:05 AM
Combination Therapy for Alzheimer's Disease: What Are We Waiting For?
P. Michael Bergstrom, MD
Duke University Medical Center
8:05 - 8:30 AM
Questions and Answers

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis.

For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-559-5300.

Sponsored by an unrestricted educational grant from JANSSEN
INDUSTRY-SUPPORTED SYMPOSIUM 43
Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.
Hall E, Exhibit Level, Moscone Center

INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton
INDUSTRY-SUPPORTED SYMPOSIUM 45
Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.
Salons 7 & 8, Lower B-2 Level, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 46
Wednesday, May 21, 7:00 p.m. - 10:00 p.m.
Gateway Ballroom, Exhibit Level, Moscone Center
INDUSTRY-SUPPORTED SYMPOSIUM 47
Wednesday, May 21, 7:00 p.m. - 10:00 p.m.
Hall E, Exhibit Level, Moscone Center

Juvenile Bipolar Disorder: Contemporary Issues in Research
Presented at the APA 156th Annual Meeting
Wednesday, May 21, 2003
7:00 p.m. - 10:00 p.m.
Moscone Center (Hall E, Exhibit Level)
San Francisco, California

Overview
Despite the increasing recognition of bipolar disorder (BD) in youth, controversy and clinical inertia exist as to its clinical presentation, comorbidity, biological underpinnings, and treatment in this symptom. Recent information on the similarities and differences of BD in youth and adults will be elucidated. The neurobiology and familial burden of BD and schizoaffective BD will be explored. The literature suggests very high levels of psychiatric comorbidity in BD in youth. The overlap of specific clinical presentations with BD in youth. Treatment of specific symptoms, BD, and schizoaffective BD of BD with BD will be presented, with an emphasis on the clinical presentation and treatment strategies. Treatment of youth with BD continues to be a complex issue. A review and recent work on the use of lithium and anticonvulsants used in combination children and adolescents with BD will be presented. Contemporary findings on the use of atypical antipsychotics in youth with BD will also be reported, as well as data on efficacy and adverse effects of the various medications used in the group and in the treatment of special cases (e.g., pharmacokinetics, compliance).

Target Audience
The continuing education activity is designed for psychiatrists and other clinicians who diagnose and treat juvenile BD.

Learning Objectives
Upon completion of this symposium, the participant should be able to understand:
- Clinical presentation of juvenile BD and how it relates to the adult form of the disorder
- Major comorbid conditions with BD in youth and treatment strategies
- Treatment issues in managing mood, depression, and comorbidity in youth with BD

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits towards the APA Physician's Recognition Award for the Continuing Education Requirements for Physicians.

Registration Policy
Attendance must be registered for the APA Annual Meeting to attend this symposium. Space is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at (888) 357-7712 within the U.S. or Canada at (714) 916-7200.

CHALLENGES IN DEMENTIA
EVIDENCE-BASED CONSIDERATIONS FROM EARLY DIAGNOSIS TO LONG-TERM MANAGEMENT
WEDNESDAY, MAY 21, 2003, 7:00 - 10:00 PM
THE ARGENT HOTEL, SAN FRANCISCO, CALIFORNIA

AGENDA
6:30-7:00 PM Dinner
7:00 Welcome and Introduction
John H. Grant, MD. Chairman
Clinical Professor of Psychiatry
University of Rochester Medical Center
7:10 Validated Screening Tools in the Detection and Treatment of Alzheimer's Disease
John H. Grant, MD
7:35 Real World Assessment and Management of Mild Cognition Impairment: A Case Study
Michael S. Tylavsky, MD
Senior Instructor in Psychiatry
University of Rochester Medical Center
8:00 Practical Lessons from Clinical Trials in Cholinesterase Inhibitors
Bonnie F. Weir, MD
PhD Effie Marie Cain Professor in Alzheimer's Disease Research
Rush University Medical Center
8:15 Cholinesterase Inhibitors in Vascular Dementia: A New Treatment Model?
Stephen P. Nestoroff, MD, PhD
Director of Neurology and The Memory Disorders Program
Rush University Medical Center
8:30 Strategies for Keeping the Brain Young
Gary W. Small, MD
Director, UCLA Center on Aging
Parlor Session: Prevention of Aging
9:00 Director, Memory and Aging Research Center
9:15 Neuropsychiatric Institute
The David Geffen School of Medicine
University of California at Los Angeles
Los Angeles, California
9:15 Break and Answer Session
10:00 Adjournment

Supported by an unrestricted educational grant from Elanco Animal Health, Inc. and Pfizer Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 49
Wednesday, May 21, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salon B, Grand Ballroom Level, Hilton

COMBINED PHARMACOTHERAPY FOR BIPOLAR DISORDERS

Wednesday, May 21
Hilton San Francisco ~ Grand Ballroom Salon B
6:30-7 PM Dinner ~ 7-10 PM Clinical Program

Frederick K. Goodwin, MD, Symposium Chair
The Rationale for Combined Pharmacotherapy
Frederick K. Goodwin, MD
George Washington University Medical Center
Co-author of the standard medical text
Manic-Depressive Illness

Potential Synergies in the Mechanisms of Actions of Mood Stabilizers
L. Trevor Young, MD, PhD
University of Toronto

Mood Stabilizer Combinations: Multimodal Therapy or Polypharmacy?
Terence A. Ketter, MD
Stanford University School of Medicine

Antidepressants in Combination Therapy of Bipolar Disorder
S. Nassir Ghaemi, MD
Cambridge Hospital
Harvard Medical School

Atypical Antipsychotics Combined with Standard Mood Stabilizers for Bipolar Disorder
Joseph F. Goldberg, MD
 Payne Whitney Clinic
New York Presbyterian Hospital
Weill Medical College of Cornell University

SERIOUS OBJECTIVE
- Benefits from specific added pharmacologic agents and care for bipolar patients
- Effective therapy over time

INDUSTRY-SUPPORTED SYMPOSIUM 50
Wednesday, May 21, 7:00 p.m. - 10:00 p.m.
Continental Ballroom, Ballroom Level, Hilton
INDUSTRY-SUPPORTED SYMPOSIUM 51
Wednesday, May 21, 7:00 p.m. - 10:00 p.m.
Salons 7 & 8, Lower B-2 Level, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 52
Wednesday, May 21, 7:00 p.m. - 10:00 p.m.
Salon 9, Lower B-2 Level, Marriott
Get Connected to the American Psychiatric Association

The Promise of the Profession is in the Power of APA Membership

Annual meeting attendees visiting the APA Resource Center will find new research abstracts on CD-ROM, the latest publications of APA programs, resident fellowship opportunities, HIV/AIDS treatment information, position openings, practice tools, and how to report, track, and attain additional CME credits as well as other useful resources. Visitors can also consult with government affairs representatives regarding the latest regulations and upcoming legislation. It’s all just part of the way that APA is working to keep psychiatrists engaged with the progress of the field.

So whether you’re a prospective, new, long-time, or international member, visit the Resource Center and find out how APA can help your professional life.

APA Resource Center
Hall D, Exhibit Level
Moscone Center

Hours of Operation
Sat, May 17: 10:00 a.m. - 5:00 p.m.
Sun, May 18: 8:00 a.m. - 4:30 p.m.*
Mon, May 19: 10:00 a.m. - 6:00 p.m.
Tues, May 20: 10:00 a.m. - 6:00 p.m.
Wed, May 21: 10:00 a.m. - 3:00 p.m.

*Early closing for Opening Session